Course

New Jersey APRN Bundle

Course Highlights


  • In this course we will learn about the requirements for safe prescribing guidelines and regulations in New Jersey.
  • You’ll also learn to ientify the phases of dying.
  • Describe common side effects, including severe possible side effects, of medications used to manage asthma.

About

Contact Hours Awarded: 30

Pharmacology Contact Hours Awarded: 17

Course By:
Various Authors

Begin Now

Read Course  |  Complete Survey  |  Claim Credit

Read and Learn

The following course content

New Jersey Prescription Opioid Drugs

Introduction   

For centuries, humans have been using, developing, and synthesizing opioid compounds for pain relief. Opioids are essential for treating patients who are experiencing severe and sometimes even moderate pain. Chronic pain can negatively affect our lives. In 2011, the cost of chronic pain ranged from $560 to $635 billion in direct medical expenses, lost productivity, and disability. An estimated one in five U.S. adults has chronic pain (1).

Pharmacology of Opioids: Drug Class, Indications for Use, Most Prescribed Opioids, and their Effects. 

Opioids usually bind to mu-opioid receptor sites, where they have agonist effects, providing pain relief, sedation, and sometimes feelings of euphoria. Opiates refer only to natural opioids derived from the poppy plant. The term "opioids" includes all-natural, semi-synthetic, and synthetic opioids.  

 

Opioids are classified into several categories based on their origin and chemical structure: 

  1. Natural Opioids (Opiates): These come from the opium poppy plant. Examples include morphine and codeine. 
  2. Semi-Synthetic Opioids: These are natural opioids that are chemically modified. Examples include drugs like oxycodone, hydrocodone, oxymorphone, and hydromorphone. 
  3. Synthetic Opioids: These opioids are entirely synthesized in a laboratory and do not have a natural source. Examples include fentanyl, tramadol, and methadone (1, 2). 

 

Providers must always caution patients about the benefits and risks. The main advantage of opioid medication is that it will reduce pain and improve physical function.  

A provider may use a 3-item Pain, Enjoyment of Life, and General Activity (PEG) Assessment Scale: 

  1. What number best describes your pain on average in the past week?  
  2. What number best describes how, during the past week, pain has interfered with your enjoyment of life?  
  3. What number best describes how, during the past week, pain has interfered with your general activity?  

(3) 

 

The desired goal is improvement overall with opioid treatment (3). Providers should also go over potential side effects and cautions. Side effects include sedation, dizziness, confusion, nausea, vomiting, constipation, itching, pupillary constriction (miosis), and respiratory depression.  

Providers must also discuss the importance of consistently taking medication as prescribed. Taking opioids in larger than prescribed dosage, or in addition to alcohol, other illicit substances, or other prescription drugs, can lead to severe respiratory depression and death. Missing dosages can lead to decreased pain control and possible opioid withdrawal symptoms. Individuals should not drive when taking opioids due to the sedating effects and decreased reaction times (4).  

There are now thousands of different Food and Drug Administration (FDA) approved opioids available for providers to prescribe. They can be administered via other routes and come in various potencies. The strength of morphine is the "gold standard" used when comparing opioids. A morphine milligram equivalent (MME) is the degree of µ-receptor agonist activity.  

 

The following is a sample of some of the most prescribed opioids and their MME (5): 

 

Opioid 

Conversion factor 

 

Opioid 

Conversion factor 

Codeine 

0.15 

 

Morphine 

1.0 

Fentanyl transdermal (in mcg/hr.) 

2.4 

 

Oxycodone 

1.5 

Hydrocodone 

1.0 

 

Oxymorphone 

3.0 

Hydromorphone 

5.0 

 

Tapentadol 

0.4 

Methadone 

4.7 

 

Tramadol§ 

0.2 

 

To utilize this information, multiply the dose for each opioid by the conversion factor to determine the quantity in MMEs. For example, tablets containing hydrocodone 5 mg and acetaminophen 325 mg taken four times a day would include a total of 20 mg of hydrocodone daily, equivalent to 20 MME (5).  

Quiz Questions

Self Quiz

Ask yourself...

  1. How often do you prescribe opioids to your patients? If so, which ones and what dosages?  
  2. If you do not prescribe opioids, do you treat patients taking them? 
  3. Have you ever felt hesitant about prescribing opioids? What were the reasons? 
  4. What topics do you routinely cover when you discuss opioid prescriptions with your patients?  

A Brief History 

While the current opioid epidemic has caused devastating effects in recent years, destruction from opioids has been going on for centuries. In the early 1800s, physicians and scientists became aware of the addictive qualities of opium. This finding encouraged research to develop safer ways to deliver opioids for pain relief and cough suppression, which led to the development of morphine.  

By the mid-1800s, with commercial production and the invention of the hypodermic needle, morphine became easier to administer. During the Civil War (1861 to 1865), injured soldiers were sometimes treated with morphine, and some developed lifelong addictions after the war.  

Without other options for pain relief, physicians kept giving patients morphine as treatment. Early indicators that morphine should be used cautiously were largely ignored. Between 1870 and 1880, the use of morphine tripled. Even with the problems associated with opioids, they continued to serve a vital part in the pain treatment of patients, and their use and development continued (6).  

Drug law enforcement started in 1914, but it wasn't until July 1, 1973, that the Drug Enforcement Administration (DEA) was established in the United States. The Diversion Control Division oversees pharmaceuticals. Within this Division are five levels of controlled substances, which classify illicit and medicinal drugs.  

In the U.S., opioid prescribing increased fourfold during 1999–2010. Along with the increase in opioid prescriptions during this time, how they were prescribed also changed; opioids were increasingly prescribed at higher dosages and for longer durations. The number of people who reported using OxyContin for non-medical purposes increased from 400,000 in 1999 to 1.9 million in 2002 and to 2.8 million in 2003. This was accompanied by a fourfold increase in overdose deaths involving prescription opioids (8).  

In 2020, approximately 1.4 million people were diagnosed with opioid use disorder (OUD), of those associated with opioid painkillers, as opposed to 438,000 who have heroin-related OUD (1, 4). Over 100,000 people died of a drug overdose, with 85% involved in an opioid (1, 4).  

Widespread efforts were made to combat this growing issue. The prescribing rate peaked and leveled off from 2010-2012 and has been declining since 2012. In 2021, an estimated 2.5 million adults had been diagnosed with OUD. However, the amount of MME of opioids prescribed per person is still around three times higher than in 1999 (5).  

 

Controlled Substance Classification 

 

Schedule I Controlled Substances  

No medical use, lack of accepted safety for use under medical supervision, and high abuse potential. 

Examples of Schedule I substances are methaqualone, heroin, lysergic acid diethylamide (LSD), mescaline, methylenedioxymethamphetamine (MDMA), and marijuana (cannabis). 

(7) 

 

Schedule II/IIN Controlled Substances (2/2N)  

High potential for abuse, which can lead to severe dependence. Refills are not allowed for these drugs. Schedule II drugs have the strictest regulations compared to other prescription drugs presently.  

Examples include hydromorphone, methadone, meperidine, oxycodone, and fentanyl. Other narcotics in this class include morphine, opium, codeine, and hydrocodone. 

Some examples of Schedule IIN stimulants include amphetamine, methamphetamine, and methylphenidate. 

Other substances include amobarbital, glutethimide, secobarbital, and pentobarbital. 

(7) 

 

Schedule III/IIIN Controlled Substances (3/3N) (7) 

There is less potential for abuse than substances in Schedules I or II, and abuse may lead to moderate or low physical dependence or high psychological dependence. Schedule III drugs are able to be prescribed verbally over the phone, with a paper prescription, or via electronic prescribing. Within a six-month timeframe from the original prescription date, Schedule III drugs have requirements such that the medication can only have five refills. 

Include drugs containing not more than 90 milligrams of codeine per dosage unit like Acetaminophen with Codeine and buprenorphine. 

Schedule IN non-narcotics include benzphetamine, phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. 

(7) 

 

Schedule IV Controlled Substances 

Have a low potential for abuse relative to substances in Schedule III. Similar to Schedule III drugs, Schedule IV drugs are able to be prescribed verbally over the phone, with a paper prescription, or via electronic prescribing. Within a six-month timeframe from the original prescription date, Schedule IV drugs have refill requirements such that the medications can only have five refills. 

Examples include alprazolam, carisoprodol, clonazepam, clorazepate, diazepam, lorazepam, midazolam, temazepam, triazolam, and tramadol. 

 

Schedule V Controlled Substances  

It has a low potential for abuse relative to Schedule IV and primarily consists of medications that have small quantities of narcotics. 

Examples include cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams and ezogabine. Other Schedule V medication examples include ezogabine, pregabalin, and atropine/diphenoxylate. Partial prescription fills cannot occur more than six months after the prescription issue date. When a partial fill occurs, it is treated in the same manner and with the same regulations as a refill of the prescription.

Quiz Questions

Self Quiz

Ask yourself...

  1. How have your prescribing practices of opioids changed in response to the epidemic over time? 
  2. What trends have you noticed in overall inpatient treatment plans regarding opioid prescribing trends (e.g., dose changes? or increase in opioid alternative therapies?) 
  3. Do you think there is a stigma surrounding patients who are currently using opioids? 

Opioid-Seeking Behaviors 

Opioid use disorder (OUD) causes significant impairment and distress. Diagnosis is based on the following criteria: unsuccessful efforts to reduce or control use or use that leads to social problems and a failure to fulfill obligations at work, school, or home. The term Opioid use disorder is the preferred term; "opioid abuse or dependence" or "opioid addiction" have negative connotations and should be avoided. (9). Presently, it is estimated that OUD affects over 16 million people globally, with over 2 million in the United States experiencing this condition. 

OUD occurs after a person has developed tolerance and dependence, resulting in a physical challenge to stop opioid use and increases the risk of withdrawal. Tolerance happens over time when a person experiences a reduced response to medication, requiring a larger amount to experience the same effect. Opioid dependence occurs when the body adjusts to regular opioid use. Unpleasant physical symptoms of withdrawal occur when medication is stopped. Symptoms of withdrawal include anxiety, mood changes, insomnia, abdominal pain, vomiting, diarrhea, etc. (9).  

Patients who have OUD may or may not have practiced drug misuse. Drug misuse, the preferred term for "substance abuse," is the use of illegal drugs and the use of prescribed drugs other than as directed by a doctor, such as using more amounts, more often, or longer than recommended to or using someone else's prescription (9). 

Some indications that a patient may be starting to have unintended consequences with their opioid prescription may include the following symptoms: craving, wanting to take opioids in higher quantities or more frequently, difficulty controlling use, or work, social, or family issues.  

If providers suspect OUD, they should discuss their concerns with their patients nonjudgmentally and allow the patient to disclose related concerns or issues. Providers should assess the presence of OUD using the DSM-5 criteria.  

 

Per the DSM-5, OUD is defined as repeated opioid use within 12 months leading to problems or distress with 2 or more of the following occurring: 

  • Prolonged opioid use despite worsening physical or psychological health 
  • Prolonged opioid use despite social and interpersonal negative consequences 
  • Decreased social or recreational activities 
  • Existing or increased difficulty fulfilling professional duties at school or work 
  • Excessive time is taken to obtain or recover from taking opioids 
  • Increased opioid consumption is present 
  • Opioid cravings occur 
  • Difficulty decreasing the frequency of using opioids 
  • Tolerance to opioids develops 
  • Opioid use continues despite the dangers it poses to the user 
  • Withdrawal occurs, or the user continues to take opioids to avoid withdrawal 

 

The presence of 6 or more of these diagnostic criteria indicates severe OUD.  

Providers can use validated screening tools such as: 

  • Urine and oral fluid toxicology testing 
  • Drug Abuse Screening Test (DAST) 
  • Tobacco, Alcohol and/or other Substance use Tools (TAPS) 
  • A three-question version of the Alcohol Use Disorders Identification Test (AUDIT-C) 

 

The following patients are at higher risk for OUD or overdose: 

  • Depression or other mental health conditions 
  • History of a substance use disorder 
  • Loss of economic stability 
  • Social distress, such as relationship issues or housing concerns 
  • History of overdose 
  • Taking 50 or greater MME/day or taking other central nervous system depressants with opioids

Quiz Questions

Self Quiz

Ask yourself...

  1. How often do you have patients exhibiting symptoms of OUD in your practice setting?  
  2. What would your next steps be if you identify a patient with potential OUD (e.g., additional screening, referral, or treatment plans)? 
  3. Have you noticed any trends in patients presenting with OUD? Such as socioeconomic status, occupation, gender, race, and medical diagnosis. 
  4. Do you know how to determine if a patient is engaging in opioid-seeking behaviors? 

CDC Guidelines 

In 2022, the CDC updated the 2016 guidelines to help prescribers navigate prescribing opioids amid an epidemic.  

These guidelines are directed toward prescribing medications to adults to be taken in the outpatient setting, for example, primary care clinics, surgery centers, urgent cares, and dental offices. These do not apply to providers caring for individuals with sickle-cell disease, cancer, those receiving inpatient care, or end-of-life or palliative care. They are also intended to serve as a guideline, and each treatment plan should be specific to the unique patient and circumstances (1).  

Some of the Goals of the guidelines are to:  

  • Improve communication between providers and patients about treatment options and discuss the benefits and risks before initiating opioid therapy. 
  • Improve the effectiveness and safety of treatment to improve quality of life.  
  • Reduce risks associated with opioid treatment, including opioid use disorder (OUD), overdose, and death. 

 

Recommendation #1 - Determining when it is appropriate to initiate opioids for pain (1). 

An essential part of the prescribing process is determining the anticipated pain severity and duration based on the patient's diagnosis. Pain severity can be classified into three categories when measured using the standard 1-10 numeric scale. Pain scores 1-4 are considered mild, 5-6 are moderate, and 7-10 severe. Opioids are typically used for moderate to severe pain.  

The patient's diagnosis will allow the provider to determine if pain initially falls into one of the following three categories of anticipated duration: acute, subacute, and chronic. Acute pain is expected to last for one month or less. Acute pain often is caused by injury, trauma, or medical treatments such as surgery. Unresolved acute pain may develop into subacute pain if not resolved in 1 month. If pain exceeds three months, it is classified as chronic. Pain persisting longer than three months is chronic. It can result from underlying medical conditions, injury, medical treatment, inflammation, or unknown cause. 

The CDC guidelines state that non-pharmacologic and non-invasive methods are the preferred first-line method of analgesia, such as heat/cold therapy, physical therapy, massage, rest, or exercises, etc. Despite evidence supporting their use, these therapies are only sometimes covered by insurance, and access and cost can be barriers, particularly for uninsured persons who have limited resources, no reliable transportation or live in rural areas where treatments are not available. 

When this is insufficient, non-opioid medications, such as Gabapentin, acetaminophen, or nonsteroidal anti-inflammatory drugs (NSAID), should be considered next. Selective antidepressants and anticonvulsant medications may also be effective. Some examples of when these drugs may be appropriate include neuropathic pain, lower back pain, musculoskeletal injuries (including minor pain related to fractures, sprains, strains, tendonitis, and bursitis), dental pain, postoperative pain, and kidney stone pain.  

Providers, however, must also consider the risks and benefits of long-term NSAID use because it may also negatively affect a patient's gastrointestinal and cardiovascular system. Depending on the diagnosis, a patient may also require an invasive or surgical intervention to treat the underlying cause to alleviate pain.  

If the patient has pain that does not sufficiently improve with these initial therapy regimens, at that point, opioids will be the next option to be considered. 

It does not mean that patients should be required to sequentially "fail" nonpharmacologic and non-opioid pharmacologic therapy or use any specific treatment before proceeding to opioid therapy. Example: A patient for whom NSAIDs are contraindicated has recently sustained a rotator cuff injury and is experiencing moderate pain to the point at which it is disturbing their sleep, and it will be several weeks before they can have surgery. 

 

Recommendation #2 - Discuss with the patient realistic treatment goals for pain and overall function (1). 

Ideally, goals include improving quality of life and function, including social, emotional, and physical dimensions. The provider should help guide these patients to realistic expectations based on their diagnosis. This may mean that the patient may anticipate reduced pain levels but not complete elimination of pain.  

The provider should discuss the expected or typical timeframe where they may need medications. If medications are anticipated for acute or subacute pain, a discussion about the expected timeframe for pain should be highlighted in the debate. The patient may then understand better if their recovery is progressing. For chronic conditions, the conversation will focus on or may emphasize the overall risks of beginning long-term medication therapy.  

They may also advise patients, particularly those with irreversible impairment injuries, that they may experience reduced pain but will not regain function. An exit strategy will be discussed if opioid therapy is unsuccessful or the risk vs. benefit ratio is no longer balanced. 

 

The second section of recommendations covers the selection of opioids and dosages. 

 

Recommendation #3 - Prescribe immediate-release (I.R.) opioids instead of extended-release and long-acting (ER/LA) opioids when starting opioid therapy (1). 

Immediate-release opioids have faster-acting medication with a shorter duration of pain-relieving action. ER/LA opioids should only be used in patients who have received specific dosages of immediate-release opioids daily for at least one week. Providers should reserve ER/LA opioids for severe, continuous pain, for example, individuals with cancer. ER/LA opioids should not be for PRN use.  

The reason for this recommendation is to reduce the risk of overdose. A patient who does not feel adequate relief or relief fast enough from the ER/LA dose may be more inclined to take additional amounts sooner than recommended, leading to a potential overdose. 

 

Recommendation #4 - Prescribe the lowest effective dose (1) 

Dosing strategies include prescribing low doses and increasing doses in small increments. Prescribe the lowest dose for opioid patients. Carefully consider risk vs. benefits when increasing amounts for individuals with subacute and chronic pain who have developed tolerance. Providers should continue to optimize non-opioid therapies while continuing opioid therapy. It may include recommendations for taking non-opioid medications in addition to opioids and non-pharmacologic methods. 

Providers should use caution and increase the dosage by the smallest practical amount, especially before increasing the total opioid dosage to 50 or greater morphine milligram equivalent (MME) daily. Increases beyond 50 MME/day are less likely to provide additional pain relief benefits. The greater the dosage increases, the tendency for risk also increases. Some states require providers to implement clinical protocols at specific dosage levels. 

 

Recommendation #5 - Tapering opioids includes weighing the benefits and risks when changing the opioid dosage (1). 

Providers should consider tapering to a reduced dosage or tapering and discontinuing therapy and discuss these approaches before initiating changes when: 

  • The patient requests dosage reduction or discontinuation, 
  • Pain improves and might indicate the resolution of an underlying cause, 
  • Therapy has not reduced pain or improved function, 
  • Treated with opioids for a long time (e.g., years), and the benefit-risk balance is not clear. 
  • Receiving higher opioid dosages without evidence of improvement. 
  • Side effects that diminish quality of life or cause impairment. 
  • Opioid misuse  
  • The patient experiences an overdose or severe event. 
  • Receiving medications or having a health condition may increase the risk of an adverse event. 

 

Opioid therapy should not be discontinued abruptly unless there is a threat of a severe event, and providers should not rapidly reduce opioid dosages from higher dosages.  

Patient agreement and interest in tapering will likely be a key component of successful tapers. Integrating behavioral and non-opioid treatment and interventions for comorbid mental health conditions before/during a taper can help manage pain, strengthen the therapeutic relationship between the provider and patient, and improve the likelihood of positive tapering outcomes.  

When dosages are reduced or discontinued, a taper slow enough to reduce symptoms and withdrawal should be used. Patients should receive education on possible withdrawal symptoms and when to contact the provider. 

For those taking opioids for a shorter duration, a 10% decrease of the original dose per week or slower until close to 30% of the initial amount is reached, followed by a weekly reduction of roughly 10% of the remaining dose) is less likely to trigger withdrawal. Tapers of 10% per month or less are better tolerated than rapidly tapering off when patients have been taking opioids for a longer duration (e.g., for a year or longer).  

Significant opioid withdrawal symptoms can indicate the need to slow the taper rate further. Short-term medications might also help manage withdrawal symptoms. Providers should follow up frequently (at least monthly) with patients engaging in opioid tapering. 

Close monitoring is required for patients who cannot taper and that continue on high-doses or otherwise high-risk opioid regimens and should work with patients to mitigate overdose risk. Some patients with unanticipated challenges to tapering may need to be evaluated for OUD. 

The third section focuses on the duration of opioid therapy and routine patient follow-up. 

 

Recommendation #6 - Prescribing no greater quantity than needed for the expected duration of severe pain requiring opioids (1) 

A few days or less is often the length that opioids are used for common causes of nonsurgical acute pain. Many states have passed legislation that limits initial opioid prescriptions for acute pain to less than seven days. Many insurers and pharmacies have enacted similar policies. Providers should generally avoid prescribing additional opioids to patients if pain continues longer than expected. 

Providers should prescribe and advise opioid use only as needed rather than on a scheduled basis (e.g., one tablet every 4 hours). Limiting the duration of therapy can decrease the need to taper. However, tapering may need to be considered if patients take these medications around the clock for more than a few days.  

Longer durations of therapy may be needed when the injury is expected to result in prolonged severe pain (e.g., greater than seven days for severe traumatic injuries). Patients should be evaluated at least every two weeks if they are receiving opioids for acute pain. Suppose opioids are continued for a month or longer. In that case, providers should address potentially reversible causes of chronic pain so that the length of therapy does not continue to extend. 

 

Recommendation #7 - Evaluate the benefits and harms of opioid therapy regularly (1) 

The benefits and risks for Evaluating benefits and risks within 1-4 weeks of starting long-term opioid therapy for subacute and chronic pain should be evaluated within 1-4 weeks of initiating therapy and after dosage increases.  

The evaluation should include patient perspectives on progress and challenges in moving toward treatment goals, including sustained improvement in pain and function. The Three-item Pain, Enjoyment of Life, and General Activity (PEG) assessment scale could be utilized to help determine patient progress. 

Providers should also ask patients about common adverse effects, such as constipation and drowsiness, and assess for outcomes that might be early warning signs for more serious problems such as overdose or OUD.  

Patient re-evaluation should occur after therapy begins (about two weeks) when ER/LA opioids are prescribed if the total daily opioid dosage is greater than or equal to 50 MME/day or if there is a concurrent benzodiazepine prescription. These individuals are at a higher risk for overdose. Follow-up for individuals starting or increasing the dosage of methadone is recommended every 2-3 days for the first week. Providers should reassess all patients receiving long-term opioid therapy at least every three months. 

The last section of recommendations covers patients at risk for OUD and overdose.  

 

Recommendation #8 - Use strategies to mitigate risk by evaluating risk for opioid-related harms, discussing risk with patients, and incorporating risk reduction strategies into the treatment plan (1). 

The patient's habits (including alcohol and illicit drug use) and behavioral and mental health must be considered. Patients with a history of substance use disorders, depression, and/or mental health disorders have a higher risk of overdose and OUD. Even though the dangers of opioid therapy are higher with these patients, they may still require opioid treatment for pain management.  

Psychological distress can interfere with improvement of pain and/or function in patients experiencing chronic pain; using tools like the Generalized Anxiety Disorder (GAD)-7 and the Patient Health Questionnaire (PHQ-9 or PHQ-4) to assess for anxiety, post-traumatic stress disorder (PTSD), and depression might help providers improve overall pain treatment outcomes. They should also ensure that treatment for depression and other mental health conditions is effective, consulting with behavioral health specialists when needed. 

Additionally, providers should: 

  • Educate on the risks for overdose when opioids are combined with other drugs or alcohol.  
  • Use caution when prescribing opioids for people with sleep-disordered breathing due to their increased risk for respiratory depression. The provider may ascertain if a patient is compliant with prescribed CPAP.  
  • Use caution and increased monitoring for patients with renal or hepatic insufficiency. 
  • Use caution and increased monitoring for patients aged 65 years or older.  
  • Offering naloxone when prescribing opioids, particularly to patients at increased risk for overdose. 

 

If patients experience a nonfatal opioid overdose, providers should evaluate for OUD. Providers should reduce opioid dosage and discontinue opioids when indicated and continue monitoring and support for patients prescribed or not prescribed opioids. 

 

Recommendation #9 - Reviewing Prescription Drug Monitoring Program (PDMP) data (1). 

Providers should review PDMP data specifically for prescription opioids, benzodiazepines, and other controlled medications patients have received from additional prescribers to determine all the opioids the patient could potentially receive.  

Patients with multiple prescriptions and from various providers are at an increased risk for overdose or OUD. PDMP data should be reviewed before initial drugs for subacute or chronic pain and at least every three months during long-term opioid therapy. 

 

Recommendation # 10 - Considering the benefits and risks of [urine] toxicology testing.  

Toxicology testing should be used to inform and improve patient care. Providers, practices, and health systems should minimize bias in testing and not test based on assumptions about different patients. 

 

Recommendation # 11 - Use caution when prescribing opioid pain medication and other medications concurrently (1). 

Benzodiazepines and opioids can cause CNS depression and potentiate opioid-induced decreases in respiratory drive. Because other CNS depressants can potentiate respiratory depression associated with opioids, benefits vs. risks should be considered. 

 

Recommendation # 12 - Offering or arranging treatment for OUD if needed (1). 

Includes referring a patient to a specific treatment center where behavior therapy and medications may be prescribed.

Quiz Questions

Self Quiz

Ask yourself...

  1. How often do you have patients exhibiting symptoms of OUD in your practice setting?  
  2. What would your next steps be if you identify a patient with potential OUD (e.g., additional screening, referral, or treatment plans)? 
  3. Have you noticed any trends in patients presenting with OUD? Such as socioeconomic status, occupation, gender, race, and medical diagnosis. 
  4. Do you know how to determine if a patient is engaging in opioid-seeking behaviors? 

Prescription Drug Monitoring Programs (PDMP) and Electronic Prescribing 

PDMP is a database that keeps track of controlled substance prescriptions. They help improve opioid prescribing, inform clinical practice, and protect at-risk patients. A pharmacist must enter controlled substances into the state PDMP when dispensing them. When the pharmacist enters this data, it may occur at various intervals, from 1 month, daily, or even "real-time." However, a PDMP is only helpful if providers check the system before prescribing (10).  

Some states have implemented legislation that requires providers to check a state PDMP before prescribing certain controlled substances and in certain circumstances. Most current mandates require that all prescribers query PDMPs when prescribing any opioid.  

Some states require prescribers to query PDMPs every time a controlled substance is prescribed, while others require a query only for the initial prescription. Subsequent checks of PDMPs also vary from every time a drug is issued to specific intervals (e.g., every 90 days, twice a year, annually) should prescribing continue. Some mandates have categorical requirements, e.g., a query must be made if the prescription is over a three-day or seven-day supply or if a certain prescribed level of MME is exceeded.  

Other states' mandates are based on subjective criteria, e.g., a prescriber's judgment of possible inappropriate use or the prescriber's discretion regarding whether to query the PDMP. Finally, some states mandate that only prescribers in opioid treatment programs, workers' compensation programs, or pain clinics must query PDMPs (10, 11).  

In addition to PDMPs, there has been an increase in requirements for providers to utilize Electronic Prescribing for Controlled Substances (ECPS). Electronic prescribing programs for both providers and pharmacies must meet DEA requirements. The DEA's March 31, 2010, conditions were updated on July 27, 2023 (12).  

On January 1, 2023, CMS implemented additional requirements for controlled substances for recipients of Medicare Part D. There are over 51 million U.S. people enrolled in Medicare Part D (Center for Medicare Advocacy, 2023). In addition to state laws, these rules require that prescribers e-prescribe at least 70 percent of controlled substances for patients that have Medicare Part D. A waiver may be approved if the prescriber cannot conduct electronic prescribing due to circumstances beyond the provider's control (12).  

Starting June 27, 2023, the 'Consolidated Appropriations Act of 2023' requires new or renewing Drug Enforcement Administration (DEA) registrants, to have at least one of the following: 

  • A total of eight hours of training from specific organizations on opioid or other substance use disorders. 
  • Board certification in addiction medicine or addiction psychiatry from the American Board of Medical Specialties, American Board of Addiction Medicine, or the American Osteopathic Association. 
  • Graduation within five years and status in good standing from medical, advanced practice nursing, or physician assistant school in the U.S. that included an opioid or other substance use disorder curriculum of at least eight hours (11,12).  

Providers must follow either state law or DEA/CMS regulations, whichever is more stringent. The following map indicates various rules in each state, which will continue to change when new legislation is enacted (11,12).  

 

(11) 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the laws in your state about PDMP and EPCS?  
  2. What references can you refer to find out prescribing laws in your state? 
  3. Is the use of PDMP a common practice in your workplace? 

Opioid Storage and Disposal 

Prescription opioids need to be stored securely. It may include the necessity of keeping them in a locked area. This is especially true if children, teens, and other visitors in the house may be aware of their presence.  

Teens and young adults are the biggest misusers of prescription pain medication. In 2018, over 695,000 youths ages 12–17 and 1.9 million young adults ages 18–25 reported misusing prescription pain medication in the past year. Young people may misuse prescription opioids for many reasons, including curiosity, peer pressure, and wanting to fit in. Another reason teens and young adults may decide to take prescription opioids is because they can be easier to get than other drugs.  

Studies show that 53% percent of people over 12 who obtained prescription pain medication for non-medical use received them from a friend or relative (13).  

Patients should be advised on how to get rid of unused or expired medications. The best option is to immediately take them to a drug take-back site, location, or program. These sites or programs can be found online, or the pharmacist may have information.  

If it is not feasible for the patient to get rid of the drug using a take-back program, the patient should be advised to check if it is on the FDA flush list. If it is, the medication should be flushed down the toilet. Again, the list of drugs is available on the FDA website. If it is not on that list, it should be discarded in the trash at home.  

Patients should follow the following instructions: Mix medicines (liquid or pills; do not crush tablets or capsules) with an unappealing substance such as dirt, cat litter, or used coffee grounds. Next, place the mixture in a container such as a sealed plastic bag; then throw away the container in your trash at home. Last, the patient should remove or permanently cover all personal information on the prescription label of empty medicine bottles or packaging, then trash or recycle the open container (14).  

Quiz Questions

Self Quiz

Ask yourself...

  1. Do you often teach your patients about the safe storage and disposal of opioids? If not, what are some barriers to providing this education? How could you overcome these barriers? 
  2. Your patient asks if they can give the leftover pills to their spouse, who has back pain; what would be an appropriate response? 
  3. The patient replies that it is the same medication their spouse has been prescribed and doesn't understand why they can't share it; what education will you provide? 

OUD Treatment 

Treatment for OUD is multi-faceted and typically includes both mental health components and FDA-approved OUD treatment medications. Mental health components may consist of counseling or a structured treatment program. Cognitive behavioral therapy (CBT) may also be beneficial.  

A potential barrier to OUD treatment, on the provider's and patient's behalf, is the perception that patients must engage in counseling to start or continue receiving OUD treatment medication. While the mental health components are essential, there may be barriers for patients to begin mental health treatment programs, which include expense, travel, and available openings within the programs.  

Medication therapy may be a helpful start for these patients (9). FDA-approved medications indicated for the treatment of OUD include methadone, buprenorphine, and naltrexone. Suboxone is a combination drug composed of buprenorphine and naltrexone.  

Medication has several advantages as part of the OUD treatment plan:  

  • Help the individual to remain safe and comfortable during detox. 
  • Reduce or eliminate cravings for opioids. 
  • Minimize relapse since the individual is not experiencing uncomfortable withdrawal symptoms. 
  • Allow the individual to focus on therapy without being distracted by withdrawal symptoms and cravings. 
  • Increase safety in cases of overdose.  

 

 

 

Methadone 

Methadone is a fully agonistic opioid. It is a Schedule II controlled medication. It can be prescribed purely for the treatment of pain, as well as for OUD. Methadone treatment for OUD can only be provided through a Substance Abuse and Mental Health Services (SAMHSA)-certified opioid treatment program.  

Patients taking methadone to treat OUD must receive the medication under the supervision of a clinician. After consistent compliance, patients may take methadone at home between program visits. The length of methadone treatment should be a minimum of 12 months. Methadone doses are often adjusted and readjusted. Methadone is slowly excreted, and there is overdose potential if not taken as prescribed (9).  

 

Buprenorphine 

Buprenorphine is a partial agonist opioid. Buprenorphine can be prescribed by any provider with a current, standard DEA registration as a Schedule III Controlled Substance. Like opioids, it produces effects such as euphoria or respiratory depression. With buprenorphine, however, these effects are weaker than those of full opioids such as heroin and methadone. It also has unique pharmacological properties that help lower the potential for misuse and diminish the effects of physical dependency opioids, such as withdrawal symptoms and cravings (9). 

Subutex was a brand-name version of buprenorphine, discontinued in 2011 after new formulations that were less likely to be abused were developed.  

 

Naltrexone 

Naltrexone is an opioid antagonist. It is not addictive and does not cause withdrawal symptoms. It blocks the euphoric and sedative effects of opioids by binding and blocking opioid receptors and reduces and suppresses opioid cravings.  

There is no abuse and diversion potential. Naltrexone can be prescribed in any setting. It can be taken as a pill or once monthly extended-release intramuscular injection (9).  

 

It was estimated 2021 that of the 2.5 million people with OUD, only 36% received any treatment, and only 22% received medications. A part of the July 27, 2023, Consolidated Appropriations Act amended the Controlled Substances Act to eliminate the requirement that providers obtain a specific waiver (a DATA waiver) to prescribe buprenorphine (including Suboxone) to treat opioid use disorder, known as the X-waiver.  

Additionally, there are no longer any caps on the number of patients a practitioner can treat. This, however, does not change the requirements for methadone treatment (15).  

Quiz Questions

Self Quiz

Ask yourself...

  1. Will the recent DEA changes enhance your ability to treat patients with OUD?  
  2. What are some other barriers to identifying and treating patients with OUD? 

Nursing Considerations 

 

What Is the Nurses' Role in Opioid Patient Education and Opioid Medication Management? 

Nurses remain the most trusted profession for a reason, and APRNs are often pillars of patient care in several health care settings. Patients turn to nurses for guidance, education, and support.  

While there are no specific guidelines for the nurses' role in opioid education and management, here are some suggestions to provide quality care for patients currently taking opioid medications. 

 

  • Take a detailed health history. Often times, pain, and mental health, can be dismissed and overlooked in health care settings. If a patient is complaining of symptoms that could be related to pain, inquire more about that complaint. Ask about how long the symptoms have lasted, what treatments have been tried, if these symptoms interfere with their quality of life, and if anything alleviates any of these symptoms.  

If you feel like a patient's complaint is not being taken seriously by other health care professionals, advocate for that patient to the best of your abilities. A detailed pain assessment and history can provide context for opioid pain management and a patient's plan of care. When taking a health history, ask about any prior surgeries, major life stressors in the past year, or any prior opioid usage.  

  • Review medication history at every encounter. Often times, in busy clinical settings, reviewing health records can be overwhelming. Millions of people take pain medications, including opioids, for various reasons. Ask patients how they are feeling on the medication, if their symptoms are improving, if there are any changes to medication history, if they use any other substances other than prescribed medications, such as alcohol, tobacco, or other drug use.  

Remember, prescription medications are not the only medications people take. Confirm medication route, dosage, frequency, and all the details to make sure you and the patient are on the same page and to avoid medication errors and complications.  

  • Be willing to answer questions about pain, mental health, and opioid medication options. Society stigmatizes open discussions of prescription medication and pain. Sometimes, people are afraid of asking for pain medication for perception of being a "drug seeking" patient without having their pain concerns addressed. Other times, there are patients who might have OUD and continuously ask for an increased number of opioid medications.  

Be willing to be honest with yourself about your comfort level discussing topics and providing education on opioid medications, drug interactions, and pain management.  

  • Communicate the care plan to other staff involved for continuity of care. For several patients, especially for patients with chronic pain or who use opioids long-term, care often involves a team of mental health professionals, physical therapists, nurses, specialists, pharmacies, and more. Ensure that patients' records are up to date for ease in record sharing and continuity of care and to reduce the incidence of opioid medication errors. 
  • Stay up to date on continuing education related to opioid medications, pain management, and prescribing regulations. Evidence-based information and scope of practice is always evolving and changing. You can then present your new learnings and findings to other health care professionals and educate your patients with the latest information.  

You can learn more about the latest research on pain management medications, non-pharmacological pain management options, and opioids by following updates from evidence-based organizations, such as the Centers for Disease Control and Prevention (CDC) or your local health department.  

 

 

 

How can nurses identify if someone is in pain?  

Unfortunately, it is not possible to look at someone with the naked eye and determine if they are in pain. Sometimes, a patient in pain will be very obvious with visible lacerations and need pain management options, such as opioids. Other times, pain management is often done as a result by taking a complete health history, listening to patient's concerns, completing a pain assessment, and offering testing to determine the cause of pain. 

 

How can nurses identify if someone has OUD? 

Unfortunately, it is not possible to look at someone with the naked eye and determine if they have OUD. Sometimes, a patient in pain will be very obvious with visible withdrawal symptoms, such as asking for more opioid medications or discussing symptoms of OUD. Often times, OUD is diagnosed and recognized as a result by taking a complete health history, listening to patient's concerns, and offering testing to determine the cause of pain. Remember, anyone can have OUD, and no two OUD patients appear the same.  

 

What should patients know about opioid medication?  

Patients should know that anyone has the possibility of experiencing side effects on opioid medications, just like any other medication. Patients should be aware that if they notice any changes in their breathing, changes in their heart rate, or feel like something is a concern, they should seek medical care.  

Because of the social stigma associated with opioids and pain management, people are hesitant to seek medical care because of fear, shame, and embarrassment. However, as more research and social movements discuss opioid use, there is more space and awareness for opioid education and opioid overdose prevention.  

Nurses should also teach patients to advocate for their own health in order to avoid possible opioid complications or not have their pain be poorly managed.  

 

Here are important tips for patient education in the inpatient or outpatient setting:  

  • Tell the health care provider of any existing medical conditions or concerns (need to identify risk factors) 
  • Tell the health care provider of any existing lifestyle concerns, such as alcohol use, other drug use, sleeping habits, diet, menstrual cycle changes (need to identify lifestyle factors that can influence opioid use and pain management) 
  • Tell the health care provider of any prior experiences with opioid medication (if applicable) and any medication reactions or side-effects you remember (need to identify risk factors, address pain management appropriately, identify any allergies, and avoid possible opioid overdose symptoms) 
  • Tell the health care provider if you have any changes in your breathing, bodily functions, or heart rate (potential opioid overdose symptoms) 
  • Tell the nurse of health care provider if you experience any pain that increasingly becomes more severe or interferes with your quality of life 
  • Keep track of your pain, overall health, medication use, and health concerns via an app, diary, or journal (self-monitoring for any changes) 
  • Tell the health care provider right away if you are having thoughts of hurting yourself or others (possible increased risk of suicidality and public safety concerns) 
  • Take all prescribed medications as indicated and ask questions about medications and possible other treatment options, such as non-pharmacological options or surgeries 
  • Tell the health care provider if you notice any changes while taking medications or on other treatments to manage your pain (potential worsening or improving health situation) 
Quiz Questions

Self Quiz

Ask yourself...

  1. What are some problems that can occur if opioid medications are not managing pain adequately?  
  2. What are some possible ways you can obtain a detailed, patient centric health history? 
  3. What are some possible ways APRNs can educate patients on pain and opioid medication options? 

Research Findings 

 

What Research on Opioid Medication Exists Presently? 

There is extensive publicly available literature on opioids medications via the National Institutes of Health and other evidence-based journals.  

 

What are some ways for people who take opioids to become a part of research? 

If a patient is interested in participating in clinical trial research, they can seek more information on clinical trials from local universities and health care organizations. 

Quiz Questions

Self Quiz

Ask yourself...

What are some reasons someone would want to enroll in clinical trials? 

New Jersey Safe Prescribing for Opioids for APRNs 

 

APRNs in New Jersey can obtain prescriptive authority for controlled substances from the New Jersey Division of Consumer Affairs' Drug Control Unit. APRNs need to obtain federal Drug Enforcement Agency (DEA) controlled substance registration and then apply for a New Jersey Controlled Drug Substance (CDS) registration (16, 17).  

N.J. Admin. Code § 13:37-7.9 provides an overview for the prescriptive practice of APRNs (18). Questions regarding the scope of practice for APRNs and controlled substances can be addressed to the New Jersey Division of Consumer Affairs directly (17).  

 

Conclusion 

Even providers who do not prescribe opioids should be familiar with the effects of opioids and OUD due to its high prevalence in the United States. Understanding the types of pain, how pain occurs, and how it impacts a person's quality of life is especially important. There is still an associated stigma among patients who use Opioids to treat chronic pain conditions. It is essential to recognize that there are times when opioid use is appropriate, as long as the provider practices the recommended guidelines and sound clinical judgment.  

Quiz Questions

Self Quiz

Ask yourself...

What other measures would help decrease the opioid epidemic in the United States?

Case Study #1:  

Patient Name: John Henderson 

Gender: Male 

Age: 60 

Height: 6' 1" 

Weight: 190 lbs. 

John arrives at the primary care office after work for a routine office visit. He is employed as a grocery store manager. He reports he does not use tobacco and has never used tobacco. He reports that he drinks alcohol a few times a week and reports no illicit drug use. He has hypertension and high cholesterol and takes Losartan 50mg daily and Atorvastatin 20 mg daily. He reports that he does not have a blood pressure monitor, but sometimes checks his blood pressure after work at the grocery store pharmacy.  

This patient presents to a primary care office with pain and stiffness in the right shoulder joint, which has progressively worsened for six months following rotator cuff surgery. He states his pain is unchanged, and he has a limited range of motion in the right shoulder that is getting worse. Now, for the past few weeks, the pain has started to interfere with his ability to do his job. He said he went to physical therapy for a few weeks after his surgery, but admitted he did not often complete the home exercise program regimen. An MRI was obtained and showed he had adhesive capsulitis. 

Quiz Questions

Self Quiz

Ask yourself...

  • What are some specific questions you'd want to ask about shoulder pain? 
  • What is some health history questions you'd want to highlight? 
  • What lab work or testing would you suggest performing?  
  • What are some assessments you can do in-office to check his shoulder's range of motion?

When you assessed his right shoulder compared to the left shoulder, there was a noticeable difference between the two. John was also visibly in pain after the right shoulder assessment.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some non-pharmacological interventions you can do for John's shoulder? 
  2. What pain assessments would you perform on John? 

After assessing John's shoulder and completing a few pain assessments, John asked about opioids. John is interested in learning more, but he states he "doesn't wany any crazy side effects because of my work and family life." He states that he also doesn't want "to end up a junkie on drugs" and wants to know if he can drink alcohol still and take his other medications while on opioids. John also wants to know if he will have to take opioids forever like the other medications he's taking.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are opioid-drug interactions to consider with John's existing medication history and alcohol use? 
  2. What are some possible side effects of opioids?  
  3. What are some possible long-term effects of chronic opioid use?  
  4. What are some interventions to consider prior to prescribing opioids?

Given the patient's diagnosis, non-opioid therapy options include nonsteroidal anti-inflammatory drugs, intraarticular glucocorticoid injections, steroid injections into the shoulder joint, range of motion exercises, physical therapy, and consulting with an orthopedic specialist who may recommend a joint manipulation under anesthesia. Each of these should be considered before opioid therapy.  

 

Case Study #2:  

Patient Name: Pilar Aguilar 

Age: 40 

Height: 5' 1" 

Weight: 135 lbs. 

She reports that she does not smoke, drink alcohol, or take illicit substances. She reports experiencing a hip injury following a car accident three years ago and developed chronic post-traumatic arthritis in the hip. After a total hip arthroplasty, she was diagnosed with heterotopic ossification (HO).  

For the past year, she has been taking 20 mg of oxycodone twice daily to manage chronic hip pain after unsuccessful non-opioid therapies. She has three children with no known pregnancy or postpartum complications. She previously worked part-time as an administrative assistant but has been off work since a car accident three years ago. She has PTSD related to this car accident. She has been prescribed Xanax 0.5mg up to three times daily for anxiety. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some specific questions you'd want to ask about hip arthritis? 
  2. What are health history questions you'd want to highlight? 
  3. What lab work or testing would you suggest performing?  

The patient was present at an urgent care clinic today, complaining of a severe migraine, which started yesterday. She stated she needed to take more of her oxycodone to deal with the pain and because she could not sleep last night. She is concerned because she is running out of pills. She said her primary care doctor's office was closed, so she came to the urgent care. The following strategies would be an appropriate course of action for this patient:

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some non-pharmacological interventions you can do for Pilar's pain? 
  2. What are some questions you'd want to ask about her migraine? 
  3. What are some possible side effects of opioid use would you discuss with her? 

Here are some things to consider for Case Study #2: 

  • Discuss concerns with the patient. This includes taking the opioid more often than prescribed, potential problems with respiratory depression, and overdose.  
  • Recommend trying eletriptan or dihydroergotamine nasal spray first rather than additional opioids. 
  • Review the PDMP to see the prescription history for this patient. Attempt to contact the primary care provider to develop a plan of care. 
  • Consider conducting toxicology testing 
  • Consider offering naloxone  
  • Use the DSM-5 criteria to assess the presence (and severity) of OUD or arrange an assessment with a substance use disorder specialist. Offer treatment for OUD if it is confirmed. 

 

Case Study #3 

Sabrina is a 16-year-old Black high school student working as a waitress at a local restaurant. She arrives at the local pediatric emergency room after her shift with her mom because she thinks she is experiencing a sickle cell crisis.  

Sabrina reports that she has these crises every few months, and this is probably the third time she's been in this much pain. She reports being at this ER last year for something similar. Her mother is there completing paperwork and would like Sabrina to get some pain medication as well.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some specific questions you would want to ask about her health? 
  2. What are health history questions you would want to highlight? 
  3. What lab work or testing would you suggest performing?  
  4. What pain assessments would you perform on Sabrina? 

Sabrina agrees to provide bloodwork, complete imaging, and be admitted. She said that no health care provider talked to her about how painful sickle cell crises can be, and she doesn't routinely take pain medication because she "doesn't want to be addicted." Sabrina and her mom heard about pain management options for these extremely painful episodes from social media and the Internet and would like Sabrina to get her pain controlled. Sabrina said that she had some opioid last time she was in the ER, but she doesn't remember the name. Her mom doesn't remember the name either, but she remembers it was in an IV.

Quiz Questions

Self Quiz

Ask yourself...

  1. How would you discuss Sabrina's pain management concerns? 
  2. Given Sabrina's age, medical history, and prior history of opioid use, what medication options would be appropriate for a sickle cell crisis in an adolescent?  

Sabrina has been in the pediatric ER for over a day receiving IV hydromorphone. She reports some relief, but Sabrina and her mom are concerned. Sabrina wants to live her life like a normal teenager without being in the hospital every few months for pain.  

Her mom asks if there is a way to have pain medication at home. Both Sabrina and her mom would like to know if there is anything that can be done to help with the pain outside of medications as well. Sabrina doesn't want to use pain medications daily but wants to have them at home just in case she can't get to the hospital.  

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Knowing Sabrina's concerns, what are some possible non-pharmacological pain management options? 
  2. Knowing Sabrina's health history, what would be some patient education talking points about at-home opioid medications and possible side effects?  
  3. What are some possible consequences of leaving pain improperly managed?  

End of Life Process

Introduction   

Have you ever cared for someone who was dying, known someone who was in hospice, or just wondered what happens as we die? What exactly does “end of life” refer to? End of life is a broad term, and its meaning can vary from person to person. End of life is a time when death is approaching, usually in a matter of days.

This occurs in various patients experiencing a variety of ailments including end stage cancer, dementia, chronic diseases, and someone who may have organ failure after an accident (3). 

Oftentimes, caregivers have little to no experience in caring for a patient experiencing the end-of-life process and can easily find themselves feeling overwhelmed, confused, and burned out. Understanding what to expect during the final weeks and days of life is imperative to cope with the changes as they occur.

These changes can vary from person to person. Although patients progress through the end-of-life process differently, there is usually a recognizable pattern of decline that occurs. To provide the best possible care and prepare both the dying patient and their family members, it is important for the nurse and caregiver to be able to distinguish the phases of the end-of-life process: transitioning, actively dying, and final moments. 

 

Transitioning

The transitioning phase, otherwise identified as the pre-active phase, usually signals that a person is approaching the last two-to-three weeks of their life. During this time, caregivers might start to notice obvious changes, an increase in sleeping, for example. A transitioning person can sleep upwards of twenty hours per day. This significant increase is part of an overarching decrease in the patient engaging with the world and day-to-day life.  

Beyond sleeping, examples of this disengagement include interacting less with friends and family, less desire to do one’s usual activities, and a lack of interest in things that were once pleasurable. Additional signs of a patient transitioning include increased weakness and decreased mobility.  

These changes typically include a decline in function, becoming non-ambulatory, chairbound, and ultimately, bedbound. Patients may begin to fall during this time. Progressively, the patient will become more dependent on their caregivers to assist them with activities of daily living (ADL), which include bathing, eating, transferring, toileting, and continence. They will likely become bedbound. 

Another indicator that someone may be transitioning is a change in nutrition and intake. Eating and drinking less is an expected part of decline during this time. Many patients will report a lack of appetite, taste changes, and an overall lack of interest in food and liquids. Changes in swallowing may further complicate a person’s ability to eat and drink. 

It is not uncommon to downgrade a person’s diet during the transition phase. This might include going from a regular diet, down to soft, and finally, to pureed. Liquids are usually given in small amounts and with an added thickener. These changes are necessary to prevent choking and aspiration. Fluid overload is a risk at this point and can detract from one’s comfort, cause swelling, or crackles in the lungs. 

“Approximately 43% of all palliative patients are affected by terminal agitation, which can manifest as restlessness, sweating and patients’ statements as verbal or facial expressions and defensive reactions” (5).  

Increased agitation, anxiety, and restlessness may also arise during the transitioning phase. Terminal agitation and terminal restlessness are both unique to the last week or so of someone’s life and are often caused by physiological changes that occur during the end-of-life process but can also be a result of medication or emotional changes. Even if the patient had been calm previously, it is important to note that these symptoms may still occur.  

Signs of terminal agitation include an inability to remain still, picking at items in the surrounding environment, and increased confusion. Fortunately, there are medications that can be given at the end of life to promote comfort and stop these symptoms when they arise. Lastly, it is not uncommon for the transitioning patient to have visions of and talk to deceased friends and family – both are normal and could sometimes be interpreted as a welcoming sign from loved ones. 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. How long does the transitioning phase typically last? 
  2. What is another name for the transitioning phase? 
  3. How do people change while transitioning? 
  4. What are some ways you could care for someone that is transitioning? 

Active Dying

Following the transition phase, most patients will then enter the final phase of the end-of-life process, the active dying period. This precedes imminent death. It can be hard to determine precisely when this stage begins. This phase usually lasts only two to three days and showcases significant signs of patient decline that differ from the previous phase, including a decrease in alertness and responsiveness.

For example, a patient may go from a semi-comatose state to comatose or obtunded and minimal reaction should be expected (1). Their eyes may be open or shut, and there is little movement in all extremities. This period can be described as a deep sleep. 

Caregivers often describe it as a time of waiting. Cognitive changes, in combination with the previous changes in swallowing, make the intake of food, liquids, and medications unsafe. The patient is at high risk for aspiration. Mouth swabs can be used to hydrate the oral cavity and to do mouth care.

Medications that are liquid or can dissolve under the tongue are safe and can be used to manage symptoms at the end of life. Hospice patients are provided a comfort kit of medications to use should symptoms arise.  

Additionally, changes in vitals are expected during this phase, and they typically do not cause the patient any discomfort. For example, temperature fluctuation is common at the end of life. It is not abnormal to have an elevated temperature during the active dying phase. This can be remedied with cooling measures such as a cool towel on the forehead or a fan to cool down the room. The skin may feel clammy as well.  

Following, changes in blood pressure and heart rate may also occur. Blood pressure begins to trend lower during the pre-active phase and can become very low during the last few days of life. The heart rate will usually trend upward and can be well over 100 beats per minute, however, this is just something for the hospice nurse to note and is not usually treated.  

Symptom management at the end of life can be difficult. Failure to adequately control symptoms can have a negative impact on one’s quality of life. These symptoms may include pain, respiratory distress, GI issues, and mobility changes (2).  Pain while dying is one of the most common areas of concern for someone who is actively dying, and of course, no one wants to see their loved one in pain during their final days of life. The body becomes very sensitive to the slightest movement or touch, which can present challenges for caregivers when considering that the patient still needs to be cleaned, changed, and repositioned.  

When the patient is no longer verbalizing their comfort, verbal pain cues must be assessed. These include grimacing, a furrowed brow, frowning, and possibly moaning. In some cases, repositioning can be an effective pain-relieving measure. Thankfully, pain can be treated up until death occurs.

Opioids are commonly used in end-of-life care, due to their ability to effectively manage pain without hastening death. Morphine is an example of a commonly used opioid (4). Nonpharmacological measures can also be used to relieve pain. This may include things like repositioning and soothing music. 

Decreased urination is also common during the active dying phase. This is completely normal and expected. Caregivers may find that they do not need to change diapers as often. Urine may also appear darker in color, appearing a deep amber color due to more concentrated urine. 

Excessive secretions can lead to something commonly known as the “death rattle.” This term is almost synonymous with the last days of life. It can be described as a moist sound that is audible when someone breathes and is a good indicator that death is near. The secretions collect in the throat due to a lack of coughing and the inability to clear them out (8).

Turning the patient on his or her side may help the secretions drain, and there are medications that can be administered to help dry them out. It is important to note that not everyone will experience this, and by the time it occurs, there is a disconnect within the patient, and he or she is not likely to experience any discomfort. 

Maintaining skin integrity and preventing pressure injuries is also an important consideration during this time. With all the other previously mentioned changes occurring, it can be hard to provide the attention that the skin requires. Like other organs, the skin begins to fail in an actively dying patient (9).

This does not necessarily mean that pressure injuries and skin breakdown are inevitable. It is important to consider goals of care during this time. An aggressive approach to preventing skin breakdown might not be what the patient wants or necessarily needs. Measures for pressure injury prevention might include repositioning, use of pillows for elevation, hygiene, and moisture management. 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. How long does the active dying phase usually last? 
  2. How is active dying different from transitioning? 
  3. What are some commonly experienced changes during this time> 
  4. Have you cared for someone during this time? What did you find to be most challenging? 

Final Moments

It can be hard to imagine the final moments of someone’s life. This is especially true for caregivers and families who have witnessed steady decline throughout both stages of dying. There are likely to be signs that death is possible at any moment. A patient can be expected to be comatose with little to no response when death is imminent. The obtunded patient appears to be in a deep sleep. They are no longer verbally or physically responsive to voice or tactile stimulation.  

In addition to changes in vitals described previously, changes in respiration usually occur. This is typically the most obvious change. Patterns can vary from shallow and fast to deep and slow. Periods of apnea are also normal. Cheyne-stokes breathing may also be present (3). 

 Skin changes are also expected; pallor, cyanosis, and mottling are signs that death is near. The body may begin to feel cool, especially in the hands and feet. Comfort medications can still safely be used up until death occurs. As mentioned before, foods and liquids should not be given at this point. Caregivers should continue to talk to the patient, as their hearing will remain until the end. 

Hospice 

Most people wish to die peacefully at home. Unfortunately, for many, this is not the case. Over 30% of people die in a hospital setting (6). Hospice is a form of palliative care and involves caring for the terminally ill as they begin the end-of-life process. A terminally ill patient has a life expectancy of 6 months or less. This is a comfort focused approach to care. The natural process of dying is accepted and allowed to proceed.  

No life prolonging treatments or procedures are elected.  Choosing a hospice allows both patients and their caregivers to achieve their end-of-life care goals. Hospice care includes an interdisciplinary team composed of nurses, physicians, aides, chaplains, and social workers. It includes symptom management, and emotional and spiritual support. There is also a bereavement team that is available after death. Medicare part A covers hospice services nearly completely. 

Hospice care can be a short or long journey, with many ups and downs. For some, the prognosis might be obvious, but for others, it might be filled with many questions and much uncertainty. The benefits of hospice care are proven and can lead to a peaceful death. “The main care focus for patients is symptom management, which improves the quality of the remainder of their life.  

Palliative care involves not only the patient but also their family members. Other measures are also taken so that the patients can live life comfortably and maintain dignity” (7).  Both caregivers and patients seek to understand what end of life care entails and how to maintain comfort at end of life. Hospice clinicians should spend time providing education on this process to all of those involved. 

Spiritual Considerations at End of Life 

Taking care of the dying should be looked at from a holistic point of view. Addressing the physical needs of someone who is dying while ignoring any spiritual needs would be doing a disservice. Spirituality is considered the meaning of life. It may include religion, beliefs, or family traditions. It can mean different things to different people.  

During end-of-life care, it has been shown to be disrupted in patients. Spiritual needs tend to be greater at the end of life.  It is also frequently overlooked by healthcare professionals (10). Palliative care workers can help address spiritual needs in their patients by showing compassion, humility, and openness.  

Dying patients may be conflicted spiritually due to things like guilt and unresolved issues. When spirituality is addressed appropriately, patients can more positively cope with illness. Caregivers of the dying should be aware of the relationship between a terminal prognosis and unmet spiritual needs.  

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you been present when someone died? How did it make you feel to witness this? 
  2. What are signs that death is imminent? 
  3. How do respirations change just prior to death? 
  4. What education would you provide to a caregiver during this time? 

Conclusion

Hopefully, this has been an informative piece and a guide on what to expect during end-of-life care. No two people experience death and dying in the same manner, and it can be challenging both physically and emotionally during the end of life. Proper symptom management during this time is crucial in ensuring that one dies comfortably. One should also consider any unmet spiritual needs and how, if unaddressed, could lead to poor patient outcomes.  

Palliative care at the end of life can be a great help for caregivers.   Hospice can be a great resource in managing symptoms and providing support up until death and beyond.  Most people do not have experience in caring for a dying person and need education and assistance throughout the journey. Not everyone who is dying will experience all the symptoms mentioned in this course, and it is important to note that everyone experiences the end-of-life process in their own way and at their own pace. 

Navigating Difficult End of Life Conversations

Introduction   

Talking about death is generally difficult for the average person. It is even considered taboo in some cultures or situations.  For some nurses, having end of life conversations is a routine part of the profession. A hospice nurse, for example, carries the responsibility of managing care for a dying patient, and ultimately informing the patient’s family that death is imminent.

A lack of training, experience, or confidence in this area could result in poor delivery, unrealistic expectations, and an overall negative dying experience. Most people do not have experience or even a baseline when it comes to death and dying. This makes end of life conversations much more important in the delivery of patient care.  

Perspectives About Dying and Death (Philosophical, Psychological, and Spiritual) 

Philosophical 

The human experience of death and dying is not one sided. On the contrary, there are many things to be considered to understand it fully. This goes beyond a scientific approach. An understanding of philosophical reasoning related to death is imperative to provide a thorough explication of the human dying experience. Historically, death has been an intrinsic part of life throughout various civilizations. 

Ancient Egyptians spent much time preparing for the next life. Life was perceived as a dream that passed quickly. Death was viewed as eternal. Egyptians believed that the dead would make their way over to The Kingdom of Orisis, where they would spend eternity. 

Ancient Greek civilization also viewed death in a particular light. According to San Filippo, “Greeks perceived death as a release of the soul from the body. The soul, which was considered to be part of the mind, was believed to be immortal. It was considered that the soul lived before the body and would live again in another life” (1). 

Lastly, it has been noted that when it comes to fearing death, people create philosophies and theologies due to an inability to visualize our own death and afterlife.  

Psychological 

The psychological aspect of death is just as important as the physical. The thought of death alone has the potential to evoke various memories and feelings. You will typically find that a person either accepts or fears death (positive outlook vs negative outlook). This can be a fear of suffering, pain, or of the unknown. These views are typically formed based on past experiences with death. 

 Often, a person may have no underlying baseline when it comes to dying or death. That first experience with death can potentially shape someone’s entire perspective. Fearing death could be attributed to a fear of the unknown, lack of relatable experience, a negative experience, or a lack of communication regarding death, due to a cultural taboo, for example.  

On the other hand, things like faith, positive experiences, and imminent death may cause someone to be more accepting of death. Often, someone facing imminent death may be forced to think about it and come to terms with it. In a study of terminally ill patients facing death, “The participants were afraid of death and earnestly desired to live but felt that death was imminent. To escape their distress, they attempted to accept the situation by thinking that all lives are finite, and death had to be accepted” (2). This is an example of coming to terms with an impending death and accepting it. 

Spiritual 

Spiritual perspectives on death should be considered when discussing views on dying. History shows that humans have long held beliefs that life does end when the body dies. Many tend to believe that once a person dies, their soul is then freed, and can go on to another life or be reincarnated into someone or something else. Religious ideologies contain a vast amount of knowledge and wisdom regarding death. “Religion and spirituality help individuals make sense of what awaits them near the end of life and help the dying cope with their terminal condition” (7).  

What happens after death may vary from one religion to the next. Many religions also have a heaven or heaven like final place where the deceased can rest and be with other who have also died. One of the oldest ideologies of human history is the belief that there can be life after death. 

Quiz Questions

Self Quiz

Ask yourself...

  1. Historically, how has death been viewed in different civilizations? 
  2. Why might a patient fear death and dying? 
  3. What causes patients to be more accepting of death? 

Impact on Nurses 

Imagine working as a hospice nurse.  Your sole purpose is to provide end-of-life care for terminally ill patients. This includes providing information on what to expect at the end of life. At any given time, you have patients that could be imminently dying.  

You are a source of knowledge and comfort for a patient and their family during this time. In the end, you will likely be there when the patient takes their last breath. How can one prepare to handle this scenario time and time again? Should a nurse feel sadness for a patient that was expected to die, or should they emotionally separate themselves? 

The latter may prove hard to do. The reality is that nurses are frequently exposed to death and dying in a variety of settings. A patient’s dying process can be planned or not and this distinction may mean different things for different people. Typically, nurses are taught skills to help prevent death.  

This may be a hard thought process to overcome when the goal is not curative, but comfort focused. These patient interactions help to shape a nurse’s feelings on death and dying. “Nurses are frequently exposed to dying patients and death in the course of their work. This experience makes individuals conscious of their own mortality, often giving rise to anxiety and unease.  

Nurses who have a strong anxiety about death may be less comfortable providing nursing care for patients at the end of their life” (3).  This ‘death’ anxiety could lead to disastrous outcomes for both the nurse and the patient. Nurses should be aware of their own thoughts and attitudes towards death, and how these could affect their ability to provide patient care. 

Caring for the dying involves both skill and emotional support from nurses. Younger nurses and nurses with less experience with death may have greater difficulty caring for dying patients. End of life education and an introspective look at oneself are imperative when it comes to providing quality care. “Nurses’ professional experience is positively correlated with their position, professional level (rank), EOL care experience, competence in EOL, and another knowledge. 

 Nurses who have a positive attitude seem more likely to have more competence in dealing with patients’ symptoms at EOL and better knowledge of EOL care (3). The more palliative knowledge nurses had, the more competence they felt. Moreover, competence dealing with patients’ symptoms in EOL care was correlated with older nurses” (8). Positive conversations about death and dying usually lead to a positive dying experience. 

 To reach this point, nurses and other healthcare professionals need to know how to have these conversations. In a society that is so focused on the living, receiving education on death can be difficult. When death is perceived as a part of life, only then will people feel more comfortable talking about it.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What role do nurses play in death and dying? 
  2. In what ways are nurses affected by death? 
  3. How do previous experiences shape our views about death? 
  4. What are some potential indicators of a nurse’s ability to provide quality care at EOL? 

Communication Strategies 

Many people are uncomfortable talking about death and dying and tend to shy away from such conversations. This may also be true for nurses. Talking about death should not be a formidable task. Nurses should be able to comfortably implement these conversations in their practice when needed. Effective communication is imperative throughout a patient’s trajectory.  

Conversations about death and dying can impact patient care. “Research has shown that talking about and planning the EOL is important for how the final days in a patient’s life may play out and is associated with reduced costs as well as a higher quality of care in the final weeks of life” (4). In a society so focused on life, it may be difficult for nurses and other health professionals to obtain the skills needed to confidently speak with patients about death. 

To effectively talk to patients about death, nurses should first be willing to initiate and discuss the topic. There are important strategies to remember when talking about the end of life. “Qualitative research on the end of life has revealed that medical personnel should consider the following strategies when conducting EOLD: open and honest conversation, setting treatment goals, and balancing hope with reality” (13).  

Patients should also be encouraged to express their thoughts, fears, and to ask questions. It is also important to be honest and forward with patients. No “beating around the bush”. This means using words like “dying” and “death” while having these conversations.  

One communication strategy, VALUE, “recommends to value and appreciate statements of family members, acknowledge their emotions, as well as to listen and ask questions to understand who the patient was as a person” (9). Nurses should keep the following in mind: a patient’s comfort level with death, goals of care, expectations, and cultural factors. Having this knowledge will help to guide the conversation.  

Lastly, when a nurse feels confident and exhibits calmness while talking about death, a patient will more than likely feel the same way. 

Quiz Questions

Self Quiz

Ask yourself...

  1. How do conversations about death impact patient care? 
  2. What can nurses do to effectively communicate with their patients about death? 
  3. What strategies should be utilized when talking about death? 

Stages of Grief 

Nurses are not immune from experiencing grief or loss. We mourn personally and we mourn alongside our patients and their families. “Grief and loss are something that all people will experience in their lifetime. The loss may be actual or perceived and is the absence of something that was valued. An actual loss is recognized and verified by others while others cannot verify a perceived loss.  

Both are real to the individual who has experienced the loss. Grief is the internal part of the loss; it is the emotions related to the loss” (4). Grief allows a person to begin to deal with the pain associated with loss and to heal. There are five stages of grief which were identified in Dr. Elisabeth Kübler-Ross in her book Death and Dying.  

  1. Denial: This stage Is not necessarily about denying that the loss happened. Instead, it is more about denying the feelings associated with the loss. Denial lets us face our feelings of grief. “As an individual is able to accept that this loss is their reality, they will be able to move into the healing process and denial will begin to diminish” (5). 
  2. Anger: A grieving person may feel anger towards a variety of people associated with the loss. This is a normal and a necessary part of the healing process. “Under the anger is the individual’s pain. Anger provides structure, and that is better than preceding numbness. It can be a challenge for some to feel the anger; sometimes it is easier to try and suppress the anger. Feeling anger and addressing anger is part of the grieving process” (5). 
  3. Bargaining: Grieving people may begin to say things to themselves like, “If this__, then this __”, or “I will do anything if you take the hurt away” (5). This stage may occur at any point in the grief process. Once this step is reached, the person can begin to move through the stages in different ways.  
  4. Depression: This stage involves a realization that the situation is real. “Empty feelings come forward, and one’s grief moves in on a deeper level than before. This type of depression is not a sign of mental illness; although reaching out for help may be the right step. It is an appropriate response to a great loss. An individual may withdraw from their daily life activities, and they may feel a fog of   intense sadness” (4). Depression after a major loss is normal and necessary in the healing process.  
  5. Acceptance: Entering this final stage does not mean one is completely okay with what has happened. In fact, one may never be as they once were prior to the loss. “Acceptance, as a stage, is about accepting that this is their new reality, and it is permanent. Life cannot go on as it once did, but through acceptance, life can and will go on” (5). Individuals in this stage must realize that change is necessary to adjust to the new normal. 

Not everyone experiences grief in the same way. Grief is a very personal experience that affects people in different ways. Nurses should be familiar with the stages of grief to be able to offer optimal patient care to grieving patients and their families. This includes recognizing signs of depression and possible suicidal ideation, providing empathy, compassion, education, and resources to those in need. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the stages of grief? 
  2. Why should nurses be familiar with the stages of grief? 
  3. What purpose does grief serve? 

End of Life Process 

Phases of Dying 

Although everyone experiences death differently and on their own terms, there are two main pathways that most people take before dying. The dying process can be broken up into two phases: the transitioning phase, and the actively dying phase. The amount spent in each phase varies from person to person. 

The transitioning phase usually begins 2-3 weeks prior to death. Major changes in function and the ability to do activities of daily life are observed during this time. Patients may even begin falling prior to entering this phase. Becoming bedbound is common as one will begin to spend most of their time sleeping. 

This means decreased responsiveness, less interest in normal activities and hobbies, decreased interaction with family and friends, and an overall decline in one’s interest in external factors. It is possible to be roused during this phase, but this may only be possible in short intervals. It is not uncommon for transitioning patients to speak to or about loved ones that have already passed away. They may even report seeing deceased family in the room with them (11). 

This should not be feared and is an important part of a person’s dying process. Incontinence may also begin during this time and briefs will be needed. Perhaps one of the most noticeable and difficult changes to witness, especially by friends and family, is changes in appetite. Patients will begin to show less interest in food and liquids. A greater difficulty swallowing will become apparent. “Refusal of food and fluid by a dying person is a common occurrence, particularly as the body slowly shuts down, and this may be the evidence signifying an actively dying process rather than starvation” (11). 

 Lastly, symptoms like restlessness, agitation, and pain may arise and detract from one’s comfort level. Although most patients will spend about two weeks transitioning, time can vary from days to weeks. The transitioning phase can also be skipped altogether, depending on the person. 

Once the transitioning phase has concluded, the actively dying phase will begin. Actively dying immediately precedes death. This phase is usually short, lasting about 48 hours. Once actively dying, death is imminent, and a patient is expected to pass away at any moment. This phase is markedly different from the previous phase, and symptoms tend to become more apparent. “The following five changes constitute objective evidence of the end of life: diminished daily living performance, decreased food intake, changes in consciousness and increased sleep quantity, worsening of respiratory distress, and end-stage delirium” (12). 

One key difference is one’s ability to response to tactile or verbal stimuli. The actively dying patient is obtunded and no longer responds to external forces.  There could be slight reactions, but nothing meaningful. This is a comatose state.  

There are many observable changes, including changes in vital signs. Blood pressure begins to drop, heart rate speeds up and eventually slow, respiratory rate picks up, and temperature may become elevated. Respiratory differences tend to be the most common observable changes. Cheyne-Stokes may occur, and the overall breathing pattern can be very irregular. Apnea is also common (11). 

Many patients experience what is known as the “death rattle”.  This very noticeable sound is due to an accumulation of secretions in the upper airway. This is a hallmark of the actively dying phase, but it is not experienced by everyone. “Death rattle is a strong predictor of imminent death, and nearly 80% of people die within 48 hours after its onset” (11).  

Skin changes also occur. The body may become cool to touch, cyanosis may develop in the nail beds of fingers and toes, and mottling can occur usually beginning in the lower extremities and later spreading to other parts of the body. Skin may also become very pale. Urine output will decrease and become concentrated as evidenced by an amber color. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the dying phases? 
  2. What changes are observed when someone is transitioning? 
  3. What are some expected physical changes in the active dying phase? 
  4. What education should a nurse provide to someone taking care of a patient that is actively dying? 

Nursing Assessment and Care 

Since there are so many drastic changes observed during the transitioning phase, proper education is crucial for caregivers. Nurses should reassure them that what the patient is experiencing is normal and to be expected. “At the end of life, most patients are in a state of lethargy, wherein their consciousness progressively declines, and sleep duration increases; therefore, it is necessary to provide appropriate explanations to patients and their families so that they can accept these symptoms as part of the natural end-of-life process” (12). 

Family members usually try to wake the sleeping transitioning patient and have them attempt activities that could be done in the past. This is dangerous for the pt and can lead to injuries and more agitation. Becoming bedbound is a major change and puts the patient at risk for pressure injuries and increased pain. Fragile skin combined with new episodes of incontinence are topics that should be discussed, and proper supplies should be used. 

Other potential barriers to a peaceful transitioning period are force feeding and aspiration. Nurses should provide education on what is acceptable and needed at this point. Patients will not die of hunger or lack of water. Allowing the patient to eat and drink small amounts is okay (12). 

This amount will decrease as the body starts shutting down. Ice chips can be used while the patient is still alert. Utilizing mouth swabs with water is enough to hydrate the oral cavity and keep the patient comfortable until the end. During this time, symptoms can seemingly come out of the blue.  

A once calm patient can become highly agitated in a short period of time. Medications should be added timely to ensure that the patient has a peaceful death.  Information on medication and interventions to control uncomfortable end of life symptoms like pain, agitation, and restlessness should be provided to caregivers. Hospice patients, for example, have a comfort kit with various medications to use during this time.  

Medications can be used as needed or scheduled to keep patients comfortable. (12). As the patient enters the actively dying phase and becomes less alert and aware, it is important that friends and family continue to talk to the patient and keep conversations positive around the patient. Hospice nurses, for example, are sure to tell caregivers that hearing is the last thing to go, so they should continue to speak to their loved one. Since vital signs start to become abnormal, reassurance is usually needed to keep family comfortable.  

Not all vital signs need to be taken in the final stages. Taking blood pressure, for example, could cause discomfort. Death education related to respiratory changes is imperative. “Abnormal breathing patterns such as shallow breathing sound become increasingly common starting 1 week before death” (12). 

Caregivers should be informed that breathing too fast or too slow at this point is not an emergency and there are things that can be done to promote comfort like applying oxygen, keeping the head of the bed upright, and keeping the room cool. Medications can also be given to decrease the death rattle. It should be noted that patients do not experience discomfort from the death rattle.  

Lastly, not having a bowel movement or passing urine during the last few days of life is normal and interventions are not needed. Education and support are especially important during the final phases of life. With their peaceful words and deep knowledge base, nurses can be instrumental in facilitating a peaceful death.  

Quiz Questions

Self Quiz

Ask yourself...

  1. Is it reasonable to obtain vital signs every two hours? Why or why not? 
  2. If the family expresses concern about changes in bowel or urinary habits, what can you say to reassure them? 

Resources and Support 

Planning, coordinating, and executing quality end of life care can be challenging for health care workers. This period can also be one of the most challenging times for both patients and their loved ones. There are available resources for health care workers, patients, and their loved ones that provide information on end-of-life care. 

Hospice care is an invaluable resource and source of support. This is available to terminally ill patients with a life expectancy of 6 months or less.” Hospice care is the term given to the care provided when a patient is given a prognosis of death within 6 months, and they do not pursue curative treatments They focus on improving the quality of life which can mean many things” (10).   

Care can be provided in any setting that a patient calls home. The hospice team includes a medical director, registered nurse, chaplain, social worker, home health aide, and often a nurse practitioner. Symptoms and care can be managed at home with the help of covered medications, supplies, and medical equipment. Hospice allows patients to reach their goal of dying peacefully at home. A bereavement team also provides support during the process. (10?) 

Palliative care, another form of comfort care, can also be utilized to maintain comfort at the end of life. Unlike hospice, patients receiving palliative care do not need to have a life expectancy of 6 months or less. “Research found that timely EOL care discussions allowed family members to make use of hospice and palliative care services sooner and maximize their time with the patient” (6). 

Nurses should be educated in other end of life resource topics such as advanced directives, POLST (Physician Orders for Life Sustaining Treatment), and Durable Medical Power of Attorney. Looking ahead and having meaningful discussions regarding end-of-life planning can help prevent the stress of needing to address these things when death is imminent. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What care options are there for patients at the end of life? 
  2. What is the difference between palliative and hospice care? 
  3. What tools can the nurse use to help patients in end-of-life planning? 

Conclusion

End of life conversations have a profound impact on not only patient care, but also on the dying process itself. Research shows that when implemented appropriately, these conversations improve patient relationships with healthcare workers, lead to better outcomes, and allow for a more positive dying experience. Nurses play a critical role in end-of-life processes in many different settings. With education, practice, experience, and confidence, nurses can incorporate conversations about death and dying to provide quality care. 

GI Bleed: An Introduction

Introduction   

Gastrointestinal bleeding (GI Bleed) is an acute and potentially life-threatening condition. It is meaningful to recognize that GI bleed manifests an underlying disorder. Bleeding is a symptom of a problem comparable to pain and fever in that it raises a red flag. The healthcare team must wear their detective hat and determine the culprit to impede the bleeding.  

Nurses, in particular, have a critical duty to recognize signs and symptoms, question the severity, consider possible underlying disease processes, anticipate labs and diagnostic studies, apply nursing interventions, and provide support and education to the patient. 

Epidemiology  

The incidence of Gastrointestinal Bleeding (GIB) is broad and comprises cases of Upper gastrointestinal bleeding (UGIB) and lower gastrointestinal bleeding (LGIB). GI Bleed is a common diagnosis in the US responsible for approximately 1 million hospitalizations yearly (2). The positive news is that the prevalence of GIB is declining within the US (1). This could reflect effective management of the underlying conditions.  

Upper gastrointestinal bleeding (UGIB) is more common than lower gastrointestinal bleeding (LGIB) (2). Hypovolemic shock related to GIB significantly impacts mortality rates. UGIB has a mortality rate of 11% (2), and LGIB can be up to 5%; these cases are typically a consequence of hypovolemic shock (2).  

Certain risk factors and predispositions impact the prevalence. Lower GI bleed is more common in men due to vascular diseases and diverticulosis being more common in men (1). Extensive data supports the following risk factors for GIB: older age, male, smoking, alcohol use, and medication use (7).  

We will discuss these risk factors as we dive into the common underlying conditions responsible for GI Bleed.  

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever cared for a patient with GIB?
  2. Can you think of reasons GIB is declining in the US?
  3. Do you have experience with patients with hypovolemic shock?

Etiology/ Pathophysiology

Gastrointestinal (GI) bleeding includes any bleeding within the gastrointestinal tract, from the mouth to the rectum. The term also encompasses a wide range of quantity of bleeding, from minor, limited bleeding to severe, life-threatening hemorrhage.

We will review the basic anatomy of the gastrointestinal system and closely examine the underlying conditions responsible for upper and lower gastrointestinal bleeding.

Let's briefly review the basic anatomy of the gastrointestinal (GI) system, which comprises the GI tract and accessory organs. You may have watched The Magic School Bus as a child and recall the journey in the bus from the mouth to the rectum! Take this journey once more to understand the gastrointestinal (GI) tract better.

The GI tract consists of the following: oral cavity, pharynx, esophagus, stomach, small intestine, large intestine, and anal canal (5). The accessory organs include our teeth, tongue, and organs such as salivary glands, liver, gallbladder, and pancreas (5). The primary duties of the gastrointestinal system are digestion, nutrient absorption, secretion of water and enzymes, and excretion (5, 3). Consider these essential functions and their impact on each other.

 

 

 

This design was created on Canva.com on August 31, 2023. It is copyrighted by Abbie Schmitt, RN, MSN and may not be reproduced without permission from Nursing CE Central. 

 

As mentioned, gastrointestinal bleeding has two broad subcategories: upper and lower sources of bleeding. You may be wondering where the upper GI tract ends and the lower GI tract begins. The answer is the ligament of Treitz. The ligament of Treitz is a thin band of tissue that connects the end of the duodenum  and the beginning of the jejunum (small intestine); it is also referred to as the suspensory muscle of the duodenum (4). This membrane separates the upper and lower GI tract. Upper GIB is defined as bleeding proximal to the ligament of Treitz, while Lower GIB is defined as bleeding beyond the ligament of Treitz (4). 

 

Upper GI Bleeding (UGIB) Etiology 

Underlying conditions that may be responsible for the UGIB include: 

  • Peptic ulcer disease 
  • Esophagitis 
  • Foreign body ingestion 
  • Post-surgical bleeding 
  • Upper GI tumors 
  • Gastritis and Duodenitis 
  • Varices 
  • Portal hypertensive gastropathy (PHG) 
  • Angiodysplasia 
  • Dieulafoy lesion 
  • Gastric antral valvular ectasia 
  • Mallory-Weiss tears 
  • Cameron lesions (bleeding ulcers occurring at the site of a hiatal hernia 
  • Aortoenteric fistulas 
  • Hemobilia (bleeding from the biliary tract) 
  • Hemosuccus pancreaticus (bleeding from the pancreatic duct) 

(1, 4, 5, 8. 9) 

 

Pathophysiology of Variceal Bleeding. Variceal bleeding should be suspected in any patient with known liver disease or cirrhosis (2). Typically, blood from the intestines and spleen is transported to the liver via the portal vein (9). The blood flow may be impaired in severe liver scarring (cirrhosis). Blood from the intestines may be re-routed around the liver via small vessels, primarily in the stomach and esophagus (9). Sometimes, these blood vessels become large and swollen, called varices. Varices occur most commonly in the esophagus and stomach, so high pressure (portal hypertension) and thinning of the walls of varices can cause bleeding within the Upper GI tract (9). 

 

Liver Disease + Varices + Portal Hypertension = Recipe for UGIB Disaster 

 

Lower GI Bleeding (LGIB) Etiology
  • Diverticulosis
  • Post-surgical bleeding
  • Angiodysplasia
  • Infectious colitis
  • Ischemic colitis
  • Inflammatory bowel disease
  • Colon cancer
  • Hemorrhoids
  • Anal fissures
  • Rectal varices
  • Dieulafoy lesion
  • Radiation-induced damage

(1, 4, 5, 9)

 

Unfortunately, a source is identified in only approximately 60% of cases of GIB (8). Among this percentage of patients, upper gastrointestinal sources are responsible for 30–55%, while 20–30% have a colorectal source (8).

Quiz Questions

Self Quiz

Ask yourself...

  1. How is the GI Tract subdivided?
  2. Are there characteristics of one portion that may cause damage to another? (For example: stomach acids can break down tissue in the esophagus, which may ultimately cause bleeding and ulcers (8).
  3. Consider disease processes that you have experienced while providing patient care that could/ did lead to GI bleeding.

Laboratory and Diagnostic Testing

Esophagogastroduodenoscopy (EGD) and colonoscopy identify the source of bleeding in 80–90% of patients (4). The initial clinical presentation of GI bleeding is typically iron deficiency/microscopic anemia and microscopic detection of blood in stool tests (6).

 

The following laboratory tests are advised to assist in finding the cause of GI bleeding (2):

  • Complete blood count
  • Hemoglobin/hematocrit
  • International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (PTT)
  • Liver function tests

 

Low hemoglobin and hematocrit levels result from blood loss, and blood urea nitrogen (BUN) may be elevated due to the GI system's breakdown of proteins within the blood (9).

 

The following laboratory tests are advised to assist in finding the cause of GI bleeding:

  • EGD (esophagogastroduodenoscopy)- Upper GI endoscopy
    • Clinicians can visualize the upper GI tract using a camera probe that enters the oral cavity and travels to the duodenum (9)
  • Colonoscopy- Lower GI endoscopy/ (9)
    • Clinicians can visualize the lower GI tract.
  • CT angiography
    • Used to identify an actively bleeding vessel

Signs and Symptoms 

Clinical signs and symptoms depend on the volume/ rate of blood loss and the location/ source of the bleeding. A few key terms to be familiar with when evaluating GI blood loss are overt GI bleeding, occult GI bleeding, hematemesis, hematochezia, and melena. Overt GI bleeding means blood is visible, while occult GI bleeding is not visible to the naked eye but is diagnosed with a fecal occult blood test (FOBT) yielding positive results of the presence of blood (5). Hematemesis is emesis/ vomit with blood present; melena is a stool with a black/maroon-colored tar-like appearance that signifies blood from the upper GI tract (5). Melena has this appearance because when blood mixes with hydrochloric acid and stomach enzymes, it produces this dark, granular substance that looks like coffee grounds (9). 

 

Mild vs. Severe Bleeding  

A patient with mild blood loss may present with weakness and diaphoresis (9). Chronic iron deficiency anemia symptoms include hair loss, hand and feet paresthesia, restless leg syndrome, and impotence in men (8). The following symptoms may appear over time once anemia becomes more severe and hemoglobin is consistently less than 7 mg/dl: pallor, headache, dizziness from hypoxia, tinnitus from the increased circulatory response, and the increased cardiac output and dysfunction may lead to dyspnea (8). Findings of a positive occult GI bleed may be the initial red flag. 

A patient with severe blood loss, which is defined as a loss greater than 1 L within 24 hours, hypotensive, diaphoretic, pale, and have a weak, thready pulse (9). Signs and symptoms will reflect the critical loss of circulating blood volume with systemic hypoperfusion and oxygen deprivation, so that cyanosis will also be evident (9). This is considered a medical emergency, and rapid intervention is needed. 

 

Stool Appearance: Black, coffee ground = Upper GI; Bright red blood = Lower GI. 

Quiz Questions

Self Quiz

Ask yourself...

  1. How would you prioritize the following patients: (1) Patient complains of weakness and coffee-like stool; or (2) Patient complains of constipation and bright red bleeding from the anus?
  2. Have you ever witnessed a patient in hypovolemic shock? If yes, what symptoms were most pronounced? If not, consider the signs.
  3. What are ways that the nurse can describe abnormal stool?

History and Physical Assessment

History

A thorough and accurate history and physical assessment is a key part of identifying and managing GI bleed. Remember to avoid medical terminology/jargon while asking specific questions, as this can be extremely helpful in narrowing down potential cases. It is a good idea to start with broad categories (general bleeding) then narrow to specific conditions.

Assess for the following:

  • Previous episodes of GI Bleed
  • Medical history with contributing factors for potential bleeding sources (e.g., ulcers, inflammatory bowel disease, liver disease, varices, PUD, alcohol abuse, tobacco abuse, H.pylori, diverticulitis) (3)
  • Contributory medications (non-steroidal anti-inflammatory drugs (NSAIDs, anticoagulants, antiplatelet agents, bismuth, iron) (3)
  • Comorbid diseases that could affect management of GI Bleed (8)

 

Physical Assessment
  1. Head to toe and focused Gastrointestinal, Hepatobiliary, Cardiac and Pancreatic
  2. Assessments
    Assess stool for presence of blood (visible) and anticipate orders/ collect specimen for occult blood testing.
  3. Vital Signs

 

Signs of hemodynamic instability associated with loss of blood volume (3):

  • Resting tachycardia
  • Orthostatic hypotension
  • Supine hypotension
  • Abdominal pain (may indicate perforation or ischemia)
  • A rectal exam is important for the evaluation of hemorrhoids, anal fissures, or anorectal mass (3)

 

Certain conditions place patients at higher risk for GI bleed. For example, patients with end-stage renal disease (ESRD) have a five times higher risk of GIB and mortality than those without kidney disease (2).

Quiz Questions

Self Quiz

Ask yourself...

  1. Are there specific questions to ask if GIB is suspected?
  2. What are phrases from the patient that would raise a red flag for GIB (For example: “I had a stomach bleed years ago”) 
  3. Have you ever noted overuse of certain medications in patients?
Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever shadowed or worked in an endoscopy unit?
  2. Name some ways to explain the procedures to the patient?

Treatment and Interventions

Treatment and interventions for GIB bleed will depend on the severity of the bleeding. Apply the ABCs (airway, breathing, circulation) prioritization tool appropriately with each unique case. Treatment is guided by the underlying condition causing the GIB, so this data is too broad to cover. It would be best to familiarize yourself with tools and algorithms available within your organization that guide treatment for certain underlying conditions. Image 2 is an example of an algorithm used to treat UGIB (8). The Glasgow-Blatchford bleeding score (GBS) tool is another example of a valuable tool to guide interventions. Once UGIB is identified, the Glasgow-Blatchford bleeding score (GBS) can be applied to assess if the patient will need medical intervention such as blood transfusion, endoscopic intervention, or hospitalization (4).

Unfortunately, there is currently a lack of tools available for risk stratification of emergency department patients with lower gastrointestinal bleeding (LGIB) (6). This gap represents an opportunity for nurses to develop and implement tools based on their experience with LGIB.

 

 

(8) 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Are you familiar with GIB assessment tools?
  2. How would you prioritize the following orders: (1) administer blood transfusion, (2) obtain occult stool for testing, and (3) give stool softener?

The first step of nursing care is the assessment. The assessment should be ongoing and recurrent, as the patient's condition may change rapidly with GI bleed. During the evaluation, the nurse will gather subjective and objective data related to physical, psychosocial, and diagnostic data. Effective communication is essential to prevent and mitigate potential risk factors.

 

Subjective Data (Client verbalizes)

  • Abdominal pain
  • Nausea
  • Loss of appetite
  • Dizziness
  • Weakness

 

Objective Data (Clinician notes during assessment)

  • Hematemesis (vomiting blood)
  • Melena (black, tarry stools)
  • Hypotension
  • Tachycardia
  • Pallor
  • Cool, clammy skin

 

 

 

 

Nursing Interventions

 

Ineffective Tissue Perfusion:

  1. Monitor vital signs frequently to assess blood pressure, heart rate, and oxygen saturation changes.
  2. Obtain IV access.
  3. Administer oxygen as ordered.
  4. Elevate the head of the bed (support venous return and enhance tissue perfusion).
  5. Administer blood products (packed red blood cells, fresh frozen plasma) as ordered to replace lost blood volume.

 

Acute Pain:

  1. Assess the patient's pain (quantifiable pain scale)
  2. Administer pain medications as ordered.
  3. Obtain and implement NPO Orders: Allow the GI tract to rest and prevent further irritation while preparing for possible endoscopic procedures.
  4. Apply heat/cold therapy for comfort.

 

Risk for Decreased Cardiac Output

  1. Assess the patient's heart rate and rhythm. (Bleeding and low cardiac output may trigger compensatory tachycardia.) (9)
  2. Assess and monitor the patient's complete blood count.
  3. Assess the patient's BUN level.
  4. Monitor the patient's urine output.
  5. Perform hemodynamic monitoring.
  6. Administer supplemental oxygenation as needed.
  7. Administer intravenous fluids as ordered.
  8. Prepare and initiate blood transfusions as ordered.
  9. Educate and prepare the patient for endoscopic procedures and surgical intervention as needed.

 

Risk for Deficient Fluid Volume:

  1. Monitor intake and output.
  2. Maintain hydration.
  3. Administer intravenous fluids as ordered.
  4. Monitor labs, including hemoglobin and hematocrit, to assess the effectiveness of fluid replacement therapy.
  5. Educate the patient on increasing oral fluid intake once the bleeding is controlled.
  6. Vital signs
  7. Assess the patient's level of consciousness and capillary refill time to evaluate tissue perfusion and response to fluid replacement.
  8. Collaborate with the healthcare team to adjust fluid replacement therapy based on the patient's response and laboratory findings.

 

Nursing Goals / Outcomes for GI Bleed:

  • The patient's vital signs and lab values will stabilize within normal limits.
  • The patient will be able to demonstrate efficient fluid volume as evidenced by stable hemoglobin and hematocrit, regular vital signs, balanced intake and output, and capillary refill < 3 seconds.
  • The patient will exhibit increased oral intake and adequate nutrition.
  • The patient will verbalize relief or control of pain.
  • The patient will appear relaxed and able to sleep or rest appropriately.
  • The patient verbalizes understanding of patient education on gastrointestinal bleeding, actively engages in self-care strategies, and seeks appropriate support when needed.
Quiz Questions

Self Quiz

Ask yourself...

  1. How can the nurse advocate for a patient with GIB?
  2. Can you think of ways your nursing interventions would differ between upper and lower GIB?
  3. Have you ever administered blood products?
  4. What are possible referrals following discharge that would be needed? (Example: gastroenterology, home health care)

Case Study

Mr. Blackstool presents to the emergency department with the following:

CHIEF COMPLAINT: "My stool looked like a ball of black tar this morning."

He also reports feeling "extra tired" and "lightheaded" for 3-5 days.

HISTORY OF PRESENT ILLNESS: The patient is a 65-year-old tractor salesman who presents to the emergency room complaining of the passage of black stools, fatigue, and lightheadedness. He reports worsening chronic epigastric pain and reflux, intermittent for 10+ years.

He takes NSAIDS as needed for back, and joint pain and was recently started on a daily baby aspirin by his PCP for cardiac prophylaxis. He reports "occasional" alcohol intake and smokes two packs of cigarettes daily.

PHYSICAL EXAMINATION: Examination reveals an alert and oriented 65-YO male. He appears anxious and irritated. Vital sips are as follows. Blood Pressure 130/80 mmHg, Heart Rate 120/min - HR Thready - Respiratory Rate - 20 /minute; Temperature 98.0 ENT/SKIN: Facial pallor and cool, moist skin are noted. No telangiectasia of the lips or oral cavity is noted. The parotid glands appear full.

CHEST: Lungs are clear to auscultation and percussion. The cardiac exam reveals a regular rhythm with an S4. No murmur is appreciated. Peripheral pulses are present but are rapid and weak.

ABDOMEN/RECTUM: The waist shows a rounded belly. Bowel sounds are hyperactive. Percussion of the liver is 13 cm (mal); the edge feels firm. Rectal examination revealed a black, tarry stool. No Dupuytren's contractions were noted.

LABORATORY TESTS: Hemoglobin 9gm/dL, Hematocrit 27%, WBC 13,000/mm. PT/PTT - normal. BUN 46mg/dL.

 

Discuss abnormal findings noted during History and Physical Examination; Evaluate additional data to obtain possible diagnostic testing, treatment, nursing interventions, and care plans.

Conclusion

After this course, I hope you feel more knowledgeable and empowered in caring for patients with Gastrointestinal bleeding (GIB). As discussed, GIB is a potentially life-threatening condition that manifests as an underlying disorder. Think of gastrointestinal bleeding as a loud alarm signaling a possible medical emergency. Nurses can significantly impact the recognition of signs and symptoms that determine the severity of bleeding and underlying disease process while also implementing life-saving interventions as a part of the healthcare team. As evidence-based practice rapidly evolves, continue to learn, and grow your knowledge of GIB. 

 

Constipation Management and Treatment

Introduction   

In the realm of healthcare, where every aspect of patient well-being is meticulously tended to, constipation is a condition that often remains in the shadows. Often dismissed as a minor inconvenience, constipation is a prevalent concern that can have significant repercussions on the health and comfort of hospitalized and long-term care patients (8).  

Imagine a scenario where a middle-aged patient, recently admitted to a hospital for a non-related condition, is experiencing discomfort due to constipation. Despite the patient's hesitation to bring up this seemingly "embarrassing" topic, a skilled nurse takes the initiative to initiate an open conversation.  

By actively listening and empathetically addressing the patient's concerns, the nurse alleviates the discomfort and also plays a crucial role in preventing potential complications. This scenario exemplifies the pivotal role that nurses play in the comprehensive management of constipation. 

Envision a long-term care facility where an elderly resident's mobility is limited, leading to a sedentary lifestyle. As a result, this individual becomes more susceptible to constipation, which could potentially lead to more severe issues if left unattended. Here, the nurse's expertise in identifying risk factors and tailoring interventions comes into play.  

By suggesting gentle exercises, dietary adjustments, and adequate hydration, the nurse transforms the resident's daily routine, ensuring a healthier digestive tract and enhanced overall well-being. 

Through the above scenarios, it becomes evident that constipation is not merely a minor inconvenience but a legitimate concern that warrants attention. As the first line of defense in patient care, nurses are uniquely positioned to identify, address, and holistically prevent constipation.  

Nurses possess the knowledge and skills to create a profound impact on patient lives by acknowledging and addressing this issue. This course aims to equip nurses with an in-depth understanding of constipation, enabling them to be proactive vigilant advocates for patient comfort, bowel health, and overall well-being. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What role do nurses play in constipation management? 
  2. Name one lifestyle factor that can contribute to constipation. 

Epidemiology  

To truly comprehend the significance of constipation in healthcare settings, it's essential to grasp its prevalence and impact. Statistics reveal that constipation holds a prominent spot in healthcare challenges, with up to 30% of patients in hospitals and long-term care facilities experiencing this discomfort (4). This means that in a unit with 100 patients, nearly a third of them might be grappling with constipation-related issues.  

Even though constipation transcends demographics, elderly patients, who are a substantial part of long-term care settings, are more susceptible to constipation due to factors like decreased mobility, altered dietary habits, and medication use. Understanding this demographic predisposition is crucial for nurses as it guides their vigilance in recognizing and managing constipation among this vulnerable group. By unraveling its prevalence and its penchant for affecting diverse patient groups, nurses can step into their roles armed with knowledge, ready to make a tangible difference in patient lives. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What percentage of patients in hospitals and long-term care facilities experience constipation?  

Etiology/Pathophysiology  

Embarking on the journey to comprehend constipation's root causes and underlying mechanisms offers a fascinating glimpse into the intricate workings of the digestive system. The digestive system is a well-orchestrated symphony where even a slight disruption can lead to a discordant note, constipation being one such note.  

Constipation arises from an intricate interplay of factors. Lifestyle choices, such as physical inactivity, dietary habits, and even medication use, can disturb the symphony of digestion. These disruptions impact the stool's consistency, its journey through the intestines, and the efficiency of water absorption.  

 

Some examples of how lifestyle choices can cause constipation include the following: 

  • The digestive tract, like a finely tuned instrument, requires regular movement to maintain its rhythm and balance. Without physical activity to nudge food along, its journey through the digestive process slows down, potentially leading to constipation. 
  • Mismanagement of water absorption in the colon can also contribute to constipation. Excess absorption of water in the colon can turn the stool hard and dry, making it a formidable challenge to pass.  
  • When fiber is lacking in the diet, stool encounters resistance and sluggishness, akin to a symphony losing its guiding rhythm. This lack of fiber can lead to constipation, underscoring the importance of dietary choices in maintaining a harmonious digestive process (10). 

 

Understanding the above dynamics empowers nurses to decode the origins of constipation and tailor interventions that restore the harmonious rhythm of the digestive orchestra. Just as a conductor guides a symphony to its crescendo, nurses can orchestrate the path to relief and comfort for patients grappling with constipation. 

Signs and Symptoms  

Constipation's signs and symptoms are the stars that guide nurses toward effective management. Infrequent bowel movements, excessive straining, abdominal discomfort, and bloating are like constellations, revealing the narrative of digestive imbalance. 

Recognizing the constellation of signs and symptoms becomes the compass guiding nurses toward effective care. Just as a seasoned sailor navigates by the stars, nurses navigate constipation's landscape by deciphering the cues that patients present. 

Research by Anderson and Brown (1) reveals that patients grappling with constipation often experience infrequent bowel movements as a telltale sign. Nurses, armed with this insight, recognize that infrequent bowel movements warrant vigilant assessment and timely interventions. 

Excessive straining, much like tugging at sails in adverse winds, emerges as another hallmark of constipation (6). Patients' tales of discomfort during bowel movements point to an underlying imbalance. Nurses adeptly interpret this discomfort as a call for action, initiating strategies that ease the passage of stool and restore harmony to the digestive symphony. 

Discomfort serves as an indicator of the digestive system's struggle to find its equilibrium. Nurses, like skilled navigators, probe further, discerning the nuances of the discomfort to tailor interventions that address its root cause (11). 

Bloating is another symptom. Research by Smith and Williams (9) illuminates the link between constipation and bloating. This connection heightens nurses' vigilance, prompting them to delve into patients' experiences and offer relief from the discomfort. 

Pharmacological/Non-Pharmacological Treatment 

Constipation management encompasses a harmonious blend of pharmacological and non-pharmacological strategies. Just as a symphony thrives on a balanced ensemble, nurses can orchestrate a symphony of relief and comfort by selecting the right interventions for each patient's unique needs. Through this holistic approach, nurses play a pivotal role in restoring the digestive symphony to its harmonious rhythm. 

 
Pharmacological 

As nurses step into the realm of constipation management, they encounter a diverse array of strategies that can harmonize the digestive symphony. Picture a pharmacist's shelf adorned with an assortment of medications, each with a specific role in alleviating constipation. 

Fiber supplements work by increasing stool bulk and promoting regular bowel movements. They're gentle and mimic the natural process, ensuring a harmonious flow. 

Osmotic laxatives introduce more water into the stool, creating a balanced blend of moisture, preventing dry and challenging stools, and facilitating movement.  

Stimulant laxatives stimulate bowel contractions, hastening the stool's journey through the digestive tract. They're like the energetic beats that invigorate a symphony, leading to a rhythmic and effective passage. 

Lastly, stool softeners ensure that the stool is neither too hard nor too soft, striking the perfect balance. They act by moistening the stool, making it easier to pass without straining. By introducing this harmony, stool softeners contribute to patient comfort. 

 
Non-pharmacological 

Beyond the realm of medications lies an equally vital avenue: non-pharmacological interventions. Nurses can craft a holistic care plan, carefully considering dietary adjustments and lifestyle modifications as the foundation. Examples of non-pharmacological interventions include the following: 

A diet rich in fiber guides the stool's journey with ease. Nurses can educate patients on incorporating fruits, vegetables, and whole grains, ensuring a harmonious flow through the intestines. 

Engaging in regular physical activity not only stimulates bowel movements but also enhances overall well-being. Nurses can encourage patients to integrate movement into their routines, contributing to a dynamic and efficient digestive process. 

Relaxation techniques play a vital role in constipation management. Nurses can provide guidance on techniques like deep breathing or gentle abdominal massages that soothe the digestive tract, facilitate a smoother passage, and transform discomfort into relaxation. 

Quiz Questions

Self Quiz

Ask yourself...

  1. How does fiber-rich food aid in preventing constipation? 
  2. What are the four main types of pharmacological treatment for constipation? 

Complications 

Constipation complications can disrupt the symphony of health. Nurses, armed with knowledge and interventions, become conductors of comfort, guiding patients toward a harmonious journey free from discomfort and dissonance. Through their skilled care, nurses harmonize the symphony of patient well-being, preventing complications and promoting relief. Examples of complications include the following. 

 

Hemorrhoids 

These are swollen blood vessels around the rectal area that cause pain, itching, and even bleeding during bowel movements. Nurses can educate patients about preventive measures, such as adequate fiber intake, staying hydrated, and avoiding straining during bowel movements. 

 

Anal Fissure 

This is a small tear in the anal lining that can cause pain and bleeding, disrupting daily life. Nurses can gently guide patients toward hygiene practices and proper self-care, restoring comfort and preventing further disruption. 

 

Fecal Impaction 

Here, the stool accumulates, creating an obstruction that can be likened to an unexpected pause in flow. This impaction causes severe discomfort and can even lead to bowel obstruction. Nurses should be attentive to patients at risk of fecal impaction, promptly intervening with measures such as stool softeners, gentle digital disimpaction, and regular bowel assessments.  

 

Rectal Prolapse 

This protrusion of the rectal lining is a disruptive problem that not only causes physical discomfort but also emotional distress. Nurses can empower patients by educating them about the importance of managing constipation and preventing rectal prolapse.  

 

Nausea and Vomiting 

The buildup of waste and toxins can trigger these unsettling symptoms. Nurses should be vigilant, recognizing these cues as a sign of digestive imbalance. Collaborating with healthcare teams, nurses can address the underlying constipation, restoring harmony and alleviating discomfort. 

 

Bowel Obstruction 

This is a medical emergency. Patients experience severe abdominal pain, bloating, and the inability to pass stool or gas. Nurses should be well-equipped to recognize these symptoms and act swiftly, seeking immediate medical intervention.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What is a potential complication of untreated constipation that involves swollen blood vessels around the rectal area? 
  2. What are two potential symptoms of constipation-related nausea and vomiting? 
  3. When should nurses suspect a bowel obstruction in a patient with constipation? 

Prevention  

Prevention is composed of dietary choices, hydration, exercise, and lifestyle awareness. Nurses, as conductors of preventive care, guide patients toward a harmonious journey of well-being. By embracing preventive measures, patients become active participants in the symphony of their health, ensuring that the digestive rhythm remains soothing and uninterrupted. Sample preventive measures include the following: 

 

Dietary Adjustments 

Nurses can educate patients about the importance of incorporating fiber into their diets. Picture a patient's plate adorned with vibrant fruits, vegetables, and whole grains — these fiber-rich choices act as the brushstrokes that create a smooth flow through the digestive system.  

 

Hydration 

Like the gentle spray that keeps a garden vibrant, staying adequately hydrated ensures the digestive landscape remains fluid and inviting. Nurses can encourage patients to drink sufficient water, allowing the stool's journey to be as effortless as the water's flow.  

 
Exercise 

Nurses can guide patients in incorporating regular physical activities like brisk walks, or gentle stretching into their daily routines, creating a rhythm that enhances bowel motility and overall well-being. Movements, much like instrument tuning before a performance, prepare the digestive system for optimal function.  

 

Lifestyle Awareness 

Nurses can educate patients about the importance of timely bowel movements and creating a comfortable environment for digestion. Patients can cultivate their well-being by avoiding prolonged periods of sitting and adopting healthy toileting habits.  

 

Patient Education 

Nurses can provide insights into the importance of fiber-rich foods, hydration, and movement. By empowering patients with knowledge, nurses equip them with the tools needed to prevent constipation and maintain digestive well-being.   

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the importance of dietary adjustments in preventing constipation? 
  2. How does hydration impact constipation prevention? 
  3. What is the role of exercise in preventing constipation? 

Nursing Implications 

Nurses are instrumental in managing constipation and improving patient outcomes. Nurses should be skilled in assessing patients for constipation risk factors, communicating effectively about symptoms, and tailoring interventions to individual patient needs. Collaborating with other healthcare professionals to develop comprehensive care plans is essential. Examples of useful nursing skills include: 

 

Holistic Assessment 

Nurses are vigilant observers, attuned to the nuances of patient well-being. Like skilled detectives, nurses delve into patients' histories, medications, and lifestyles, identifying constipation risk factors. Holistic assessments allow nurses to understand the unique backdrop against which constipation may unfold. Armed with this knowledge, nurses can tailor interventions that resonate with each patient's needs (12). 

 
Effective Communication 

Envision a nurse as a skilled communicator, bridging the gap between patient concerns and medical insights. Like a translator, nurses help patients express their symptoms and experiences, ensuring nothing gets lost in translation. Effective communication not only nurtures trust but also facilitates accurate assessment, enabling nurses to identify constipation-related cues and initiate timely interventions (14). 

 

Collaboration with Multidisciplinary Teams 

Consider a care setting where the patient's well-being is a collective effort, much like an orchestra composed of diverse instruments. Nurses collaborate with physicians, dietitians, physical therapists, and other healthcare professionals to ensure a harmonious approach to constipation management. This interdisciplinary collaboration ensures that each note of patient care resonates in unison, creating a symphony of comprehensive well-being (7). 

 

Patient-Centered Care Plans 

Imagine nurses as architects of care plans, designing blueprints that reflect patients' unique needs and preferences. Just as architects tailor a building to its occupants, nurses craft patient-centered care plans that incorporate dietary preferences, lifestyle routines, and individualized interventions. This tailored approach ensures that patients feel heard and empowered in their constipation management journey (13). 

 

Education and Empowerment 

Envision nurses as educators, empowering patients with knowledge that transforms them into active participants in their care. Much like a guide, nurses navigate patients through the maze of constipation management strategies, ensuring clarity and understanding. By imparting information about dietary choices, hydration, exercise, and self-care, nurses equip patients with the tools needed to harmonize their digestive well-being (2). 

 
Continuous Monitoring and Evaluation 

Imagine nurses as diligent conductors, continuously assessing the rhythm of constipation management. Just as a conductor listens to every note, nurses monitor patients' responses to interventions, ensuring their effectiveness. Regular evaluation allows nurses to fine-tune strategies, ensuring that the symphony of constipation management remains harmonious and effective (5). 

 

Compassionate Support 

Envision nurses as compassionate companions on the patient's constipation management journey. Like trusted friends, nurses offer emotional support, addressing patients' concerns and fears with empathy. This compassionate approach fosters a sense of security and trust, enabling patients to navigate the challenges of constipation with resilience and a sense of camaraderie (3). 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. How can nurses contribute to patient-centered care plans for constipation management? 
  2. What is the significance of effective communication in constipation management? 
  3. Why is continuous monitoring and evaluation important in constipation management? 

Conclusion

Constipation is a significant concern that impacts the comfort and well-being of hospitalized and long-term care patients. Nurses' proactive role in identifying, managing, and preventing constipation is essential for promoting patient health. By employing a combination of pharmacological and non-pharmacological interventions, nurses can significantly enhance patient comfort and quality of life.  

Envision nurses as educators who share the symphony of knowledge with patients, empowering them to become proactive partners in their well-being. With insights about dietary choices, hydration, exercise, and relaxation techniques, patients become active participants in the harmony of their digestive health. 

Think of nurses as vigilant observers, continuously assessing the rhythm of constipation management, listening to every note, monitoring patient responses, and adjusting interventions to ensure a harmonious and effective approach.  

Finally, visualize nurses as compassionate companions on the constipation management journey. They offer unwavering support, much like friends sharing the weight of challenges. This compassionate presence fosters trust, comfort, and a sense of unity, creating a symphony of emotional well-being alongside physical relief. 

As this course concludes, let us remember that constipation management is not just about alleviating discomfort but about orchestrating a symphony of care that encompasses every aspect of the patient’s experience.  

By blending knowledge, empathy, and skill, nurses elevate constipation management from a routine task to a transformative experience. With this newfound understanding, nurses are prepared to guide patients toward a harmonious symphony of relief, comfort, and overall well-being. 

 

 

Spinal Cord Injury: Bowel and Bladder Management

Introduction   

Imagine one day you are able to walk and take care of your own needs. Now, imagine one week later you wake up no longer able to walk, feel anything below your waist, or hold your bowels.  

This is a reality for many people who sustain spinal cord injuries. Managing changes in bowel and bladder function is one of many challenges that people with spinal cord injuries and their families or caregivers face.  

This course will provide learners with the knowledge needed to assist patients who have spinal cord injuries with bowel and bladder management to improve the quality of life in this group.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some societal misconceptions or stereotypes about people with spinal cord injuries? 
  2. What are some learning gaps among nurses regarding caring for people with spinal cord injuries? 
  3. How well does the healthcare system accommodate people with spinal cord injuries?

Spinal Cord Injuries: The Basics

Spinal Cord Function 

Before defining a spinal cord injury, it is important to understand the function of the spinal cord itself. The spinal cord is a structure of the nervous system that is nestled within the vertebrae of the back and helps to distribute information from the brain (messages) to the rest of the body [1].  

These messages result in sensation and other neurological functions. While it may be common to primarily associate the nervous system with numbness, tingling, or pain, nerves serve an important purpose in the body’s function as a whole.

Spinal Cord Injury Definition 

When the spinal cord is injured, messages from the brain may be limited or entirely blocked from reaching the rest of the body. Spinal cord injuries refer to any damage to the spinal cord caused by trauma or disease [2]. Spinal cord injuries can result in problems with sensation and body movements.  

For example, the brain sends messages through the spinal cord to muscles and tissues to help with voluntary and involuntary movements. This includes physical activity like running and exercising, or something as simple as bowel and bladder elimination.  


Spinal Cord Injury Causes 

Spinal cord injuries occur when the spinal cord or its vertebrae, ligaments, or disks are damaged [3]. While trauma is the most common cause of spinal cord injuries in the U.S., medical conditions are the primary causes in low-income countries [4] [2]. 

 

Trauma 
  • Vehicle accidents: Accounts for 40% of all cases [2] 
  • Falls: Accounts for 32% of all cases [2] 
  • Violence: Includes gun violence and assaults; accounts for 13% of all cases [2] [5] 
  • Sport-related accidents: Accounts for 8% of all cases [2] 

 

Medical Conditions 
  • Multiple Sclerosis (MS): Damage to the myelin (or insulating cover) of the nerve fibers [1] 
  • Amyotrophic Lateral Sclerosis (ALS): Lou Gehrig’s disease, damage to the nerve cells that control voluntary muscle movements [1] 
  • Post-Polio: Damage to the central nervous system caused by a virus [1] 
  • Spina Bifida: Congenital defect of the neural tube (structure in utero that eventually forms the central nervous system) [1] 
  • Transverse Myelitis (TM): Inflammation of the spinal cord caused by viruses and bacteria [1] 
  • Syringomyelia: Cysts within the spinal cord often caused by a congenital brain abnormality [1] 
  • Brown-Sequard Syndrome (BSS): Lesions in the spinal cord that causes weakness or paralysis on one side of the body and loss of sensation on the other [1] 
  • Cauda Equina Syndrome: Compression of the nerves in the lower spinal region [1] 

Spinal Cord Injury Statistics 

According to the World Health Organization, between 250,000 and 500,000 people worldwide are living with spinal cord injuries [4]. In the U.S., this number is estimated to be between 255,000 and 383,000 with 18,000 new cases each year for those with trauma-related spinal cord injuries [6]. 

 

Age/Gender 

Globally, young adult males (age 20 to 29) and males over the age of 70 are most at risk. In the U.S., males are also at highest risk, and of this group, 43 is the average age [2].  

While it is less common for females to acquire a spinal cord injury (2:1 ratio in comparison to males), when they do occur, adolescent females (15-19) and older females (age 60 and over) are most at risk globally [4].  

 

Race/Ethnicity 

In the U.S. since 2015, around 56% of spinal cord injuries related to trauma occurred among non-Hispanic whites, 25% among non-Hispanic Black people, and about 14% among Hispanics [6].  

 

Mortality 

People with spinal cord injuries are 2 to 5 times more likely to die prematurely than those without these injuries (WHO, 2013). People with spinal cord injuries are also more likely to die within the first year of the injury than in subsequent years. In the U.S., pneumonia, and septicemia – a blood infection – are the top causes of death in patients with spinal cord injuries [6]. 

 

Financial Impact 

Spinal cord injuries cost the U.S. healthcare system billions each year [6]. Depending on the type, spinal cord injuries can cost from around $430,000 to $1,300,000 in the first year and between $52,000 and $228,000 each subsequent year [6].  

These numbers do not account for the extra costs associated with loss of wages and productivity which can reach approximately $89,000 each year [6]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one function of the spinal cord? 
  2. What is one way to prevent spinal cord injuries in any group? 
  3. Why do you think injuries caused by medical conditions are least likely to occur in the U.S.? 
  4. Why do you think the first year of care after the injury is the most costly?

Think about someone you know (or cared for) who had a spinal cord injury. 

  1. Did they have total or partial loss of feeling and movement to the extremities? 
  2. What comorbidities or complications did they have associated with the injury? 
  3. In what ways did the injury affect their overall quality of life?

Spinal Cord Injuries: Types and Complications

Four Levels of the Spinal Cord 

  • Cervical (vertebrae C1 – C8): Neck; controls the back of the head down to the arms, hands, and diaphragm 
  • Thoracic (vertebrae T1 – T12): Upper mid-back; controls the chest muscles, many organs, some back muscles, and parts of the abdomen 
  • Lumbar (vertebrae L1 – L5): Lower back; controls parts of the lower abdomen, lower back, parts of the leg, buttocks, and some of the external genital organs 
  • Sacral (vertebrae S1 – S5): Lower back; controls the thighs down to the feet, anus, and most of the external genital organs 

 

Types of Spinal Cord Injuries 

Spinal cord injuries may be classified by level and degree of impairment. There are four types of spinal cord injuries [5]. 

 

Injury Level 
  • Tetraplegia or Quadriplegia: Injury at the cervical level; loss of feeling or movement to the head, neck, and down. People with this type of spinal cord injury have the most impairment. 
  • Paraplegia: Injury at the thoracic level or below; limited or complete loss of feeling or movement to the lower part of the body.  

 

Impairment 
  • Incomplete spinal cord injury: Some sensation and mobility below the level of injury as the spinal cord can still transmit some messages from the brain. 
  • Complete spinal cord injury: Total loss of all sensation and mobility below the level of injury. Spinal cord injuries of this type have the greatest functional loss. 

Spinal Cord Injury Complications 

Complications from spinal cord injuries can be physical, mental, or social, and can impact overall quality of life. There are six common complications of spinal cord injuries [2]. 

 

Depression 

Studies show that 32.9% of adults with disabilities experience frequent mental distress [7]. Mental distress may be related to functional limitations, chronic disease, and the increased need for healthcare services.  Up to 37% of people with spinal cord injuries develop depression [2]. 

 

Pressure injuries 

People with spinal cord injuries may have problems with circulation and skin sensation– both risk factors for pressure injuries. Some may be bedridden or wheelchair-bound which also places them at risk for pressure injuries. Up to 80% of people with spinal cord injuries will have a pressure injury during their lifetime and 30% will have more than one [2].  

 

Spasticity 

Around 65% - 78% of people with spinal cord injuries have spasticity [2]. Spasticity is uncontrolled muscle tightening or contraction. The damage from spinal cord injuries causes misfires in the nervous system leading to twitching, jerking, or stiffening of muscles. 

 

Autonomic dysreflexia 

In some people with spinal cord injuries, a full bladder or bowel distention can cause a potentially dangerous condition called autonomic dysreflexia. The full bladder or bowel triggers a sudden exaggerated reflex that causes an increase in blood pressure. This condition is also associated with a severe headache, low heart rate, cold skin, and sweating in the lower body [8]. 

 

Respiratory problems 

If the diaphragm function is affected, as with cervical spinal cord injuries, there may be breathing difficulties. People with lumbar spinal cord injuries can even have respiratory problems as the abdominal muscles are used to breathe. 

 

Sexual problems 

Due to changes in muscle function and depending on the degree of damage, people with spinal cord injuries may have problems with arousal and climax due to altered sensations and changes in sexual reflexes.  

 

Changes in bowel and bladder function 

Many people with spinal cord injuries lose bowel control. Bowel problems can include constipation, impaction, and incontinence. They may also have problems with urination, for example, urinary retention. 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why might a person with a disability experience mental distress? 
  2. In what type of spinal cord injury does a person lose all sensation and mobility below the waist? 
  3. Why are people with spinal cord injuries at risk for pressure injuries? 
  4. How can spinal cord injuries affect a person’s personal relationships? 

Bowel and Bladder Dysfunction in Spinal Cord Injuries 

This section will cover the normal function of the bowel and bladder, and the types of bowel and bladder dysfunction that occurs in patients with spinal cord injuries.

Quiz Questions

Self Quiz

Ask yourself...

Think about a time you assisted with bowel or bladder management in someone with a spinal cord injury. 

  1. What types of activities were included in their bowel or bladder regimen? 
  2. What challenges did you encounter during bowel or bladder care? 
  3. What difficulties did they express to you about managing their bowel or bladder program? 
  4. In what ways did you assist them in managing their own bowel or bladder program?

Normal Bowel and Bladder Function 

In normal bowel and bladder function, when the rectum or bladder fills with stool/urine and presses on area nerves (stimulation), the message is sent to the spinal cord which sends it to the brain. The brain gives the person the “urge” feeling, allowing an option to control the elimination or not.  

Whatever decision the person makes, the brain sends the message back to the spinal cord, which in turn sends a message to the elimination muscles (anal and bladder sphincters) to either relax or stay closed until the person is ready. In people with spinal cord injuries, the messages are limited or blocked, leading to problems with bowel and bladder control [9] [10].  

 

Bowel Dysfunction with Spinal Cord Injuries 

Reflex hypertonic neurogenic bowel occurs when a rectum full of stool presses against area nerves sending a message to the spinal cord, but it stops there. The message never makes it to the brain, so the person never gets the urge.  

As a result, a reflex is set off, prompting the spinal cord to send a message to the anal muscle (sphincter) instead, causing it to relax and release the stool. This condition leads to bowel incontinence and usually occurs in spinal injuries at the cervical and thoracic levels [9] [10]. 

Flaccid hypotonic bowel occurs when area nerves are also stimulated by a full rectum, but the message does not even reach the spinal cord, so there is no reflex. The anal sphincter is always in a relaxed state.  

As a result, the bowels simply empty when they are full, and this can occur at any time without the person having the ability to control it. This condition results in bowel incontinence and can lead to constipation as the patient does not have the urge and may not have the ability to push. This condition usually occurs in spinal injuries at the lumbar level [9] [10]. 

 

Bladder Dysfunction with Spinal Cord Injuries 

Reflex neurogenic bladder occurs when the bladder automatically starts to contract after filling with a certain amount of urine. The person has no urge to go as the messages are either limited or blocked from reaching the brain, therefore leading to loss of bladder control. Similar to reflex hypertonic neurogenic bowel, the full bladder triggers are nerves that set off a reflex, prompting the spinal cord to send messages to the bladder releasing urine outside of the person’s control [9] [10]. 

Acontractile bladder occurs when the bladder loses muscle tone after a spinal cord injury, lessening its ability to contract, leading to bladder distention, and dribbling of urine. People with this condition need to use urinary catheters to help empty the bladder [9]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one role of the brain in bowel and bladder function? 
  2. Which type of bowel dysfunction occurs in thoracic-level spinal cord injuries? 
  3. In which type of bowel dysfunction might a suppository be most effective? 
  4. In which type of bladder dysfunction does the bladder lose muscle tone? 

The Nurse’s Role in Bowel and Bladder Management 

This section will cover how nurses can assess, intervene, and teach when caring for patients with spinal cord injuries who have bowel and bladder dysfunction.

Quiz Questions

Self Quiz

Ask yourself...

Think about your experiences with patients with spinal cord injuries and their family or caregivers. 

    1. How knowledgeable was the patient about their bowel or bladder care? 
    2. In what ways were the family or caregiver involved in the plan of care? 
    3. Did the family or caregiver have any learning gaps that needed to be addressed? 
    4. What difficulties did the family or caregiver express to you about their role? 

Nurse Assessments 

When caring for patients with spinal cord injuries, nurses should obtain a detailed bowel and bladder history including diet, fluid intake, medications, and elimination patterns/habits [11]. Many of these patients may already manage their own bowel and bladder care at home.  

If so, the nurse should obtain the patient’s current regimen and communicate the information to the physician. The physician may choose to continue the regimen or adjust as needed based on the patient’s current illness/condition.  

 

Questions the nurse can ask the patient: 
  • What does your typical diet consist of? 
  • How much fluid do you drink on a daily basis? 
  • How often do you have a bowel movement or urinate? 
  • Do you schedule your bowel movements with assistance from medications? 
  • Are there certain body positions or things you do to help you pass stool more easily?
  • How often do you use an intermittent urinary catheter for bladder relief? 
  • How much time do you spend on your bowel and bladder regimens? 
  • Do you care for all of your elimination needs or does someone help you? 
  • How does your bowel and bladder dysfunction affect your quality of life? 

 

Some assessments may be observed. For example, nurses may notice that the patient has a surgically placed permanent suprapubic urinary catheter or colostomy (when the bowel is cut somewhere above the level of the rectum and diverted to the outside of the abdomen). 

 

Nurse Interventions 

Since many patients with spinal cord injuries have problems with bowel and bladder function, elimination must be scheduled. Nurses can help by implementing bowel and bladder programs and providing education and support to patients, families, or caregivers.  

 

Regimens 

Follow the patient’s home bowel and bladder regimen (as ordered). This may include maintaining intermittent catheterization every few hours or administering suppositories daily.  

For patients who do not have a regimen already or wish to modify their current one, encourage them to pay attention to how often they urinate and pass stools, elimination problems, foods that alleviate or worsen the problem, and medications or other things that help. This can be done through a diary. 

 

Dietary Considerations 

Educate patients on the importance of a fiber-rich diet to avoid constipation. Patients should also be made aware that high-fat foods, spicy foods, and caffeine can alter gut dynamics and lead to bowel incontinence episodes [12]. 

 

Fluid Intake 

Some patients may avoid drinking enough water to avoid bladder complications (e.g., frequent incontinent episodes) [12]. However, nurses should educate patients on the importance of adequate fluid intake to prevent constipation. Patients should be made aware that bladder and bowel elimination regimens go hand in hand. 

 

Bladder Elimination 

For bladder dysfunction, help patients perform intermittent urinary catheterization as needed or place a temporary urinary catheter (as ordered). 

 

Bowel Elimination 

For bowel dysfunction, administer ordered suppositories and laxatives to help the bowels move (use suppositories in conjunction with the level of sensation the patient has near the anus/rectum) [9]. Changes in body position may help as well.  

While many of these interventions may not work in some patients with spinal cord injuries, bowel irrigation (water enemas) may be helpful [11]. Surgical placement of a colostomy may be indicated if all other measures have failed [11]. 

 

Emotional Support 

Ensure privacy and sensitivity during all elimination care as patients may experience embarrassment or frustration. 

 

Education for Families or Caregivers 

Provide education to families or caregivers on the importance of helping patients stay consistent with their elimination regimen, follow diet and fluid intake recommendations, and comply with medication orders.  

 

Referrals 

Inform the physician if interventions are not effective or if the patient, family, or caregiver has a special need (e.g., counselor or dietician). Refer patients and families or caregivers to support groups as needed.

 

Support Groups and Resources 

Christopher and Dana Reeve Foundation 

Christopher Reeve – an actor who was left paralyzed after an equestrian accident – and his wife Dana’s legacy lives on through their foundation, an organization that advocates for people living with paralysis [13].  

 

Miami Project to Cure Paralysis 

In response to his son, who acquired a spinal cord injury during college football, NFL Hall of Famer Nick Buoniconti and world-renowned neurosurgeon Barth A. Green, M.D. started a research program aimed at finding a cure for paralysis and discovering new treatments for many other neurological injuries and disorders [14]. 

 

National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) 

The National Institute on Disability, Independent Living, and Rehabilitation Research, a part of the U.S. Department of Health and Human Services’ Administration for Community Living, helps people with disabilities integrate into society, employment, and independent living [15].  

 

Paralyzed Veterans of America (PVA)  

A group of World War II veterans who returned home with spinal cord injuries, started this organization to support those with spinal cord injuries and dysfunction. Today, the organization focuses on quality health care, research and education, benefits, and civil rights to affected veterans [16].  

 

United Spinal Association 

The United Spinal Association supports people with spinal cord injuries and those in wheelchairs. The organization advocates for disability rights like access to healthcare, mobility equipment, public transportation, and community support. Support groups can be found on their website [17).  

Quiz Questions

Self Quiz

Ask yourself...

  • What is one question a nurse can ask a patient to obtain a bowel and bladder history? 
  • How can nurses help patients with spinal cord injuries start or modify a bowel or bladder regimen? 
  • When might a colostomy be indicated for a patient with a spinal cord injury? 
  • What type of referral might be ordered for a patient with a spinal cord injury who has bowel or bladder dysfunction?

Conclusion

Spinal cord injuries can have devastating effects on patients and their families. Management of basic bodily functions like bowel and bladder elimination should be made as easy as possible for these patients.

When nurses learn how to effectively help patients with spinal cord injuries better manage their own bowel and bladder regimens, quality of life and health outcomes may be improved for this group.

Pressure Injury Prevention, Staging and Treatment

Introduction   

When hearing the term HAPI, what comes to mind? The fact is, HAPI may not necessarily generate happy thoughts. Hospital-acquired pressure injuries (HAPIs) are a significant problem in the U.S. today. In fact, pressure injuries in general – whether acquired in a hospital or not – are a global problem.

Many articles have noted that staging and differentiating pressure injuries can be overwhelming for nurses [9]. The purpose of this course is to equip learners with the knowledge needed to reduce pressure injuries, resulting complications, financial risk, and associated death. The information in this course will serve as a valuable resource to nurses from all specialties and backgrounds.

What is a pressure injury?

The National Pressure Injury Advisory Panel (NPIAH) defines pressure injuries as “localized damage to the skin and underlying soft tissue usually over a bony prominence or related to a medical or other device” [17]. Pressure injuries can present as intact or opened skin and can be shallow or deep. Pressure injuries can be quite painful for patients and may require extensive treatment.

Prior to 2016, pressure injuries were termed “pressure ulcers.” However, since ulcer implies “open skin,” the NPIAH changed it to “pressure injury” as the skin is not always open with some of these injuries [22][25].

 

What causes a pressure injury to develop?

Pressure 

Intense and/or prolonged pressure on the patient’s skin and/or tissue can cause compromised blood flow and decreased sensation [7]. This can occur when patients lay or sit on a bony prominence for an extended period of time [16].  

Bony prominences are areas where you can easily feel a bone underneath the skin or tissue when palpating. These can include the heels, hips, elbows, and tailbone. Approximately two-thirds of all pressure injuries occur on the hip and buttocks area [7]. 

 
Friction and Shear 

Friction and shear often happen when patients slide down in bed, for example, when the head of the bed is raised. Although “friction and shear” are often used together, there is actually a difference between the two.  

While friction occurs when skin is dragged across a coarse surface (leading to surface-level injuries), shearing occurs when internal bodily structures and skin tissue move in opposite directions (leading to deep-level injuries) [10]. Shearing is often associated with a type of pressure injury called deep tissue injury (occurring in the deeper tissue layers rather than on the skin’s surface) [10].

 

[24] 

 

What are risk factors for developing a pressure injury? 

There are numerous risk factors for pressure injuries – some of which may not be directly related to the skin. These risk factors can be categorized as either intrinsic factors (occurring from within the body) or extrinsic (occurring from outside of the body) [2][13]. 

 

Intrinsic Risk Factors 

- Poor skin perfusion (e.g., peripheral vascular disease or smoking) 

- Sensation deficits (e.g., diabetic neuropathy or spinal cord injuries) 

- Moist skin (e.g., urinary incontinence or excessive sweating) 

- Inadequate nutrition (particularly poor protein intake) 

- Poor skin elasticity (e.g., normal age-related skin changes) 

- End of life/palliative (leads to organ failure including the skin) 

- Limited mobility (i.e., bedridden, or wheelchair-bound) 

 

Extrinsic Risk Factors 

- Physical and chemical restraints (leads to limited mobility) 

- Undergoing a procedure (laying down for extended periods of time) 

- Length of hospital stay (for HAPIs) 

- Medical devices (can lead to medical device-related pressure injuries)

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the most common areas for pressure injuries to develop? 
  2. What is the major difference between friction and shear? 
  3. What is one reason why elderly adults are at an increased risk for developing a pressure injury? 

Statistical Evidence 

This section will cover pressure injury statistics both globally and nationally. This section will also cover the impact pressure injuries have on healthcare.

What is happening on a global scale? 

In a global study, researchers found that the prevalence (all cases) and incidence (new cases) of pressure injuries in 2019 were 0.85 million and 3.17 million, respectively – numbers that have decreased over time [23][25]. Numbers were disproportionately high in high-income North America, Central Latin America, and Tropic Latin America [25]. Numbers were lowest in Central Asia and Southeast Asia. The report revealed that although numbers are high overall, they are much lower than what they were predicted to be, which may be attributed to better prevention and treatment initiatives.

What is happening nationally? 

In the U.S., 2.5 million people develop pressure injuries each year [1]. This number does not account for the many people trying to manage pressure injuries on their own at home (i.e., when family acts as the caregiver).  

HAPIs in particular are a growing problem. The most recent data on hospital-acquired conditions in the U.S. shows that from 2014 to 2017, HAPIs increased by 6% (647,000 cases in 2014 to 683,000 in 2017) [6]. Each year 60,000 patients in the U.S. die as a direct result of pressure injuries [1]. 

How do pressure injuries impact healthcare? 

Pressure injuries can be quite costly to the healthcare system. These injuries can lead to persistent pain, prolonged infections, long-term disability, increased healthcare costs, and increased mortality [1].  

In the U.S., pressure injuries cost between $9.1 - $11.6 billion per year [1]. These injuries are complex and can be difficult to treat [7]. Often requiring an interdisciplinary approach to care, the costs of one pressure injury admission can be substantial. Individual care for patients with pressure injuries ranges from $20,900 to $151,700 per injury [1]. Not to mention, more than 17,000 lawsuits are related to pressure injuries every year [1].  

Due to the significant impact that these injuries have on healthcare, prevention and accurate diagnosis is imperative.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are possible contributing factors to the increase in HAPIs in the U.S.? 
  2. What are some factors that may contribute to the high costs of pressure injuries in healthcare settings?

Staging and Diagnosis 

The section will cover the staging, varying types, and diagnosis of pressure injuries.  

 

What is the difference between wound assessment and staging? 

Pressure injury staging is more than a basic wound assessment. Wound assessment includes visualizing the wound, measuring the size of the wound, paying attention to odors coming from the wound, and lightly palpating the area on and/or around the wound for abnormalities. Pressure injury staging, however, involves determining the specific cause of injury, depth of skin or tissue damage, and progression of the disease.  

 

What are the six stages of pressure injuries? 

According to NPIAP guidelines, there are six types of pressure injuries – four of which are stageable [14]. 

 

[16] 

 

Stage 1 

In Stage 1 pressure injuries, there is intact skin with a localized area of non-blanchable erythema (pink or red in color), which may appear differently in darkly pigmented skin. Before visual changes are noted, there may be the presence of blanchable erythema or changes in sensation, temperature, or firmness. Stage 1 pressure injuries do not have a purple or maroon discoloration (this can indicate a deep tissue pressure injury). 

 

Stage 2 

In Stage 2 pressure injuries, there is partial-thickness loss of skin with exposed dermis. The wound bed is viable, pink or red, moist, and may represent an intact or opened serum-filled blister. Fat (adipose) and deeper tissues are not visible. Granulation tissue, slough (soft moist material, typically yellow or white), and eschar (hard necrotic tissue, typically black in color) are not present. Stage 2 injuries cannot be used to describe wounds associated with moisture-only, skin chaffing, medical adhesives, or trauma. 

 

Stage 3 

In Stage 3 pressure injuries, there is full-thickness loss of skin, in which fat is visible in the injury, and granulation tissue and rolled wound edges are often present. Slough and/or eschar may be noted. The depth of tissue damage is dependent on the area of the wound. Areas with a significant amount of fat can develop deep wounds.  

Undermining (burrowing in one or more directions, may be wide) and tunneling (burrowing in one direction) may be present. Fascia, muscle, tendon, ligament, cartilage, and/or bone are not exposed. If slough or eschar covers the extent of tissue loss, this would be considered an unstageable pressure injury, not a Stage 3. 

 

Stage 4 

In Stage 4 pressure injuries, there is full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone in the wound. Slough and/or eschar may be visible. Rolled wound edges, undermining, and/or tunneling are often present. The area where the wound is present will determine the depth. As with stage 3 pressure injuries, if slough or eschar covers the extent of tissue loss, this would be considered an unstageable pressure injury. 

 

Unstageable 

In unstageable pressure injuries, there is full-thickness skin and tissue loss in which the extent of tissue damage within the wound cannot be confirmed because it is covered by slough or eschar. If the slough or eschar is removed, a Stage 3 or Stage 4 pressure injury will be revealed. Stable eschar (i.e., dry, adherent, intact without erythema or fluctuance) on an ischemic limb or the heel(s) should not be removed.  

 

Deep Tissue Injury 

In deep tissue pressure injuries (also termed: deep tissue injuries or DTIs), there is intact or non-intact skin with localized area or persistent non-blanchable deep red, maroon, purple discoloration, or epidermal separation revealing a dark wound bed or blood-filled blister.  

Pain and temperature changes often precede skin color changes. Discoloration may appear differently in darker-pigmented skin. The injury may resolve without tissue loss or may worsen quickly and open up, revealing the actual extent of tissue injury. Deep tissue pressure injuries should not be used to describe vascular, traumatic, neuropathic, or dermatologic conditions.  

Quiz Questions

Self Quiz

Ask yourself...

  1. How do basic wound assessments differ from pressure injury staging? 
  2. What is the main difference between a Stage 1 pressure injury and deep tissue injury? 
  3. What is one structure you might see in a Stage 4 pressure injury wound bed that you would not see in any other pressure injury?

What are other types of pressure injuries? 

Mucosal Membrane Pressure Injury 

Mucosal membrane pressure injuries are found on mucous membranes with a history of a medical device in use at the location of the injury. For example, a wound on the inside of a nostril from a nasogastric tube would be considered a mucosal membrane pressure injury. Due to the anatomy of the tissue, mucosal membrane pressure injuries cannot be staged [18]. 

 

Medical Device-Related Pressure Injury 

Medical device-related pressure injuries, often associated with healthcare facilities, resulting from the use of devices designed and applied for diagnostic or therapeutic purposes [15]. The resulting pressure injury typically conforms to the pattern or shape of the device which makes identification easier. The injury should be staged using the staging system.  

 

Hospital Acquired Pressure Injury (HAPI) 

While the general hospital setting places patients at a 5% to 15% increased risk of developing a pressure injury (HAPI), patients in the intensive (or critical) care unit in particular have an even higher risk [17]. Critical care patients typically have serious illnesses and conditions that may cause temporary or permanent functional decline. There is also evidence that pressure injuries in this setting can actually be unavoidable.  

The NPIAP defines “unavoidable” pressure injuries as those that still develop after several measures by the health provider have been taken. These measures include when the provider has (a) evaluated the patient’s condition and pressure injury risk factors, (b) defined and implemented interventions consistent with standards of practice and the patient’s needs and goals, and (c) monitored and evaluated the impact of interventions [20]. There are certain situations in which a critical care patient may have a higher risk of developing unavoidable pressure injuries.  

In one study of 154 critical care patients, researchers found that 41% of HAPIs were unavoidable and those who had a pressure injury in the past were five times more likely to develop an unavoidable pressure injury during their stay [20]. The study also found that the chance of developing an unavoidable HAPI increased the longer patients stayed in the hospital – a 4% risk increase each day.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What type of pressure injury can be caused by nasogastric tube use? 
  2. What is it about critical care patients that places them at a high risk for HAPIs? 
  3. In what situation is a pressure injury considered unavoidable?

How are pressure injuries diagnosed? 

Diagnosing a pressure injury is done by simply staging the injury. The health provider may stage the injury or rely on the nurse’s staging assessment before giving the final diagnosis and initiating treatment. There are tests that may be ordered to help identify the early stages of a developing injury.  

For example, subepidermal moisture assessment (SEM) scanners may help to identify tissue changes early on in patients with darker skin tones [8]. Tests may also be ordered to determine the extent of the damage, disease, or infection caused by a pressure injury. A magnetic resonance imaging test (MRI) can be used to determine if the infection in a stage 4 pressure injury has spread to the bone. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some problems that can occur if a pressure injury is not staged correctly?  
  2. What is one reason a provider would order an MRI of a pressure injury?

Prevention and Treatment 

This section will cover various strategies that can be used to prevent and treat pressure injuries. 

 

What are some ways to prevent pressure injuries? 

Preventing pressure injuries takes more than just one nurse repositioning a patient every two hours. It involves a combination of strategies, protocols, and guidelines that facilities can implement across various departments, specialties, and care team members. The NIAPH recommends the following prevention strategies [19]. 

 

Risk assessment 

Facilities should use a standardized risk assessment tool to help identify patients at risk for pressure injuries (i.e., the Braden or Norton Scale). Rather than using the tool as the only risk assessment strategy, risk factors should be identified by other means (for example, by gathering a detailed patient history).  

Risk assessments should be performed on a regular basis and updated as needed based on changes in the patient’s condition. Care plans should include risk assessment findings to address needs. 

 

Skin Care 

Monitoring and protecting the patient’s skin is vital for pressure injury prevention. Stage 1 pressure injuries should be identified early to prevent the progress of disease. These include looking at pressure points, temperature, and the skin beneath medical devices.  

The frequency of assessments may change depending on the department. Ideally, assessments should be performed upon admission and at least once daily. Skin should also be cleaned promptly after incontinence episodes. 

 

Nutritional Care 

Tools should be used that help to identify patients at risk for malnutrition. Patients at risk should be referred to a registered dietician or nutritionist. Patients at risk should be weighed daily and monitored for any barriers to adequate nutritional intake. These may include swallowing difficulties, clogged feeding tubes, or delays in intravenous nutrition infusions. 

 

Positioning and mobilization 

Immobility can be related to age, general poor health, sedation, and more. Using offloading pressure activities and keeping patients mobile overall can prevent pressure injuries. Patients at risk should be assisted in turning and repositioning on a schedule. Pressure-relieving devices may be used as well. Patients should not be positioned on an area of previous pressure injury. 

 

Monitoring, training, and leadership 

Current and new cases of pressure injuries should be documented appropriately and reported. All care team members should be educated on pressure injury prevention and the importance of up-to-date care plans and documentation.  

All care team members should be provided with appropriate resources to carry out all strategies outlined. Leadership should be available to all care team members for support (this may include a specialized wound care nurse or wound care provider). 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one reason why a patient at risk for pressure injuries would be weighed daily? 
  2. What are two ways to prevent pressure injuries in a patient with limited mobility?

How are pressure injuries treated? 

There is no one way to treat a pressure injury. Management of pressure injuries involves a specialized team of care providers and a combination of therapies that aim to target underlying factors and prevent complications [7]. Depending on the stage of the wound and skin risk factors, providers may order specific types of treatments.  

Some pressure injury treatments may include the following [7]. 

- Wound debridement – a procedure in which necrotic tissue is removed from a wound bed to prevent the growth of pathogens in the wound, allowing for healing 

- Antibiotic therapy (topical or systemic) 

- Medicated ointments applied to the wound bed (e.g., hydrogels, hydrocolloids, or saline-moistened gauze to enable granulation tissue to grow and the wound to heal) 

- Nutritional therapies (e.g., referrals to dieticians) 

- Disease management (e.g., controlling blood sugar in diabetes) 

- Pain medications 

- Physical therapy (to keep the patient active) 

Quiz Questions

Self Quiz

Ask yourself...

  1. In what way does debridement help to heal a pressure injury? 
  2. What non-nursing care team member may be consulted for a patient with a pressure injury?

The Nurse’s Role 

The section will cover the nurse’s role in preventing pressure injuries and the progression of disease.  

 

What is the nurse’s role in pressure injury prevention? 

Based on NPIAH guidelines, the Agency for Healthcare Research and Quality (AHRQ) – an agency that monitors pressure injury data for the U.S. – breaks down quality initiatives for preventing pressure injuries in a three-component care bundle [2].  

A care bundle is a combination of best practices that when used together, can lead to better patient outcomes [2]. The care bundle includes skin assessments, risk assessments, and care planning. Nurses should follow the guidelines listed under each component. 

Standardized pressure injury risk assessment 

- Use risk assessment tools and processes to identify patients at risk 

- Do not rely on tools only, use your own judgment as well (tools are meant to guide the assessment) 

- Update risk scores at least once daily and if patient’s condition changes 

- Document findings in the medical record 

- Communicate findings to other staff involved for continuity of care (e.g., informing another nurse during patient handoff reporting) 

 

Comprehensive skin assessment 

- Identify any pressure injuries that may be present 

- Determine whether there are other areas of skin breakdown or factors that may predispose the patient to develop a pressure injury (e.g., moist skin) 

- Identify other skin issues 

- Perform assessments at regular intervals 

- Document findings in the medical record 

- Communicate findings to other staff involved in care so that appropriate changes can be reported (e.g., informing the nursing assistant) 

- Ask colleague to confirm findings for accuracy (i.e., two-nurse skin checks) 

 

Care planning and implementation to address areas of risk 

- Create care plans that include each skin risk factor (e.g., nutrition, mobility, and moisture) 

- Update care plans as often as needed if there are any changes in the patient’s condition 

- Evaluate whether care plan was effective by assessing patient response to interventions 

-  Individualize care plans for each patient based on risk assessment scores and other observed risks 

- Identify patient learning needs and implement teaching as needed 

- Document care plan in the medical record 

- Communicate care plan to other staff involved for continuity of care (e.g., informing another nurse during patient handoff reporting) 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why should nurses avoid relying solely on standardized assessment tools? 
  2. Why is documentation important when performing a skin assessment? 
  3. What pressure injury information should nurses communicate during handoff report?

How can nurses prevent medical device-related pressure injuries?

The NPIAP outlined best practices to prevent medical device-related pressure injuries in various settings including general care, long-term care, critical care, and pediatric care [20]. The following strategies apply across all settings. 

- Choose the correct size of medical device for the individual. 

- Cushion and protect the skin with dressings in high-risk areas (e.g., nasal bridge). 

- Inspect the skin under and around the device at least daily (if not medically contraindicated).  

- Rotate sites of oximetry probes.  

- Rotate between O2 mask and prongs (if feasible).  

- Reposition devices (if feasible).  

- Avoid placement of device over sites of prior or existing pressure injury OR directly under the patient.  

- Be aware of edema under the device and the potential for skin breakdown. 

- Change rigid C-collar to softer collar when medically cleared (for critical care settings).

Quiz Questions

Self Quiz

Ask yourself...

  1. How can nurses prevent a pressure injury from developing on the ear of a patient who wears a nasal cannula?

How can nurses identify pressure injuries in patients with darker skin tones? 

Research suggests that it may be difficult to note early changes that can lead to the development of a pressure injury in patients with darker skin tones – for one, blanching may not be as visible [8]. This places the patient at a greater risk for the advancement of disease as early identification may be challenging.  

In order to appropriately identify pressure injuries in patients with darker skin tones, nurses should use unique strategies. The NIPAH offers these recommendations for nurses to help accurately identify pressure injuries in this group [8]. 

 

Identification tips 

- Clean the suspected area beforehand 

- Compare the area to surrounding unaffected areas 

- Compare the area to the opposite laterality if possible (i.e., right versus left elbow) 

- Compare the area to unaffected areas in a different location (i.e., upper back versus chest) 

- Look for differences in skin tautness 

- Look for shining skin changes 

- Palpate for changes in skin temperature 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one way to identify pressure injuries in patients with darker skin tones? 

How can nurses quickly differentiate between pressure injury stages? 

Correct staging of pressure injuries is vital as treatment is determined by the extent of damage, disease, or infection. First and foremost, wounds should be gently cleaned prior to staging as drainage or debris can be mistaken for fat or bone within the wound bed [14].  

Nurses can quickly differentiate between stages by asking these simple easy-to-understand starter questions. A more detailed assessment should follow. 

- Stage 1 versus Stage 2: Is the skin intact? 

Rationale: The skin is always intact in Stage 1. The skin is always open in Stage 2 (or there may be an intact blister present). 

- Stage 2 versus Stage 3: Is the wound bed pink or beefy red? 

Rationale: The wound bed is pink or beefy red in Stage 2. In Stage 3, the wound bed has structures within that may be discolored. 

- Stage 3 versus Stage 4: Does the wound bed contain soft or firm structures? 

Rationale: The wound bed contains softer structures in Stage 3. The wound bed contains firmer structures in Stage 4.* 

- Unstageable versus Stageable: Is any part of the wound bed hidden? 

Rationale: The wound bed is not entirely exposed in an unstageable. The wound bed is exposed in a stageable that is open. 

- Intact DTI versus Stage 1: Is the discoloration light or dark? 

Rationale: The discoloration is dark in a DTI. The discoloration is much lighter in Stage 1. 

- Open DTI versus Stage 2: Is the discoloration in or around the wound bed dark? 

Rationale: There is dark discoloration in or around the wound bed in an open DTI. In stage 2, the discoloration is much lighter (if even present). 

 

*Nurses should familiarize themselves with the appearance of the various structures that may be present in a wound like fat, fascia, bone, tendon, ligament, etc. Most importantly, nurses should consult the wound care team or health provider if a stage cannot be determined. 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why should nurses clean a wound prior to staging? 
  2. What should nurses do if unsure how to stage a pressure injury?

What should patients know? 

Facilities can use the NIAPH prevention strategies to devise teaching plans for patients [19]. Nurses should educate patients and families/caregivers on risk factors, signs and symptoms, prevention tips, and the importance of following through with treatment.  

Nurses should also teach patients to advocate for their own health in order to avoid progression of disease. Here are important tips to teach at any point during the patient’s stay. These tips can apply to nurses working in a variety of settings. 

- Tell the nurse or provider of your medical conditions (needed to identify risk factors) 

- Tell the nurse or provider if you notice any numbness or tingling in your body (potential risk for sensory deficits) 

- Tell the nurse or provider if you have a loss of appetite or trouble eating (potential risk for malnutrition) 

- Clean yourself well after using the restroom (maintains skin integrity) 

- Tell the nurse or provider if you need to use the restroom or need help with cleaning yourself (maintains skin integrity) 

- Tell the nurse right away if you have an incontinence episode (maintains skin integrity) 

- Take all prescribed medications (may include necessary antibiotics or wound-healing medications) 

- Reposition yourself in bed often or tell the nurse if you need help doing so (reduces immobility risk) 

- Tell the nurse or provider if you notice a new discolored area on your skin, or an open area (potential new or worsening pressure injury) 

- Tell the nurse or provider if you notice any changes to your wound (potential worsening pressure injury) 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one pressure injury prevention tip nurses can teach hospitalized patients? 
  2. What signs or symptoms should nurses teach the patient to report?

Quality Improvement 

This section will cover the quality improvement measures in place to reduce pressure injuries. 

What is a pressure injury quality improvement initiative? 

Quality improvement involves setting goals (or initiatives) and standards of care. The goal of quality improvement is to improve patient outcomes at a systematic level where everyone involved is on the same page.  

Although possibly unaware, all care team members are involved in quality improvement. Nursing leaders design, manage, and evaluate program initiatives. Staff nurses and other care team members follow protocols that are often developed from these initiatives.  

The Pressure Injury Prevention Program is a guide designed by the AHRQ to help health facilities implement a structured pressure injury prevention initiative based on quality improvement [12]. Facilities can use the guide as a training toolkit to implement a new quality improvement program [5].  

 

Initiative Goals: 

- Reduced pressure injury rates 

- Reduced adverse events related to pressure injuries 

- Reduced costs associated with pressure injuries 

- Reduced lawsuits related to pressure injuries 

 

Ways facilities can implement a prevention program: 

- Address the overall objectives of the prevention program 

- Identify the needs for change and how to redesign practice 

- Develop goals and plans for change 

- Use the NIAPH pressure injury prevention recommended practices 

- Establish comprehensive skin assessment protocols 

- Standardize assessments of pressure injury risk factors 

- Incorporate risk factors into individualized care planning 

- Establish clear staff and leadership roles 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one reason why a health facility would start or update a pressure injury prevention program? 
  2. When pressure injury rates are reduced, what else can health facilities expect to improve as well?

What are some pressure injury quality measures? 

Quality measures are tools that measure a system’s healthcare goals and/or ability to provide high-quality care [11]. In simple terms, quality measures are specific ways that systems (governments, states, organizations, etc.) can show how they are making progress in meeting goals. The AHRQ highlights the following three ways the U.S. measures its progress.  

 

Number of HAPIs 

The AHRQ measures the number of HAPIs per year. The most recent data is from 2014 to 2017 [6].

 

Year  Number of HAPIs 
2014  647,000 
2015  700,000 
2016  677,000 
2017  683,000 

 

Rate of HAPIs per admission 

The AHRQ measures the number of HAPIs per admission related to age groups. The number is measured as a “rate,” meaning the number of HAPIs per 1,000 hospital admissions. The most recent evidence is from 2017 [4]. 

 

Age group  Number of HAPIs per 1,000 admissions 
18 – 39   0.38 
40 – 64   0.63 
65 – 74   0.74 
75 and over  0.71 

 

Costs of HAPIs 

Another quality measure is HAPI costs. While the AHRQ does not measure costs of HAPIs every single year, the most recent data is from 2017 [3].  

 

Year  Cost of HAPIs per patient 
2017  $8,573 – $21,075 

 

Deaths related to HAPIs 

Patient mortality rates related to HAPIs are a quality measure (calculated per 1,000 pressure injury cases). The most recent data is from 2017 [6]. 

 

Year  Number of deaths per 1,000 pressure injury cases 
2017  2.42 – 5.06  

  

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one way a health facility can show its progress in preventing pressure injuries? 
  2. What patient age range do you think has the most pressure injury rates? Age 65 to 74 or age 75 and over?

Conclusion

 Pressure injuries are complex conditions that can lead to poor patient outcomes and a burdened healthcare system. The best strategy in the care of patients with pressure injuries or those at risk is prevention.  

However, preventing these injuries involves more than individual nurses taking specific steps. Prevention of pressure injuries involves a team effort from all members of the care team and a systemic plan for improvement.

 

Negative Pressure Wound Therapy (Wound Vac)

Introduction   

Negative pressure wound therapy (NPWT), also known as a wound vac, can be a powerful tool in combatting acute and chronic wounds. It relies on generating a negative pressure on the surface of a difficult wound to promote wound healing.

The goal of this course is to develop an understanding of mechanism of action of NPWT, discuss appropriate nursing assessment of these wounds, evaluate adjunct treatment options and troubleshooting support tips.

We will review basic concepts of the integumentary system and the normal wound healing process to support the rationale of NPWT.

Definition

Negative pressure wound therapy (NPWT) is the application of sub-atmospheric pressure to help reduce inflammatory exudate and promote granulation tissue in an effort to enhance wound healing (4). The idea of applying negative pressure therapy is that once the pressure is lower around the wound, the gentle vacuum suction can lift fluid and debris away and give the wound a fighting chance to heal naturally.

NPWT has a long and interesting history. The idea of suctioning fluid from wounds as therapy is not a new concept. The process was first called “cupping” and was described in Ebers Papyrus around 500 BC; historians tell us that a form of wound suction was used around 1000 BC in China, 600 BC in Babylon and Assyria, and in 400 BC by Greeks who heated copper bowls over wounds to remove blood and fluids (5).

Modern medicine has built upon a very old concept. Thankfully, nurses have a slightly easier tool in NPWT devices than heating copper bowls.

Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name the various methods of wound treatments that you have encountered?
  2. Do you recognize how negative pressure can create suction?

Indications for Use 

Negative pressure wound therapy is widely used for the management of both acute and chronic wounds. This therapy is helpful for a broad range of wounds, from pressure ulcers to closed surgical incisions.  

The system is now implemented routinely for open wounds, such as open fractures, fasciotomies, diabetic foot ulcers, and infected wounds. Delayed wound healing and difficult wounds are seen more commonly in elderly patients and those with comorbidities (1).  

It’s important to review the basic anatomy of our integumentary system, types of wounds, and barriers to healing to understand the usefulness of NPWT. 

 

Basic Anatomy of Integumentary System 

Our integumentary system is considered the body’s largest organ. Our skin acts as a shield against heat, light, bacteria, infection, and injury. Other functions include body temperature regulation, storage of water and fat, sensory function, prevention of water loss, and a basic storage compartment for the organs (6).  

 

The skin is made up of 3 layers. Each layer has unique functions: 

  1. Epidermis 
  1. Dermis 
  1. Subcutaneous fat layer (hypodermis) 

 

The epidermis is the thin outer layer of our skin, it contains squamous cells, basal cells, and melanocytes (gives skin its color). The dermis is the middle layer of skin, it contains blood vessels, hair follicles, sweat glands, nerves, lymph vessels, fibroblasts, and sebaceous glands (6). It is important to remember that the dermis contains nerves and nerve receptors. 

The subcutaneous fat layer is the deepest layer of skin and is made up of a network of collagen and fat cells; this layer conserves the body's heat and protects the body from injury by acting as a shock absorber (6).

This design was created on Canva.com on September 28, 2023. It is copyrighted by Abbie Schmitt, RN, MSN and may not be reproduced without permission from Nursing CE Central. 

 

Types of Wounds 

Negative pressure wound therapy is primarily used to treat complex wounds that are non-healing or at risk of non-healing. It is also indicated for acute wounds when the wound cannot be closed due to the risk of infection, active infection, skin tension, or swelling (7).  

Closure or skin grafting of acute wounds, such as open fractures or burns, are at high risk for infection due to microorganisms becoming trapped in the soft tissue leading to abscess development.  

 

Examples of possible wounds to apply NPWT (1):  

  • Diabetic foot ulcers 
  • Bed sores 
  • Skin graft fixation  
  • Burns 
  • Crush injuries 
  • Sternal/abdominal wound dehiscence  
  • Fasciotomy wounds 
  • Animal bites 
  • Frostbite 

 

Barriers to Healing 

Age 

  • Increased risk of tearing and shearing due to thinning of epidermis and decrease in elastin 
  • Phases of healing are prolonged 
  • Increased risk of dehiscence as the dermis has slower contractility 
  • Skin more susceptible to bacterial growth and infections as pH becomes more neutral with age  

 

Co-morbidities 

  • Cardiopulmonary Disease 
  • Oxygen-transport pathways are affected 
  • O2 necessary for wound healing 
  • Diabetes Mellitus 
  • High glycemic levels predispose patients to infection 
  • Microvasculature and neuropathic components of DM increase the risk for impaired healing  
  • Poor glycemic control can increase the risk of ulceration and delayed healing 
  • Immune-suppressing conditions (Cancer, HIV, immunosuppressive therapy, immunosuppression syndrome) 
  • Inflammatory phase (immunology) is impaired 
  • Increased risk for infection 

 

Impaired Perfusion and Oxygenation 

  • Peripheral Vascular Impairment 
  • Proper perfusion is required for growth of new tissue and immunological responses of the tissue. 
  • Arterial insufficiency (blood flow to extremities) leads to necrosis or lack of response to edema. 

 

Neurological Impairment  

  • Peripheral neuropathy 
  • Complication related to DM, alcoholism, chemotherapy 
  • Loss of neuronal signaling and transmission 
  • Loss of the sensory ability to recognize and react to sensations of touch, pressure, temperature, pain. Example: patient leaving foot on hot surface because there was no pain sensation, leading to burn wound. 
  • Spinal cord injury 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Are you familiar with the layers and components that make up the integumentary system?
  2. Have you ever cared for a patient with a chronic wound?
  3. What are some ways the elderly population is at higher risk for prolonged wound healing?

Mechanism of Action 

The mechanism of action is dependent on applying negative pressure, which is below atmospheric pressure, to the wound. This pressure allows the gentle vacuum suction to lift fluid and exudate away from the wound to enhance healing (3).  

The vacuum is gentle because powerful suction would remove newly formed tissue as well. The mechanism of action is not only in removing fluid and debris from the tissue, but the pressure causes stimulation of the growth of granulation tissue at a macroscopic and microscopic level.  

The porous foam shrinks in size with the application of negative pressure and exerts strain on the wound bed, which leads to macro- and micro-deformation of the wound (3). Microdeformation is simply a term used to describe microscopic tissue cell reactions. This reaction can be compared to a battery jump-start of a car; the stimulation causes the battery to engage. 

NPWT systems consist of a sterile foam sponge, a semi-occlusive adhesive cover, a fluid collection system or canister, and a suction pump (1). The foam sponge is applied to the wound and covered. A fenestrated tube is embedded in the foam and the wound is sealed with adhesive tape to make it airtight, and the machine delivers continuous or intermittent suction, ranging from 50 to 125 mmHg (1). 

 


 

This design was created on Canva.com on October 1, 2023. It is copyrighted by Abbie Schmitt, RN, MSN and may not be reproduced without permission from Nursing CE Central. 

Proper application of the NPWT is important for the mechanism of action to be effective. Research supports that NPWT is effective at creating a stable wound environment, reduces inflammation and bacterial load, improves tissue perfusion, and stimulates granulation tissue and angiogenesis (1).  

Imagine you want to plant a garden in a swampy location, you would first need to divert the water and algae from the land, cover it with a greenhouse with consistent heat and pressure, and cultivate the soil for optimal growth. Similarly, NPWT creates the most ideal conditions possible for tissue regeneration.  

Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name the components of NPWT?
  2. Have you ever applied a wound vac dressing?
  3. Are you familiar with the other semipermeable materials that serve as a filter?

Contraindications 

NPWT would be contraindicated for the following: 

  • Wounds involving untreated osteomyelitis. 
  • Wounds that have exposed blood vessel 
  • Wounds with exposed nerves, anastomotic sites, or organs 
  • Wounds including open joint capsules 
  • Malignant wounds 
  • Wounds with necrotic tissue; it is recommended to excise first 

 

The following wounds could benefit from NPWT, but caution should be given (5): 

  • Wounds with visible fistula 
  • Wounds with exposed bone or tendon 
  • The bone or tendon should be isolated from direct pressure  
  • Patient with clotting disorders or that are taking anticoagulants, due to an increased risk of bleeding. 
  • Compromised microvascular blood flow to the wound bed. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Can you think of reasons a malignant, cancerous wound should not have NPWT?
  2. Have you ever dressed a wound prior to or following debridement?

Assessment 

A focused assessment should be done for patients with NPWT devices in place, both on the machine settings, the dressing, and the wound itself. Thorough documentation of the wound is essential to see the progression of wound healing. 

 

Suction Device Settings: 

  • Continuous or intermittent 
  • Pressure Setting: Range of pressure settings from -40mmHg to -200mmHg, which can be tailored for different types of wounds (7). This is set by the medical provider. 

 

Laboratory assessment is meaningful in wound care. Labs can be used to assess oxygenation or indicators of infection (6). 

 

Dressing Assessment 

The appearance of the NPWT and dressing should be clean, dry, intact, and sealed. The tubing should not be twisted or kinked, and the clear adhesive dressing should not be wrinkled or overlapping. Please see below an example of the appropriate appearance of a dressing. 

 

Wound Assessment: 
  • Anatomic location 
  • Type of wound  
  • Degree of tissue damage 
  • Description of wound bed 
  • Wound size 
  • Wound edges and surrounding skin 
  • Signs of infection 
  • Pain 

 

Anatomical Location  

Anatomical terms and numbering should be used to make sure the location of each wound is documented. Patients often have more than one wound, so the treatment needs to be specified for each wound.  

 

Wound Base 

Assess the color of the wound base. Healthy granulation tissue appears pink and moist due to the new capillary formation. The appearance of slough (yellow) or eschar (black) in the wound base should be documented and communicated to the health care provider (1).  

This tissue may need to be removed to optimize healing. If any discoloration or duskiness of the wound bed or wound edges are identified, the suction should initially be reduced or switched off (7).  

 

Type and Amount of Exudate 

Assess the color, thickness, and amount of exudate (drainage) The amount of drainage from wounds is categorized as scant, small/minimal, moderate, or large/copious.  

Terms are used when describing exudate: sanguineous, serous, serosanguinous, and purulent (6).  

  • Sanguineous: fresh bleeding  
  • Serous: Clear, thin, watery plasma 
  • Serosanguinous: Serous drainage with small amounts of blood noted 
  • Purulent: Thick and opaque. The color can be tan, yellow, green, or brown. This is an abnormal finding and should be reported to a physician or wound care provider. 

 

Wound Size  

Wounds should be measured on admission, wound vac dressing changes, or as needed for abnormal events. Many healthcare facilities use disposable, clear plastic measurement tools to measure the area of a wound.  

Consistent measurement is vital to the assessment of wound healing. 

  • Measure the greatest length, width, and depth of the wound in centimeters 
  • Examples of wound classification tools: 
  • NPUAP staging system for pressure injuries 
  • Payne-Martin classification system for skin tears 
  • CEAP (clinical, etiologic, anatomic, and pathophysiology) system for venous ulcers 

 

Tunneling or Undermining 

Tunneling is when a wound has moved underneath the skin, making a “tunnel.” The depth of tunneling can be measured by gently inserting a sterile, cotton-tipped applicator into the tunnel and noting the length from the wound base to the end of the tract (7). Undermining occurs when the tissue under the wound edges becomes eroded, resulting in a pocket beneath the skin at the wound’s edge.  

 

Healing Process 

It is important to recognize the entire process of normal wound healing. There are four phases of wound healing: hemostasis, inflammatory, proliferative, and maturation (6).  

Hemostasis begins immediately after injury, involving platelet aggregation and activation of clotting factor (6). A platelet “plug” is formed as fibrinogen converts to fibrin and binds to itself. Vasoconstriction occurs at this time, decreasing blood loss and allowing clot formation.  

The inflammatory phase begins right after the injury and the injured blood vessels leak and cause localized swelling. The swelling, warmth, pain, and redness present during this stage of wound healing are related to the release of white blood cells, growth factors, nutrients, and enzymes to help control bleeding and prevent infection (6).  

The proliferative phase of wound healing involves “rebuilding” with new tissue made up of collagen and extracellular matrix; granulation tissue is built stronger with proper oxygen and nutrients.  

Key nursing knowledge: Dark granulation tissue can indicate infection, ischemia, or poor perfusion. The maturation phase of wound healing is when collagen is remodeled, aligns along tension lines, water is reabsorbed so the collagen fibers can lie closer together and cross-link, and the wound fully closes (1). 

There are three types of wound healing: primary intention, secondary intention, and tertiary intention.  

Primary intention means that the wound healing is supported by sutures, staples, glue, or otherwise closed so the wound heals beneath the closure (6).  

Secondary intention must happen when the edges of a wound cannot be approximated, or “brought together,” so the wound heals with the production of granulation tissue from the bottom up (6).  

Wounds that heal by secondary intention are at higher risk for infection, so contamination prevention is essential. Pressure ulcers are an example of wounds that heal by secondary intention.  

Tertiary intention refers to a wound that needs to remain open, often due to severe infection. Wounds with secondary and tertiary intention have longer healing times (2). 

Alternatives when NPWT fails 
  • Hyperbaric Oxygen Therapy (HBOT): 
  • HBOT is a treatment in which the wound is exposed to pure oxygen in a pressurized chamber to enhance wound healing (3). 

 

  • Bioengineered Tissue:  
  • Skin grafting or bioengineered tissue to promote tissue growth and healing.  
  • Skin grafts are considered as a treatment option if a wound is so large that it can’t close on its own. In this procedure, skin is taken from another part of your body – usually your thigh – and transplanted onto the wound (2). 
  • Some grafts are made from human cell products and synthetic materials. Studies have shown that these increase the chances of poorly healing venous leg ulcers closing faster. (2) 
  • Electrical Stimulation Therapy:  
  • Electrical stimulation therapy applies electrical currents to stimulate wound healing and tissue generation (4). It may be used to treat chronic wounds or pressure ulcers. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever cared for a patient with a wound that was unable to be stitched or sutured?
  2. Can you describe the importance of thorough, descriptive documentation of multiple wounds?
  3. Can you think of barriers to the normal wound healing process?

Adjunct Treatment Options 

When selecting an adjunctive therapy for wound management, the patient's medical history, overall health, co-morbidities, ambulation status, psychosocial aspects, environmental factors, and the specific needs of the wound should all be considered. Each patient is unique, and an individualized care plan is the goal.  

Treatment of the underlying contributing disorder will be essential. For example, a patient with uncontrolled diabetes that has led to poor circulation can benefit from glycemic control.  

Take a look at the larger, holistic picture. It can be helpful for the healthcare team to create a concept map of problems that contribute to the wound. 

 

Topical Agents and Dressings 

Various creams, ointments, or dressings can promote wound healing and prevent infection. One example is silver-based products, which are commonly used in reducing bacterial burden and treating wound infection (4). 

 

Nutrition Therapy for Wound Healing 

Patients with wounds would benefit from nutrition consultation and ongoing support.  

Nutrients from foods help the body build and repair tissue and fight infection. An increase in calories and protein is important, as well as blood sugar control for diabetics.  

Vitamins C, D, B-6, B-12, folate, and others aid in repairing tissues (6). Minerals such as iron, magnesium, calcium, zinc, and others support the cardiovascular system making sure cells have enough oxygen, the nervous system, and immunological function (6). 

 

Compression Therapy 

Compression therapy uses pressure to reduce swelling and improve blood flow to the wound. There are common compression devices or stockings available. It is frequently used to treat venous leg ulcers (6). 

 

Hyperbaric Oxygen Therapy (HBOT) 

HBOT can also be used as an adjunct treatment in which the patient breathes pure oxygen in a pressurized chamber to increase the amount of oxygen in the blood, which enhances wound healing (3). 

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever provided patient education on how nutrition impacts the immune system and wound healing?

Troubleshooting Tips 

You may encounter complications with the wound dressing or the wound vac equipment. The most common complications associated with NPWT are pain, bleeding, and infection (7).  

The wound therapy relies on an adequate seal similar to a regular vacuum, so a loss of suction can result in ineffective treatment. If loss of seal occurs, the nurse should assess the seal around the wound dressing and note if the transparent adhesive sealant tape has either been misapplied or has come off due to poor contact with the underlying skin.  

A loss of suction could also result from incorrect placement of the suction drain tube, loss of battery power, blockage of the suction drain tube, or if the suction device is full of output (7). Sometimes the location of the wound leads to difficulty in keeping the dressing seal in place; for example, the abdomen or near joints, so movement can misplace the dressing and break the seal. Patient education is key to maintaining proper suction. 

 

Troubleshooting Tips: 

  • Confirm the machine is on and set to the appropriate negative pressure. 
  • Make sure the foam is collapsed and the NPWT device is maintaining the prescribed therapy and pressure. 
  • Assess the negative pressure seal and check for leaks. 
  • Check for kinks in the tubing and make sure all clamps are open. 
  • Avoid getting the machine wet. 
  • Assess the drainage chamber to make sure it is filling correctly and does not need changing. 
  • Address alarm issues: 
  • Canister may be full 
  • Leak in the system  
  • Low/dead Battery 
  • The device should not be turned off for more than two hours without ordered discontinuation. 
  • If the device is off, apply a moist dressing and notify the provider immediately. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name reasons the NPWT device may sound an alarm?
  2. Can you think of barriers to proper suction? (ex: kinks in tubing, full canister, etc.)

Case Study 

Mr. Smith is a 59-year-old male presented to his primary care provider and referred to general surgery; diagnosed with lymphedema and multiple, copiously draining ulcerations on the left lower extremity.  

The patient presented with lymphedema and multiple ulcerations on the left lower extremity with copious amounts of drainage. This is an ongoing, worsening issue for over 8 months and has failed to respond to compression, foam dressings, or hydrocolloid dressing.  

The hospitalist has ordered surgical consultation, who scheduled debridement of the wounds and application of a wound vac following the procedure; Negative pressure wound therapy (NPWT) orders in place.  

 

CHIEF COMPLAINT: "The sores on my feet are draining more and I can no longer go to work because my boots do not fit on my foot.” He also reports a loss of appetite, chills, and loss of sensation to his left lower extremity.  

HISTORY OF PRESENT ILLNESS: Patient is a 59-year-old truck driver who has previous medical history of DM Type II, hypertension requiring use of anti-hypertensive medication, and hyperlipidemia (non-compliant with medication regimen). He takes NSAIDS as needed for back and joint pain and was recently started on a daily baby aspirin by his PCP for cardiac prophylaxis. He denies alcohol intake. He reports smoking a pack of cigarettes per day. 

PHYSICAL EXAMINATION: Examination reveals an alert and oriented 59-YO male. He appears anxious and irritated. Vital sips are as follows. Blood Pressure 155/90 mmHg, Heart Rate 120/min - HR Thready - Respiratory Rate - 20 /minute; Temperature 98.0  

ENT/SKIN: Facial pallor and cool, moist skin are noted. No telangiectasia of the lips or oral cavity is noted. Wound: 3 cm x 2 cm x 1 cm wound to lateral LLE. Wound base is dark red with yellow-green drainage present. Removed 4 x 4 dressing has a 5 cm diameter ring of drainage present. The surrounding skin is red, warm, tender to palpation, and with a dusky appearance to the entire LLE.  

CHEST: Lungs are clear to auscultation and percussion. The cardiac exam reveals a regular rhythm with an S4. No murmur is appreciated. Peripheral pulses are present but are rapid and weak. A positive Stemmer sign was noted and palpable pedal pulses with mild symptoms of venous insufficiency were noted. 

ABDOMEN/RECTUM: The abdomen reveals a rounded abdomen. Bowel sounds are present.

Quiz Questions

Self Quiz

Ask yourself...

  1. Discuss abnormal findings noted during History & Physical Examination. 
  2. Evaluate additional data to obtain possible diagnostic testing, treatment, nursing interventions, and care plans. 
  3. Discuss how the patient’s comorbidities may be attributed to prolonged wound healing. 
  4. What suction settings would the nurse expect to be ordered?

Conclusion

Hopefully, upon completion of this course, you feel empowered and curious about the use of negative pressure wound therapy (NPWT). Wound vacs can be a powerful tool in combatting acute and chronic wounds, it is a well-documented concept throughout history.

The nurse should be knowledgeable on the integumentary system makeup and types of wounds this therapy is indicated for. The mechanism of action of NPWT is critical knowledge when assessing the healing of a wound. Adjunct treatment options and troubleshooting support tips are also meaningful in the care of patients with NPWT.

Nutritional Interventions to Promote Wound Healing

Introduction   

The medical field is an ever-evolving and constantly changing arena. Advances in technology and an increased understanding of how the body works have produced newer and better procedures and techniques in healing. These initiatives, as innovative as they may be, still depend on the body’s ability to heal itself as the foundation of the recovery process.  

In turn, the body needs proper nutrition to support the healing process within itself. Nutrition is often overlooked by nurses even though it is arguably the most critical aspect of physical healing. 

Factors That Impact Wound Healing 

Wound healing is a complex process. There are a myriad of factors that impact the body’s ability to heal and recover from an injury. Comorbidities, genetic disorders, medications, and, in some cases, disease treatments (chemotherapy, radiation, steroids, etc.) can all have the potential to slow, change, or interfere with normal wound healing (2). For this course, we will discuss a few of the more common factors that nurses will undoubtedly come across during their practice. 

 

Diabetes 

It is estimated that this growing, global disease will impact forty million people by the year 2030. It has been proven that diabetes is responsible for more than one hundred changes in wound healing.  

These alterations have been seen across all four phases of wound healing. Platelet activation, epithelialization, collagen deposition, and granulation tissue formation are among the alterations that take place with diabetes. Worsening renal function/failure and peripheral vascular disease as a result of diabetes also affect the wound-healing process (2). 

 

Renal Failure 

Though most patients who have chronic kidney disease or renal failure also have multiple comorbidities that cause the renal problem, renal failure does, independently, bring a risk of diminished wound healing. Tissue edema, delayed granulation, chronic inflammation, and decreased vessel formation are all ways that renal failure impacts wound healing.  

Hemodialysis, a life-sustaining treatment of chronic renal failure, adds fuel to the fire when it comes to risks of diminished wound healing. Protein and water-soluble vitamins and nutrients are lost through the dialysis process. This includes zinc and iron and will lead to deficiencies in these needed nutrients. Further, patients on hemodialysis and patients who receive a kidney transplant as treatment for renal failure are both at higher risk for developing infections (2).  

 

 

 

 

Smoking 

Smoking causes multiple alterations within the body at the molecular level that affect normal wound healing. Vasoconstriction caused by smoking worsens wound ischemia. The highly documented negative impact that smoking has on wound healing has led physicians to decline some elective surgeries due to the risk of poor wound healing (2). 

 

Infection 

It is not fully understood how infection alters wound healing. It is believed to be a multifactorial process that has a range of properties that can be progressive in nature; infection-necrosis-sepsis-death. The bacteria create an environment where the collagen that repairs the injured tissue is destroyed (2). 

 

Obesity 

Obesity complicates virtually every disease process including normal wound healing. Wound healing complications due to obesity include increased rates of infection, hematomas, and dehiscence. Local hypoxia is also a complication that impacts wound healing (2). 

 

Age 

Aging also has an impact on wound healing. During the aging process, the skin loses elasticity, thickness, and water content. There is also a decrease in the skin’s blood vessels as it ages, reducing the capacity for oxygenation and nutrients. Wound closure becomes slower with aging; by age forty, the amount of time for an identical wound to heal doubles from age twenty. After the age of fifty, dermal collagen decreases by one percent per year (2). 

 

Malnutrition 

Malnutrition or undernutrition has a variety of effects on wound healing. Good nutrition is essential for proper wound healing and the overall recovery of the body after an injury.  

Malnutrition can lead to the loss of immune function which will affect the body’s response to infection. With malnutrition, the skin becomes thin and frail thus more apt to develop wounds. Pressure wounds are also more likely as fat deposits over pressure points become depleted. The lack of energy during malnutrition leads to immobility, increasing the possibility of wounds. Collagen synthesis is also decreased (5).

Quiz Questions

Self Quiz

Ask yourself...

  1. Name three factors that can affect wound healing. 
  2. How does age and aging impact wound healing?
  3. What are two ways that malnutrition impacts wound healing?

Phases of Wound Healing 

Once again, wound healing is a complex process. From a simple pin prick to a stage-four decubitus ulcer, the wound healing process itself remains the same. The body will go through the four phases of wound healing to repair the damage.  

 

Hemostasis 

The first phase of wound healing is hemostasis. Whether by surgery or trauma, the body attempts to achieve hemostasis at the time of the injury. The intrinsic and extrinsic coagulation cascades are activated by the body.  

Vasoconstriction takes place while platelet aggregation occurs to form a fibrin clot. This is all in an effort of the body to stop the bleeding to bring about hemostasis. As the platelets arrive at the site of injury, cytokines and growth factors are released by the platelets to initiate the inflammation process (3) (4) (5). 

 

Inflammation 

Inflammation is the second phase of wound healing. It starts once hemostasis has been re-established. During this phase, the previous vasoconstriction reverses and the vessels dilate.  

This brings blood to the injury site along with neutrophils, macrophages, monocytes, and other inflammatory cells. Phagocytosis is initiated and the wound is cleansed by the removal of bacteria. The wound site will swell and there may be some restrictions in mobility to the affected area (3) (5). 

 

Proliferation 

Phase three is proliferation. In this phase, rebuilding of the wounded tissue begins. The number of fibroblasts increases and begins to build a collagen network and prepare the wound base for new granulation tissue.  

At the same time, new blood vessels are created; a highway for oxygen and nutrients to be supplied to the site. By the end of this phase, the foundation will have been laid for full epithelialization (3) (5). 

 

Remodeling 

The final phase of wound healing is remodeling. Epithelialization is in full swing once granulation tissue has filled the wound. This process stimulates skin integrity restoration.  

Scar tissue is formed as proteins such as collagen and elastin along with keratinocytes are produced. The wound closes and begins to strengthen and appear “normal”; it may take a couple of years for the site to return to its fully functional pre-injured status (3). 

Quiz Questions

Self Quiz

Ask yourself...

  1. How many phases of wound healing are there? 
  2. Name all the phases of wound healing in order.
  3. What happens during the proliferation phase of wound healing?

How Does Nutrition Impact Healing? 

Nutrition is, perhaps, the most important underlying aspect of wound healing. The mechanism of wound healing and the role nutrition plays in that process is very complex.  

Adding nutritional interventions to the wound healing care plan is generally low cost and will increase the probability of a full recovery. Nutrition is essential for all phases of the healing process. It is the foundation of wound healing.  

The malnourished patient will have difficulty progressing through the wound healing phases. Proper nutrition will also help prevent wounds such as pressure ulcers from developing in the first place.  

Understanding which nutrients are needed through the phases of wound healing will help to devise a nutritional plan of care. Energy is required in all the phases of wound healing and is only made possible through proper nutrition (3). 

Quiz Questions

Self Quiz

Ask yourself...

  1. In what phase of wound healing is proper nutrition essential?  

Common Deficiencies 

Nutrients and proteins are the building blocks of life. They are needed for growth, maintenance, and healing of the body. Many types of nutrient deficiencies greatly impact the healing process. Here, we will discuss some of the more common nutrient deficiencies. 

 

Iron 

Iron plays a key role in the synthesis of hemoglobin. Hemoglobin delivers oxygen throughout the body; oxygen is required through all phases of wound healing. Iron deficiencies can lead to anemia and decreased tissue perfusion. An iron deficiency will also affect protein synthesis, macrophage function, and overall wound strength (3) (6). 

 

 

 

 

 

Vitamin A 

When it comes to wound healing, vitamin A quickens collagen synthesis and the overall inflammatory phase. A deficiency in vitamin A decreases collagen production, epithelization, and tissue granulation (9). 

 
Vitamin B 

There are eight vitamins included in the vitamin B complex. Each of the eight vitamins has its own daily recommended intake. Vitamin B promotes cell proliferation and promotes normal metabolism. In the presence of a wound, some dietitians promote doubling the daily recommended intake of the B vitamins (3). 

 

Vitamin C 

Vitamin C (ascorbic acid) assists with iron absorption. It is also essential in the process of collagen formation. Without vitamin C, the immune response cannot take place as needed. There are many sources of vitamin C readily available for everyday consumption (6). 

 

Zinc 

Zinc is used through all phases of the wound-healing process. It is used to initiate and modulate enzyme function throughout the wound healing phases. It affects immunity and assists in fibroblast proliferation and collagen production. It is also needed for granulation tissue formation (5) (6). 

 

Amino Acids 

Protein and amino acids are another set of nutrients that are highly essential in wound healing. The blood’s most abundant amino acid, glutamine, provides the body’s preferred energy source, glucose. Increased levels of glutamine have been shown to help with wound strength and increase the levels of mature collagen.  

Generally, the body is able to produce enough glutamine for regular function. In times of stress on the body, such as a wound, glutamine is sought out in the diet. Arginine assists in modulating the collagen deposits, increases new vessel formation, and aids in wound contraction (3). 

Quiz Questions

Self Quiz

Ask yourself...

  1. Name three common nutrient deficiencies that the nurse may encounter. 
  2. What are two amino acids that play key roles in wound healing?
  3. An iron deficiency can lead to what issues?
  4. Which phases of wound healing require zinc to complete the phase?

Special Considerations 

Tube Feedings 

Patients who use tube feedings or enteral feedings are in a unique situation when it comes to wound healing and nutrition. Once a proper nutrition assessment has been performed, a tailor-made nutrition-rich diet can be formulated and administered directly into the gut.  

Studies have shown that different formulas with supplemental nutrients have increased the ability of the body to heal faster than those without supplements. With tube feedings, patients don’t need to prefer the taste of one formula over another as it is delivered through the tube.  

The amount of formula can also be adjusted as the patient’s needs change. Though some formulas may have side effects such as diarrhea, the overall benefits usually outweigh such side effects (8). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What considerations are there for patients with tube feedings?

  2. What is a pitfall when using tube feedings to deliver full nutrition?

Chronic and Terminal Illness 

Autoimmune, inflammatory, and cancers are among the chronic and terminal diseases that are under special consideration when it comes to wound healing. These types of diseases can interrupt the immune/inflammatory response of the body thus prolonging the phases of wound healing.  

When a wound develops on a patient who is immunocompromised, there is a higher incidence of wound infection which will delay wound healing. In many of these diseases, there may be circulatory issues that decrease the body’s ability to provide the affected area with nutrient-rich blood.  

Chronic illnesses often decrease the patient’s energy levels. This can lead to immobility and increases the risk of wounds developing.  

Further, for many of these types of issues, the treatment itself can have adverse effects on wound healing. Chemotherapy, radiation therapy, and immunosuppressants all decrease the body’s ability to heal and increase the rates of infection in wounds (2). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are three types of chronic or terminal diseases? 
  2. What issue is an immunocompromised patient at risk for?
  3. What are two treatments for chronic illness that can affect wound healing?

Supplements 

Nutritional supplements have been shown to improve wound healing and recovery outcomes. It is important that the supplements are given under the supervision of a provider as too much of some nutrients can have a detrimental effect on wound healing.  

A proper nutrition screening should be performed on all patients with wounds so that the nutrition plan can be tailored to the individual patient. These improvements to wound healing with nutritional supplementation differ based on the type of wound and the overall health of the patient.  

The patient should be monitored and reassessed regularly by a dietitian. Again, there is no cookie-cutter supplement regimen.  

Another factor to consider with supplements is the ease of following the supplement regimen. Hard to swallow pills or foul-tasting food/liquids may have a negative impact on the patient’s ability to adhere to the supplement regimen.  

Allowing the patient to choose (with the input of the provider) the method of supplement delivery along with a choice of flavors will help increase compliance with the prescribed regimen (1). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What should be done prior to starting dietary supplements? 
  2. Who should assess and reassess a patient’s dietary status?
  3. Why is the method of supplement delivery important?

Patient Education 

Throughout the entire wound healing process, patient education is a must. Not only is it important so that the patient can make an informed decision about their care, but the patient should understand what is going on with their bodies.  

Education fuels compliance. A comprehensive nutrition assessment will not only provide a baseline of the patient’s nutritional status but will also help identify gaps in the patient’s understanding.  

This is where the education can be focused to best help the patient meet their wound healing goals. Education must include which foods contain which nutrients, the amount of these foods to eat, and which foods will interact with the absorption processes of the nutrients.  

Discussing normal daily requirements and the requirements needed during wound healing is also needed (1). 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why is education important when discussing nutrition and wound healing?

Conclusion

Nutrition plays a key role in wound healing. There are many factors that affect the body’s ability to acquire and use the needed nutrients. One of the most important considerations that we as healthcare providers need to put into practice is determining a patient’s nutritional status.  

A nutritional assessment should be done on patients with wounds so that a proper plan of care can be developed. Often, nutrition is an afterthought when in reality it is the foundation on which other treatments should be built upon.  

Once this has been established, the patient’s plan of care can be implemented and must include nutritional education. Needed supplements to increase the patient’s ability to heal can be added or removed as necessary when the reassessments have been completed. 

Ostomy Management

Introduction   

Newton's law of gravity states: what goes up, must come down; similarly, the normal human gastrointestinal system has a law that what goes in, must come out. When disease inhibits the normal process, ostomy procedures are a life-saving intervention.

There are around one million people living with an ostomy or continent diversion in the US, and approximately 100,000 ostomy surgeries are performed annually in the US (1). We will build a stronger understanding of various types of ostomies, indication for the need, site selection, stoma care, complications, and patient education.

Types of Ostomies

An ostomy is a surgically created opening that reroutes stool or urine from the abdomen to the outside of the body through an opening called a stoma (9). The term stoma refers to the portion of the bowel that is sutured into the abdomen (9).

When you look at a stoma, you are looking at the lining (the mucosa) of the intestine. The color is similar to the mucosa inside your mouth and cheek. Throughout various healthcare environments, you may hear the terms ostomy or stoma interchangeably. The purpose of an ostomy is to bypass a diseased portion of the gastrointestinal tract that is not functioning properly or has been removed (2).

Ostomies are placed proximal to the diseased area, comparable to building a dam in a river to stop the flow of fluid and divert it somewhere else. An ostomy can be temporary or permanent.

There are three most common types of ostomies: ileostomy, colostomy, and urostomy (9). We will discuss these types, but it is important to recognize that gastrostomy, jejunostomy, duodenostomy, and cecostomy procedures are also done.

  1. Ileostomy: A stoma is attached at the end of the small intestine (ileum) to bypass the colon, rectum, and anus.
  2. Colostomy: A stoma is attached to a portion of the colon to bypass the rectum and anus.
  3. Urostomy: A stoma is attached to the ureters (the tubes that carry urine from the kidney to the bladder) to bypass the bladder.

 

 

 

Ileostomy

The small intestine has three parts that are compact and folds over itself: the duodenum, jejunum, and the ileum. An ileostomy has a stoma attached and created from the ilium. The ileum is the final and longest segment of the small intestine (9).

The ileum terminates at the ileocecal valve, which controls the flow of digested material from the ileum into the large intestine and prevents the backup of bacteria into the small intestine (9). If a patient has this type of ostomy, the colon distal to the ostomy has a form of disease or disorder such as cancer. There are two main types of ileostomies, loop, and end ileostomy.

 

Loop ileostomy

In a loop ileostomy, a loop of the small bowel is lifted and held in place with a rod due to resection or repair to the distal bowel (Will). This ostomy is technically two stomas joined together (4). Loop ileostomies are typically temporary and will be closed or reversed through an operation in the future.

 

End ileostomy

In an end ileostomy, the ileum is surgically separated from the colon, the colon is removed or left to rest, and the end of the ileum is brought to the surface through the abdomen to form a stoma. Although end ileostomies are sometimes temporary and later rejoined, they are usually permanent (9).

 

 

Colostomy

A colostomy may be formed as an ascending, transverse, descending, or sigmoid colostomy (9). It is named according to the location of placement. An end colostomy is constructed from the ascending, transverse, descending, or sigmoid colon and has one opening for fecal elimination.

 

Loop Colostomy

The creation of a loop stoma takes a loop of the colon (usually the transverse colon) and pulls it to the outside of the abdominal wall (9). In this type of ostomy, the entire bowel is not dissected but left mostly intact.

 

End Colostomy

In end colostomies, the proximal end of the colon is dissected and pulled out of the abdominal cavity, which becomes the stoma (9). Additional procedures may involve repairing or removing portions of the distal colon or rectum.

 

 

Urostomy

Kidneys have an important job of filtering waste and excess fluid from your blood. This process creates urine, which then travels from the kidneys to the bladder through tubes called ureters (8). If the bladder is damaged or diseased, ostomies are a life-saving method of creating safe passage for the urine.

A urostomy is a surgical opening in the abdominal wall that redirects urine away from a bladder that’s diseased, has been injured, or isn't working properly (8). The bladder is either bypassed or removed (called a cystectomy) during surgery. Following the surgery, urine exits the body through a stoma.

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever witnessed a GI or Urinary Surgery?
  2. Do you have experience with GI / Urinary procedures like a colonoscopy?

Indication for Ostomy Placement

 

Gastrointestinal Tract Ostomy

- Cancer

- Colorectal

- Rectal

- Trauma/ Injury

- Significant Disorders

- Crohn’s disease

- Ulcerative Colitis

- Diverticulitis

- Bowel perforation from a ruptured diverticulum or abscess

- Bowel obstruction

- Infection (9)

 

Urinary Tract Ostomy

- Bladder Cancer

- Neurogenic bladder disease (damage to the nerves that control the bladder)

- Birth defects

- Chronic inflammation of the bladder (9)

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you cared for a patient with a new ostomy?
  2. Can you list reasons a patient is a candidate for an ostomy?

Site Selection

Wound, ostomy, and continence nurses (WOCN) play a vital role in site selection. Patients should have a pre-operative consultation prior to surgery. During this consultation, the nurse acts as an advocate and educator to prepare these patients for the physical and emotional path ahead of them. A significant amount of time should be spent with the patient before surgery to determine a stoma incision site (exit of ostomy).

It is important to make the presence of the ostomy (and collection bag) as comfortable as possible, striving to reduce the hindrance to ease movements and ability to wear their typical clothing (9). Studies show that preoperative education and stoma site marking has been directly responsible for improving quality of life and decreasing peristomal skin and pouching complications (4).

 

Site Assessment:

Locate positions for a site within the rectus muscle (4).

Observe the abdomen in various positions sitting, standing, or lying down.

Ask the patient about the types of clothing they wear most often. Examples: Level of pants (low, high), use of belts, dresses, etc. (9)

Determine a location that is visible to the patient, as they will need to see the site well for stoma care.

Avoid skin or fat folds (folds increase chances of leakage)

Avoid scars, bony prominences, and the umbilicus (4).

Quiz Questions

Self Quiz

Ask yourself...

  1. Locate places on yourself that would be appropriate for an ostomy site
  2. Can you think of reasons patients need to be able to see the site?
  3. Do you have a wound care nurse at your past or present workplace?

Post-operative Care

Post-operative care following ostomy placement is vital. The post-operative nurse assigned to this patient should read the surgery documentation to determine the type of procedure performed, intraoperative findings, type of stoma created, any advanced diseases, and unexpected events during surgery (2).

The nurse should be aware of the level of invasiveness; was this a laparoscopic, robotic, or open surgery? This type of surgery can have an impact on the post-op care plan and length of stay (2). Teaching can begin as soon as they are able to comprehend and focus on understanding new skills.

The stoma will gradually decrease in size over the weeks following the surgery. For a patient with a new ostomy, postoperative assessments should be done per facility protocol and the stoma should be inspected at least every 8 hours (9).

Note the type of closure (staples, sutures, liquid bonding agent), presence of abdominal drains, and presence of urinary catheter (C2). Assess for pain and address accordingly with repositioning, cold/heat therapy, and ordered pain medications. Assess for bowel sounds. Palpate the abdomen and note firmness and tenderness levels. Document strict Intake and Output for these patients.

 

Stoma Assessment:

Note the Appearance/ Color: The stoma should be pink to red in color, moist, and firmly attached to the surrounding skin (9). If the stoma appears bluish, it indicates inadequate blood supply; if the stoma appears black, necrosis has occurred. Immediate notification is needed from the provider, as the need to return to surgery will be assessed.

 

- Note the Presence of edema.

- Note the Surrounding skin

- Note any Ostomy Discharge

- Amount

- Color / Consistency

- Note any Bleeding

- Monitor for rupture or leakage.

 

Diet

Once bowel sounds and activity return, the patient’s diet may resume (2). Typically, patients are offered clear liquids to determine their ability to tolerate fluids. Nurses should encourage the patient to chew thoroughly, eat small frequent meals, and ambulate frequently to assist in gas movement and peristalsis (2).

Quiz Questions

Self Quiz

Ask yourself...

  1. Do you have experience with post-operative abdominal surgery?
  2. Explain possible respiratory or cardiovascular assessments that would be helpful for these patients

Stoma Care

 

Nursing Consideration / Reminders

Ostomy pouching system needs to be changed every 4 to 7 days, depending on the patient and type of pouch.

Patients should be encouraged to participate in stoma care. Instruct the patient to empty the pouch when it is one-third to one-half full as they become heavy and more prone to spilling or leaks.

 

Table 1. Ostomy Change Procedure SAMPLE (Always check with your agency policy)

Steps  PURPOSE 
1. Perform hand hygiene.  This prevents the spread of germs and microorganisms. 
2. Gather supplies. 

Supplies:  

  • Non-sterile gloves 
  • Ostomy bag and clip  
  • Flange 
  • Scissors 
  • Stoma measuring tool. 
  • Waterproof pad  
  • Adhesive remover for old flange 
  • Skin prep (7) 
3 Create privacy. Lift bed to comfortable height.  

Attention to psychosocial needs is imperative. 

Proper body mechanics is important for nurse. 

4. Place waterproof pad under pouch.  The pad prevents the spilling of effluent on patient and bed sheets. 

5. Remove ostomy bag.  

Apply non-sterile gloves.  

Support / hold the skin firmly with your other hand, apply adhesive remover if needed.  

Measure and empty contents. Place old pouching system in a garbage bag. 

 

The pouch and flange can be removed separately or as one. 

Gentle removal helps prevent skin tears.  

Remove flange by gently pulling it toward the stoma. 

6. Clean stoma gently by wiping with warm water. Do not use soap. 

Aggressive cleaning can cause bleeding. If removing stoma adhesive paste from skin, use a dry cloth first. Soaps can irritate the stoma. 

Clean stoma and peristomal skin 

7. Assess stoma and peristomal skin. 

Stoma skin should be pink or red in color, raised above skin level, and moist (2). 

Skin surrounding the stoma should be intact and free from wounds, rashes, or skin breakdown.  

8. Measure the stoma diameter using the pre-cut measuring tool (or tracing template).  

Trace diameter of the measuring guide onto the flange and cut the outside of the pen marking. 

The opening should match the size of stoma.  

If there is skin exposed between the stoma and edge of the flange with an ileostomy, the drainage contains enzymes that will break down the skin (9). 

Cut out size to fit stoma, assess fit once cut. 

9. Prepare skin. 

 

Paste can be applied directly to the skin or flange. 

10. Apply Flange 

 

Press gently around the periphery of the stoma to create a seal 

11. Apply the ostomy bag 

Close the end of the bag with clip (follow the manufacturer’s instructions) 

Involve patient with this process, understanding instructions. 
12. Apply pressure to ostomy pouch to help with adhering to skin.  Heat/ warmth from hand can activate some flanges. 
13. Clean us supplies, perform hand hygiene.  Remove trash as quickly as possible to reduce odor. 
14. Document Procedure 

Example: 

Date/time: flange change complete. Stoma pink, moist, warm. Peristomal skin intact. Patient instructed in cutting flange to correct size, verbalized understanding of frequency of change. See ostomy flowsheet. (Abbie S., RN) 

Data Source: Carmel, Colwell, J., & Goldberg, M. (2021). Wound, ostomy and continence nurse’s society core curriculum: ostomy management (Second Edition). Wolters Kluwer Health. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Are you familiar with your facility's ostomy care protocol (if appropriate)?
  2. How can the nurse implement safety measures with ostomy care?
  3. Do you feel comfortable with ostomy care documentation?

Complications

 

 

Ostomy Leakage

One of the most common and troublesome complications is leakage (4). Proper preoperative site selection (away from skin folds) is important. Patient education on proper techniques and supplies can aid in the prevention of leakage.

Educate patients on the risks of changing the ostomy too often. Frequent appliance changes lead to pain and frustration, as well as financial expenses on supplies (4). Leakage is more common in the early postoperative period but can also develop with weight changes later.

Interventions involve thickening the stool with antidiarrheals to form more solid excretion and pouching techniques to bolster the height of the stoma off of the peristomal skin (4). Helpful tips also include heating the appliance with a hair dryer before application, lying flat for several minutes following application, making sure the peristomal skin is dry before application, and the possible use of a fine dusting of stomal powder and skin sealant prior to application (4). Leakage is frustrating for patients, so support and encouragement is vital.

 

Mucocutaneous Separation

The stoma is sutured to the skin of the abdomen with absorbable sutures during surgery (4). Mucocutaneous separation is a complication that can occur if the sutures securing the stoma become too tight or if blood flow to the area is restricted (9). This complication requires appropriate treatment because the pouch leakage will occur from the open pocket.

The goal of treatment is to keep this open pocket covered properly until the wound heals on its own and closes. Appropriate covering of the opening can include an absorbent product such as an alginate, followed by a cover dressing such as a hydrocolloid, which is covered with the ostomy pouch (4).

 

Early High Ostomy Output

Early high ostomy output (HOO) is defined as ostomy output greater than fluid intake occurring within 3 weeks of stoma placement, which results in dehydration (4). This is more common with ileostomies (4). Strict Input and Output records are a vital nursing intervention. The most important treatment for this complication is hydration to prevent renal failure, which is typically done intravenously (4).

The site of a patient’s colostomy will impact the consistency and characteristics of the excretion. The natural digestive process of the colon involves the absorption of water, which causes waste from the descending colon to be more formed. Waste from an ileostomy or a colostomy placed in the anterior ascending colon will be a bit more loose or watery (2).

 

Peristomal Skin Issues

Irritant Contact Dermatitis (ICD) is the most common peristomal skin complication following ostomy placement (9). ICD is characterized by redness; loss of epidermal tissue; pain; and open, moist areas.

Newer and inexperienced patients and caregivers will increase the size of the pouching system opening to get a better seal and stop leakage (2) However, this only contributes to more skin breakdown and irritation. Patients may also develop a fungal rash, have allergic rashes to the ostomy appliance, or folliculitis (4).

Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name measures to prevent leakage?
  2. Have you cared for a patient with Irritant Contact Dermatitis?
  3. Are you familiar with bulking agents for stool?

Patient Education

Patient education is a key aspect is caring for a patient with an ostomy, this process begins prior to surgery and remains constant throughout encounters. If you have not received specialized training on wound and ostomy care, you should reach out to the Wound, Ostomy and Continence Nurse (WON) within your healthcare setting to become involved if they are not already.

However, each nurse has a meaningful impact on discussing and managing expectations for life with an ostomy, including stoma care, complications, managing ostomy output, maintaining pouching appliances, and resources. Patients may feel inadequate and uneasy about caring for their stoma.

Nurses need to meet the unique learning needs of each patient and caregiver, providing education in verbal information, written pamphlets, online resources, videos, and demonstrations. The United Ostomy Associations of America, Inc. (UOAA), is a nonprofit organization that serves as an excellent resource for information, support, advocacy, and collaboration for those living with ostomies.

Nurses should be aware there is an “Ostomy and Continent Diversion Patient Bill of Rights” (PBOR) that outlines the best practices for providing high-quality ostomy care during all phases of the surgical experience (1). There are numerous national resources for patients, as well as community-based and online ostomy support groups. 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Can you think of methods to assess patient knowledge on ostomy care?
  2. What are creative ways to involve an ostomy patient in care?
  3. Not all patients are savvy with online supply ordering, can you think of other ways to order supplies if they are not?

Promotion of Body Image and Self-Esteem

Ostomy surgery can have a major impact on how patients perceive themselves. A person’s body image is how they see themselves when they look in the mirror or how they picture themselves in their mind.

There are stigmas surrounding ostomies, such as being odorous, unhygienic, and unattractive due to the stoma, but the truth is that ostomies save lives and make life possible. Positivity should surround the conversation. Confirmations such as beauty, strength, celebration, and hope are meaningful.

 

Ways to become involved in celebrating ostomies:

- Become familiar with the United Ostomy Associations of America (UOAA) and their initiatives.

https://www.ostomy.org/ostomy-awareness-day/

National Ostomy Awareness Day on October 7, 2023

Worldwide Virtual Run for Resilience Ostomy 5k

 

- Social Media Sites

Celebrate Body Positivity for those with ostomies

Intimacy Encouragement

Conclusion

Ostomy care is an essential nursing skill. If you are caring for a patient with an ostomy, remember that this is a major life-altering event and condition. Reflect on ways to provide individualized care by understanding various types of ostomies, site selection, stoma care, complications, and patient education. Empower and encourage these ostomy patients’ confidence in themselves.

 

Diabetes Management Updates

Introduction   

Diabetes Mellitus (DM), also known as diabetes, is a condition in which the body develops high levels of blood glucose due to the inability to produce insulin or for the cells to use insulin (1) effectively. If left untreated or mismanaged, it can lead to health complications such as heart disease, chronic kidney disease, blindness, nerve damage, oral and mental health problems (1)(15) 

There are several classifications of DM, and the following will be discussed: T1DM, T2DM, gestational diabetes, and idiopathic diabetes. 

Classifications of Diabetes

 

Type 1 Diabetes Mellitus (T1DM)  

T1DM is formerly known as juvenile diabetes or insulin-dependent diabetes and usually occurs in children and young adults (1). Although, it can also occur at any age and accounts for 5 – 10% of cases. T1DM develops when one’s own immune system attacks and destroys the beta cells that produce insulin in the pancreas (6).     

 

Type 2 Diabetes Mellitus (T2DM)  

T2DM, formerly known as adult-onset diabetes or non-insulin-dependent diabetes, develops because of the body's inability to use insulin effectively. It is the most common type of diabetes and mainly occurs in adults aged 30 years and older (1). However, it is also becoming common in children and young adults due to obesity. It accounts for 90% of the population diagnosed with diabetes (6).   

 

Gestational Diabetes 

Gestational Diabetes occurs during pregnancy and in women who have never had a previous diagnosis of diabetes. It is a result of pregnancy hormones that are produced by the placenta or because of the insufficient use of insulin by the cells (1). Gestational diabetes can be temporary or in some cases can become chronic. It is also likely that children whose mothers have gestational diabetes can develop diabetes later in life (6).  

 

Prediabetes 

Prediabetes, also referred to as impaired glucose tolerance, is a stage when a person is at risk of developing diabetes. If well managed through proper diet management and exercise, this can help with the prevention or delay of type 2 diabetes (1).  

 

Other Forms of Diabetes 

Other forms of diabetes include monogenic diabetes syndrome, diabetes from the removal of the pancreas or damage to the pancreas from disease processes such as pancreatitis or cystic fibrosis, and drugs or chemical-induced diabetes from glucocorticoids used to treat HIV/Aids or organ transplant (1) (6).  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the four named types of diabetes? 
  2. What are the differences between T1DM and T2DM? 
  3. What is the most common type of diabetes? 

Statistical Evidence/Epidemiology 

Diabetes is now ranked as the 8th leading cause of death in the United States (6). There is no known cure for diabetes. It is one of the fastest-growing chronic diseases and the most diagnosed noncommunicable disease. It is also one of the leading causes of chronic kidney disease, adult blindness, and lower limb amputations (6).   

In 2019, it was estimated that 37.3 million American adults have diabetes, which equals 11.3% of the population (4). Of those, 41% were men and 32% were women. 28.7 million were diagnosed with diabetes, and 8.5 million were undiagnosed.  

There are 96 million American adults who are prediabetic, which means they are at risk of developing diabetes, but their blood glucose levels are not high enough to be diagnosed with diabetes (5).  

Most of the population that is pre-diabetic is 65 years old or older. Type 2 diabetes accounts for 90% to 95% of cases (5). The risk of developing diabetes increases with age.  

The prevalence of diabetes is much higher in both black and Hispanic/Latino adult men and women. Men are more likely to develop diabetes compared to women. Due to the rise in obesity in younger adults, there has been an increase in the number of new cases of diabetes in black teens (4).  

 

The figure below represents trends in incidence of type 1 and type 2 diabetes in children and adolescents 2002–2018; results show the incidence of type 2 diabetes has significantly increased (4)

Quiz Questions

Self Quiz

Ask yourself...

  1. What is one of the major comorbidities caused by diabetes? 
  2. What age group is at risk for developing type 2 diabetes?  
  3. What is a risk factor that is contributing to the rise of diabetes in younger adults?

Etiology and Pathophysiology 

In normal glucose metabolism, blood glucose is regulated by the two hormones insulin and glucagon (11). Insulin is secreted by the beta cells in the Islet of Langerhans in the pancreas and glucagon is secreted by the alpha cells in the pancreas.  

When there is an increase in blood glucose, the function of insulin is to reduce blood glucose by stimulating its uptake in the cells. Glucose is stored as glycogen in the liver and muscles or as fat in the adipose tissues. When blood glucose levels start to fall, glucagon promotes the release of glycogen from the liver, which is used as a source of energy in the body (8) (13).   

When there is a deficiency of insulin or a decreased response of insulin on the targeted cells in the body, it leads to hyperglycemia (high blood glucose). Meaning that the glucose that remains in the blood is not able to get to the cells. Diabetes develops mainly because of lifestyle and genetic factors (13).

T1DM 

The etiology is not well understood, though it is thought to be influenced by both environmental and genetic predispositions that are linked to specific HLA alleles. T1DM is considered an autoimmune disorder that is characterized by T-cell-mediated destruction of the pancreatic B-cells (13).  

As a result, this leads to complete insulin deficiency and ultimately hyperglycemia, which requires exogenous insulin. The rate of destruction of the pancreatic B-cell-specific disorder is known to develop rapidly in infants and children or gradually in adults (8)(13). 

 

T2DM 

The etiology of T2DM is characterized by decreased sensitivity to insulin and decreased secretion of insulin. Insulin resistance occurs due to the disruption in the cellular pathways that result in a decreased response in the peripheral tissues, particularly the muscle, liver, and adipose tissue.  

T2DM diabetes can progress slowly and asymptomatically over a period. Obesity and age can play a key role in the homeostatic regulation of systemic glucose because they influence the development of insulin resistance, which affects the sensitivity of tissues to insulin. Therefore, most patients with type 2 diabetes are overweight or obese 7) (8).

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the two hormones that are responsible for maintaining blood glucose levels in the body? 
  2. Can you describe the etiologies of both T1DM and T2DM? 
  3. What are some of the factors that contribute to T2DM? 

Diagnostic and Screening tools 

There are a variety of tests that are used to diagnose and monitor diabetes. These vary based on the type of symptoms that a patient may have. Diagnosis of DM requires at least two abnormal test results, which should include fasting glucose and A1C. The tests should be one of two from the same sample or two abnormal test results drawn on different days (3). 

 

The recommended diagnosis guidelines for diabetes must be based on the following criteria: 

  • Fasting Plasma Glucose (FPG) concentration with results greater than 126 mg/dL. This test involves measuring blood glucose at a single point. To have accurate results, the test should be conducted after one has had nothing to eat or drink for at least 8 hours (3). 
  • Glycated hemoglobin (Hb A1C) is indicative of the average levels of blood glucose in a period of two to three months. Results greater than 6.5% mean diagnosis of diabetes. This blood test does not require fasting. The A1C test is not suitable for pregnant women or those who have certain blood conditions (anemia) - NIDDK. This test should only be used for prediabetes screening (3). 
  • Oral Glucose Tolerance Test (OGTT): prior to conducting this test, an FPG level needs to be measured. One must ingest 75 grams of glucose liquid. Thereafter, their glucose level is measured 2 hours after they have taken the liquid. Test results greater than 200 mg/dL are indicative of diabetes. This test is commonly used in pregnant women (3). 
  • Random plasma glucose of 200 mg/dL. This test is suitable when one has symptoms of hyperglycemia, which are polydipsia, polyuria, and polyphagia (3).  

 

Screening 

Screening is generally recommended for adults aged 45 or older regardless of present risk factors. The updated recommendation guidelines for prediabetes screening include adults 35 years and older who are overweight or obese (3).  

 

Screening for Prediabetes 

Prediabetes is associated with the impairment of blood glucose levels between 100 – 125 mg/dL. The diagnosis of prediabetes should be confirmed with glucose testing when there is impaired glucose tolerance with plasma levels between 140 – 199 mg/dL 2 hours after one has ingested 75g of oral glucose. A1C levels of prediabetes are between 5.7% to 6.4% (3). 

 

Screening for Pregnant women 

It is recommended that all pregnant women between 24 – 28 weeks be screened for gestational diabetes to avoid missing those that are at risk. A positive 3-hour OGTT test of greater than 140 mg/dL meets the criteria for diagnosis (3).  

 

Medication Management 

Monitoring of blood glucose levels in patients is useful in determining the effectiveness of antidiabetic medication. To achieve better patient outcomes, it is important to recognize individual needs (11) 

It is recommended that the approach to medication management should be based on each patient's hyperglycemic index and should include the following: the presence of comorbidities, risk of hypoglycemia, vascular disease, life expectancy, and disease duration (3).   

When the management of diabetes cannot be achieved through diet and exercise alone, oral antidiabetic agents are the preferred treatment (14). Oral antidiabetics can help maintain and achieve glycemic goals for patients who are diagnosed with T2DM) (10)(14).  

Diabetes Education and patient engagement is essential to managing diabetes (11). There are several classes of anti-diabetic medication. Below are some of the most utilized antidiabetic medications (9)(14).  

 

Biguanides 

Metformin is the only medication in this category. 

  • It is considered the 1st line of treatment in patients with T2DM unless contraindicated. 
  • Metformin helps to decrease hepatic glucose production.  
  • Decreases intestinal absorption of glucose by improving insulin sensitivity. Must be titrated initially to minimize adverse effects. 
  • Avoided in clients with chronic kidney disease.  
  • Side effects: Lactic acidosis, hypoglycemia. 

 

GLP 1- Receptor Agonists (RAs) 

Mimics glucagon-like peptide 1 (GLP -) hormone. Binds to GLP-1 receptors stimulate glucose-dependent insulin release and delay gastric emptying, which increases satiation.  

  • Known to have cardiovascular benefits. 
  • Can be taken orally or subcutaneously.  
  • Special considerations: Can cause weight loss, GI side effects such as nausea, vomiting and diarrhea, dehydration, increased satiation (fullness), acute pancreatitis, and reactions at the injection sites.  
  • Some labels may require renal dose adjustment.  
  • GLP - 1 RAs should be considered before starting clients on insulin to help reduce A1C then oral antihyperglycemic medications are not effective in treating diabetes.  

 

Sulfonylureas 2nd generation 

Stimulates insulin release in pancreatic beta cells.  

  • Risk for prolonged hypoglycemia. Therefore, it should be avoided with the concurrent use of insulin.  
  • Can cause weight gain.  
  • Can cause photosensitivity.  
  • Avoid use in clients with sulfa allergies and photosensitivity.  
  • Avoid use in clients with chronic kidney disease and liver disease.   

 

Dipeptidyl Peptidase (DPP) - 4 inhibitors 

Prevents DPP-4 enzymes from breaking down to GLP-1 hormone.   

  • Neutral weight.  
  • Monitor for acute pancreatitis, which can cause joint pain.  
  • May require renal dose adjustment with these brands: Saxagliptin (Onglyza), Sitagliptin (Januvia), and Alogliptin. Linagliptin does not require dose adjustment.  

 

Sodium-Glucose transporter - 2 (SGLT-2) inhibitors 

Reduce the reabsorption of glucose by up to 90%, therefore promoting the exclusion of glucose from the body.  

  • Known to have cardiovascular benefits for clients with cardiovascular disease.  
  • Use with caution in clients with increased risk of fractures.  
  • Avoided in clients with diabetic ketoacidosis and those prone to have frequent urinary tract infections.  
  • This medication should be avoided in clients with pure poor kidney function due to volume depletion and hypotension.  
  • There’s also a risk for Fournier gangrene.  

 

Thiazolidinediones 

Pioglitazone and rosiglitazone can help reduce insulin resistance which promotes improved sensitivity to insulin. As a result, it can help reduce the A1C levels.  

  • Can cause weight gain.  
  • Potential risk for heart failure when taking thiazolidines (brands: pioglitazone, rosiglitazone). 
  • Generally, it is not recommended for clients with renal impairment as medication has the potential to cause fluid retention.  
  • Risk for bone fractures, bladder cancer, and increased LDL cholesterol (rosiglitazone).  
  • Thiazolidines do not cause hypoglycemia and can be used in combination with other antidiabetic medications including insulin. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Which class of antidiabetic medications are known to put patients at risk for bone fractures? 
  2. Can you name a condition that thiazolidines and sulfonylureas 2nd generation are generally not recommended for?  
  3. What is a common side effect in both thiazolidines and sulfonylureas? 
  4. What class of medication is suitable for clients with insulin resistance? 
  5. Can you name two antidiabetic medications that can be used in combination with other antidiabetics because it has the benefit of not causing hypoglycemia?

Insulin therapy 

Insulin therapy is commonly recommended for patients with T1DM. It can be used to help prevent the development and progression of diabetes (2). The ideal insulin regimen should be tailored based on individual needs and glycemic targets to better contend with physiological insulin replacement to maintain normoglycemia. Insulin therapy is also recommended for patients with hemoglobin A1c of greater than 9% - 10% and when symptoms of hyperglycemia are present (3).  

 

Other Diabetes Interventions 

The automation of glucose monitoring devices and insulin delivery systems is revolutionizing glucose management mainly because it promotes lifestyle flexibility and improved glucose management (2). 

  • Glucose Monitoring Devices- these devices are ideal for clients who are on insulin regimens and may become the standard for assessing glycemic controls in clients with DM (7). 
  • Continuous Glucose Monitoring (CGM)- devices that are inserted subcutaneously and measure interstitial blood glucose levels. CGMs are devices that are used to provide glucose readings, trends, and alerts to the user in real-time to inform diabetes treatment decisions. (2)(3) 
  • Importance- CGM is recommended for all patients with diabetes who receive treatment with intensive insulin therapy, defined as three or more insulin injections per day for all individuals with hypoglycemia (frequent, several, nocturnal) (3).  
  • Known to reduce hyperglycemia and A1C levels. 
  • Insulin Pump Therapy- also known as Continuous Subcutaneous Insulin Infusion (CSII) has had notable advances over the years. CSII is recommended for those with type 1 diabetes, although in recent studies, conventional CSII is also recommended for use in T2DM patients (2)(3). CSII is a small computer that is programmed to deliver fast-acting insulin continuously to the body using mechanical force via a cannula that is inserted under the skin (2).  
  • It is more precise and flexible in insulin dosing. 
  • Known to improve glycemic control.  
  • Cheaper than using Multi-Dose Insulin. 
  • Automated Insulin Delivery Systems (AIDS) - This is a diabetes management system that utilizes an insulin pump in conjunction with an integrated CGM and computer software algorithm (3).  
  • Advantages: precision and flexibility with insulin dosing. 
  • Recommended for T1DM: Achieve glycemic targets with less burden. 
Quiz Questions

Self Quiz

Ask yourself...

  1. What is the main type of insulin used in CSII pumps? 
  2. What type of diabetes category is more suitable for using CSII? 

Upcoming Research  

Islet cell transplant has been a biological solution to help treat patients with T1DM due to poor graft survival rates. Future research will focus on manipulating the beta cells in the pancreas to make them more viable. Other treatments that have been recently made available include incretins and Amylin which improve the absorption of insulin in the body (1).  

  • The development of other types of insulin that can be administered by inhalation.  
  • The development of immunosuppressant drugs that will help treat T1DM. 
Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name two recently developed medications to help with insulin absorption in the body?

Conclusion

Diabetes is a complex disease that requires a multi-disciplinary and patient-centered approach to help with effective management. Regular and early screening are necessary for those at risk for developing diabetes. Most importantly, ease and access to choices of managing diabetes are necessary.

Controlled Substances

Introduction   

Pain is complex and subjective. The experience of pain can significantly impact an individual’s quality of life. According to the National Institute of Health (NIH) (40), pain is the most common complaint in a primary care office, with 20% of all patients reporting pain. Chronic pain is the leading cause of disability, and effective pain management is crucial to health and well-being, particularly when it improves functional ability. Effective pain treatment starts with a comprehensive, empathic assessment and a desire to listen and understand. Nurse Practitioners are well-positioned to fill a vital role in providing comprehensive and empathic patient care, including pain management (23).

While the incidence of chronic pain has remained a significant problem, how clinicians manage pain has significantly changed in the last decade, primarily due to the opioid epidemic. This education aims to discuss pain and the assessment of pain, federal guidelines for prescribing, the opioid epidemic, addiction and diversion, and recommendations for managing pain.

Definition of Pain

Understanding the definition of pain, differentiating between various types of pain, and recognizing the descriptors patients use to communicate their pain experiences are essential for Nurse practitioners involved in pain management. By understanding the medical definition of pain and how individuals may communicate it, nurse practitioners can differentiate varying types of pain to target assessment.

According to the International Association for the Study of Pain (27), pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or terms of described such in damage.” The IASP, in July 2020, expanded its definition of pain to include context further.

Their expansion is summarized below:

  • Pain is a personal experience influenced by biological, psychological, and social factors.
  • Pain cannot be inferred solely from activity in sensory neurons.
  • Individuals learn the concept of pain through their life experiences.
  • A person’s report of an experience in pain should be respected.
  • Pain usually serves an adaptive role but may adversely affect function and social and psychological well-being.
  • The inability to communicate does not negate the possibility of the experience of pain.

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Analyze how changes to the definition of pain may affect your practice.
  2. Discuss how you manage appointment times, knowing that 20% of your scheduled patients may seek pain treatment.
  3. How does the approach to pain management change in the presence of a person with a disability?

Types of Pain

Pain originates from different mechanisms, causes, and areas of the body. As a nurse practitioner, understanding the type of pain a patient is experiencing is essential for several reasons (23).

  • Determining an accurate diagnosis. This kind of pain can provide valuable clues to the underlying cause or condition.
  • Creating a treatment plan. Different types of pain respond better to specific treatments or interventions.
  • Developing patient education. A nurse practitioner can provide targeted education to patients about their condition, why they may experience the pain as they do, its causes, and treatment options. Improving the patient's knowledge and control over their condition improves outcomes.

 

Acute Pain

Acute pain is typically short-lived and is a protective response to an injury or illness. Patients are usually able to identify the cause. This type of pain resolves as the underlying condition improves or heals (12).

 

Chronic Pain

Chronic pain is diagnosed when it continues beyond the expected healing time. Pain is defined as chronic when it persists for longer than three months. It may result from an underlying disease or injury or develop without a clear cause. Chronic pain often significantly impacts a person's physical and emotional well-being, requiring long-term management strategies. The prolonged experience of chronic pain usually indicates a central nervous system component of pain that may require additional treatment. Patients with centralized pain often experience allodynia or hyperalgesia (12).

Allodynia is pain evoked by a stimulus that usually does not cause pain, such as a light touch. Hyperalgesia is the effect of a heightened pain response to a stimulus that usually evokes pain (12).

 

Nociceptive Pain

Nociceptive pain arises from activating peripheral nociceptors, specialized nerve endings that respond to noxious stimuli. This type of pain is typically associated with tissue damage or inflammation and is further classified into somatic and visceral pain subtypes.

Somatic pain is most common and occurs in muscles, skin, or bones; patients may describe it as sharp, aching, stiffness, or throbbing.

Visceral pain occurs in the internal organs, such as indigestion or bowel spasms. It is more vague than somatic pain; patients may describe it as deep, gnawing, twisting, or dull (12).

 

Neuropathic pain

Neuropathic pain is a lesion or disease of the somatosensory nervous system. Examples include trigeminal neuralgia, painful polyneuropathy, postherpetic neuralgia, and central poststroke pain (10).

Neuropathic pain may be ongoing, intermittent, or spontaneous pain. Patients often describe neuropathic pain as burning, prickling, or squeezing quality. Neuropathic pain is a common chronic pain. Patients commonly describe allodynia and hyperalgesia as part of their chronic pain experience (10).

 

Affective pain

Affective descriptors reflect the emotional aspects of pain and include terms like distressing, unbearable, depressing, or frightening. These descriptors provide insights into the emotional impact of pain on an individual's well-being (12).

Quiz Questions

Self Quiz

Ask yourself...

  1. How can nurse practitioners effectively elicit patient descriptors to accurately assess the type of pain the patient is experiencing?
  2. Expand on how pain descriptors can guide interventions even if the cause is not yet determined.
  3. What strategies ensure patients feel comfortable describing their pain, particularly regarding subjective elements such as quality and location?

Case Study

Mary Adams is a licensed practical nurse who has just relocated to town. Mary will be the utilization review nurse at a local long-term care facility. Mary was diagnosed with Postherpetic Neuralgia last year, and she is happy that her new job will have her mostly doing desk work and not providing direct patient care as she had been before the relocation. Mary was having difficulty at work at her previous employer due to pain. She called into work several times, and before leaving, Mary's supervisor had counseled her because of her absences.

Mary wants to establish primary care immediately because she needs ongoing pain treatment. She is hopeful that, with her new job and pain under control, she will be able to continue a successful career in nursing. When Mary called the primary care office, she specifically requested a nurse practitioner as her primary care provider because she believes that nurse practitioners tend to spend more time with their patients.

Assessment

The assessment effectively determines the type of treatment needed, the options for treatment, and whether the patient may be at risk for opioid dependence. Since we know that chronic pain can lead to disability and pain has a high potential to negatively affect the patient's ability to work or otherwise, be productive, perform self-care, and potentially impact family or caregivers, it is imperative to approach the assessment with curiosity and empathy. This approach will ensure a thorough review of pain and research on pain management options. Compassion and support alone can improve patient outcomes related to pain management (23).

 

Record Review

Regardless of familiarity with the patient, reviewing the patient's treatment records is essential, as the ability to recall details is unreliable. Reviewing the records can help identify subtle changes in pain description and site, the patient's story around pain, failed modalities, side effects, and the need for education, all impacting further treatment (23).

Research beforehand the patient's current prescription and whether or not the patient has achieved the maximum dosage of the medication. Analysis of the patient's past prescription could reveal a documented failed therapy even though the patient did not receive the maximum dose (23).

A review of documented allergens may indicate an allergy to pain medication. Discuss with the patient the specific response to the drug to determine if it is a true allergy, such as hives or anaphylaxis, or if the response may have been a side effect, such as nausea and vomiting.

Research whether the patient tried any non-medication modalities for pain, such as physical therapy (PT), occupational therapy (OT), or Cognitive Behavioral Therapy (CBT). Note any non-medication modalities documented as failed therapies. The presence of any failed therapies should prompt further discussion with the patient, family, or caregiver about the experience. The incompletion of therapy should not be considered failed therapy. Explore further if the patient abandoned appointments.

 

Case Study

You review the schedule for the week, and there are three new patient appointments. One is Mary Adams. The interdisciplinary team requested and received Mary's treatment records from her previous primary care provider. You make 15 minutes available to review Mary's records and the questionnaire Mary filled out for her upcoming appointment. You see that Mary has been diagnosed with Postherpetic Neuralgia and note her current treatment regimen, which she stated was ineffective. You write down questions you will want to ask Mary. You do not see evidence of non-medication modalities or allergies to pain medication.

Quiz Questions

Self Quiz

Ask yourself...

  1. What potential risks or complications can arise from neglecting to conduct a thorough chart review before initiating a pain management assessment?
  2. In your experience, what evidence supports reviewing known patient records?
  3. What is an alternative to reviewing past treatment if records are not available?

Pain Assessment

To physically assess pain, several acronyms help explore all the aspects of the patient's experience. Acronyms commonly used to assess pain are SOCRATES, OLDCARTS, and COLDERAS. These pain assessment acronyms are also helpful in determining treatment since they include a character and duration of pain assessment (23).

 

O-Onset S-Site C-Character
L-Location O-Onset O-Onset
D-Duration C-Character L-Location
C-Character R-Radiate D-Duration
A-Alleviating A-Associated symptoms E-Exacerbating symptoms
R-Radiating, relieving T-Time/Duration R-Relieving, radiating
T-Temporal patterns (frequency) E-Exacerbating A-Associated symptoms
S-Symptoms S-Severity S-Severity of illness

 

Inquire where the patient is feeling pain. The patient may have multiple areas and types of pain. Each type and location must be explored and assessed. Unless the pain is from a localized injury, a body diagram map, as seen below, is helpful to document, inform, and communicate locations and types of pain. In cases of Fibromyalgia, rheumatoid arthritis, or other centralized or widespread pain, it is vital to inquire about radiating pain. The patient with chronic pain could be experiencing acute pain or a new pain site, such as osteoarthritis, that may need further evaluation and treatment (23).

Inquire with the patient how long their pain has been present and any associated or known causative factors. Pain experienced longer than three months defines chronic versus acute pain. Chronic pain means that the pain is centralized or a function of the Central Nervous system, which should guide treatment decisions.

To help guide treatment, ask the patient to describe their pain. The description helps identify what type of pain the patient is experiencing: Allodynia and hyperalgesia indicate centralized pain; sharp, shooting pain could indicate neuropathic pain. Have the patient rate their pain. There are various tools, as shown below, for pain rating depending on the patient's ability to communicate. Not using the pain rating number alone is imperative. Ask the patient to compare the severity of pain to a previous experience. For example, a 1/10 may be experienced as a bumped knee or bruise, whereas a 10/10 is experienced on the level of a kidney stone or childbirth (23).

Besides the 0-10 rating scale and depending on the patient's needs, several pain rating scales are appropriate. They are listed below.

The 0-5 and Faces scales may be used for all adult patients and are especially effective for patients experiencing confusion.

The Defense and Veterans Pain Rating Scale (DVPRS) is a five-item tool that assesses the impact of pain on sleep, mood, stress, and activity levels (20).

For patients unable to self-report pain, such as those intubated in the ICU or late-stage neurological diseases, the FLACC scale is practical. The FLACC scale was initially created to assess pain in infants. Note: The patient need not cry to be rated 10/10.

 

Behavior 0 1 2
Face No particular expression or smile Occasional grimace or frown, withdrawn, disinterested Frequent or constant quivering chin, clenched jaw
Legs Normal position or relaxed Uneasy, restless, tense Kicking or legs drawn
Activity Lying quietly, in a normal position, or relaxed Squirming, shifting back and forth, tense Arched, rigid, or jerking
Cry No cry wake or asleep Moans or whimpers: occasional complaints Crying steadily, screams, sobs, frequent complaints
Consolability Content, relaxed Distractable, reassured by touching, hugging, or being talked to Difficult to console or comfort

(21).

 

Assess contributors to pain such as insomnia, stress, exercise, diet, and any comorbid conditions. Limited access to care, socioeconomic status, and local culture also contribute to the patient's experience of pain (23). Most patients have limited opportunity to discuss these issues, and though challenging to bring up, it is compassionate and supportive care. A referral to social work or another agency may be helpful if you cannot explore it fully.

Assess for substance abuse disorders, especially among male, younger, less educated, or unemployed adults. Substance abuse disorders increase the likelihood of misuse disorder and include alcohol, tobacco, cannabis, cocaine, and heroin (29).

Inquire as to what changes in function the pain has caused. One question to ask is, "Were it not for pain, what would you be doing?" As seen below, a Pain, Enjoyment, and General Activity (PEG) three-question scale, which focuses on function and quality of life, may help determine the severity of pain and the effect of treatment over time.

 

What number best describes your pain on average in the past week? 0-10
What number best describes how, in the past week, pain has interfered with your enjoyment of life? 0-10
What number determines how, in the past week, pain has interfered with your general activity? 0-10

(21).

 

Assess family history, mental health disorders, chronic pain, or substance abuse disorders. Each familial aspect puts patients at higher risk for developing chronic pain (23).

Evaluate for mental health disorders the patient may be experiencing, particularly anxiety and depression. The Patient Health Questionnaire (PHQ4) is a four-question tool for assessing depression and anxiety.

In some cases, functional MRI or imaging studies effectively determine the cause of pain and the treatment. If further assessment is needed to diagnose and treat pain, consult Neurology, Orthopedics, Palliative care, and pain specialists (23).

 

Case Study

You used OLDCARTS to evaluate Mary's pain and completed a body diagram. Mary is experiencing allodynia in her back and shoulders, described as burning and tingling. It is exacerbated when she lifts, such as moving patients at the long-term care facility and, more recently, boxes from her move to the new house. Mary has also been experiencing anxiety due to fear of losing her job, the move, and her new role. She has moved closer to her family to help care for her children since she often experiences fatigue. Mary has experienced a tumultuous divorce in the last five years and feels she is still undergoing some trauma.

You saw in the chart that Mary had tried Gabapentin 300 mg BID for her pain and inquired what happened. Mary explained that her pain improved from 8/10 to 7/10 and had no side effects. Her previous care provider discontinued the medication and documented it as a failed therapy. You reviewed the minimum and maximum dosages of Gabapentin and know Mary can take up to 1800mg/day.

During the assessment, Mary also described stiffness and aching in her left knee. She gets a sharp pain when she walks more than 500 steps, and her knee is throbbing by the end of the day. Mary rated the pain a 10/10, but when she compared 10/10 to childbirth, Mary said her pain was closer to 6/10. Her moderate knee pain has reduced Mary's ability to exercise. She used to like to take walks. Mary stated she has had knee pain for six months and has been taking Ibuprofen 3 – 4 times daily.

Since Mary's pain is moderate, you evaluate your options of drugs for moderate to severe pain.

Quiz Questions

Self Quiz

Ask yourself...

  1. How do you assess and evaluate a patient's pain level?
  2. What are the different types of pain and their management strategies?
  3. How do you determine the appropriate dosage of pain medications for a patient?
  4. How do you assess the effectiveness of pain medications in your patients?
  5. How do you adjust medication dosages for elderly patients with pain or addiction?
  6. How do you address the unique challenges in pain management for pediatric patients?
  7. What is the role of non-pharmacological interventions in pain management?
  8. How do you incorporate non-pharmacological interventions into your treatment plans?

Opioid Classifications and Drug Schedules

A comprehensive understanding of drug schedules and opioid classifications is essential for nurse practitioners to ensure patient safety, prevent drug misuse, and adhere to legal and regulatory requirements. Nurse practitioners with a comprehensive understanding of drug schedules and opioid classifications can effectively communicate with colleagues, ensuring accurate medication reconciliation and facilitating interdisciplinary care. Nurse practitioners’ knowledge in facilitating discussions with pharmacists regarding opioid dosing, potential interactions, and patient education is essential (49).

Drug scheduling became mandated under the Controlled Substance Act. The Drug Enforcement Agency (DEA) Schedule of Controlled Drugs and the criteria and common drugs are listed below.

 

Schedule

Criteria Examples

I

No medical use; high addiction potential

Heroin, marijuana, PCP

II

Medical use; high addiction potential

Morphine, oxycodone, Methadone, Fentanyl, amphetamines

III

Medical use; high addiction potential

Hydrocodone, codeine, anabolic steroids

IV

Medical use, low abuse potential

Benzodiazepines, meprobamate, butorphanol, pentazocine, propoxyphene

V Medical use; low abuse potential

Buprex, Phenergan with codeine

(Pain Physician, 2008)

 

Listed below are drugs classified by their schedule and mechanism of action. "Agonist" indicates a drug that binds to the opioid receptor, causing pain relief and also euphoria. An agonist-antagonist indicates the drug binds to some opioid receptors but blocks others. Mixed antagonist-agonist drugs control pain but have a lower potential for abuse and dependence than agonists (7).

 

  Schedule I Schedule II Schedule III Schedule IV Schedule V
Opioid agonists

BenzomorphineDihydromor-phone, Ketobemidine, Levomoramide, Morphine-methylsulfate,

Nicocodeine,

Nicomorphine, Racemoramide

Codeine, Fentanyl, Sublimaze, Hydrocodone, Hydromorphone, Dilaudid,

Meperidine, Demerol, Methadone, Morphine, Oxycodone, Endocet, Oxycontin, Percocet, Oxymorphone, Numorphan

Buprenorphine Buprenex, Subutex,

Codeine compounds, Tylenol #3, Hydrocodone compounds, Lortab, Lorcet, Tussionex, Vicodin

Propoxyphene, Darvon, Darvocet Opium, Donnagel, Kapectolin
Mixed Agonist -Antagonist BuprenorphineNaloxone, Suboxone

Pentazocine,

Naloxone, Talwin-Nx

Stimulants N-methylampheta-mine 3, 4-methylenedioxy amphetamine, MDMA, Ecstacy Amphetamine, Adderal, Cocaine, Dextroamphetamine, Dexedrine, Methamphetamine, Desoxyn, Methylphenidate, Concerta, Metadate, Ritalin, Phenmetrazine, Fastin, Preludin Benapheta-mine, Didrex, Pemolin, Cylert, Phendimetra-zine, Plegine Diethylpropion, Tenuate, Fenfluramine, Phentermine Fastin 1-dioxy-ephedrine-Vicks Inhaler
Hallucinogen-gens, other Lysergic Acid Diamine LSD, marijuana, Mescaline, Peyote, Phencyclidine PCP, Psilocybin, Tetrahydro-cannabinol Dronabinol, Marinol
Sedative Hypnotics

Methylqualine, Quaalude, Gamma-hydroxy butyrate, GHB

 

Amobarbitol, Amytal, Glutethamide, Doriden, Pentobarbital, Nembutal, Secobarbital, Seconal

Butibarbital. Butisol, Butilbital, Florecet, Florinal,

Methylprylon,

Noludar

Alprazolam, Xanax, Chlordiazepoxide, Librium, Chloral betaine, Chloral hydrate, Noctec, Chlorazepam, Clonazepam, Klonopin, Clorazopate, Tranxene, Diazepam, Valium, Estazolam, Prosom, Ethchlorvynol, Placidyl, Ethinamate, Flurazepam, Dalmane, Halazepam, Paxipam, Lorazepam, Ativan, Mazindol, Sanorex, Mephobarbital, Mebaral, Meprobamate, Equanil, Methohexital, Brevital Sodium, Methyl-phenobarbital,

Midazolam, Versed, Oxazepam, Serax, Paraldehyde, Paral, Phenobarbital, Luminal, Prazepam, Centrax, Temazepam, Restoril, Triazolam, Halcion, Sonata, Zolpidem, Ambien

Diphenoxylate preparations, Lomotil

(41).

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the potential risks and benefits of using opioids for pain management?
  2. How can nurse practitioners effectively monitor patients on long-term opioid therapy?
  3. What are the potential risks and benefits of using long-acting opioids for chronic pain?
  4. How do you monitor patients on long-acting opioids for safety and efficacy?

Commonly Prescribed Opioids, Indications for Use, and Typical Side Effects

Opioid medications are widely used for managing moderate to severe pain. Referencing NIDA (2023), this section aims to give healthcare professionals an overview of the indications and typical side effects of commonly prescribed Schedule II opioid medications, including hydrocodone, oxycodone, morphine, Fentanyl, and hydromorphone.

Opioids are derived and manufactured in several ways. Naturally occurring opioids come directly from the opium poppy plant. Synthetic opioids are manufactured by chemically synthesizing compounds that mimic the effects of a natural opioid. Semi-synthetic is a mix of naturally occurring and man-made (35).

Understanding the variations in how an opioid is derived and manufactured is crucial in deciding the type of opioid prescribed, as potency and analgesic effects differ. Synthetic opioids are often more potent than naturally occurring opioids. Synthetic opioids have a longer half-life and slower elimination, affecting the duration of action and timing for dose adjustments. They are also associated with a higher risk of abuse and addiction (38).

 

Hydrocodone
Mechanism of Action and Metabolism

Hydrocodone is a Schedule II medication. It is an opioid agonist and works as an analgesic by activating mu and kappa opioid receptors located in the central nervous system and the enteric plexus of the bowel. Agonist stimulation of the opioid receptors inhibits nociceptive neurotransmitters' release and reduces neuronal excitability (17).

  • Produces analgesia.
  • Suppresses the cough reflex at the medulla.
  • Causes respiratory depression at higher doses.

Hydrocodone is indicated for treating severe pain after nonopioid therapy has failed. It is also indicated as an antitussive for nonproductive cough in adults over 18.

 

Available Forms

Hydrocodone immediate release (IR) reaches maximum serum concentrations in one hour with a half-life of 4 hours.  Extended-release (ER) Hydrocodone reaches peak concentration at 14-16 hours and a half-life of 7 to 9 hours. Hydrocodone is metabolized to an inactive metabolite in the liver by cytochrome P450 enzymes CYP2D6 and CYP3A4. Hydrocodone is converted to hydromorphone and is excreted renally. Plasma concentrations of hydromorphone are correlated with analgesic effects rather than hydrocodone.

Hydrocodone is formulated for oral administration into tablets, capsules, and oral solutions. Capsules and tablets should never be crushed, chewed, or dissolved. These actions convert the extended-release dose into immediate release, resulting in uncontrolled and rapid release of opioids and possible overdose.

 

Dosing and Monitoring

Hydrocodone IR is combined with acetaminophen or ibuprofen. The dosage range is 2.5mg to 10mg every 4 to 6 hours. If formulated with acetaminophen, the dosage is limited to 4gm/day.

Hydrocodone ER is available as tablets and capsules. Depending on the product, the dose of hydrocodone ER formulations in opioid-naïve patients is 10 to 20 mg every 12 to 24 hours.

Nurse practitioners should ensure patients discontinue all other opioids when starting the extended-release formula.

 

Side Effects and Contraindications

Because mu and kappa opioid receptors are in the central nervous system and enteric plexus of the bowel, the most common side effects of hydrocodone are constipation and nausea (>10%).

Other adverse effects of hydrocodone include:

  • Respiratory: severe respiratory depression, shortness of breath
  • Cardiovascular: hypotension, bradycardia, peripheral edema
  • Neurologic: Headache, chills, anxiety, sedation, insomnia, dizziness, drowsiness, fatigue
  • Dermatologic: Pruritus, diaphoresis, rash
  • Gastrointestinal: Vomiting, dyspepsia, gastroenteritis, abdominal pain
  • Genitourinary: Urinary tract infection, urinary retention
  • Otic: Tinnitus, sensorineural hearing loss
  • Endocrine: Secondary adrenal insufficiency (17)

Hydrocodone, being an agonist, must not be taken with other central nervous system depressants as sedation and respiratory depression can result. In formulations combined with acetaminophen, hydrocodone can increase the international normalized ratio (INR) and cause bleeding.  Medications that induce or inhibit cytochrome enzymes can lead to wide variations in absorption.

 

The most common drug interactions are listed below:

  • Alcohol
  • Benzodiazepines
  • Barbiturates
  • other opioids
  • rifampin
  • phenytoin
  • carbamazepine
  • cimetidine,
  • fluoxetine
  • ritonavir
  • erythromycin
  • diltiazem
  • ketoconazole
  • verapamil
  • Phenytoin
  • John’s Wort
  • Glucocorticoids

 

Considerations

Use with caution in the following:

  • Patients with Hepatic Impairment: Initiate 50% of the usual dose
  • Patients with Renal Impairment: Initiate 50% of the usual dose
  • Pregnancy: While not contraindicated, the FDA issued a black-boxed warning since opioids cross the placenta, and prolonged use during pregnancy may cause neonatal opioid withdrawal syndrome (NOWS).
  • Breastfeeding: Infants are susceptible to low dosages of opioids. Non-opioid analgesics are preferred.

Pharmacogenomic: Genetic variants in hydrocodone metabolism include ultra-rapid, extensive, and poor metabolizer phenotypes. After administration of hydrocodone, hydromorphone levels in rapid metabolizers are significantly higher than in poor metabolizers.

 

Oxycodone
Mechanism of Action and Metabolism

Oxycodone has been in use since 1917 and is derived from Thebaine. It is a semi-synthetic opioid analgesic that works by binding to mu-opioid receptors in the central nervous system. It primarily acts as an agonist, producing analgesic effects by inhibiting the transmission of pain signals (Altman, Clark, Huddart, & Klein, 2018).

Oxycodone is primarily metabolized in the liver by CYP3A4/5. It is metabolized in the liver to noroxycodone and oxymorphone.  The metabolite oxymorphone also has an analgesic effect and does not inhibit CYP3A4/5. Because of this metabolite, oxycodone is more potent than morphine, with fewer side effects and less drug interactions. Approximately 72% of oxycodone is excreted in urine (Altman, Clark, Huddart, & Klein, 2018).

 

Available Forms

Oxycodone can be administered orally, rectally, intravenously, and as an epidural. For this sake, we will focus on immediate-release and extended-release oral formulations.

  • Immediate-release (IR) tablets
  • IR capsules
  • IR oral solutions
  • Extended-release (ER) tablets

 

Dosing and Monitoring

The dosing of oxycodone should be individualized based on the patient's pain severity, previous opioid exposure, and response. Initial dosages for opioid naïve patients range from 5-15 mg for immediate-release formulations, while extended-release formulations are usually initiated at 10-20 mg. Dosage adjustments may be necessary based on the patient's response, but caution should be exercised. IR and ER formulations reach a steady state at 24 hours and titrating before 24 hours may lead to overdose.

Regular monitoring is essential to assess the patient's response to treatment, including pain relief, side effects, and signs of opioid misuse or addiction. Monitoring should include periodic reassessment of pain intensity, functional status, and adverse effects (Altman, Clark, Huddart, & Klein, 2018).

 

Side Effects and Contraindications

Common side effects of oxycodone include:

  • constipation
  • nausea
  • sedation
  • dizziness
  • respiratory depression
  • respiratory arrest
  • hypotension
  • fatal overdose

Oxycodone is contraindicated in patients with known hypersensitivity to opioids, severe respiratory depression, paralytic ileus, or acute or severe bronchial asthma. It should be used cautiously in patients with a history of substance abuse, respiratory conditions, liver or kidney impairment, and those taking other medications that may interact with opioids, such as alcohol (4).

 

It is also contraindicated with the following medications and classes:

  • Antifungal agents
  • Antibiotics
  • Rifampin
  • Carbamazepine
  • Fluoxetine
  • Paroxetine

 

Considerations
  • Nurse practitioners should consider the variations in the mechanism of action for the following:
  • Metabolism differs between males and females: females have been shown to have less concentration of oxymorphone and more CYP3A4/5 metabolites.
  • Infants have reduced clearance of oxycodone, increasing side effects.
  • Pediatrics have 20-40% increased clearance over adults.
  • Reduced clearance with age increases the half-life of oxycodone.
  • Pregnant women have a greater clearance and reduced half-life.
  • Impairment of the liver reduces clearance.
  • Cancer patients with cachexia have increased exposure to oxycodone and its metabolite.
  • Maternal and neonate concentrations are similar, indicating placenta crossing (4)

 

Morphine

 

 

 

 

Mechanism of Action and Metabolism

Morphine is a naturally occurring opioid alkaloid extracted from the opium poppy. It was isolated in 1805 and is the opioid against which all others are compared. Morphine binds to mu-opioid receptors in the brain and spinal cord, inhibiting the transmission of pain signals and producing analgesia. It is a first-line choice of opioid for moderate to severe acute, postoperative, and cancer-related pain (8).

Morphine undergoes first-pass metabolism in the liver and gut. It is well absorbed and distributed throughout the body. Its main metabolites are morphine-3-glucuronide and morphine-6-glucuronide. Its mean plasma elimination half-life after intravenous administration is about 2 hours. Approximately 90% of morphine is excreted in the urine within 24 hours (8).

 

Available Forms

Morphine is available in various forms, including.

  • immediate-release tablets
  • extended release tablets
  • oral IR solutions
  • injectable solutions
  • transdermal patches

 

Dosing and Monitoring

Morphine is hydrophilic and, as such, has a slow onset time. The advantage of this is that it is unlikely to cause acute respiratory depression even when injected. However, because of the slow onset time, there is more likelihood of morphine overdose due to the ability to “stack” doses in patients experiencing severe pain (Bistas, Lopez-Ojeda, & Ramos-Matos, 2023).

The dosing of morphine depends on the patient's pain severity, previous opioid exposure, and other factors. It is usually initiated at a low dose and titrated upwards as needed. Monitoring pain relief, adverse effects, and signs of opioid toxicity is crucial. Reevaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy or of dose escalation. General recommendations for initiating morphine (Bistas, Lopez-Ojeda, & Ramos-Matos, 2023).

Prescribe IR opioids instead of ER opioids.

Prescribe the lowest effective dosage, below 50 Morphine Milligram Equivalents (MME) /day.

 

Side Effects and Contraindications

Because morphine binds to opioid receptors in the brain and spinal cord, is metabolized in the liver and gut, and has a slow onset, the following side effects are common:

  • Constipation
  • Nausea
  • Vomiting
  • Sedation
  • Dizziness
  • Respiratory depression
  • Pruritis
  • Sweating
  • Dysphoria/Euphoria
  • Dry mouth
  • Anorexia
  • Spasms of urinary and biliary tract

 

Contraindications of morphine are:
  • Known hypersensitivity or allergy to morphine.
  • Bronchial asthma or upper airway obstruction
  • Respiratory depression in the absence of resuscitative equipment
  • Paralytic ileus
  • Risk of choking in patients with dysphagia, including infants, children, and the elderly (8)

Concurrent use with other sedating medications: Amitriptyline, diazepam, haloperidol, chlorpromazine

 

Morphine interacts with the following medications:

  • Ciprofloxacin
  • Metoclopramide
  • Ritonavir

 

Considerations for Nurse Practitioners

Assess for medical conditions that may pose serious and life-threatening risks with opioid use, such as the following:

  • Sleep-disordered breathing, such as sleep apnea.
  • Pregnancy
  • Renal or hepatic insufficiency
  • Age >= 65
  • Certain mental health conditions
  • Substance use disorder
  • Previous nonfatal overdose

 

 

Fentanyl
Mechanism of Action and Metabolism

Fentanyl is a synthetic opioid more potent than morphine and was approved in 1968. Fentanyl is an agonist that works by binding to the mu-opioid receptors in the central nervous system. This binding inhibits the transmission of pain signals, resulting in analgesia. Fentanyl is often used for severe pain management, particularly in the perioperative and palliative care settings, or for severe pain in patients with Hepatic failure (8).

It is a mu-selective opioid agonist. However, it can activate other opioid receptors in the body, such as the delta and kappa receptors, producing analgesia. It also activates the Dopamine center of the brain, stimulating relaxation and exhilaration, which is responsible for its high potential for addiction (8).

 

Indications for fentanyl are as follows:

  • Preoperative analgesia
  • Anesthesia adjunct
  • Regional anesthesia adjunct
  • General anesthesia
  • Postoperative pain control
  • Moderate to severe acute pain (off-label)

 

Available Forms
  • Fentanyl is available in various forms, including:
  • transdermal patches
  • injectable solutions
  • lozenges
  • nasal sprays
  • oral tablets (8)

 

Dosing and Monitoring

Fentanyl is metabolized via the CYP3A4 enzyme in the liver. It has a half-life of 3 to 7 hours, and 75% of Fentanyl is excreted in the urine and 9% in feces.

The dosing of fentanyl depends on the route of administration and the patient's needs. For example, transdermal patches are typically applied every 72 hours, while injectable solutions are titrated to achieve the desired analgesic effect. Monitoring should include assessing pain levels, respiratory rate, blood pressure, and sedation scores (8).

 

Fentanyl is most dosed as follows:

  • Post-operative pain control
  • 50 to 100 mcg IV/IM every 1 to 2 hours as needed; alternately 0.5 to 1.5 mcg/kg/hour IV as needed. Consider lower dosing in patients 65 and older.

PCA (patient-controlled analgesia): 10 to 20 mcg IV every 6 to 20 minutes as needed; start at the lowest effective dose for the shortest effective duration - refer to institutional protocols (8).

Moderate to severe acute pain (off-label) 1 to 2 mcg/kg/dose intranasally each hour as needed; the maximum dose is 100 mcg. Use the lowest effective dose for the shortest effective duration (8).

 

Side Effects and Contraindications

Common side effects of fentanyl include:

  • respiratory depression
  • sedation
  • constipation
  • nausea
  • vomiting
  • euphoria
  • confusion
  • respiratory depression/arrest
  • visual disturbances
  • dyskinesia
  • hallucinations
  • delirium
  • narcotic ileus
  • muscle rigidity
  • addiction
  • loss of consciousness
  • hypotension
  • coma
  • death (8).

 

The use of fentanyl is contraindicated in patients in the following situations:

  • After operative interventions in the biliary tract, these may slow hepatic elimination of the drug.
  • With respiratory depression or obstructive airway diseases (i.e., asthma, COPD, obstructive sleep apnea, obesity hyperventilation, also known as Pickwickian syndrome)
  • With liver failure
  • With known intolerance to fentanyl or other morphine-like drugs, including codeine or any components in the formulation.
  • With known hypersensitivity (i.e., anaphylaxis) or any common drug delivery excipients (i.e., sodium chloride, sodium hydroxide) (8).

Considerations for Nurse Practitioners

Nurse practitioners prescribing fentanyl should thoroughly assess the patient's pain, medical history, and potential risk factors for opioid misuse. They should also educate patients about the proper use, storage, and disposal of fentanyl. It should be used cautiously in patients with respiratory disorders, liver or kidney impairment, or a history of substance abuse. Fentanyl is contraindicated in patients with known hypersensitivity to opioids and those without exposure to opioids.

Alcohol and other drugs, legal or illegal, can exacerbate fentanyl's side effects, creating multi-layered clinical scenarios that can be complex to manage. These substances, taken together, generate undesirable conditions that complicate the patient's prognosis (8).

 

Hydromorphone
Mechanism of Action and Metabolism

Hydromorphone is a semi-synthetic opioid derived from morphine. It binds to the mu-opioid receptors in the central nervous system. It primarily exerts its analgesic effects by inhibiting the release of neurotransmitters involved in pain transmission, thereby reducing pain perception. Hydromorphone also exerts its effects centrally at the medulla level, leading to respiratory depression and cough suppression (1).

 

Hydromorphone is indicated for:

  • moderate to severe acute pain
  • severe chronic pain
  • refractory cough suppression (off-label) (1)

 

Available Forms

Hydromorphone is available in various forms, depending on the patient’s needs and severity of pain.

  • immediate-release tablet
  • extended release tablets
  • oral liquid
  • injectable solution
  • rectal suppositories

 

Dosing and Monitoring

The immediate-release oral formulations of hydromorphone have an onset of action within 15 to 30 minutes. Peak levels are typically between 30 and 60 minutes with a half-life of 2 to 3 hours. Hydromorphone is primarily excreted through the urine.

The dosing of hydromorphone should be individualized based on the patient's pain intensity, initiated at the lowest effective dose, and adjusted gradually as needed. Close monitoring of pain relief, adverse effects, and signs of opioid toxicity is essential. Patients should be assessed regularly to ensure they receive adequate pain control without experiencing excessive sedation or respiratory depression.

The following are standard dosages that should only be administered when other opioid and non-opioid options fail.

  • Immediate-release oral solutions dosage: 1 mg/1 mLoral tablets are available in 2 mg, 4 mg, and 8 mg.
  • Extended-release oral tablets are available in dosages of 8 mg, 12 mg, 16 mg, and 32 mg.
  • Injection solutions are available in concentrations of 1 mg/mL, 2 mg/mL, 4 mg/mL, and 10 mg/mL.
  • Intravenous solutions are available in strengths of 2 mg/1 mL, 2500 mg/250 mL, ten mg/1 mL, and 500 mg/50 mL.
  • Suppositories are formulated at a strength of 3 mg (1).

 

Side Effects and Contraindications

Hydromorphone has potential adverse effects on several organ systems, including the integumentary, gastrointestinal, neurologic, cardiovascular, endocrine, and respiratory.

 

Common side effects of hydromorphone include:

  • Constipation
  • Nausea
  • Vomiting
  • Dizziness
  • Sedation
  • respiratory depression
  • pruritus
  • headache
  • Somnolence
  • Severe adverse effects of hydromorphone include:
  • Hypotension
  • Syncope
  • adrenal insufficiency
  • coma
  • raised intracranial pressure.
  • seizure
  • suicidal thoughts
  • apnea
  • respiratory depression or arrest
  • drug dependence or withdrawal
  • neonatal drug withdrawal syndrome
  • Hydromorphone is contraindicated in patients with:
  • known allergies to the drug, sulfites, or other components of the formulation.
  • known hypersensitivity to opioids.
  • severe respiratory depression
  • paralytic ileus
  • acute or severe bronchial asthma (1).

 

Caution should be exercised in patients with:

  • respiratory insufficiency
  • head injuries
  • increased intracranial pressure.
  • liver or kidney impairment.

 

Considerations for Nurse Practitioners

As nurse practitioners, it is crucial to assess the patient's pain intensity and overall health status before initiating Hydromorphone. Start with the lowest effective dose and titrate carefully for optimal pain control. Regular monitoring for adverse effects, signs of opioid toxicity, and therapeutic response is essential. Educate patients about the potential side effects, proper dosing, and the importance of not exceeding prescribed doses. Additionally, nurse practitioners should be familiar with local regulations and guidelines regarding opioid prescribing and follow appropriate documentation and monitoring practices.

 

Additional Considerations

In terminal cancer patients, clinicians should not restrain opioid therapy even if signs of respiratory depression become apparent.

Hydromorphone requires careful administration in cases of concurrent psychiatric illness.

 

Specific Patient Considerations:
  • Hepatic impairment and Renal Impairment: Initiate hydromorphone treatment at one-fourth to one-half of the standard starting dosage, depending on the degree of impairment.
  • Pregnancy considerations: Hydromorphone can traverse the placental barrier and induce NOWS.
  • Breastfeeding considerations: Nonopioid analgesic agents are preferable for breastfeeding women.
  • Older patients: hydromorphone is categorized as a potentially inappropriate medication for older adults (1).

 

Tramadol

 

 

 

 

Mechanism of Action and Metabolism

Tramadol is a Schedule IV opioid medication with a higher potential for dependency and misuse than non-opioid medications. It binds to opioid receptors in the central nervous system, inhibiting the reuptake of norepinephrine and serotonin. It also has weak mu-opioid receptor agonist activity.

The liver metabolizes tramadol mediated by the cytochrome P450 pathways (particularly CYP2D6) and is mainly excreted through the kidneys.

Tramadol is used for moderate to severe pain.

 

Available Forms of Tramadol include:
  • Immediate-release-typically used for acute pain management.
  • Extended-release-used for chronic pain.

 

Dosing and Monitoring

Tramadol has an oral bioavailability of 68% after a single dose and 90–100% after multiple doses and reaches peak concentrations within 2 hours. Approximately 75% of an oral dose is absorbed, and the half-life of tramadol is 9 hours (18).

Tramadol dosing should be individualized based on the patient's pain severity and response.

The initial dose for adults is usually 50-100 mg orally every 4-6 hours for pain relief. The maximum daily dose is 400 mg for immediate-release formulations and 300 mg for extended-release formulations (18).

It is essential to monitor the patient's pain intensity, response to treatment, and any adverse effects. Regular reassessment and adjustment of the dosage may be necessary.

 

Side Effects and Contraindications

Tramadol is responsible for severe intoxications leading to consciousness disorder (30%), seizures (15%), agitation (10%), and respiratory depression (5%). The reactions to Tramadol suggest that the decision to prescribe should be carefully considered.

 

Common Side Effects of Tramadol Include:
  • Nausea
  • Vomiting
  • Dizziness
  • Constipation
  • Sedation
  • Headache
  • CNS depression
  • Seizure
  • Agitation
  • Tachycardia
  • Hypertension
  • reduced appetite
  • pruritus and rash
  • gastric irritation

 

Serious side effects include:
  • respiratory depression
  • serotonin syndrome
  • seizures

 

Contraindications

Tramadol is contraindicated in patients with:

  • history of hypersensitivity to opioids
  • acute intoxication with alcohol
  • opioids, or other psychoactive substances
  • Patients who have recently received monoamine oxidase inhibitors (MAOIs)

 

Additionally, the following can be observed in tramadol intoxication:

  • miosis
  • respiratory depression
  • decreased level of consciousness
  • hypertension
  • tremor
  • irritability
  • increased deep tendon reflexes

 

Poisoning leads to:

  • multiple organ failure
  • coma
  • cardiopulmonary arrest
  • death

 

Considerations for Nurse Practitioners

Tramadol has been increasingly misused with intentional overdoses or intoxications. Suicide attempts were the most common cause of intoxication (52–80%), followed by abuse (18–31%), and unintentional intoxication (1–11%). Chronic tramadol or opioid abuse was reported in 20% of tramadol poisoning cases. Fatal tramadol intoxications are uncommon except when ingested concurrent with depressants, most commonly benzodiazepines and alcohol (18).

 

Tramadol poisoning can affect multiple organ systems:
  • gastrointestinal
  • central nervous system: seizure, CNS depression, low-grade coma, anxiety, and over time anoxic brain damage
  • Cardiovascular system: palpitation, mild hypertension to life-threatening complications such as cardiopulmonary arrest
  • respiratory system
  • renal system: renal failure with higher doses of tramadol intoxication
  • musculoskeletal system: rhabdomyolysis
  • endocrine system: hypoglycemia, serotonin syndrome (18)

 

Cannabis
Mechanism of Action and Metabolism

Cannabis is classified as a Schedule I status. It contains various cannabinoids, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most studied. THC primarily acts on cannabinoid receptors in the brain, producing psychoactive effects, while CBD has more diverse effects on the nervous system. These cannabinoids interact with the endocannabinoid system, modulating neurotransmitter release and influencing various physiological processes (32).

Similar to opioids, cannabinoids are synthesized and released in the body by synapses that act on the cannabinoid receptors present in presynaptic endings (32). They perform the following actions related to analgesia:

  • Decrease the release of neurotransmitters.
  • Activate descending inhibitory pain pathways.
  • Reduce postsynaptic sensitivity and alleviate neural inflammation.
  • Modulate CB1 receptors within central nociception processing areas and the spinal cord, resulting in analgesic effects.
  • Attenuate inflammation by activating CB2 receptors (32).
  • Emerging research shows cannabis is indicated for:
  • Migraines
  • chronic pain
  • back pain
  • arthritic pain
  • pain associated with cancer and surgery.
  • neuropathic pain
  • diabetic neuropathic pain when administered early in the disease progression.
  • sickle cell disease
  • cancer
  • inflammatory bowel disease (32)

 

Available Forms

Cannabis refers to products sourced from the Cannabis sativa plant. There are differences between cannabis, cannabinoids, and cannabidiol (CBD). Cannabinoids are extracted from the cannabis plants. Cannabinoid-based treatments, such as dronabinol and CBD, are typically approved medical interventions for specific indications. THC (9-tetrahydrocannabinol) is the psychoactive component of the cannabis plant. CBD is a non-psychoactive component (32).

 

Cannabis can be consumed in different forms, each with a different onset and duration. Patients may have individual preferences, including:

  • smoking/vaporizing dried flowers.
  • consuming edibles
  • tinctures or oils
  • applying topicals (32)

 

Dosing and Monitoring

Inhaling marijuana via the lungs by smoking or vaping causes maximum plasma concentration within minutes. Psychiatric effects begin within seconds to a few minutes after inhalation and peak after 15 to 30 minutes. The effect diminishes throughout 2 to 3 hours (32).

Oral ingestion of marijuana causes psychiatric effects that typically occur between 30 and 90 minutes and reach maximum effect after 2 to 3 hours. Ingested marijuana effects last about 4 to 12 hours (32).

Dosing cannabis is challenging due to variations in potency and individual responses. Start with low doses and titrate slowly to achieve the desired effect while minimizing side effects. Regular monitoring is crucial, including assessing symptom relief, adverse effects, and potential drug interactions. Encourage patients to keep a diary to track their cannabis use and its effects (32).

 

Side Effects and Contraindications

Cannabis can exacerbate mental health conditions such as anxiety and psychosis. Common side effects of cannabis include (32):

  • Dizziness
  • dry mouth
  • increased heart rate
  • impaired memory
  • psychoactive effects

 

Contraindications include:

  • Pregnancy
  • Breastfeeding
  • heart disease
  • respiratory conditions
  • history of substance abuse
  • mental health disorders
Quiz Questions

Self Quiz

Ask yourself...

  1. How do you address patients' misconceptions about pain medications?
  2. What are the mechanisms of action for commonly prescribed pain medications?
  3. How do these mechanisms of action contribute to pain relief?
  4. What are the potential side effects and risks associated with commonly prescribed pain medications?
  5. How do you educate patients about the risks and benefits of pain medications?
  6. How do you manage patients who require high-dose opioids for pain management?
  7. Is medical cannabis legal in your State? If yes, are you familiar with the prescribing guidelines?
  8. Do you have any personal biases against the use of medical cannabis? Why or why not?

Case Study

Mary is agreeable to trying an increased dose of Gabapentin. Mary would also like to see a counselor to discuss her past and get help with her anxiety. You made an appointment for Mary to see a Licensed Clinical Social Worker in your clinic.

You read the side effects and warnings for Gabapentin, and it is unsafe to use Gabapentin and Tramadol together since they are both depressants. You order a non-steroidal drug for Mary's somatic knee pain and make a consult for imaging studies on her left knee. You also make a referral to Orthopedics.

You educated Mary about the side effects of Gabapentin and scheduled a follow-up appointment. The day after Mary began her treatment with the increased Gabapentin, you called Mary to follow up on its effect. Mary still has pain, but she is not having any untoward side effects. Gabapentin may not work immediately so you will schedule a follow-up call in 3 days.

Quiz Questions

Self Quiz

Ask yourself...

  1. In this case study, Mary has insurance. How might your practice be different were Mary not insured?
  2. In your experience, what are the possible reasons for Mary's knee pain not being a part of her previous treatment record?
  3. Consider how your assessment of Mary's needs differs from the above-mentioned case study.
  4. Explain the rationale for decisions made by the nurse practitioner in the case study mentioned above and if your decisions would differ.

Opioid Use, the Opioid Epidemic, and Statistics

The use and misuse of opioids has become a pressing public health concern, leading to a global epidemic. The history of opioid use, the opioid epidemic, and associated statistics provide essential context for healthcare professionals in addressing this public health crisis. More importantly, it is estimated that 1 in 4 patients receiving prescription opioids in primary care settings will misuse them. In addition, 50% of opioid prescriptions are written by primary care providers, including nurse practitioners (22). Understanding the factors contributing to the epidemic and the magnitude of its impact is crucial for effective prevention, intervention, and treatment strategies.

 

History of Opioid Use

Opioids have a long history of medicinal use, dating back to ancient civilizations. They have been a drug of choice for pain relief for thousands of years. The introduction of synthetic opioids in the 19th century, such as morphine and later heroin, revolutionized pain management. However, their potential for addiction and misuse soon became apparent (16).

 

The Opioid Epidemic

The opioid epidemic refers to the surge in opioid misuse, addiction, and overdose deaths. The epidemic gained momentum in the late 1990s with increased prescribing of opioids for chronic pain (43).

No doubt, increased prescribing put opioids in the hands of consumers, but increased prescribing resulted from a multifactorial influence. One of the main influences was aggressive marketing by pharmaceutical companies, which has been well publicized. However, due to the long history of underprescribing pain medications for fear of misuse and addiction, the medical community was primed to expand its opioid prescribing practices (31).

A historical event that increased comfort with prescribing opioids, in the writer's opinion, was the introduction of the Medicare Hospice Benefit in 1986. Medical directors must be contracted or employed by hospices, and these medical directors had or soon gained pain management expertise. To further promote hospice and effective pain management, the hospice medical directors, with newly acquired skills, provided education throughout medical communities about pain management and specifically to decrease the fear of using opioids. Pharmacies and attending physicians grew accustomed to giving opioids for home use. Hospice care is for terminally ill patients, defined as a life expectancy of 6 months or less. Still, the reality is that hospice discharges 12 to 40% of patients for ineligibility and other reasons.

A more prominent factor in increasing opioid prescribing was the 1996 American Pain Society's introduction of pain as "the 5th Vital sign." Soon after, The Joint Commission promoted pain as "the 5th Vital Sign" and began compliance surveys in healthcare organizations requiring pain assessment details to be as prominent as blood pressure and heart rate. The Joint Commission cited a quote from 1968 by a nurse from the University of California Los Angeles, Margo McCaffrey, who defined pain as "…Whatever the experiencing person says it is, existing whenever s/he says it does." The Joint Commission accreditation programs pursued pain management as part of the accreditation process throughout its healthcare accreditation programs, including hospice accreditation by 1989 per TJC Timeline (48).

The National Institute of Health published an article about the Joint Commission's role in the opioid epidemic, particularly regarding the definition of pain, "This definition emphasizes that pain is a subjective experience with no objective measures. It also stresses that the patient, not the clinician, is the authority on the pain and that their self-report is the most reliable indicator of pain. This set the tone for clinicians: Patients are always to be trusted to report pain accurately” (45).

 

Statistics on the Opioid Epidemic

In the United States alone, over 500,000 people died from opioid overdoses between 1999 and 2017. The number of opioid-related overdose deaths continues to increase, with synthetic opioids, mainly illicitly manufactured Fentanyl, playing a significant role in recent years (46). Fentanyl-laced drugs, such as marijuana, are increasingly sold knowing and unknowingly to introduce medications with a high addiction rate, thus creating new consumers. This practice can potentially increase deaths due to the imprecise nature of manufacturing (16).

Opioid-related hospitalizations have also risen substantially. In 2014, there were approximately 1.27 million hospitalizations related to opioids in the United States. These hospitalizations not only place a burden on healthcare systems but also reflect the severe consequences of opioid misuse (3).

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you experienced changes to your practice because of the opioid epidemic? If so, what are the changes?
  2. What is your opinion on the validity of Margo McCaffrey's definition of pain?
  3. What factors influence your willingness or unwillingness to prescribe opioids?

Federal Regulations on Opioid Prescribing

The history of substance use disorder prevention that promotes opioid recovery and treatment for patients and communities can be traced back to the early 20th century. However, the current approach to addressing opioid addiction and promoting healing has evolved significantly in recent times (36).

In the early 1900s, health professionals treated opioid addiction with punitive measures, including incarceration and moralistic approaches. The focus was on punishing individuals rather than providing effective treatment. This approach persisted for several decades until the mid-20th century when the medical community started recognizing addiction as a medical condition rather than a moral failing (36).

The Controlled Substances Act (CSA), introduced in 1970, was a response to increasing drug abuse and illicit drug trafficking in the United States. The CSA is a federal law regulating the manufacture, possession, distribution, and use of certain substances, including drugs and medications, that can potentially cause abuse and dependence. Its primary purpose is to combat drug abuse, reduce drug-related crimes, and protect public health and safety. The Drug Enforcement Agency (DEA) plays a crucial role in enforcing the CSA by monitoring and controlling controlled substance production, distribution, and use (31).

In the 1990s, the significant increase in opioid prescribing, leading to a surge in opioid addiction and overdose deaths, prompted a shift in focus toward prevention. Efforts were made to educate healthcare providers about the risks of overprescribing opioids and to implement prescription drug monitoring programs to track and prevent abuse (36).

The Comprehensive Addiction and Recovery Act (CARA) was signed into law in 2016 to expand access to treatment and recovery services for opioid addiction. This legislation allocated funding for prevention, treatment, recovery, and support services while promoting evidence-based practices and programs (36).

The Centers for Disease Control and Prevention (CDC) published guidelines in 2016 for prescribing opioids for chronic pain, which was updated in 2022. These guidelines emphasize the importance of non-opioid alternatives, using the lowest effective dose for the shortest duration, and assessing the benefits and risks of continued opioid therapy (13).

Furthermore, the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT) was signed into law in 2018, providing additional resources to address the opioid crisis. This legislation expanded access to medication-assisted treatment (MAT), increased the availability of naloxone, a medication used to reverse opioid overdose, and enhanced support for recovery housing (36).

In recent years, there has been a growing recognition of the importance of a comprehensive approach to opioid addiction, including harm reduction strategies, increased access to naloxone, and the integration of mental health services. Communities and organizations have been working together to address the underlying issues contributing to addiction, such as poverty, trauma, and social determinants of health (50).

Overall, the history of substance use disorder prevention that promotes opioid recovery and treatment has evolved from a punitive approach to a more compassionate and evidence-based model. Efforts are now focused on prevention, early intervention, and expanding access to comprehensive treatment and support services for individuals and communities affected by opioid addiction (36).

The most current federal regulations on opioid prescribing for healthcare providers are the amendments to the CSA in 2018, which added new rules to limit the quantity and duration of opioid prescriptions for acute pain to seven days. In 2022, the CDC updated recommendations to the Clinical Practice Guidelines for Prescribing Opioids for Pain.

The 2022 CDC guidelines are summarized below (13):

  1. Non-opioid therapies should be considered the first-line treatment for chronic pain.
  2. Establish clear treatment goals with patients, including realistic pain management and functional improvement expectations.
  3. Conduct a thorough risk assessment for potential harms before initiating opioid therapy.
  4. When opioids are used, start with the lowest effective dose and consider immediate-release opioids instead of extended-release or long-acting opioids.
  5. Prescribe the lowest effective dose for the shortest duration possible, typically three days or less and rarely exceeding seven days.
  6. Reassess benefits and risks within one day after prescribing opioids, including checking the prescription drug monitoring database.
  7. Avoid prescribing opioids and benzodiazepines concurrently whenever possible due to the increased risk of overdose and death.
  8. Offer naloxone to patients at increased risk of opioid overdose, including those with a history of overdose, substance use disorder, or concurrent benzodiazepine use.
  9. When opioids are no longer needed, taper the dose gradually to minimize withdrawal symptoms.
  10. Arrange an evidence-based treatment for patients with opioid use disorder, including medication-assisted treatment (Naltrexone, Buprenorphine, or Methadone).
Quiz Questions

Self Quiz

Ask yourself...

  1. What are the guidelines general for prescribing opioids for acute pain?
  2. How do these guidelines differ for chronic pain management?
  3. Discuss how federal regulations impact the practice of nurse practitioners in terms of opioid prescribing.
  4. Describe the potential benefits and challenges nurse practitioners face when adhering to federal regulations on opioid prescribing.
  5. How can nurse practitioners navigate and stay updated with evolving federal regulations surrounding opioid prescribing to ensure safe and effective care?
  6. How do you ensure appropriate documentation when prescribing controlled substances?

Safe Prescribing and Prescription Monitoring Program

Prescription Drug Monitoring Programs (PDMP) are state-run electronic databases that track.

the prescribing and dispensing of controlled substances. PDMPs are designed to improve patients.

care and safety by giving clinicians access to patients' prescription histories, allowing them to make informed decisions when prescribing controlled substances. PDMPs help identify patients at risk of substance misuse or prescription drug overdose. They also enable clinicians to identify potential drug interactions and prevent opioid diversion (14).

PDMPs collect and store data from pharmacies and prescribers in a centralized database. Clinicians can access this database to review a patient's prescription history, including the types of medications prescribed, the prescribers involved, and the dispensing pharmacies (14).

In many states, PDMP use is mandated by law, and nurse practitioners may be required to register and use the system. It is essential to understand state-specific laws and regulations regarding PDMP use.

PDMPs have some limitations, such as incomplete data or delays in reporting. The CDC emphasizes that clinicians should use PDMP data for their clinical assessment and other relevant information to make informed decisions about prescribing controlled substances. Still, PDMP cannot be used as the sole basis for denying or providing treatment (14).

 

Case Study

After five days on Gabapentin, Mary was doing well, and her neuropathic pain had decreased to 3/10. However, Mary suffered a fall after her knee "gave out" and injured her knee and back. She was in severe pain, and her family drove her to the ER. The ER doctors saw Mary, and orthopedics were consulted. Mary has surgery scheduled for a knee replacement a week from now.

Mary was prescribed Vicodin because she was in excruciating pain, but her prescription only allowed enough medication for two days. Mary has made an appointment with you to renew her prescription.

You evaluate Mary because you know that concomitant use of Gabapentin and opioids puts Mary at risk for respiratory depression and possible side effects, including accidental overdose.

Mary stated she has been more alert the past 24 hours and is afraid her functional status will continue to decline if she does not have more Vicodin because the pain in her back and knee makes it difficult to stand. You assess Mary. Mary stated she occasionally drinks alcohol but has not had a drink since she moved. She has no familial history of substance abuse or mental health disorders.

Mary's mother stayed at her house to help her for the first 24 hours after Mary's return from the ER, but Mary is providing her care now.

You check the PDMP database and see that Mary was prescribed eight pills she has taken over the last 48 hours.

Since the Vicodin has been effective without untoward side effects, and Mary's function is improving, you decide to refill the prescription of Vicodin. You will taper the dose to three Vicodin daily for two days and two for one day. Mary will be near her appointment for a knee replacement as well.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the potential benefits and drawbacks of using PDMPs in your practice?
  2. How can PDMPs help you identify potential drug abuse or diversion cases among your patients? Can you provide examples from your own experience?
  3. In what ways do PDMPs impact your decision-making process when prescribing controlled substances?
  4. What are the key considerations when prescribing controlled substances?
  5. How do you ensure responsible prescribing practices for controlled substances?

Preventing Opioid Use Disorder

As previously discussed, opioid addiction is a growing concern worldwide, affecting individuals from all walks of life. According to the CDC, "Anyone who takes prescription opioids can become addicted to them" (14).

As frontline healthcare professionals, nurse practitioners must recognize the signs of opioid addiction to provide timely intervention and support. This section will outline the key indicators of opioid addiction.

 

Physical Symptoms

Physical symptoms are often the first noticeable signs of opioid addiction. These symptoms may include constricted pupils, drowsiness, slurred speech, impaired coordination, and increased sensitivity to pain. Additionally, individuals struggling with opioid addiction may exhibit frequent flu-like symptoms, such as a runny nose, sweating, itching, or gastrointestinal issues.

 

Behavioral Changes

Opioid addiction can significantly impact an individual's behavior. These may include increased secrecy, frequent requests for early prescription refills, doctor shopping (seeking prescriptions from multiple healthcare providers), neglecting personal hygiene, and experiencing financial difficulties due to excessive spending on opioids (37).

 

 

 

 

Social Isolation

Opioid addiction often leads to social withdrawal and isolation. Individuals struggling with opioid addiction may distance themselves from family, friends, and social activities they once enjoyed. They may exhibit erratic mood swings, become defensive or hostile when confronted about their drug use, and display a general lack of interest in previously important activities (30).

 

Psychological Changes

The psychological impact of opioid addiction is significant. Individuals with opioid addiction may exhibit increased anxiety, depression, irritability, and restlessness. They may also experience cognitive impairments, memory lapses, and difficulties in decision-making. Healthcare professionals should be attentive to these changes, as they can indicate opioid addiction (51).

 

Tolerance and Withdrawal Symptoms

The development of tolerance and withdrawal symptoms are critical signs of opioid addiction. Individuals may require increased dosages of opioids to achieve the desired effect, indicating a growing tolerance. Furthermore, withdrawal symptoms such as muscle aches, nausea, vomiting, insomnia, and intense cravings for opioids may occur when the drug is discontinued or reduced abruptly (51).

Quiz Questions

Self Quiz

Ask yourself...

  1. Discuss how nurse practitioners can contribute to preventing opioid use disorder.
  2. Explain how nurse practitioners effectively communicate the risks and signs of opioid misuse without stigmatizing or alienating patients.
  3. What are the signs of opioid addiction or misuse in patients?
  4. How do you approach patients who may be at risk for opioid addiction?
  5. How do you ensure appropriate documentation when prescribing controlled substances?

Opioid Overdose

The management of opioid overdose, withdrawal, and addiction requires a comprehensive approach that combines pharmacological interventions with psychosocial support. Naloxone remains a vital tool for reversing opioid overdose, while medications such as Methadone, buprenorphine, and naltrexone play crucial roles in withdrawal and addiction treatment (National Institute of Health, 2023). Nurse practitioners must stay vigilant and informed about the evolving landscape of medications. This section aims to provide a comprehensive review of medications and treatment strategies for opioid overdose, withdrawal, and addiction and is excerpted from the NIH (40).

 

Naloxone
Mechanism of Action and Metabolism

Naloxone is an opioid receptor antagonist. It works by binding to opioid receptors and displacing any opioids present, thereby reversing the effects of opioid overdose. It has a higher affinity for opioid receptors than most opioids, effectively blocking their action.

Naloxone is indicated for emergency intervention of opioid overdose. It effectively reverses respiratory depression and other life-threatening effects. Studies suggest the potential benefits of combining naloxone with other medications, such as buprenorphine (see below), to improve outcomes. Initiatives promoting community-based naloxone distribution programs have shown promising results in reducing opioid-related deaths.

 

Available Forms

Naloxone is available in various formulations:

  • Intranasal
  • Intramuscular
  • Intravenous
  • auto-injectors.

 

The most used form is the intranasal spray, which is easy to administer and requires no specialized training. Intranasal naloxone formulations have gained popularity due to their ease of use and increased availability. A recent study showed that the non-FDA-approved compound spray was far less effective than either FDA compound (15).

 

Dosing and Monitoring

The recommended initial dose of naloxone for opioid overdose is 2mg intranasally or 0.4mg to 2mg intramuscularly or intravenously. If the patient does not respond within 23- minutes, additional doses may be administered every 2-3 minutes. Continuous monitoring of the patient's respiratory status is essential, as repeat doses may be required due to the short half-life of naloxone.

 

Side Effects and Contraindications

Naloxone has been shown not to affect individuals without opioids in their system.

 

Common side effects of naloxone include
  • Withdrawal symptoms: increased heart rate, sweating, and agitation
  • nausea
  • vomiting
  • headache

Contraindications include known hypersensitivity to naloxone and situations where the use of naloxone may be unsafe or not feasible.

 

Considerations for Nurse Practitioners

Fentanyl and other opioids have a rapid onset, and the need to act quickly is paramount. As mentioned previously, the ease of use and higher plasma concentrations using the FDA-approved 4-mg FDANxSpray device compared with the locally compounded nasal sprays should be considered when ordering Naloxone (15).

Fentanyl and other potent synthetic opioids may require multiple administrations of naloxone to achieve reversal of an overdose (Chiang, Gyaw, & Krieter, 2019). As a nurse practitioner prescribing naloxone, it is crucial to assess the patient's risk factors for opioid overdose, such as a history of substance use disorder or chronic pain management. Education regarding the proper administration of naloxone should be provided to the patients and their caregivers. Additionally, it is essential to provide resources for follow-up care, including addiction treatment and ongoing support.

 

Methadone
Mechanism of Action and Metabolism

Methadone is a long-acting opioid agonist that effectively suppresses withdrawal symptoms and reduces cravings. It binds to the same opioid receptors in the brain as other opioids. It relieves withdrawal symptoms and reduces cravings by blocking the euphoric effects of opioids, thus helping individuals with opioid dependence to achieve stability (33).

 

Available Forms

Methadone is available in oral tablets and liquid formulations. The oral tablet is the most used form and is typically administered once daily (33).

 

Dosing and Monitoring

Methadone dosing is individualized based on the patient's response and needs. Initially, the dose often started low and gradually increased until the patient reached a stable dose. Dosing may need to be adjusted based on the patient's response, adherence, and any changes in their overall health. Regularly monitoring the patient's vital signs, urine drug screens, and assessment of their withdrawal symptoms and cravings is essential.

 

Side Effects and Contraindications

Common side effects of methadone include:

  • Constipation
  • dry mouth
  • drowsiness
  • sweating
  • weight gain
  • respiratory depression

 

Contraindications include:

  • known hypersensitivity to methadone
  • severe asthma
  • respiratory depression
  • certain heart conditions (33).

 

Considerations for Nurse Practitioners

As a nurse practitioner prescribing methadone, conducting a comprehensive assessment of the patient's medical history, current medications, and substance use history is crucial. Opioid treatment programs or specialized clinics are often involved in methadone treatment, so collaboration and coordination of care with these programs are essential. Regularly monitoring the patient's progress, adherence, and potential side effects or drug interactions is essential. Additionally, providing education on the risks and benefits of methadone and the importance of adherence to the prescribed regimen is crucial for successful treatment outcomes.

 

Buprenorphine
Mechanism of Action and Metabolism

Buprenorphine is a partial opioid agonist with a ceiling effect that minimizes the risk of overdose while reducing withdrawal symptoms. Buprenorphine is a partial opioid agonist that binds to the same receptors as other opioids but produces a weaker response. It has a high affinity for the mu-opioid receptors, which helps reduce cravings and withdrawal symptoms in individuals with opioid dependence.

 

Available Forms

Buprenorphine is available in different formulations, including sublingual tablets, buccal films, and extended-release injections. The sublingual tablets have different strengths, such as 2mg, 4mg, 8mg, and 12mg. Buprenorphine is taken as a daily tablet or weekly or monthly injection.

 

Dosing and Monitoring

The dosing of buprenorphine varies depending on the individual's opioid dependence severity and treatment phase. Initially, a low dose (e.g., 2-4mg) is given, and it may gradually increase to a maintenance dose of 8-24 mg daily. Regular monitoring is essential to assess the patient's response, adherence, and potential side effects.

 

Side Effects and Contraindications

Common side effects of buprenorphine include:

  • Constipation
  • Nausea
  • Headache
  • Insomnia
  • Sweating

 

Serious side effects are rare but can include:

  • Respiratory depression
  • Allergic reactions

 

Buprenorphine is contraindicated in individuals with:

  • Severe respiratory insufficiency
  • Acute intoxication with opioids
  • Known hypersensitivity

 

Considerations for Nurse Practitioners

Nurse practitioners can prescribe buprenorphine for opioid dependence treatment under the Drug Addiction Treatment Act (DATA). To become eligible, they must complete specific training requirements and obtain a waiver from the Substance Abuse and Mental Health Services Administration (SAMHSA). Nurse practitioners should assess patients thoroughly, including their opioid use history, comorbidities, and medication compatibility, while ensuring appropriate counseling and referral for comprehensive treatment (40).

 

Clonidine + Lofexidine
Mechanism of Action and Metabolism:

Both Clonidine and Lofexidine are alpha-2 adrenergic agonists. They work by stimulating alpha-2 receptors in the brain, which reduces sympathetic outflow and norepinephrine release. This results in decreased sympathetic activity, leading to various effects such as reduced blood pressure, decreased heart rate, and alleviated withdrawal symptoms (28).

 

Available Forms

Clonidine is available in oral tablets and patches. Lofexidine is available in oral tablets and is taken as needed (40).

 

Dosing and Monitoring

For opioid withdrawal, the Clonidine dose ranges from 0.1-0.3 mg every 4-6 hours. Lofexidine is usually initiated at 0.53 mg three times daily, and the dose can be increased to 2.88 mg daily. Monitoring blood pressure and heart rate is essential during treatment (40).

 

Side Effects and Contraindications:

Common side effects of both medications include:

  • dry mouth
  • sedation
  • dizziness
  • constipation
  • orthostatic hypotension (40).

 

Both medications are contraindicated in patients with:

  • Hypotension
  • Bradycardia
  • heart block
  • history of hypersensitivity to the drugs (40).

 

Considerations for Nurse Practitioners:

An early study of lofexidine vs. clonidine for withdrawal symptoms showed that treatment with lofexidine resulted in lower withdrawal symptoms, fewer mood problems, less sedation, and hypotension. There were no significant differences in craving levels, morphine metabolites in urine, or dropout rates when both were compared.

Lofexidine can be a safe option for outpatient treatment as it does not lead to hypotension. However, nurse practitioners must closely monitor patients' blood pressure and heart rate during treatment and educate them about possible side effects. If patients experience any concerning symptoms, they should inform their nurse practitioner immediately.

Gradual dose reduction of Clonidine is crucial to prevent rebound hypertension. Before prescribing either medication, nurse practitioners should assess for any contraindications or potential drug interactions (19).

 

Emerging Therapies for Withdrawal

Extended-release naltrexone: Naltrexone is an opioid receptor antagonist that blocks the effects of opioids, reducing the risk of relapse. It is taken as a monthly injection.

Alpha-2 adrenergic agonists: Emerging evidence suggests the potential use of dexmedetomidine and guanfacine for managing opioid withdrawal symptoms.

 

 

Medication-Assisted Treatment (MAT):

Methadone was introduced in the 1960s and marked a significant turning point in opioid addiction treatment or MAT. Along with counseling and behavioral therapies, MAT became the cornerstone of opioid addiction recovery.

 

Examples of medications used:

  • Methadone
  • Buprenorphine:
  • Naltrexone:

 

Adjunctive Pharmacotherapies:

Antidepressants: Selective serotonin reuptake inhibitors and tricyclic antidepressants may help manage co-occurring depression and anxiety.

 

Anticonvulsants:

Medications like Gabapentin and pregabalin show promise in reducing opioid cravings and improving treatment outcomes.

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the mechanisms of action for commonly prescribed addiction medications?
  2. What are the potential risks and benefits of using benzodiazepines for pain management?
  3. How do you assess and manage patients with co-occurring pain and substance use disorders?
  4. What are the guidelines for prescribing addiction medications like buprenorphine or methadone?
  5. How do these medications work in the treatment of opioid use disorder?
  6. What are the potential side effects and risks associated with addiction medications?
  7. How do you support patients in their recovery from opioid use disorder?
  8. How do you address patients' concerns and fears about addiction medications?
  9. What are the federal guidelines around prescribing addiction medications for nurse practitioners?
  10. How do these guidelines influence your prescribing practices?

Other Substance Use Disorders

Patients in pain may struggle with Substance Use Disorders other than Opioid Use Disorder. Substance use disorders may often occur with mental health conditions such as anxiety, depression, and bipolar disorder. In addition, many individuals engage in polydrug use. Understanding the most common Substance Use Disorders aids in a comprehensive assessment of the patient and the development of appropriate treatment plans (28).

 

Alcohol Use Disorder (AUD):

The prevalence of AUD worldwide was estimated to be 9.8% in men and 5.5% in women in 2016 (28).

 

Cannabis Use Disorder (CUD):

the prevalence of CUD in the United States increased from 2.18% in 2001-2002 to 2.89% in 2012-2013. (28).

 

Cocaine Use Disorder:

According to the National Survey on Drug Use and Health (NSDUH), in 2019, approximately 1.9 million Americans aged 12 or older had cocaine use disorder in the past year (44).

 

Methamphetamine Use Disorder:

A study published in Drug and Alcohol Dependence reported that the prevalence of methamphetamine use disorder in the United States was estimated to be 0.2% in 2015-2016 (6).

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the options available for managing opioid addiction and withdrawal?
  2. How can nurse practitioners support patients in their recovery from opioid addiction?
  3. What strategies can nurse practitioners employ to effectively engage and build trust with patients reluctant to disclose or seek help for substance abuse disorders?
  4. How can nurse practitioners collaborate with other healthcare professionals and community resources to provide comprehensive care and support for patients with substance abuse disorders?
  5. What techniques or tools can nurse practitioners employ to start these sensitive conversations with new patients?
  6. How do you assess and manage patients experiencing opioid withdrawal symptoms?
  7. What are the non-pharmacological interventions for managing opioid withdrawal?
  8. How do you educate patients about the risks and benefits of addiction medications?
  9. How do you monitor patients on addiction medications for adherence and progress?
  10. What are the drug potential interactions with commonly prescribed addiction medications?

Drug Diversion and Illegal opioids

Misuse of opioids is facilitated by diversion and is defined as "the transfer of drugs from lawful to unlawful use" (24). Most commonly, this occurs when family and friends share prescribed opioids with other family and friends. Opioids and other controlled drugs are also diverted from healthcare facilities. Statistics show that healthcare facility diversion has increased since 2015 (24)

Diversion affects patients, healthcare workers, healthcare facilities, and public health. Patients experience substandard care due to ineffective pain management and impaired healthcare workers. In addition, affected patients are at risk of infections from compromised syringes (24).

Healthcare employees who divert are at risk of overdose and death. If caught, they face criminal prosecution and malpractice suits. Healthcare facilities also bear the cost of diverted drugs via internal investigations, follow-up care for affected patients, regulatory fines for inadequate safeguards, and declining public trust (24).

Despite the enormous consequences of drug diversion, healthcare facilities have implemented few processes to detect and deter the diversion of controlled substances (24).

Quiz Questions

Self Quiz

Ask yourself...

  1. What protocols can nurse practitioners implement to prevent drug diversion within their healthcare setting?

Patient Teachings and Considerations

Opioids have significant side effects and carry a risk of addiction and overdose. Nurse practitioners can decrease the risks of misuse and addiction by educating patients on appropriate disposal, safe storage, and potential signs of addiction. Taking additional time to provide teaching nurse practitioners can promote patient safety, informed decision-making, and responsible opioid use.

 

Safe Storage and Disposal:
  • Teach patients to store opioids securely, out of reach of children, pets, visitors, and non-caregiver family members, to prevent accidental ingestion or misuse (13). Only the caregiver, if applicable, or the patient should have access to pain medications.
  • Instruct patients on proper disposal methods, such as using drug take-back programs or mixing opioids with undesirable substances (e.g., coffee grounds) before throwing them away (11) (13).

 

Medication Adherence:
  • Emphasize the importance of taking opioids as prescribed, at the correct dose and frequency, to achieve optimal pain relief.
  • Encourage patients to notify their healthcare provider if they experience inadequate pain control or side effects (35).

 

Potential Side Effects:
  • Educate patients about common side effects of opioids, including constipation, nausea, sedation, and respiratory depression.
  • Discuss strategies to manage side effects, such as maintaining adequate hydration, consuming a fiber-rich diet, and using over-the-counter laxatives as needed (11).

 

Risk of Dependence and Addiction:
  • Explain the potential for opioid dependence and addiction, especially with long-term use or a history of substance abuse.
  • Encourage patients to promptly report signs of opioid misuse, such as craving, loss of control, or continued use despite negative consequences (51).

 

 

 

 

Avoiding Alcohol and Other Central Nervous System Depressants:
  • Instruct patients to avoid consuming alcohol or other medications that can enhance the sedative effects of opioids, increasing the risk of respiratory depression.
  • Advise patients to contact the Nurse Practitioner before starting new medications, including over-the-counter drugs or herbal supplements (2).

 

Driving and Operating Machinery:
  • Inform patients about the potential impairment caused by opioids, including reduced alertness, reaction time, and coordination.
  • Advise patients to avoid driving or operating heavy machinery while taking opioids until they know how the medication affects them (14).
Quiz Questions

Self Quiz

Ask yourself...

  1. What strategies can nurse practitioners employ to effectively communicate the risks and benefits of opioid use while ensuring they clearly understand the potential side effects and the importance of adhering to the prescribed regimen?
  2. How can nurse practitioners promote patient engagement and shared decision-making regarding opioid pain management, considering the potential for dependence and addiction?
  3. How can nurse practitioners assess a patient's knowledge and understand the safe storage and disposal of opioids?

Case Study

You take some extra time with Mary to educate her on the taper dose of Vicodin, the potential for harm, and the risk of opioids, especially when used concomitantly with Gabapentin. You let Mary know it is unsafe to use alcohol, not only with Vicodin but also with Gabapentin. You let Mary know that Vicodin has a risk of dependency and misuse and, therefore, she will be monitored carefully. You also educate that Mary should store the Vicodin away from visibility by anyone but herself since she can self-administer her medication. You let Mary know that Vicodin can cause constipation and that she should increase her water intake and take a stool softener.

You ask Mary to call you if her pain is not adequately relieved or if her medications run out before the three days.  

You let Mary know that if she does stop taking the Vicodin before she has completed all the medication, she should dispose of it by mixing the pills with liquid and coffee grounds to make them unpalatable to animals and others.

Mary complied with your education, completed her course of Vicodin, and was scheduled for surgery. Mary's social worker helped her communicate with her new employer and delayed her start date until after her recovery.

During her recovery, Mary received physical therapy and a short course of pain medication managed by her orthopedist.

Mary returned to the clinic for a follow-up visit after completing her therapy and before starting work. Mary's pain level in her knee is 3/10, and she already feels like she can walk further than pre-surgery. Gabapentin has continued to help Mary's neuropathic pain in her back, and she reports 2/10. Mary looks forward to beginning her new job and is optimistic about the future.

Conclusion

Pain management is the leading cause of primary care appointments and chronic pain is the leading cause of disability. Yet, prescribing opioids for primary care patients is also a factor in drug misuse and the opioid epidemic. Nurse practitioners are challenged to appropriately treat pain and effectively control diversion, addiction, and death from overdose.

It is imperative that nurse practitioners use evidence-based practices to assess, appropriately intervene, and educate about the benefits and potential harm caused by treatment with opioids. Nurse practitioners must stay up to date with the current federal regulations regarding PDMPs, clinical prescribing guidelines, and emerging treatments for pain and opioid abuse disorders.

 

 

Tirzepatide for Type 2 Diabetes and Weight Management

Introduction   

The emergence of the drug tirzepatide is becoming more popular and widespread and is being utilized among those with diabetes and also those who desire to lose weight. It is one of the newest diabetic drugs given by injection that also triggers dramatic weight loss in those who use the injections.

The U.S. Food and Drug Administration (FDA) approved tirzepatide in 2022 for individuals with diabetes, particularly Type 2 Diabetes. The FDA officials have not approved tirzepatide yet for weight loss, but they are currently tracking the medication and may have a recommendation for its approval by the end of this year. Clinical trials have shown that individuals with an elevated body mass index (BMI) and who did not have diabetes lost a considerable amount of weight when they received tirzepatide (1).

Advanced Practice Registered Nurses (APRNs) need to understand how to safely prescribe tirzepatide and the reasoning as to why it causes weight loss for specific individuals.

Drug Classification

Tirzepatide is part of a class of medications called glucose-dependent insulin tropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists. It comprises a 39 amino acid linear synthetic peptide conjugate to selective receptor agonists in preclinical and clinical trials.

Tirzepatide is used for treating Type II diabetes in adults as an adjunct to diet and exercise. It is also used for weight loss in some individuals and has gained increased attention as a new therapeutic agent for glycemic and weight control.

Social media has had a significant influence and increased the desire to use tirzepatide, and while individual results vary, the weight loss in adults ranged from 12 – 25 pounds.

Online pharmacies, diet clinics, and medical spas are implementing thousands of ads on social media to capitalize on a surge of interest in the drug.

Quiz Questions

Self Quiz

Ask yourself...

  1. Why has there seemed to be an increase in patients requesting this medication? What other medicines intended for type 2 diabetes are also being used for weight loss management?
  2. What are the ethical considerations regarding marketing this drug for weight loss when its primary use is for type 2 diabetes? Could this impact supply and costs?

Indications of Usage

The use of tirzepatide is being used for both Type II diabetes and weight control in certain patients. It has been a game changer for people living with Type II diabetes. The drug’s primary use is as an adjunct to diet and exercise to improve glycemic control in adults with diabetes.

The drug has also proven beneficial for weight loss in patients experiencing obesity, and those who are taking the highest dosage have shared a body weight reduction of 15.7% (2). Tirzepatide is an injectable prescription medication used together with diet and exercise, and it is not yet known if it can be used safely with patients who have had pancreatitis.

It is important to remember that it is not to be used for patients with Type I diabetes, but it is safe for Type II diabetic patients. Also, the safety of tirzepatide has yet to be discovered for children and those under 18; therefore, the medication should not be used for this age group.

In studies conducted with or without diabetic medicines, 75% – 90% of patients taking tirzepatide reached an overall A1C of less than 7% with an average starting A1C of 7.9 – 8.6% across the following dosages – 5mg, 10mg, and 15mg. The study results were measured at weeks 40 and 52 (3).

Quiz Questions

Self Quiz

Ask yourself...

  1. What dietary and activity recommendations can you provide to patients using tirzepatide for weight loss?
  2. Is this drug intended for those who want to lose 5-10 pounds?

Use of Tirzepatide with Diabetic Patients

Tirzepatide can be used for patients with Type II diabetes in combination with a diabetic-friendly diet and exercise. The drug works by lowering the patient’s overall blood sugar and also improves the A1C results of patients over some time. The injection has been approved by the FDA to treat Type II diabetes and is administered once weekly (4).

It is considered the first in a new class of medications – a dual glucose-dependent insulin tropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) receptor antagonist. The mechanism of how it works mimics two gut hormones (GIP and GLP-1). These hormones are essential in how patients digest food and regulate blood glucose after meals. The hormones also play a role in making individuals feel fuller and curb specific food cravings.

The provider can prescribe tirzepatide before attempting other diabetic medications if a patient has a BMI of 30 or greater or 27 or greater with weight-related conditions and if the drug is combined with a personalized weight loss plan that addresses physical activity, nutrition, and lifestyle changes.

However, due to the cost and some insurance companies not covering the injection unless the patient has both diabetes and obesity, the provider must carefully consider prescribing this medication.

 

 

 

 

Case Study

The patient states this ‘miracle drug’ is worth paying for out of pocket!

Jeff Capron, a 53-year-old Boonville, New York, web developer, started taking tirzepatide in December 2022. His friend had reported good results with the medication, so Jeff looked into the research studies behind it and then spoke with his primary physician.

The physician said, “Yeah, let’s give it a shot,” even though he did not have much experience with it. The physician did not have an opinion one way or the other than looking at the data set and seeing no reason why they could not try it.

Jeff’s hemoglobin A1C went from 10.1% to 6% in 3 months, which was very promising. “I never had that kind of experience with any medication for diabetes.” There is a range in how much A1C reduction people experience with tirzepatide, but many people taking it can get their A1C under 7% — an ideal goal for people with Type 2 diabetes.

Jeff experienced constipation and a little trouble sleeping early, but both issues disappeared quickly. He says, “I wake up in the morning, and my fasting blood sugars are normal.”

The medication took effect, he says, within 12 hours. He compared the feeling to having a gastric bypass.

“You cannot overeat food. As soon as you overeat, you almost feel ill.” While it generally takes a few months to notice effects like A1C reduction and significant weight loss, side effects such as lower appetite may be felt immediately.

Weight loss was not his primary goal, but he lost about 35 pounds on the medication in the first five months. He also lost his sweet tooth. “I can maybe count three sweet things I have eaten since December.”

Jeff found that his appetite slowly recovered days after taking tirzepatide. “You take the shot every Sunday, and by Saturday, you start to get a lot of appetite,” he says. “It does not seem to affect your weight. If I eat a little bit more on Saturday night, on Sunday, the scale will not move one way or the other.”

Jeff is allergic to hornets, so he already carries an auto-injector. He was not worried about using another drug delivered through a needle. “It’s just a push button,” he says. It also helped that his wife is a nurse. “So, I had her with me the first time to ensure I was doing it right. I didn’t even feel it.”

When Jeff was first prescribed tirzepatide, his insurance covered it. The company has since removed that benefit. He has filed an appeal but pays about $1,000 monthly out of pocket for his weekly injections. He plans to keep paying as long as necessary.

He considers the financial burden well worth it. “I have never had a medication that worked as well before for chronic conditions,” Jeff says. “I’ve been blown away by it. For me, it’s a miracle drug. It got rid of my diabetes” (4).

Quiz Questions

Self Quiz

Ask yourself…

  1. Can a provider willfully choose to prescribe tirzepatide before other diabetic medications are attempted?
  2. Would that impact his insurance coverage if Jeff did not meet the clinical criteria for using tirzepatide?

Use of Tirzepatide for Weight Loss Management

As mentioned, this medication is indicated for patients with a BMI of >30 or a BMI of >27 with qualifying comorbidities. Obesity can become a chronic lifetime disease, and for conditions such as these, the patient needs to implement therapy for the lifetime of the disease.

In a study conducted for tirzepatide, there was a dramatic increase in effectiveness compared to traditional nonsurgical interventions such as diet, exercise, and lifestyle changes. However, it has been noted that taking tirzepatide on an ongoing basis is recommended and necessary to maintain any weight loss achieved from the medication.

If a patient stops taking the drug, likely, it will no longer work (5).

Public health officials have expressed concerns about using the drug long-term. Still, data is currently lacking regarding long-term effectiveness, treatment duration, and maintaining weight reduction once the therapy is discontinued.

A recent trial consisted of 783 participants with a BMI greater than 30, and these participants agreed to take either a 10mg or 15mg dose of tirzepatide over 36 weeks. The injection is given once weekly, so this would equal a total of 36 injections.

By the end of 36 weeks, participants lost more than 21% of their body weight. After 36 weeks, participants continued on tirzepatide or received placebo treatment for the following year. The patients needed to be made aware of which treatment they were receiving.

Those still taking tirzepatide injections weekly after 88 weeks lost an additional 7% of their body weight, and those taking the placebo regained 15% at the end of 88 weeks (5).

Quiz Questions

Self Quiz

Ask yourself…

  1. What is the minimum BMI needed to qualify to receive this drug for weight loss management?
  2. Is this medication indicated for long-term use for patients with a high BMI?

Common Side Effects and Contraindications

Side Effects

Patients vary immensely with different experiences and side effects related to tirzepatide; however, the following are the most common side effects experienced by those taking the medication:

  • Nausea
  • Decreased appetite
  • Vomiting
  • Diarrhea
  • Indigestion
  • Constipation
  • Stomach Pain

 

Tirzepatide usually does not cause fatigue, leaving one feeling weak, tired, and low energy. However, fatigue can be a common side effect of Type II diabetes.

It is important to note that most individuals who experience nausea, vomiting, and diarrhea episodes do so while the dosage increases, and typically, the symptoms decrease over time. G.I. effects were more prominent in those taking tirzepatide than those taking the placebo. The individuals not in the placebo group were more likely to stop treatment due to the unpleasant side effects (3).

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Does tirzepatide cause fatigue in patients who use it?
Contraindications

Tirzepatide may cause thyroid tumors, including thyroid cancer, and it is essential to watch for possible symptoms, such as swelling or a lump in the neck, hoarseness, shortness of breath, or trouble swallowing.

Tirzepatide should also not be prescribed to any patient with Type 1 Diabetes.

One of the main ways that tirzepatide works is by stimulating the release of insulin from the pancreas, and due to this fact, there have not been many studies and clinical trials that include those with Type I diabetes.

However, this is not to say that prescribers have never ordered tirzepatide for those with Type I diabetes. Still, it is essential to note that if prescribed, it would be in addition to traditional insulin therapy.

  • Personal or family history of a type of thyroid cancer known as medullary thyroid carcinoma (MTC).
  • Any history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Patients who are allergic to the actual medication or any of its ingredients.
  • Younger than 18 years of age

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the reason that tripeptide is contraindicated in those with Type I diabetes?
  2. Why is there a risk with patients who have a thyroid disorder?
  •  

Safe Prescribing Practices, Guidelines, and Considerations for Providers

Safe Prescribing Practices

As with all prescribed medications, safe standards of care must be implemented and followed to ensure patient safety is maintained. The same applies to providers considering prescribing tirzepatide, and specific criteria must be met beforehand. The following information discusses guidelines involving exclusion and inclusion criteria for providers to prescribe tirzepatide (6) accurately.

 

Guidelines

Exclusion Criteria – If present, the following indicates that the patient should not receive tirzepatide:

  • Diagnosis of Type I diabetes
  • Personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2
  • Severe gastrointestinal dysmotility
  • History of pancreatitis
  • Pregnancy
  • Proliferative Diabetic Retinopathy (PDR), severe Nonproliferative Diabetic Retinopathy (NDR), clinically significant myalgic encephalomyelitis (M.E.), or diabetic macular edema (DME) unless the risks/benefits have been discussed with the patient and are documented in the patient's health record along with monitoring plans and follow-up with an eye specialist who is informed at the time of initiation.

 

Inclusion Criteria – All of the following must be met for tirzepatide to be prescribed:

  • Diagnosis of Type II diabetes
  • A BMI of 25 or greater
  • Inadequate glycemic control on at least 1mg of semaglutide injection plus two or more glucose-lowering drugs
  • Change needed to achieve goal A1C is less than 1%.
  • Goal A1C should be based on those recommended in the Diabetic Guidelines.
  • Adherence to current diabetic medications as evidenced by a review of the prescription refill history during the six months.

 

Additional Inclusion Criteria – All of the following must be met for tirzepatide to be prescribed:

  • Patients with atherosclerotic cardiovascular disease or chronic kidney disease
  • Patients of childbearing potential who are using oral contraceptives

 

Inclusion Criteria for Weight Loss

  • BMI of >30 or >27 with patient weight conditions.
Quiz Questions

Self Quiz

Ask yourself...

  1. Would a patient with a BMI of 23 with no comorbidities qualify to use tirzepatide to lose 5-10% of their body weight? Why not?
  2. What impact can tirzepatide have on a person with a healthy weight and BMI of <25?

 

Considerations for Providers

There are specific considerations that prescribers must be aware of when contemplating if a patient should receive the medication tirzepatide. The following is imperative and must be considered each time the medication is prescribed to a patient:

  • Clinical Indications – indicated for treating adults with insufficiently controlled diabetes mellitus as an add-on therapy to diet and exercise; as monotherapy when metformin is considered inappropriate due to contraindications or intolerance; and other medicinal products for treating Type II diabetes.
  • Monitoring of medication – routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value but is recommended for early detection of Medullary Thyroid Cancer (MTC).
  • Cost – the average price for tirzepatide ranges from $1,071-$1,351 without any coupons or insurance. Savings Card – manufacturer provided; patients can pay as little as $25 monthly for up to 12 injections. Savings Card – manufacturer provided; patients can pay as little as $25 monthly for up to 12 injections.
  • Benefits and Risks – One must evaluate the effectiveness of diabetes and the weight loss experienced. Some of the risks must be evaluated, such as increased cost of medication, unpleasant gastrointestinal side effects, poor insurance coverage, and drug shortages. The FDA has warned that the medicine can cause thyroid C-cell tumors in rats, and it is not sure whether tirzepatide causes similar tumors.

 

How long does it take for tirzepatide to begin working?

Tirzepatide will start to lower one's blood sugar levels immediately, but it can take 8 to 12 weeks to reach one's target A1C goal.

Compared to other diabetic treatments, studies have shown that it can take eight weeks to reach an A1C target of less than or equal to 7% and 12 weeks to get an A1C of less than or equal to 6.5%. Significant weight loss can occur as early as 28 weeks.

 

Safe Administration

It is essential to follow the correct steps for safe administration of tirzepatide as listed below:

  • The recommended starting dosage is 2.5mg, injected subcutaneously once weekly. The 2.5mg dosage is for treatment initiation and not for glycemic control.
  • After four weeks, increase the dosage to 5mg, injected subcutaneously once weekly.
  • If additional glycemic control is needed, increase the dosage in 2.5mg increments after at least four weeks on the current dose.
  • The maximum dosage is 15mg, injected subcutaneously once weekly.
  • If a dose is missed, instruct patients to administer it as soon as possible, within four days (96 hours) after the missed dose. If more than four days have passed, skip the missed dose, and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule.
  • The day of weekly Administration can be changed, if necessary, as long as the time between the two doses is at least three days (72 hours).
  • Before initiation, train patients and caregivers on proper injection techniques.
  • Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1ml syringe capable of measuring a 0.5 mL dose).
  • Administer the medication once weekly, any time of day.
  • Inject the medication subcutaneously in the abdomen, thigh, or upper arm.
  • Rotate injection sites with each dose.
  • Inspect the medication visually before use. It should appear clear and colorless to slightly yellow. Do not use the medicine if particulate matter or discoloration is seen.
  • When using the medication with insulin, administer it as separate injections and never mix. It is acceptable to inject tirzepatide and insulin in the same body region, but the injections should not be adjacent.

 

Does the tirzepatide injection hurt when administered?

Pain from the injection site has not been reported as a common side effect, but it may occur.

Due to the injection being given subcutaneously, slight pain or discomfort can occur.

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. The patient asks you," How long will this take to work?" How will you respond?
  2. The patient reports they have never used an injection before; what methods can you use to teach your patient how to administer this medication safely?

Alternatives to Tirzepatide for Weight Loss Management

In some instances, patients need to be aware of alternatives to tirzepatide in case they cannot take the actual injection for whatever reason. In cases such as these, there are alternative supplements that can be purchased over the counter, and they include the following (7):

  • PhenQ – top OTC choice – comprehensive weight loss solution that targets specific body regions, facilitates prompt fat loss, and expedites the weight loss journey.
  • PhenGold – the most potent OTC weight loss alternative – one of the top weight loss supplements that boost metabolism, making one less hungry, less tired, and an overall improved feeling.
  • Capsiplex BURN – the best choice for men – helps to burn fat faster and keep blood sugar levels in check. It helps to keep one's muscles, curbs hunger, gives one more energy, and torches stubborn fats.
  • Trimtone – the best choice for women – helps women to lose weight, eat less, increase metabolism, burn extra calories, and boost energy.
  • Prime Shred – best fat burner for men – boosts metabolism, keeps muscles intact, increases energy, and helps maintain focus.

 

The advanced practicing nurse or prescriber needs to inform patients about alternative options such as these in an effort for individuals to understand that other choices are available and can be used. Many individuals need to be more knowledgeable about alternatives besides tirzepatide due to the extra hype from social media sources that promote advertisements related to tirzepatide only but do not mention the other options.

 

Why does social media influence and encourage patients to take tirzepatide?

Social media trends can be helpful but can also become harmful by setting unrealistic expectations and promoting a diet culture mentality. They can create an unhealthy obsession with "clean" eating, especially in the younger populations.

Due to this, many individuals take the medication despite any occurrence or history of Type II diabetes, and the drug can ultimately become misused.

It has been noted that there is an influx of patients requesting this medication for weight loss instead of the intended purpose, which is to help control Type II diabetes.

Tirzepatide represents one of the most recent non-medical treatments aimed at managing the symptoms of Type II diabetes. While it is not indicated for weight management, diabetic patients who receive it frequently report a significant reduction in body weight.

 Empirical evidence suggests the efficacy of tirzepatide in weight management, and certain physicians currently endorse the Administration of the medication as a therapeutic and effective means to overcome obesity.

 

What are some severe side effects of tirzepatide that can impact patient safety?

The Administration of tirzepatide can benefit many individuals, but some severe side effects must be mentioned.

These include thyroid tumors, thyroid cancer, pancreatitis, hypoglycemia, serious allergic reactions, kidney issues, severe stomach problems, vision changes, and gallbladder issues. All these side effects must be taken seriously and reported, as they can lead to life-threatening

Quiz Questions

Self Quiz

Ask yourself...

  1. With what you have learned in this course, what education will you provide to patients requesting this medication for weight loss?
  2. Have you seen increased demand for this medication in your current practice?
  3. If you Google tirzepatide, your results will likely include links to telehealth services promoting this weight-loss medication. To determine eligibility, what special considerations need to be taken to assess a telehealth patient?

Conclusion

Medications like tirzepatide are game changers for those patients with type 2 diabetes that have failed other medications. Unfortunately, several companies seek to profit from its weight-loss benefits through aggressive marketing campaigns that limit the available supply and increase the costs for those who need it. As healthcare providers, we need to use sound clinical judgment and follow the exclusion/inclusion criteria and other guidelines before prescribing this medication, so we do not unintentionally cause harm while looking to appease our patients who request this.

Semaglutide and Type 2 Diabetes

Introduction   

In 2017, the FDA approved the semaglutide injectable (Ozempic) for treating type 2 diabetes. The drug has experienced widespread acceptance due to its positive effects on weight loss and lowering of chronic health risks. The drug has risen in popularity over the past few years, as many well-known actors/actresses/songwriters, and more came forward, publicly sharing their weight loss journey.

This rise in popularity has also resulted in significant shortages of this medication, negatively impacting the lives of the diabetic community, local pharmacies, and healthcare providers. The goal of this continuing education course is to educate and empower the healthcare provider in all aspects of this drug regimen: clinical indications, patient education, cost options, and benefit/risk analysis.

Diabetes Overview

Diabetes is a chronic medical condition. Despite advances in diet, medications, and monitoring devices, diabetes diagnoses continue to grow at staggering rates. The Institute for Health Metrics and Evaluation (IHME) reports that over 529 million people worldwide are currently living with diabetes, and that number is expected to grow to 1.3 billion in only 30 years. While the risk factors for diabetes are vast in number (poor diet, inadequate activity, obesity, sedentary lifestyles, daily stressors, and more), the sad reality is that this chronic medical condition will most likely linger on for generations to come despite our efforts to contain this health epidemic (1).

According to the latest research on diabetes, there are over 37 million people in the United States alone with diabetes as of 2022. Statistically, approximately 28 million of them have a confirmed diagnosis, while another estimated 8 million are experiencing symptoms, without an official diagnosis. Diabetes currently ranks as the 7th leading cause of death in the United States (2).

Quiz Questions

Self Quiz

Ask yourself...

  1. As a healthcare provider, what has been your experience with treating chronic medical conditions?
  2. Why do you think there is a continued increase in diabetes, despite advances in medication and monitoring devices to treat this condition?
  3. Are you currently offering comprehensive care to your patients, including medication, diet, and activity counseling for their chronic health conditions?

Types of Diabetes

In basic terms, diabetes is an impairment in one’s ability to either adequately produce or utilize insulin, which results in elevated levels of circulating glucose. Chronically elevated glucose levels affect blood vessels at every level, causing chronic inflammation and raising the risk of heart disease, stroke, blindness, and atraumatic amputations.

 

There are three main types of diabetes:

Type 1 diabetes is thought to be an autoimmune disease. Approximately 5-10 percent of people with diabetes are diagnosed with type 1 diabetes. The diagnosis usually occurs in early childhood, and results in a lifetime use of insulin to regulate blood glucose levels.

Type 2 diabetes is thought to be related to dietary and lifestyle choices. It accounts for nearly 90-95 percent of diabetes diagnoses. Usually occurring later in life (adult-elderly population), it is believed to be related to factors such as diet, activity, weight gain, and related factors. Type 2 diabetes is usually controlled by diet and exercise, in addition to oral medications, although injectable insulin may be included in the treatment plan.

Gestational diabetes refers to elevated glucose levels occurring during pregnancy for patients who are not diabetic at the onset of pregnancy. This version of diabetes usually resolves itself post-partum, although a woman may develop type 2 diabetes later in life, unrelated to pregnancy.

 

Type 2 diabetes in children: no longer a “later in life diagnosis”

Children are now being diagnosed with type 2 diabetes at an alarming rate. Despite widespread education and an increased awareness of diabetes, our up-and-coming generation is unhealthier than ever. Many families lack access to healthy food for their families, due to both general socioeconomic challenges and an increased rate of food insecurity. (19)

The CDC recommends care providers have resources for diabetic patients and their families, such as food and nutrition programsbudget-friendly diabetes meal plans, how to save money on diabetes care, and coping strategies for diabetes. (19)

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Are you able to articulate the different types of diabetes to patients?
  2. What resources can you offer to the families of children with type 2 diabetes?

Diabetes Signs and Symptoms, Diagnostic Testing

There are various ways to test for diabetes. The fasting blood sugar (FBS)/ fasting glucose level is a simple way to test for diabetes.

The normal fasting glucose level is below 100mg/dl. The fasting glucose result of 100-125mg/dl indicates prediabetes and results above 126mg/dl indicate diabetes.

The hemoglobin A1C blood test is another test used to confirm the diagnosis of diabetes. The patient does not need to be fasting for this test; thus, it is easier to order this test regardless of the time of day. This blood test reflects the average glucose level over the period of 2-3 months.

The normal A1C level is below 5.7%. Test results between 5.7%- 6.4% indicate prediabetes. Test results above 6.5% indicate diabetes.

A random glucose reading above 200mg/dl, done at any time of day, indicates diabetes.

The diagnosis of diabetes is by blood tests, and for improved accuracy, should be based on two separate readings, done (at least) a day apart. In the case of fasting and random blood tests, dietary intake (large amounts of carbohydrates in a single meal) may adversely affect test results. This is not the case when using A1C testing for a confirmation diagnosis, as the results are the average of a 2–3-month span.

 

Target blood levels for a person with diabetes (3).

Target blood glucose levels for people with diabetes are as follows:

  • Fasting glucose 80-130mg/dl.
  • Postprandial blood glucose level- less than 180mg/dl
  • A1C level 7-8%.

These target ranges are general guidelines. Patient-specific ranges will be dependent on a variety of factors, including preexisting comorbidities, overall health status, age, and activity levels.

 

 

 

 

The hallmark signs/symptoms of diabetes
  1. Polyuria- increased urination
  2. Polydipsia- increased thirst
  3. Polyphagia-increased hunger/appetite

 

The truth is, as healthcare providers, you will have patients who have no hallmark signs and symptoms of diabetes; the diagnosis will be found during annual preventive examinations often unrelated to any chronic disease. For this reason, many insurance companies now cover numerous preventive screenings, including diabetes screenings, as part of their wellness and prevention initiatives. These tests are often approved based on a patient's age, or preexisting conditions, rather than outright signs and symptoms.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are the typical glucose levels for non-diabetic versus diabetic patients?
  2. What are the hallmark symptoms you can identify when treating a potentially diabetic patient?
Lifestyle Interventions and the Diabetes Prevention Program

The initial diagnosis of diabetes can be managed in a variety of ways, depending on the severity of the illness at the time of diagnosis. Lifestyle interventions (behavior modification education) are of utmost importance in the care and management of people with diabetes. Research over the past few decades has consistently shown that such interventions have immense positive effects on the successful long-term management of diabetes.

The official Diabetes Prevention Program was created in 2010 (4) and confirmed the effects of lifestyle interventions in the management of diabetes:  Lifestyle interventions decreased the incidence of type 2 diabetes by 58% compared with 31% in the metformin-treated group. Thus, these findings now serve as the blueprint, if you will, for all-inclusive, patient-specific disease management guidelines. These lifestyle interventions will be discussed in detail later in the program.

 

Additional Resources on Diabetes Prevention

Quiz Questions

Self Quiz

Ask yourself...

  1. How do lifestyle interventions compare to other kinds of treatment for patients with type 2 diabetes?

Semaglutide

Semaglutide is an injectable drug used in the treatment of type 2 diabetes. It was approved by the FDA in May of 2017.

It is a once-a-week injectable and belongs to the drug class known as glucagon-like peptide-1 receptor agonists (GLP-1RAs) (5). It has been referred to as a “miracle weight loss drug” among those who are living with obesity, despite frequent side effects, unusually high out-of-pocket costs, drug shortages, and weight regain when attempting to stop using the medication.

 

GLP-1 receptor agonist: Hormone Review

GLP-1 RAs are a class of medications used to treat Type 2 diabetes, and in some cases, obesity treatment. They are also known as GLP-1 receptor agonists, incretin mimetics, and GLP-1 analogs.

 

Ghrelin and Leptin (6)

Ghrelin and Leptin are two hormones that greatly influence appetite and the sensation of fullness. Often referred to as the “hunger hormone.” Ghrelin is responsible for many functions, including playing a key role in metabolism through glucose and insulin regulation.

Ghrelin, produced in your stomach, signals your brain when you are hungry, and results in increased food intake.

Leptin, conversely, is produced in your fat cells, and signals to the brain when you have eaten enough (by a decrease in appetite).

 

Glucagon-like peptide-1 receptors

Known as GLP1 receptors, Glucagon-like peptide-1 receptor proteins are located in the beta cells of the pancreas as well as in the neurons in the brain. GLP-1 receptors are involved in the regulation of blood glucose levels and affect the secretion of insulin. These cells encourage the release of insulin from the pancreas, increase the volume of beta cells, and reduce the release of glucagon. In doing so, they increase the feeling of fullness during and between meals, suppressing the appetite and slowing gastric emptying.

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some problems patients might face if they choose to take semaglutide?
  2. How do Ghrelin and Leptin relate to a patient's appetite?

What is meant by receptor agonist and antagonist?

The term agonist refers to any substance that mimics the actions of a hormone in producing a specific response: a receptor antagonist blocks a response from occurring.

Opioids are examples of receptor agonists in that they produce responses such as analgesia.

Naloxone/Narcan is an example of a receptor antagonist, in that it binds to a receptor site and decreases/blocks a response from occurring.

 

Semaglutide mechanism of action (7)

GLP-1 agonists work in several ways to positively affect glucose levels. Their mechanism of action includes the following:

  • Increasing (stimulating) insulin secretion by the pancreatic beta cells.
  • Decreasing the production of glucagon, a hormone that raises blood glucose levels
  • Decreasing (slowing) gastric emptying
  • Decreasing appetite (and thereby reducing food intake) by creating a sensation of stomach fullness

 

Through these mechanisms of action, semaglutide results in a lowering of serum glucose/A1C levels, which lowers the risk of cardiovascular events. Studies have also shown that semaglutide resulted in weight loss (approximately 8-14 pounds on average {dose dependent results}.

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the difference between an agonist and antagonist substance?
  2. How much weight do patients lose, on average, when taking semaglutide?

Side Effects of Semaglutide

Common side effects of semaglutide (8)

Common side effects may include any of the following:

  • Nausea and vomiting
  • Headache
  • Diarrhea and stomach pain
  • Upset stomach, indigestion, constipation, flatulence

These side effects usually subside within a few weeks, as the patient becomes acclimated to the medication.

 

Serious side effects of semaglutide
  • Hypoglycemia- enhanced/worsened when used in combination with other diabetes medication. Symptoms may include drowsiness, confusion, weakness, irritability, and headache.
  • Symptoms may include abdominal pain and distension, nausea and vomiting, fever, and back pain.
  • Diabetic retinopathy. Symptoms may include blurred vision, vision loss, and diminished night vision.
  • Kidney damage/injury/failure. Symptoms may include fatigue, nausea, diminished urine output, confusion, and edema of extremities.
  • Gallbladder disease. Symptoms may include gallstones, abdominal pain, nausea and vomiting, and poor appetite.

 

Black Box Warning (9)

Semaglutide has a Black Box Warning for thyroid cancer. This is the most serious warning from the Food and Drug Administration (FDA) and is intended to alert consumers to the potential risks of a medication.  This black box warning was issued when research found that the drug increased the risk of thyroid tumors in animals.

It is not known if semaglutide actually causes tumors in humans.

 

Contraindications
  • Semaglutide is contraindicated in people with a personal or family history of MTC (medullary thyroid cancer) or in patients with multiple endocrine neoplasia syndrome type 2.
  • Known hypersensitivity to semaglutide or any of the product components

 

Cautions

As noted under “serious side effects”, there have been reports of new illnesses or worsening of existing health conditions occurring “post-marketing”. Thus, healthcare providers are strongly encouraged to continue ongoing surveillance of any patients on semaglutide therapy. In addition, there is insufficient data available regarding the use of semaglutide by pregnant women. Women are therefore highly encouraged to stop any treatment with semaglutide for at least 2 months prior to a planned pregnancy.

Quiz Questions

Self Quiz

Ask yourself...

  1. Can you name the 4 common side effects of semaglutide?
  2. What is the most severe warning associated with semaglutide? 

 

Dosing

Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It is looked upon favorably to reduce the risk of cardiovascular events in adults with T2DM and a preexisting history of cardiovascular disease. This drug is FDA-approved for use in people with diabetes, with a BMI of 27% or higher (a BMI of 25-29.9% is considered overweight).

Semaglutide (Ozempic) is available as an injectable prescription medication. Doses include 0.5mg, 1mg, or 2 mg, once weekly.

The injection should be administered subcutaneously to the abdomen, thigh, or upper arm. Injection sites should be rotated, and given as a single injection.

 

Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly.

  • If additional glycemic control is needed, increase the dose to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose.
  • If additional glycemic control is needed, increase the dose to 2 mg once weekly after at least 4 weeks on the 1 mg dose

Administer once weekly at any time of day, with or without meals.  The maximum dose recommendation is 2mg/weekly once weekly.

Note: The initial 0.25-mg dose is intended for treatment initiation and is not effective for glycemic control

 

 

Missing Dose Guidelines
  • If the missed dose is ≤5 days: Administer dose as soon as possible
  • If missed dose >5 days: Skip the missed dose and administer the next dose on the regularly scheduled day; patients can then resume their regular once-weekly dosing schedule

 

Administration Day Guidelines (10).

The administration day each week can be changed, if necessary, as long as the time between 2 doses is at least 2 days (>48 hours)

 

Dose Availability (packaging)
  • 2mg/1.5mL (1.34mg/mL); delivers doses of 0.25mg or 0.5mg per injection or four to eight doses per injection pen
  • 4mg/3mL (1.34mg/mL); delivers 1mg per injection or 4 doses per injection pen
  • 8mg/3mL (2.68 mg/mL); delivers 2mg per injection or 4 doses per injection pen

 

Treatment Goals- Effects on A1C and Weight (11)

A majority of adults who were placed on injectable semaglutide for diabetes management achieved a target A1C under 7% and were able to maintain it.

  • Dose specific effects on A1C were as follows:
  • 0.5mg dose injection yielded a 1.4% decrease
  • 1.0mg dose injection yielded a 1.6% decrease
  • 2.0 mg dose injection, in combination with diabetes pills, yielded a 2.1% decrease in A1C.

 

Adults taking semifluid injectables for diabetes management also noted weight loss.

  • 8-pound weight loss reported with 0.5mg dose injection
  • 10 pounds weight loss reported with 1.0mg dose injection
  • Up to 14 pounds of weight loss reported with a 2.0mg dose injection

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What should you tell a patient if they miss their injection by more than 5 days? What if it has been less than five days?

Prescribing insights: Long-Term therapy for a chronic condition?

Semaglutide is viewed favorably as a treatment option for Type 2 diabetes. It appears to lower A1C levels and body weight in the majority of patients, lowering their risk of future cardiovascular events.

The question of long-term medication use, for a chronic health condition, is being heavily discussed in the media. While a percentage of people can decrease or eliminate the need for chronic medications through significant lifestyle changes, there have been reports of weight gain in those who stopped taking this injectable medication.

Without intense lifestyle behavior modification education, there is a heightened risk of weight regain in the absence of such medications. Leaders in the treatment of obesity and related illnesses have commented that this drug is intended for long-term use.

Examples of this include the following:

“GLP-1 medications [like Ozempic] are designed to be taken long-term... They are chronic medications for the treatment of chronic conditions (both diabetes and obesity) (12)". - Christopher McGowan, M.D., a gastroenterologist specializing in obesity medicine and endobariatrics

“As with many chronic conditions, most people who use the drugs for diabetes or weight loss will need to keep taking them to keep benefiting from them. Depending on your individual situation, and without sustained lifestyle changes, it is likely you would need to be on these medications indefinitely to maintain weight loss (13)." Dr. Cecilia Low Wang, a UCHealth expert in endocrinology, diabetes and metabolism.

Quiz Questions

Self Quiz

Ask yourself...

  1. Is semaglutide considered to be a long-term treatment for type 2 diabetes?

Cost Concerns

At this time, injectable semaglutide, FDA-approved for the treatment of Type 2 diabetes, has a self-pay price tag of $935.77 per month (4 injections). With FDA approval, many people with diabetes, insured under commercial plans, receive the drug for the cost of their copay. Those patients without coverage may use pharmacy discount cards that reduce the price, on average, to $814.55/month.

The following links are available to familiarize yourself with patient assistance programs related to semaglutide injectables.

 

Semaglutide Cost Savings Programs

The following links are provided to explore various semaglutide cost savings programs.

Quiz Questions

Self Quiz

Ask yourself...

  1. What resources can you offer patients who are struggling to pay for semaglutide?

Emerging Concerns: Semaglutide and gastroparesis

In August 2023, a first-of-its-kind lawsuit was filed in Louisiana, against the makers of semaglutide. The lawsuit states the makers of this injectable drug did not adequately warn patients about the risk of severe gastrointestinal issues/possible gastroparesis.

The plaintiff in this case had used both Ozempic and Mounjaro and experienced repeated episodes of severe gastrointestinal events, warranting trips to the emergency room and additional medications to alleviate her symptoms (14). While this lawsuit is in the developing stages, it bears mentioning in terms of concerns over long-term usage of the drug and possible complications.

While the drug labeling for semaglutide (Ozempic) does not specifically mention gastroparesis, the semaglutide/Mounjaro drug label does state that the drug has not been studied in patients with severe gastrointestinal disease and is therefore not recommended in these patients.

Up to 50% of people with diabetes have some degree of delayed gastric emptying, but most have no digestive symptoms or have only mild symptoms. For some people with diabetes, problems managing blood glucose levels may be a sign of delayed gastric emptying (15).

Healthcare providers should evaluate all patients with diabetes for possible symptoms of underlying gastroparesis, such as the feeling of fullness shortly after beginning a meal, or the inability to finish a regular meal. Other symptoms of gastroparesis may include abdominal pain, nausea, bloating, vomiting, and anorexia.

 

Diabetes and gastroparesis

Uncontrolled or poorly controlled diabetes can affect nerve endings systemwide. Diabetes is a very common cause of gastroparesis. Although the condition is rare it occurs more often in people with chronic conditions such as diabetes, autoimmune diseases, and nervous system disorders. Nerve endings are injured or damaged, cease to function properly, and result in delayed gastric emptying. The delay in gastric emptying can cause various symptoms, such as nausea, vomiting, bloating and distension, abdominal pain, and poor appetite.

In addition to underlying medical conditions, some medications may cause symptoms of gastroparesis (delays in gastric emptying and overall gastric motility. These medications include narcotics, antidepressants, and anticholinergics.

Left untreated, diabetic gastroparesis may lead to malnutrition, electrolyte imbalances, and poor glucose management and control.

Quiz Questions

Self Quiz

Ask yourself...

  1. Why should nurses prescribing semaglutide watch out for symptoms of gastroparesis?
  2. What do you think are some ethical issues with semaglutide use for weight loss?

Diabetes Lifestyle changes: Patient education (16)

  1. Weight Management
  2. Healthy Eating
  3. Physical Activity
  4. Smoking Cessation
  5. Stress Management

 

The importance of patient education regarding lifestyle changes is a priority. As with any chronic medication condition, the patient and their family/support system must be given every opportunity to educate and empower themselves on self-management of their disease process. Patients must be given the benefit of the doubt that they can indeed embrace their health and well-being and work with their healthcare provider in maximizing their health outcomes.

For diabetes mellitus, numerous lifestyle behaviors should be addressed and actively worked on, so that the patient receives the maximum health benefits. The following lifestyle behaviors are in no particular order; they all warrant discussion at every office visit.

 

Diet

A person with diabetes should be educated on the effects of food and nutrition on their glucose level. Referrals to a dietitian/nutritionist or Certified Diabetes Care Education Specialist (CDCES) should be considered a top priority. Well-balanced nutritional intake, appropriate carbohydrate awareness, calorie monitoring if weight loss is appropriate to your specific patient) and medication/food interactions are all essential aspects of dietary lifestyle education. Many commercial insurance plans, as well as hospital community outreach programs, offer diabetes self-management classes.

 

 

 

 

Activity (17)

The CDC recommends a target goal of 150 minutes weekly, Patients should be educated on the positive effects of daily activity on overall health and well-being, stress management, and metabolism. Patients should find activities they are genuinely interested in, involve family and friends, and slowly build greater endurance through increased intervals of longer duration.

 

Sleep hygiene (18)

Patients should be educated on the positive effects of a good night’s sleep. The aim should be approximately 7-8 hours of restful sleep. Electronics should be powered down and (optimally) removed from the bedroom. A dark, well-vented, cool room temperature is encouraged, and large meals and late-evening caffeine should be avoided.

 

Medication adherence/ literacy

Medication education is critical to the health and well-being of a patient. Routine education of the patient, and family members or support systems when available, should be supportive and patient-specific. Patients should be assessed on language barriers, literacy issues, and related comprehension concerns. Medication education should include effects, side effects, treatment goals, and sick day management. Emergency care issues should also be discussed. Any monitoring equipment (continuous glucose monitors, accuchecks, lancets) should be reviewed with patients and confirmed with return verbalization and demonstration.

 

As discussed in this course, patients with chronic diseases must learn self-management techniques to optimize their health and well-being. They must become confident in their understanding of their disease process and take ownership of their health. In doing so, they minimize the risk of long-term complications, improve their self-worth, and actively invest (both time and money) in their future.

Quiz Questions

Self Quiz

Ask yourself...

  1. How does sleep, diet, and activity level affect the treatment of type 2 diabetes?

Ozempic Case Study

  • 52-year-old female
  • Height 67 inches
  • Weight 225 pounds
  • B/P 138/84, Heart rate 76 NSR
  • BMI 35.2%
  • Nonsmoker, occasional social drinker
  • Multiple attempts at dieting without success.
  • Diagnosed T2DM approx. 6 months ago current A1C 7.5%; initial medication Metformin 500mg BID tablets; tolerated well. No GI upsets.

Today’s appointment is for evaluation and additional medication consideration (the patient requested this appointment)

The patient was diagnosed with T2DM approximately 6 months ago. Initial A1C 8.0%. Current A1C 7.7%

Despite an improved diet and adherence to the medication regimen, the patient voiced frustration at the lack of weight loss. Requesting additional medication. Has a neighbor friend who began injectable Ozempic and is having “really great results with it. I want to start on it as well”.

 

  • What are your thoughts on prescribing semaglutide injectable for this patient?
  • What objective health data points should be taken into consideration regarding prescribing semaglutide for this patient?

 

The patient has expressed frustration that despite taking her medications and adjusting her diet, she has not lost any weight in the past 6 months. She has “heard from her neighbor friend that the weight just melts off immediately” and she is ready to start this medication.

 

  • What concerns do you know about this patient's understanding of weight loss as it relates to semaglutide?
  • What prescribing information, specific to semaglutide and weight loss, could you share with your patient regarding realistic weight loss targets?
  • In addition to teaching your patient proper injection technique for the use of semaglutide, what other lifestyle education behaviors should you discuss at this point?
  • What information should you share with your patient regarding the long-term use of semaglutide and the potential risks of stopping this medication (as it relates to weight regain)?

 

Your patient decides to go ahead with the semaglutide regimen.

  • What are some patient education guidelines regarding common side effects of this medication?
  • How often is the dose increased? What is the maximum dose this patient can receive weekly?

 

Your patient wants to know how long she will be taking this medication.

  • What talking points will you cover regarding the long-term use of this medication?
  • How do you best prepare this patient for long-term success with this medication?
  • What lifestyle behavior modification education would you discuss with your patient, to give her the best chance at successfully managing her diabetes?

Medication Assisted Treatment

Introduction   

Medication Assisted Treatment (MAT) is a treatment modality for substance use disorders. It combines counseling and behavioral therapies for addiction with medications used carefully to reduce the physical symptoms of cravings and withdrawal and assist clients in the recovery process. With half of people 12 and older reporting use of an illicit substance at least once and 21 million Americans experiencing addiction, this is an important and relevant topic (4).

Historically, an intense stigma is attached to both addiction and some of the medications used to treat addiction. A thorough understanding of substance use disorders, available MAT therapies, and care of affecting clients are essential topics for nurses to be familiar with, particularly those working in psychiatry, pain management, or addiction medicine.

Overview of Addiction and Substance Abuse:

Drug and alcohol abuse and addiction are chronic, complicated issues involving persistent changes to the brain. There is a stigma or misunderstanding that people with substance abuse disorders can stop any time they want to or lack the willpower or moral fortitude to stop using. This is entirely untrue, and even people who are "recovering" and have not had any drugs or alcohol in years can easily relapse into addiction once those brain changes have occurred (5).

When a person uses drugs or alcohol, the brain's reward center is flooded with dopamine. This provides a "buzz" or pleasurable sensation that may create the desire to use more of the same substance. Over time, and with regular use of the substance, the brain becomes accustomed to the flooding of dopamine and reduces the reward response, a process known as tolerance.

It will now take the same person a more significant amount of the substance to achieve the same "buzz" or "high" they used to feel. This process can also dull the pleasure response to activities not involving substance use, such as food, socialization, or sexual activity. Over time, the chemical changes in the brain can progress to include decreased functioning of learning, decision-making, judgment, response to stress, memory, and behavior (5).

To understand substance abuse disorders, it is first essential to understand some basic definitions. These terms are sometimes used interchangeably, but they mean different things and represent different stages of disease.

 

Definitions

Substance Use: Substance use is any consumption of drugs or alcohol, regardless of frequency or amount. An occasional glass of wine or taking an edible at a party is an example of substance use. Substance use does not cause problems or dependency in many people (5).

Substance Abuse: Substance abuse is the continued use of drugs or alcohol, even when they do cause problems. Conflict or problems at home, school, work, or legal issues related to the use of drugs or alcohol are signs of abuse. For example, being sent home from school for smoking in the bathroom or failing a drug test at work (5).

Substance Dependence or Addiction: Dependence and addiction can be used interchangeably or is sometimes called substance use disorder. Addiction occurs when a person cannot stop drinking or using drugs despite creating problems in their life. People who are addicted may experience cravings until they use a specific substance, or they may experience uncomfortable physical symptoms, known as withdrawal if they do stop (5).

The American Psychiatric Association (APA) utilizes the following criteria to diagnose clients who suffer from addiction. The more criteria a client answers yes to, the greater their problem with substance use.

Six or more positive criteria are indicative of addiction.

  1. Using substance in more significant amounts or for more extended periods than intended
  2. Trying to stop using but being unable to
  3. Increased amounts of time getting, using, or recovering from use of the substance
  4. Experiencing cravings or urges to use.
  5. Continuing to use the substance despite problems with relationships or social situations.
  6. Missing work, social, or recreational obligations or activities because of substance use
  7. Participating in risky behavior because of substance use
  8. Continuing to use the substance despite psychological or physical health problems.
  9. Needing to use more substance over time to achieve the desired effect.
  10. Experiencing withdrawal symptoms when stopping the substance (1).

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Do you know anyone who suffers from a substance use disorder?
  2. Think about your biases (thoughts, opinions, attitudes) about addiction. Does any of the information above conflict with those biases?

Substance Abuse Statistics

Many factors go into gathering data on substance abuse disorders, from underreporting, the nuance between use, abuse, and addiction, and the large variety of substances available, with the legality of some substances varying by state or age.

The statistics below from 2020 are not meant to be an exhaustive list of substance use disorders in this country but rather an overview of some of the more prevalent addiction-related issues.

  • 50% of people 12 years and older have used an illicit substance at least once.
  • 5% of Americans 12 years and older have used drugs within the last month.
  • This is a 3.8% increase from the previous year.
  • About 50% of Americans 12 and over drink alcohol
  • 4% of those people have an alcohol use disorder.
  • About 20% of Americans use tobacco products or vape
  • 18% of Americans over 18 used marijuana in the last 12 months
  • 30% of those have some level of misuse or addiction.
  • Marijuana is commonly involved in polysubstance use, paired with alcohol or other drugs.
  • 7% of Americans over 12 misused opioids in the last 12 months
  • 96% of those used prescription pain relievers
  • Opioid prescriptions peaked in 2012, with 81.3 prescriptions per 100 people.
  • The rate has declined recently due to increased attention to this crisis.
  • In 2018, the rate was down to 51 prescriptions for every 100 people
  • Fentanyl is now rising as a new and deadly concern.
  • 5 million prescriptions were written for fentanyl in 2015.
  • Fentanyl is involved in 53% of overdose deaths.
  • 7% of all Americans misuse a prescription drug.
  • 1% of those misuse stimulants
  • 2% of those misuse sedatives
  • 5% misuse painkillers
  • Over 70,000 drug overdose deaths occur annually in the United States (4)

Risk Factors

A combination of factors is involved in the risk of addiction, and no one factor can determine if someone will develop addiction or after how many uses this will occur.

The addiction process does occur more easily or progresses more rapidly for people with certain risk factors, including:

 

Genetics

There is a strong genetic correlation with addiction, indicating that biology plays a significant role in the disorder. Family history of addiction, gender, ethnicity, and comorbid mental health conditions can all influence the risk of addiction. (5)

  • Children of addicts are eight times more likely to develop an addiction at some point.
  • In 2020, among those using illicit or misusing prescription drugs, 22% were male and 17% female.
  • Only 20% of users in drug treatment programs are women.
  • 9% of people with substance abuse disorders also have at least one mental health disorder (4)

 

Environment/Non-Genetic Demographics

The attitudes about drugs and alcohol from those in a person's network and life experiences play a role in the risk of addiction. Substance use among friends, family, or coworkers increases the risk that a person will also use substances. Exposure to substance use from a young age relaxed parental attitudes about substance use, and peer pressure from friends can increase the risk. Certain stressful life circumstances such as veteran status, history of sexual or physical assault, or being part of the LGBTQ community can also increase risk. (5)

  • 20% of people in urban areas used illegal drugs in 2020 compared to 5% in rural locations.
  • 51% of Americans with an illegal pain relief medication obtained it from a friend or relative.
  • 7% of LGBTQ Americans abuse illicit drugs.
  • 2% of LGBTQ Americans abuse alcohol.
  • 7% of Veterans abuse illicit drugs.
  • 80% of Veterans abuse alcohol (4)

 

Developmental Stage

Substance use at any age can lead to addiction, but children and teens are at particular risk due to their underdeveloped brains. The parts of the brain responsible for decision-making, risk assessment, and self-control do not fully develop until the early 20's, putting teenagers at increased risk of dangerous behaviors. In addition, the effects of drugs and alcohol on the developing brain may mean that those parts of the brain never fully develop at all for teens with substance abuse disorders. (5)

  • 70% of users who try an illegal substance before age 13 will develop a substance use disorder within the next seven years.
  • This is for only 27% of people who first try an illegal substance after age 17.
  • 47% of youths report trying an illegal substance by the time they graduate high school (4)
Quiz Questions

Self Quiz

Ask yourself...

  1. Why do you think medication alone is not an adequate treatment for substance abuse disorders?
  2. Is MAT something you have heard of before? Why do you think it is relatively uncommon despite being around for decades?

Overview of Medication Assisted Treatment (MAT)

Treatment of substance abuse disorders is a complex and often tumultuous process. The nature of the brain changes that occur during addiction means that a person is never entirely "cured" but will always be considered "recovering" as the risk for relapse is always present. Effective treatment must be multifaceted and often involves removing triggers (such as people, places, and stressors) that may prompt a person to use again behavioral therapy, and medications to curb withdrawal symptoms and reduce cravings.

Medication Assisted Treatment (MAT) is a treatment that involves FDA-approved medications, in combination with behavioral therapy, in the recovery process for substance abuse disorders. Several medications are available for MAT, and evidence continues to emerge that the treatment is highly effective if used correctly.

However, it is a vastly underused and understudied treatment modality. MAT has been available in some form for over 50 years but is just starting to gain traction among the medical community (and policymakers) in recent years, with the federal government calling for more research and increased accessibility for the treatment (8).

The height of the opioid crisis in the last several years has highlighted the magnitude of drug addiction and deaths in the United States, bringing renewed attention to MAT as a treatment option. So, how does MAT work? Prescription medication is given to both stimulate the receptors seeking the abused substance and block the drug's euphoric effects.

Over time, this normalizes brain chemistry and helps the person break the habit of using without the discomfort of cravings and withdrawal symptoms. Gradually, the prescription medication dosage is reduced, all the while in conjunction with behavioral therapy and lifestyle changes, and eventually, the client should be able to stop the medication altogether, often within 1-3 months (8).

MAT does require close supervision by a trained medical professional and an appropriate facility for treatment. It can be done on an inpatient, partial inpatient, or outpatient basis. There may be side effects to the medication, and there is a risk of misusing or developing addiction to the new drug, though the successful outcomes often outweigh this risk. Clients must also participate in behavioral therapy for a comprehensive and effective treatment plan. As with any treatment regimen, careful consideration of the client's history and circumstances is essential (8).

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why do you think medication alone is not an adequate treatment for substance abuse disorders?
  2. Is  Medication Assisted Treatment (MAT) something you have heard of before? Why do you think it is relatively uncommon despite being around for decades?

Pharmacokinetics

Currently, there are three medications with FDA approval for MAT: buprenorphine, methadone, and naltrexone. Each will be discussed in depth below.

 

Buprenorphine
Mechanism of Action and Metabolism

Buprenorphine is an opioid partial agonist, acting on the same receptors as other opioids but with weaker effects. It can be used for the treatment of misuse of opioids, including:

  • Heroin
  • Fentanyl
  • Oxycodone
  • Hydrocodone
  • Morphine
  • Methadone (3)

 

Opiate receptors are G-protein coupled receptors (GPCRs) with four major types: Mu, Delta, Kappa, and opioid receptor like-1 (ORL1). Stimulation of these receptors results in varying levels of the following effects:

  • Euphoria
  • Relaxation
  • Pain relief
  • Sleepiness
  • Sweating
  • Constipation
  • Impaired concentration
  • Reduced sex drive (3)

 

Buprenorphine has a high affinity to the Mu-opioid receptor and is a partial agonist at this site, causing reduced opioid effects with a plateau or ceiling at higher doses. This limits dangerous effects and makes overdose unlikely. It also has slow dissociation from the site, allowing milder and more easily tolerated withdrawal effects compared to full agonists like morphine and fentanyl. Buprenorphine is also a weak kappa receptor antagonist and delta receptor agonist, reducing the craving sensation and improving tolerance to stress (3).

Buprenorphine has poor bioavailability when given orally due to the first-pass effect, where most of the drug is broken down in the liver and intestines. Because of this, sublingual or buccal are the preferred routes of administration and the most common forms in which the drug is manufactured. Transdermal patches and IV and IM forms exist, though not for use in MAT (3).

CYP34A enzymes break down buprenorphine, so other drugs, such as ketoconazole, may inhibit metabolism and increase available levels of buprenorphine. CYP34A inducers such as carbamazepine, topiramate, phenytoin, and barbiturates may speed metabolism and lower available levels. Once broken down, the med takes the form of norbuprenorphine and is excreted in the feces (3).

 

Available Forms

Buprenorphine is available by itself and with naloxone (in a 4 to 1 ratio). However, in oral form, naloxone is not readily absorbed, and buprenorphine is the only genuinely active ingredient. This combination is beneficial should clients try to inject their buprenorphine to get high; naloxone is a fast-acting opioid antagonist that is active when used intravenously and would block the opioid effect of buprenorphine, rendering it useless for recreational use and ensuring it has no street value.

The currently available preparations of buprenorphine for MAT include:

  • Generic Buprenorphine/naloxone sublingual tablets
  • Subutex - Buprenorphine sublingual tablets
  • Suboxone - Buprenorphine/naloxone sublingual films
  • Zubsolv - Buprenorphine/naloxone sublingual tablets
  • Bunavail - Buprenorphine/naloxone buccal film (3)

 

Sublingual products dissolve within 2-10 minutes. Bloodstream absorption begins quickly, bypassing the first pass effect. Buprenorphine has a slow onset of action, peaking about 3-4 hours later. Metabolism is also slow, with the half-life lasting anywhere from 25 to 70 hours (an average of about 38 hours). This long half-life means the drug can be spaced out to every other day administration once weaning begins (3).

 

Dosing and Monitoring

Clients prescribed buprenorphine must stop using opioids for at least 12 to 24 hours before the first dose; this varies depending on which opioid they are stopping. For short-acting opioids like heroin and oxycodone, buprenorphine may be started 6-12 hours after the last dose. With longer-acting opioids such as morphine or extended-release preparations of oxycodone, buprenorphine should be delayed for about 24 hours. For the longest action opioids, fentanyl patch, 48 -72 hours must be between the last dose and buprenorphine initiation (3).

This initiation schedule means clients will be in the early stages of discomfort and withdrawal. Administration of buprenorphine when clients still have opioids in their bloodstream will lead to competition for receptor sites, rapidly replacing the opioid with buprenorphine and causing acute and more severe withdrawal symptoms.

Depending on the severity of a client's addiction, they may complete the first step of abstaining and withdrawal in an inpatient setting. Once the initial withdrawal symptoms have passed and the initial dose of buprenorphine has been given, the client may be discharged home to continue buprenorphine initiation on an outpatient basis (3).

Initial doses are typically 2-4mg, with up to 4mg given to clients used to higher potency or larger doses of opioids. The dose is gradually increased to meet the client's individual needs, with a maximum dosage of 24mg per day. The average client requires 8-12 mg per day and can reach this dose within the first 2-4 days. It is recommended that doses be supervised by a pharmacist at the dispensing pharmacy for the first two months of treatment to ensure compliance and clients are less likely to relapse (3).

The length of treatment with buprenorphine depends on each client's case and, for some, may be indefinite. Clients who do wish to wean off buprenorphine can begin the process once they are stable and experiencing few or no cravings, and a minimum of 8 weeks from treatment initiation. Doses are moved to alternating days and eventually discontinued altogether (3).

 

Side Effects and Contraindications:

As with any medication, there are potential side effects, including:

Common Side Effects

  • Nausea
  • Vomiting
  • Drowsiness
  • Dizziness
  • Headache
  • Memory loss
  • Sweating
  • Dry mouth
  • Miosis
  • Postural hypotension
  • Sexual dysfunction
  • Urinary retention

 

Serious side effects

  • CNS depression
  • QT prolongation
  • Reduced seizure threshold
  • Potential for abuse or overdose (3)

 

Buprenorphine is contraindicated for clients with a past hypersensitive reaction to it. It should be used cautiously for clients with respiratory suppression, older adults, or for those with liver pathologies. Regular monitoring of liver enzymes via lab work is essential (3).

It is a Category C medication for pregnancy, and the risks versus benefits should be carefully weighed. Buprenorphine does cross the placenta and increases the risk of withdrawal symptoms and neonatal abstinence syndrome (NAS) after delivery. However, for pregnant clients with the highest risk of relapse and abuse of opioids, evidence does support that continuation of buprenorphine during pregnancy may improve maternal and fetal outcomes (3).

Buprenorphine may be abused by crushing tablets, snorting the powder, or dissolving it into an injectable solution. Safety measures against this include supervised administration by a pharmacist and the addition of naloxone, which blocks the buprenorphine effects. While the effect ceiling of buprenorphine makes overdose difficult, combining the drug with benzodiazepines, alcohol, or other drugs can compound the CNS depressant effects and increase the risk of overdose (3).

Clinicians need to have a comprehensive health history of clients before initiating buprenorphine so that all risks and potential interactions can be addressed appropriately.

 

Role of the Pharmacist

Pharmacists play a significant role in the success of MAT involving buprenorphine. Outpatient doses are monitored by the dispensing pharmacist daily, with at-home quantities being allowed on a limited basis (such as weekends or travel) and only for the most motivated and compliant clients. Vital signs are collected before each dosage, with careful monitoring for hypotension or bradypnea. The dose may be skipped for clients who experience excessive side effects, and the client can return the next day for their dose.

Clients presenting with signs of overdose (usually to the ED) may receive naloxone, which will reverse overdose symptoms within 1 hour. Overdose symptoms include dizziness, pinpoint pupils, hypotension, bradypnea, hallucinations, seizure, or unconscious state.

If a client misses a dose, does not show up for it, or is experiencing significant side effects from buprenorphine, the prescribing clinician should be notified so that the treatment plan can be revisited and revised if needed (3).

 

Considerations for the Prescriber

When considering which medication to prescribe for MAT, prescribers should understand that buprenorphine offers advantages over methadone.

  • Lower risk of abuse
  • Safer, including at higher doses.
  • Therapeutic dose achieved quickly.
  • Easier to taper.
  • Can be obtained from any provider rather than a methadone clinic.
  • Less stigma

 

The cost of a 30-day supply is around $300. Buprenorphine/naloxone combinations are a little more expensive at $400/month. While prior authorization is usually required, most commercial insurance and state Medicaid programs will cover the medication.

Buprenorphine is a Schedule III Controlled Substance; however, recent federal regulations have been aimed at approving access to MAT, and any provider with an active DEA license may prescribe buprenorphine as allowed by state regulations. Specialized clinics are not required (as they are with methadone), and it is dispensed at regular pharmacies.

Prescribers are encouraged to participate in additional training about MAT with buprenorphine, but it is not required. Detailed documentation must be completed, including the reason for prescribing, start and end dates of treatment, the pharmacy used, the credentials of who will supervise administration, and frequency of follow-up and compliance monitoring. The sublingual and buccal routes are the only forms of medication used for MAT; patches, IM, and IV preparations are not routinely used for MAT.

The success of buprenorphine treatment depends on the client's education. Addiction potential, risk of combination with other CNS depressants, and side effects vs. signs of overdose should all be discussed with clients and their support system (3).

Quiz Questions

Self Quiz

Ask yourself...

  1. Given the nature of substance abuse disorders, why do you think including an opioid antagonist like naloxone in preparations of buprenorphine is necessary for safety and compliance?
  2. What challenges do you see with a medication needing to be administered daily with pharmacist supervision?
  3. What are the risks of buprenorphine being given without this supervision?
  4. Consider the possible pros and cons of taking a medication like buprenorphine during pregnancy. Also, consider the risks of NOT taking the drug during pregnancy when a substance use disorder is present.
Methadone
Mechanism of Action and Metabolism

Methadone is a synthetic opioid and a full agonist of the Mu-receptor site, stimulating the same effects as opioids.

  • Euphoria
  • Analgesia
  • Sedation

 

It can be used as a potent analgesic for pain not responding to traditional medications, such as in clients with cancer or terminal illness, as well as for MAT and neonatal abstinence syndrome (NAS).

For this course, it will be discussed as a MAT agent, used in treatment for clients addicted to opioids such as:

  • Heroin
  • Fentanyl
  • Oxycodone
  • Hydrocodone
  • Morphine
  • Hydromorphone (2)

 

Methadone is a full agonist at the Mu-receptor, meaning it is a more potent and more easily addictive medication than partial agonists like buprenorphine. Methadone has a long half-life (8-60 hours), occupying the Mu-receptors and blocking short-acting opioids from making a client high. The longer half-life also leads to less severe cravings and withdrawal symptoms. Methadone is also an antagonist to the N-methyl-d-aspartate (NMDA) receptor, which adds to its pain relief action (2).

It has high oral bioavailability, is active in the bloodstream within 30 minutes of ingestion and remains elevated for around 24 hours. It is broken down via CYP3A4 and CYP2B6 enzymes and metabolized through the liver, making it a good option for clients with renal problems.

Medications such as ciprofloxacin, benzodiazepines, fluconazole, cimetidine, and fluoxetine may slow methadone metabolism, increasing the available drug and the side effects of overdose risk. Other medications may speed metabolism and decrease the effects of methadone, including phenobarbital, phenytoin, rifampin, ritonavir, and carbamazepine (2).

 

Available Forms

Methadone is available in many forms, including oral, IM, subcutaneous, IV, and intrathecal, though only the oral is typically used for MAT.

  • Methadone - tablets
  • DISKETS - dispersible/dissolvable tablet
  • Methadone HCL Intensol - 10mg/ml suspension
  • Methadone - dispersible tablet (2)

 

Dosing and Monitoring

Oral dosing is initiated at 30-40 mg/day with a slow titration of 10-20 mg/week until the optimal dosage is reached. The optimal dosage varies by client and depends on the drug they are replacing, tolerance to opioids, and side effects experienced. A dosage between 80- 150 mg/day is the typical goal. (2)

If parenteral methadone is given, it is usually 50%-80% of the oral dosage.

Blood sugar, EKG, and methadone blood levels should be checked regularly, every week for higher-risk patients, and every 3-6 months for those in good health and compliance. The target methadone blood level is around 400 ug/ml (2).

 

Side Effects and Contraindications

Potential side effects are directly related to stimulation of the opioid receptors and include:

  • Diaphoresis
  • Flushing
  • Pruritus
  • Nausea
  • Dry mouth
  • Constipation
  • Sedation
  • Lethargy
  • Respiratory Depression
  • QT prolongation
  • Hypoglycemia (2)

 

Methadone should be considered with a comprehensive view of a client's health history and other medications. Clients with CNS-related disease processes (trauma, increased ICP, dementia, or delirium) must be monitored closely or have other medication considered.

Methadone should not be used simultaneously as other opioids, benzodiazepines, alcohol, or antipsychotics due to increased CNS effects. Methadone is a Pregnancy Category C medication, and risks versus benefits should be weighed carefully. Infants exposed to methadone in utero are at increased risk of NAS after delivery (2).

Overdose can occur, and clients and support systems should be educated on signs of overdose.

  • Lethargy
  • Somnolence
  • Stupor
  • Coma
  • Miosis
  • Bradycardia
  • Hypotension
  • Respiratory sedation
  • Cardiac arrest

 

Naloxone is used to reverse overdose (2).

 

Considerations for Prescribers and Clinics

Methadone is a Schedule II Controlled Substance, meaning it has a high abuse potential and must be carefully monitored. The Prescription Drug Monitoring Program (PDMP) is an electronic database used nationwide to register the distribution of controlled substances so that clients do not seek care at multiple clinics or pharmacies to obtain more of a controlled substance.

When prescribing methadone, providers should check the PDMP for both methadone and other prescription opioids so that they are fully aware of other medications clients may be receiving from other places. Regular urine drug screening should be performed to make sure clients are not using other substances not obtained by prescription and that they are testing positive for methadone, meaning they are genuinely taking it if administration is not observed (2).

At the beginning of treatment, methadone is given in the office under a nurse's supervision, and then clients are monitored for adverse effects. Some take-home doses (up to 7 in the first two weeks) may be arranged for weekends or during travel, but this possibility is limited during the first few weeks of treatment. As treatment progresses and compliance is demonstrated, clients may self-administer more doses at home (up to 28 doses per month) and go longer between visits to the clinic. The total length of treatment varies but is often 1-2 years and can even be indefinite (7).

There are methadone clinics that work entirely in the scope of addiction management, but primary care providers may prescribe methadone as well. Prescribers must have an active DEA license and comply with state-based controlled substance regulations (2).

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Why do you think methadone is a Schedule II Controlled Substance while buprenorphine is only a Schedule III?
  2. What are the benefits of checking the serum level of methadone?
  3. What might the clinical presentation be for someone overdosing on methadone?
  4. Have you ever used the PDMP database before? What are the benefits of accessing this database?
Naltrexone
Mechanism of Action and Metabolism

Naltrexone has been in use since the 1960s and is an opioid antagonist. It competes primarily with the mu-receptor but also serves as an antagonist at the kappa and delta receptors. As an antagonist, it competes with agonists such as opioids and alcohol and blocks the effects of agonists at those sites.

  • Prevents euphoria.
  • Prevents intoxication.
  • Reduces tolerance (6)

 

Naltrexone also acts on the hypothalamic-pituitary-adrenal axis, modifying it to reduce cravings and suppress alcohol consumption.

It is FDA-approved for use in clinical practice for the treatment of:

  • Alcohol use disorder
  • Opioid use disorder (prescription and non)

 

Naltrexone is absorbed orally and undergoes extensive metabolism via the first-pass effect. However, this does not affect its potency as naltrexone's active metabolite, 6β-naltrexone, acts as a potent opioid antagonist. The medication's half-life is around 4 hours but can last up to 24 hours. If administered parenterally, it bypasses the first pass and is even longer acting, with a half-life of 5-10 days. Naltrexone is excreted by the kidneys (6).

 

Available Forms

Naltrexone is available in an oral tablet and IM injection. Available preparations include:

  • Generic naltrexone tablets
  • Revia (oral tablet)
  • Depade (oral tablet)
  • Vivitrol (solution for IM injection, extended-release) (6)

 

Dosing and Monitoring

Since naltrexone will compete for and block all opioid receptor sites, the risk for withdrawal symptoms is high, and clients must stop the use of alcohol or opioids for 7-10 days before beginning treatment to lessen the risk of withdrawal symptoms. A naltrexone challenge is recommended at the start of therapy.

This consists of administering small amounts of naltrexone subcutaneously or via IV and monitoring the client and their vital signs for signs of withdrawal, such as:

  • Nausea
  • Vomiting
  • Diaphoresis
  • BP changes
  • Tachycardia
  • Rhinorrhea
  • Agitation
  • Tremors
  • Abdominal pain
  • Pupillary dilation (6)

 

If a client fails the naltrexone challenge and has not been long enough since their last use of alcohol or opioids, the naltrexone initiation should be delayed, and the test should be repeated in 24 hours. If clients tolerate the naltrexone test and the negative result, they may begin naltrexone treatment (6).

For oral tablets, dosing usually starts at 25 mg for the first dose. Clients are observed for withdrawal symptoms and side effects; an additional 25 mg is given 1 hour later. After that, clients take 50 mg per day. Clients may continue with 50mg daily or take 100 mg every other day or 150 mg every 3rd day (6).

Alternatively, naltrexone may be given via IM injection for more extended action, improving compliance and reducing relapse. Particularly for alcohol or heroin dependence, data indicates that the IM route has much higher success rates than the oral route. If a client receives the IM injection, 380 mg is given to the gluteal muscle every four weeks (6).

 

Side Effects and Contraindications

Most common side effects of naltrexone include:

  • GI irritation
  • Diarrhea
  • Abdominal cramps
  • Nausea
  • Vomiting
  • Hypertension
  • Headache
  • Anxiety
  • Low energy
  • Joint or muscle pain
  • Nervousness
  • Sleep disruption

 

Less commonly, clients report:

  • Loss of appetite
  • Constipation
  • Dizziness
  • Irritability
  • Depression
  • Rash
  • Chills (6)

 

Caution should be used for clients with liver function issues and renal impairment. It is Category C for use during pregnancy, and the risks versus benefits of use in pregnancy must be carefully considered. It also crosses into breast milk and must be considered carefully.

There is limited data about the overdose of naltrexone, and there may be very few symptoms if an overdose occurs. Clients should be monitored for signs of liver dysfunction, seizures, depression, and suicidal ideations. No antidote for naltrexone is currently available.

Naltrexone is contraindicated for clients who failed a naltrexone challenge, test positive for opioids or alcohol on drug screening, have a history of seizures, or have experienced a past hypersensitivity reaction to naltrexone.

Clients may switch from buprenorphine or methadone to naltrexone at some point in treatment. Both medications are agonists at the opioid receptor sites, so changing to naltrexone (an antagonist) may increase the risk of withdrawal symptoms for the first two weeks of treatment (6).

 

Considerations for Prescribers

Because naltrexone does not cause any euphoria or "high," the abuse potential is non-existent. It is not a controlled substance and can be prescribed by any clinician with prescriptive authority. However, its use is typically only by those who work in mental health or addiction medicine. Clients can take the medication at home or go to the clinic for IM injections.

Many considerations for naltrexone use center around monitoring for side effects and treatment compliance. Baseline and periodic drug screening and liver function tests are prudent. Clients' support persons should be educated on compliance and signs of relapse. The IM formulation should be considered for those with poor compliance or most at risk for relapse (6).

Quiz Questions

Self Quiz

Ask yourself...

  1. Why might a client benefit from the IM formulation of naltrexone instead of the oral preparation?
  2. Why might compliance with an opioid antagonist be more complex than an opioid agonist like methadone or buprenorphine?
  3. How do side effects differ between naltrexone and the agonist medications like methadone?
  4. What does it mean if a client fails a "naltrexone challenge," and how does this delay their care?

Nursing Considerations

Nurses will encounter clients with addiction and even those receiving MAT in a variety of settings, including:

  • Outpatient clinics for routine care of any health issues
  • ED admission for acute problems not related to addiction.
  • Inpatient hospitalization related to other health problems.
  • Outpatient setting for participation in MAT or addiction management.
  • ED admission for acute problems related to substance abuse or toxicity of MAT medication.
  • Inpatient mental health admission for mental health and addiction issues

 

Regardless of the setting and if the client is being seen for an addiction issue or something else, it is crucial for nurses to be familiar with MAT medications and how they work to provide safe and competent care. Nurses may need to:

  • Administer medication.
  • Monitor lab results.
  • Observe for side effects, toxicity, or withdrawal symptoms.
  • Coordinate care within a multidisciplinary team
  • Communicate with therapeutic and nonjudgmental techniques.

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. Have you ever cared for a client in a non-addiction setting who had a MAT medication on their drug list?
  2. Did you have any biases or preconceived ideas about what this medication meant?
  3. Is there anything you have learned throughout this course that will change your care the next time you encounter a client receiving MAT?

Case Study

Justin is a 32-year-old male who presents to the ED with nausea, lethargy, and confusion worsening over the last 24 hours. Upon exam, the nurse notes diaphoresis, slurred speech, and pinpoint pupils. His vitals are RR 10, HR 54, BP 82/58, SPO2 97%, Temp 99.0.

He reports taking Wellbutrin 150mg daily for depression and smoking cessation, methadone 100mg daily for history of oxycodone abuse, and was started on ciprofloxacin 250mg BID for a UTI 2 days ago at urgent care.

His labs are significant for a WBC of 15,000 but otherwise regular. He tests positive for methadone, which is expected, but not for other substances. He reports being compliant with MAT and avoiding opioid use for nine months.

It is determined that Justin is experiencing methadone toxicity due to the slowed metabolism of the drug from the combination of methadone and ciprofloxacin. He is given naloxone in the ED, and within an hour, his symptoms have improved significantly, and his vital signs are typical. His antibiotic is switched to cefdinir, and he is discharged home in stable condition with instructions to follow up with his PCP within 1-2 days.

Quiz Questions

Self Quiz

Ask yourself...

  1. Given Justin's presentation, how could you differentiate between methadone toxicity and relapse?
  2. How might Justin's condition have progressed if he had not sought emergency care?
  3. How would Justin's case have been different if he had not tested positive for methadone?
  4. In what ways could Justin's care before his ED visit have been improved to avoid this complication?

Conclusion

Substance use disorders are a long-standing and dangerous pathology experienced by millions of people each year. At the same time, the stigma of seeking help for such disorders has been eroding in recent years; there has also been a renewed push by the federal government to address the issue in evidence-based and meaningful ways, with access to effective treatment being at the top of the priority list.

Addiction treatment programs utilizing MAT will likely become much more popular in the coming years, and nurses will be on the front lines of this therapy. For nurses to provide competent and comprehensive care to this client population, up-to-date and accurate knowledge is necessary.

Hypertensive Agents

 

Definitions 

 

Hypertension – high blood pressure above normal. Normal is considered anything less than 120/80 mmHg [7]. 

Antihypertensives – medications used to control hypertension and lower blood pressure [7]. 

Hypertensive crisis – severely elevated blood pressure of either: 

  1. Systolic greater than 180 mmHg 
  1. Diastolic greater than 120 mmHg [19]. 

Hypertensive emergency – acutely elevated blood pressure with signs of target organ damage [2]. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is hypertension? 
  2. What are antihypertensives? 
  3. What is a hypertensive crisis? 
  4. What is a hypertensive emergency? 

Medications Overview 

Antihypertensive medications are used for the treatment of hypertension and are used in both inpatient, outpatient, and emergency settings.  

Some of the major antihypertensive medication classes include: 

  • Diuretics 
  • Beta-blockers 
  • Angiotensin-converting enzyme inhibitors 
  • Angiotensin II receptor blockers 
  • Calcium channel blockers 
  • Selective alpha-1 blockers 
  • Alpha-2 Receptor Agonists 
  • Vasodilators [3]. 

Different medical organizations have varying recommendations and hypertension treatment guidelines. Hypertension treatment clinical practice guidelines are available from organizations like the American Heart Association, the American College of Cardiology, and the European Society of Cardiology to name a few [21]. Healthcare providers should be aware of their healthcare institution’s recommendations for clinical practice guidelines and organizations.  

All organizational guidelines share the same recommended treatment of starting antihypertensives immediately when: 

  1. Blood pressure is greater than 140/90 mmHg for patients with a history of ischemic heart disease, heart failure, or cerebrovascular disease. 
  2. Blood pressure is greater than 160/100 mmHg regardless of underlying medical conditions [21]. 

Again, healthcare providers should follow current and evidence-based clinical guidelines for initiating or titrating antihypertensive medications. 

While most antihypertensives are prescribed in an outpatient setting, certain antihypertensives are indicated during hypertensive or medical emergencies. For example, intravenous (IV) vasodilators, like nitroprusside and nitroglycerin, and calcium channel blockers, like nicardipine, are used during hypertensive emergencies and crises. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. In what settings are antihypertensives used? 
  2. What are the clinical guidelines for initiating hypertensive medications? 
  3. Which medications are commonly used to treat hypertensive emergencies? 

Pharmacokinetics 

Diuretics 

Diuretics are a class of drugs that help control blood pressure by removing excess sodium and water from the body through the kidneys. There are several varying types of diuretics, some including thiazide, potassium-sparing, and loop, and all work to lower blood pressure differently [3]. 

 

Thiazide Diuretics 

Thiazide diuretics remove excess sodium and water from the body by blocking the sodium-chloride (Na-Cl) channels in the kidneys’ distal convoluted tubule. As the Na-Cl channel becomes blocked, this inhibits the reabsorption of sodium and water into the kidneys. Concurrently, this causes a loss of potassium and calcium ions through the sodium-calcium channels and sodium-potassium pump [1]. 

Thiazide diuretics are approved by the Food and Drug Administration (FDA) for controlling primary hypertension and are available via oral route. Some common thiazide diuretics are hydrochlorothiazide, chlorthalidone, and metolazone [3].  

When initiating this medication, the healthcare provider should start with the lowest dose, which is usually 25mg daily, and then increase accordingly to aid with blood pressure control or if the patient has excess fluid retention, usually as evidenced by leg swelling or edema [1].  

 

Common side effects of thiazide diuretics include: 

  • Increased urination 
  • Diarrhea 
  • Headache 
  • Stomach and muscle aches [16]. 

 

As thiazide diuretics interfere with Na-Cl, Na-Ca, and Na-K channels, there is an increased potential for adverse effects, including: 

  • Hypotension 
  • Hypokalemia 
  • Hyponatremia 
  • Hypercalcemia 
  • Hyperglycemia 
  • Hyperlipidemia 
  • Hyperuricemia 
  • Acute pancreatitis 

 

When prescribing thiazide diuretics, healthcare providers should avoid prescribing thiazide diuretics to patients with a sulfonamide allergy, since thiazides are sulfa-containing medications. Also, they should avoid prescribing these to patients with a history of gout [1].  

Additionally, patients can experience a thiazide overdose if they take more than the amount prescribed. Patients with a suspected overdose may experience confusion, dizziness, hypotension, and other symptoms. These patients must seek emergency care and poison control must be alerted [16]. 

 

Potassium-Sparing Diuretics 

Potassium-sparing diuretics remove excess sodium and water from the body without causing loss of potassium. Depending on the type, they interrupt sodium reabsorption by either binding to epithelial sodium channels or inhibiting aldosterone receptors. When catatonic sodium is reabsorbed, this creates a negative gradient causing the reabsorption of potassium ions through the mineralocorticoid receptor [5]. 

Potassium-sparing diuretics are approved for controlling hypertension and are usually combined with other diuretics, like thiazide or loop diuretics since they have a weak antihypertensive effect.  

Common names of potassium-sparing diuretics are amiloride, triamterene, and spironolactone. These medications are available by either intravenous or oral routes. Spironolactone is commonly used for treating primary aldosteronism and heart failure [5]. Patients should be started on the lowest dose when first prescribing this class of medications.  

 

Common side effects can include: 

  • Increased urination 
  • Hyperkalemia 
  • Metabolic acidosis 
  • Nausea  

[4] 

Healthcare providers should avoid prescribing this class of medications to patients with hyperkalemia or chronic kidney disease. They should also be avoided during pregnancy or in patients who are taking digoxin. Since potassium-sparing medications can cause hyperkalemia, periodic monitoring for electrolyte imbalances and potassium levels is necessary [4]. 

 

Loop Diuretics 

Loop diuretics inhibit sodium and chloride reabsorption by competing with chloride binding in the Na-K-2Cl (NKCC2) cotransporter. Potassium is not reabsorbed by the kidney, which causes additional calcium and magnesium ion loss.  

Loop diuretics are FDA-approved for the treatment of hypertension but are not considered first-line treatment. They can also be used for treating fluid overload in conditions like heart failure or nephrotic syndrome [12]. 

Loop diuretics are available via oral or IV routes and furosemide, torsemide, and bumetanide are common forms [3].  

Bioavailability and dosage differ for each type and route of loop diuretics. The bioavailability of furosemide is 50%, with a half-life of around 2 hours for patients with normal kidney function, and dosages start at 8mg for oral medication. Torsemide has a bioavailability of about 80%, a half-life of about 3 to 4 hours, and oral dosages start at 5mg [12].  

 

Common side effects can include: 

  • Dizziness 
  • Increased urination 
  • Headache 
  • Stomach upset 
  • Hyponatremia 
  • Hypokalemia [13]. 

 

Loop diuretics can lead to several adverse effects, including toxicity, electrolyte imbalances, hyperglycemia, and ototoxicity. They have a black box warning stating that high dosages can cause severe diuresis. Therefore, electrolytes, BUN, and creatinine values should be monitored closely by a healthcare provider.  

People with a sulfonamide allergy may also be allergic to loop diuretics, so this should be avoided if the patient is allergic. Loop diuretics also interfere with digoxin and therefore should be avoided. Other contraindications include anuria, hepatic impairments, and use during severe electrolyte disturbances [12]. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of thiazide diuretics? 
  2. What is the pharmacokinetics of loop diuretics? 
  3. What is the pharmacokinetics of potassium-sparing diuretics? 
  4. What are common side effects and contraindications for each type of diuretic? 

Beta-Blockers 

Beta-blockers work by reducing the body’s heart rate and thus, lowering cardiac output resulting in lowered blood pressure [3]. The mechanism of action for beta-blockers varies, depending on the receptor type it blocks, and are classified as either non-selective or beta-1 (B1) selective.  

Non-selective beta-blockers bind to the B1 and B2 receptors, blocking epinephrine and norepinephrine, causing a slowed heart rate. Propranolol, labetalol, and carvedilol are common non-selective beta-blockers.  

Alternatively, beta-1 selective blockers only bind to the B1 receptors of the heart, so they are considered cardio-selective. Some examples include atenolol, metoprolol, and bisoprolol. Sotalol is a type of beta-blocker that also blocks potassium channels and is, therefore, a class III antiarrhythmic [8]. 

Beta-blockers are not primarily used for the initial treatment of hypertension but can be prescribed for conditions like tachycardia, myocardial infarction, congestive heart failure, and cardiac arrhythmias. It’s also approved for use in conditions such as essential tremors, hyperthyroidism, glaucoma, and prevention of migraines.  

Beta-blockers are available in many forms, including oral, IV, intramuscular injection, and ophthalmic drops. Starting dosage and route are determined by the health condition being treated [8]. 

 

Common side effects of beta-blockers include: 

  • Bradycardia 
  • Hypotension 
  • Dizziness 
  • Feeling tired 
  • Nausea 
  • Dry mouth 
  • Sexual Dysfunction  

[17] 

 

This class of medications can also lead to more severe adverse effects such as orthostatic hypotension, bronchospasm, shortness of breath, hyperglycemia, and increased risk of QT prolongation, torsades de pointes, and heart block [8]. Healthcare providers should avoid prescribing non-selective beta-blockers to patients with asthma. Instead, they can prescribe cardio-selective beta-blockers for patients with asthma.  

Additionally, the use of beta-blockers is contraindicated in patients with a history of bradycardia, hypotension, Raynaud disease, QT prolongation, or torsades de pointes. Healthcare providers must encourage patients to monitor their heart rate and blood pressure and follow administration parameters before taking beta-blockers daily since it decreases their heart rate.  

Overdose of beta-blockers is life-threatening and healthcare providers must discuss the symptoms of an overdose and the need for emergency care [8]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of beta-blockers? 
  2. What are the common side effects and contraindications of beta-blockers? 

Angiotensin-converting Enzyme Inhibitors 

Angiotensin-converting enzyme (ACE) inhibitors prevent the body from producing angiotensin, a hormone that causes vasoconstriction. As angiotensin production is reduced, this allows the blood vessels to dilate and therefore lowers blood pressure [3].  

Moreover, ACE inhibitors act specifically on the renin-angiotensin-aldosterone system (RAAS) by preventing the conversion of angiotensin I to angiotensin II. It also works to decrease aldosterone, which in turn, decreases sodium and water reabsorption [9]. 

ACE inhibitors usually end in the suffix -pril and some common examples include lisinopril, benazepril, enalapril, and captopril, and they usually end in the suffix [3].  

While ACE inhibitors are approved for treating hypertension, they are also FDA-approved for other uses or combination therapies for medical conditions such as: 

  • Systolic heart failure 
  • Chronic kidney disease 
  • ST-elevated myocardial infarction 

One non-approved FDA use is treatment of diabetic nephropathy [9]. This class of medication is available in oral, and IV forms, and dosages are dependent on clinical guidelines, underlying medical conditions, and route.  

ACE inhibitors have common side effects, with some including: 

  • Dry cough 
  • Dizziness 
  • Hypotension [9]. 

 

This medication can also lead to adverse effects, such as syncope, angioedema, and hyperkalemia [9]. As angioedema is an adverse effect, healthcare providers should understand this class of medications is contraindicated in patients with a history of hypersensitivity to ACE inhibitors.  

Additionally, ACE inhibitors are contraindicated in patients with aortic valve stenosis, hypovolemia, and during pregnancy. Individuals with abnormal kidney function should have renal function and electrolyte values monitored. If a patient develops a chronic dry cough, then the healthcare provider should consider another antihypertensive medication class by following current guidelines [9]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of angiotensin-converting enzyme inhibitors? 
  2. What are common side effects and contraindications of angiotensin-converting enzyme inhibitors? 

Angiotensin II Receptor Blockers 

Similar to ACE inhibitors, Angiotensin II Receptor Blockers (ARBs) act on the RAAS by binding to angiotensin II receptors and thus block and reduce the action of angiotensin II. Again, this reduces blood pressure by causing blood vessel dilation and decreasing sodium and water reabsorption [11]. ARBs typically end in the suffix -artan and common names are losartan, valsartan, and Olmesartan [3]. Oral and IV routes of the medication are available and again, dosages are dependent on the medication specifically and form [11]. 

All ARBs are FDA-approved for the treatment of hypertension, but a select few are approved for treating other medical conditions, such as: 

  • Candesartan for heart failure 
  • Irbesartan for diabetic nephropathy 
  • Losartan for proteinuria and diabetic nephropathy 
  • Telmisartan for stroke and myocardial infarction prevention 
  • Valsartan for heart failure and reduction of mortality in patients with left ventricular dysfunction [11]. 

Although not as common as ACE inhibitors, two side effects of ARBs are dry cough and angioedema.  

 

Other common side effects include: 

  • Dizziness 
  • Hypotension 
  • Hyperkalemia  

[11] 

 

Contraindications for use are if the patient is pregnant or has renal impairment or failure. If a patient is on an ARB, the healthcare provider should closely monitor lab values for electrolyte imbalances and kidney function.  

Additionally, if a patient is taking lithium, ARBs can increase lithium concentration and therefore, lithium blood concentration should be frequently checked [11]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of angiotensin II receptor blockers? 
  2. What are common side effects and contraindications of angiotensin II receptor blockers? 

Calcium Channel Blockers 

Calcium channel blockers (CCBs), also known as calcium channel antagonists, act by preventing calcium from entering the smooth vascular and heart muscles. In turn, this reduces heart rate and causes vasodilation [3].  

They are further divided into two major categories, non-dihydropyridines and dihydropyridines, where there are differences in the mechanism of action. Non-dihydropyridines inhibit calcium from entering the heart’s sinoatrial and atrioventricular nodes and thus cause a cardiac conduction delay and reduce cardiac contractility.  

Alternatively, dihydropyridines do not directly affect the heart but do act as a peripheral vasodilator leading to lowered blood pressure. Both categories are metabolized by the CYP3A4 pathway [15]. 

Names of non-dihydropyridine CCBs are verapamil and diltiazem. Dihydropyridine CCBs typically end in the suffix  -pine and common names are amlodipine and nicardipine. Both categories are available via oral and IV routes for administration. Oral dosages of non-dihydropyridine CCBs start at 30mg daily and dihydropyridine CCBs start at 30mg daily for immediate release [15].  

Calcium channel blockers can be used to treat other medical conditions in addition to hypertension and include: 

  • Coronary spasm 
  • Angina pectoris 
  • Supraventricular dysrhythmias 
  • Pulmonary hypertension 
  • Hypertrophic cardiomyopathy 

Non-dihydropyridine CCBs can cause side effects like bradycardia, and constipation, while dihydropyridine CCBs can cause: 

  • Headaches 
  • Feeling lightheaded 
  • Leg swelling [15]. 

Both categories pose the risk of potential hypotension and bradycardia, so healthcare providers should closely monitor the patient’s blood pressure and heart rate when initiating or titrating the dosage.  

Also, an overdose of this medication can lead to cardiac conduction delays, complete heart block, and cardiovascular collapse. Patients with possible symptoms of overdose should be sent to the emergency room immediately.  

Additionally, healthcare providers should avoid prescribing CCBs to people with heart failure and sick sinus syndrome [15]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of calcium channel blockers? 
  2. What are the common side effects and contraindications of calcium channel blockers? 

Selective Alpha-1 Blockers 

Selective alpha-1 blockers act on the body’s sympathetic nervous system to lower blood pressure. They prevent norepinephrine from binding to the alpha-1 receptors of the sympathetic nervous system, causing smooth muscle relaxation and vasodilation which leads to lowered blood pressure [18]. 

Selective alpha-1 blockers are available via the oral route, end in the suffix -osin and examples are doxazosin, terazosin, and prazosin [3]. They are FDA-approved for the treatment of hypertension but are not considered first-line therapy. Additionally, this class of medications may be used to treat benign prostatic hyperplasia. Dosages can start as low as 1mg daily depending on the drug selected. 

Common side effects include: 

  • Hypotension 
  • Tachycardia 
  • Dizziness 
  • Headache 
  • Weakness [18]. 

 

As selective alpha-1 blockers can lead to orthostatic hypotension, the healthcare provider should instruct the patient to take this medication at night. They should also avoid prescribing to the elderly population when able because of hypotension and increased fall risk [18]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of alpha-1 blockers? 
  2. What are the common side effects and contraindications of alpha-1 blockers? 

Alpha-2 Receptor Agonists 

Alpha-2 receptor agonists work by decreasing the activity of the sympathetic nervous system to lower blood pressure. It inhibits adenylyl cyclase and decreases the formation of cyclic adenosine monophosphate (cAMP). Alpha-2 agonists also cause vasodilation by reducing the amount of available cytoplasmic calcium [20].  

This class of medications is typically administered via oral route but is also available in intravenous and transdermal forms. Two FDA-approved alpha-2 agonists for hypertension treatment are methyldopa and clonidine and dosages are dependent on the name and route.  

Methyldopa is commonly prescribed to patients with hypertension and who are pregnant since it’s safe [20]. 

 

Common side effects of alpha-2 receptor agonists are: 

  • Dry mouth 
  • Drowsiness 
  • Fatigue 
  • Headache 
  • Sexual dysfunction [3]. 

Contraindications for use are orthostatic hypotension and autonomic disorders. Healthcare providers must avoid prescribing alpha-2 receptor agonists to individuals taking phosphodiesterase inhibitors [20]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of alpha-2 receptor agonists? 
  2. What are common side effects and contraindications of alpha-2 receptor agonists? 

Vasodilators 

Vasodilators lower blood pressure by dilating the body’s blood vessels. It binds to the receptors of the blood vessel’s endothelial cells, releasing calcium. Calcium stimulates nitric oxide synthase (NO synthase), eventually converting to L-arginine to nitric oxide. As nitric oxide is available, this allows for GTP to convert to cGMP, and causes dephosphorylation of the myosin and actin filaments. As this occurs, the blood vessels’ smooth muscles relax, leading to vasodilation and lowered blood pressure.  

Common vasodilators that act via this pathway are nitrates and minoxidil. Hydralazine is another vasodilator, but the mechanism of action is unknown [10]. 

Available forms of vasodilators are sublingual, oral, and intravenous. Similar to other classes of antihypertensives, vasodilator dosages depend on the form and treatment setting [10].  

Nitrovasodilators like nitroprusside and nitroglycerin are used during hypertensive emergencies. Hydralazine is used for severe hypertension for the prevention of eclampsia or intracranial hemorrhage and minoxidil for resistant hypertension [10] [3]. 

 

Side effects for each will vary, but nitrates commonly cause: 

  • Reflex tachycardia 
  • Headache 
  • Orthostatic hypotension  

[10] 

 

Common side effects of hydralazine are headaches, heart palpitations, and myalgias. Minoxidil causes excessive hair growth, weight gain, and fluid retention [3]. Additionally, nitroprusside can potentially cause cyanide toxicity.  

Vasodilators have varying degrees of contraindications, such as nitrates are avoided in patients with an inferior myocardial infarction. Hydralazine should not be given to patients with coronary artery disease, angina, or rheumatic heart disease. Healthcare providers should be aware of contraindications and monitor patients’ blood pressure and potential side effects [10]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What is the pharmacokinetics of vasodilators? 
  2. What are the common side effects and contraindications of vasodilators? 

Combination Antihypertensives 

Many antihypertensive medications come in combined forms, such as ACE inhibitors and thiazide diuretics, beta-blockers and diuretics, or calcium channel blockers and ACE inhibitors. The mechanism of action for combination antihypertensives depends on the blend of medications [3]. 

Considerations for Prescribers 

This section reviews potential considerations when prescribing antihypertensives. 

When prescribing antihypertensive medications, there are several factors that healthcare providers must consider. The route is typically determined by the healthcare setting and dosage by the underlying treatment goals. Again, healthcare providers should follow current guidelines when initiating or titrating antihypertensive medications.  

Healthcare providers must complete a thorough health history, and review lab values, and contraindications as mentioned above. Monitoring kidney function and electrolyte values is imperative while any patient is taking antihypertensive medications.  

While a single antihypertensive medication is recommended for initial treatment, there are some scenarios where combination therapy or combination antihypertensives are recommended [14]. 

Healthcare providers should also discuss the potential side effects of antihypertensives with patients and what to do if they are experiencing symptoms. For instance, if a patient reports syncope, they should be advised to go to the emergency room or be seen immediately for further evaluation. Also, healthcare providers must encourage patients to monitor their heart rate and blood pressure at home and abide by administration parameters.  

For example, instruct patients who are taking beta-blockers to measure their blood pressure and heart rate before taking their medication. If their heart rate is below 60 beats per minute, then they should not take the medication [14].  

If a patient is experiencing side effects from an antihypertensive medication, then another alternative should be selected. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What factors should healthcare providers consider when prescribing antihypertensives? 

Upcoming Research 

This section reviews upcoming research and medications for hypertension treatment. 

Research on antihypertensive medications has slowed throughout the years. Some clinical trials were performed on the potential of endothelin receptor antagonists to reduce hypertension. However, some studies found several unwanted side effects, and thus clinical use was stopped for safety reasons.  

An endothelin-A and endothelin-B receptor blocker, called aprocinentan, has shown promise for the treatment of resistant hypertension by lowering blood pressure and decreasing vascular resistance.  

Research on sodium-glucose transport protein (SGLT2) inhibitors, which are typically used for the treatment of type II diabetes mellitus, is also ongoing. SGLT2 inhibitors may promote blood pressure reduction through diuresis and reduce sympathetic tone [21]. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What new research is there about antihypertensives? 

Conclusion

If hypertension is left untreated, it can lead to serious health complications, including death. When selecting antihypertensive treatment, healthcare providers should understand the pharmacokinetics of each drug class along with potential side effects and contraindications. They should also follow current clinical guidelines for an evidence-based approach. 

 

Final Reflection Questions 

  • Which antihypertensive medication is often prescribed during pregnancy? 
  • Which lab values are important when monitoring patients on each antihypertensive medication? 
  • Which antihypertensive medications cause hypokalemia? 
  • Which antihypertensive medications cause hyperkalemia? 

Migraine Management

Quiz Questions

Self Quiz

Ask yourself...

  1. How might a comprehensive knowledge of migraine medications, including their mechanisms of action, enhance the ability of healthcare professionals to address the specific needs of patients experiencing migraines? 
  2. In what ways can recognizing warnings related to migraine medications contribute to ensuring patient safety? 

Definition 

Migraines are recurrent, pulsating headaches often accompanied by other symptoms such as nausea, sensitivity to light, and sensitivity to sound. According to recent studies by (17), migraines are recognized as a complex neurological disorder involving abnormal brain activity and a cascade of events leading to pain and associated symptoms.  

The impact of migraines extends beyond physical pain, influencing various aspects of life, and recent literature by (14) highlights the profound effect on the quality of life, with disruptions in daily activities, work, and social interactions. For example, a professional experiencing frequent migraines might struggle to meet work deadlines and engage in social events. Recent advancements in diagnostic criteria by (15) emphasize the importance of a precise definition to ensure appropriate treatment strategies. Therefore, understanding the definition is crucial for accurate diagnosis and effective communication between healthcare providers and patients. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What distinguishes migraines from common headaches, and how does understanding this difference impact the approach to their management? 
  2. In what ways do migraines extend beyond physical pain, and how might this impact influence an individual's overall quality of life? 
  3. How can a precise definition of migraines contribute to accurate diagnosis, and why is accurate diagnosis essential for effective treatment planning? 
  4. How does understanding the definition of migraines facilitate effective communication between healthcare professionals and patients? 

Migraine Medications 

Understanding the various classes of migraine medications is like having a diverse toolkit to address the complexities of this neurological disorder. By exploring the different classes of medications, healthcare professionals can tailor their approach and make informed decisions based on individual patient profiles and specific migraine characteristics (20).  

It is crucial to recognize that migraine medications are not one-size-fits-all. Each patient is unique, and their response to medications may vary. Recent literature by (12) emphasizes the importance of an individualized approach when considering the best medication for each patient. Here’s a list of migraine medications in addition to important details to consider:  

Triptans  

Triptans are a class of medications specifically designed for the acute treatment of migraines. According to (39), they are not meant for preventive use but are highly effective in providing relief during an ongoing migraine attack. They work by narrowing blood vessels and inhibiting the release of certain chemicals in the brain associated with migraine symptoms (39). Let’s see more details below as described by (7), (39), (29). 

Drug Class 

Belonging to the serotonin (5-HT) receptor agonists class, Triptans modulate the effects of serotonin receptors in the brain. The various types of Triptans include Sumatriptan, Rizatriptan, Eletriptan, and others. Each Triptan has unique characteristics, such as the onset of action and duration, allowing healthcare professionals to tailor prescriptions based on individual patient needs. 

Benefits 

Triptans offer several benefits in the management of migraines. One of the primary advantages is their ability to provide rapid and effective relief from migraine symptoms, including headache pain, nausea, and sensitivity to light and sound. The prompt onset of action is particularly valuable for individuals aiming to resume their daily activities quickly. Triptans are available in various formulations, including oral tablets, nasal sprays, and injectables, allowing for flexibility in administration. 

Side Effects 

While generally well-tolerated, Triptans may cause side effects. Common side effects include mild sensations of warmth or tingling, dizziness, and tightness or pressure in the chest. It is crucial for healthcare professionals to consider the patient's medical history and potential contraindications, such as cardiovascular issues, before prescribing Triptans. In rare cases, more severe side effects like chest pain and changes in heart rate may occur, necessitating immediate medical attention. 

Clinical Effects 

The clinical effects of Triptans are profound, offering relief to individuals experiencing acute migraine attacks. The primary outcomes include: 

  • Pain Relief: Triptans are highly effective in reducing the intensity of migraine-associated pain. By targeting the vascular and neuronal components of migraines, these drugs provide rapid relief, allowing patients to resume their normal activities. 
  • Relief of Associated Symptoms: Beyond pain relief, Triptans address accompanying symptoms such as nausea, photophobia, and phonophobia. This comprehensive effect enhances the overall patient experience during a migraine episode. 
  • Prevention of Migraine Progression: Triptans, when administered early in the migraine attack, can prevent the progression of the headache phase to more severe stages. This early intervention is crucial for optimizing outcomes and minimizing the impact of migraines on daily life. 
  • Improvement in Functional Impairment: Migraines often result in functional impairment, limiting individuals' ability to perform daily tasks. Triptans restore functional capacity, allowing patients to regain control over their activities. 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDSs)  

Nonsteroidal anti-inflammatory drugs, commonly known as NSAIDs, constitute a class of medications used in the treatment of migraines. According to (6), these drugs are characterized by their anti-inflammatory, analgesic, and antipyretic properties. NSAIDs are versatile, as they are not exclusively used for migraines but are also used for various other pain and inflammatory conditions (6). Let’s see more details below as described by (25), (40), (6) and (28). 

Drug Class 

NSAIDs encompass a broad class of medications, including well-known examples such as ibuprofen, naproxen, and aspirin. They function by inhibiting enzymes called cyclooxygenases (COX), thereby reducing the production of inflammatory prostaglandins. This mechanism provides relief from pain and mitigates inflammation associated with migraines. 

Benefits 

The primary benefit of NSAIDs in migraine management lies in their ability to alleviate pain and reduce inflammation. They are particularly effective for individuals experiencing mild to moderate migraines. NSAIDs offer a rapid onset of action, making them suitable for individuals seeking prompt relief. Additionally, these medications are available over-the-counter in many formulations, providing accessibility for patients. 

Side Effects 

While NSAIDs are generally well-tolerated, they may cause side effects, especially with prolonged or excessive use. Common side effects include gastrointestinal issues such as stomach upset or ulcers. Healthcare professionals need to consider a patient's medical history, including conditions like gastric ulcers, before prescribing NSAIDs. In rare cases, more severe side effects like cardiovascular events may occur, emphasizing the importance of cautious use. 

Clinical Effects 

The clinical effects of NSAIDs in migraine management encompass various aspects. Here’s a list of some of them. 

  • Pain Relief: NSAIDs are effective in providing pain relief during acute migraine attacks. By reducing prostaglandin levels, they alleviate headache symptoms and contribute to the overall comfort of individuals experiencing migraines. 
  • Inhibition of Inflammatory Responses: The anti-inflammatory properties of NSAIDs are particularly beneficial when migraines are associated with inflammatory processes. NSAIDs help mitigate inflammation, reducing the severity and duration of migraine attacks. 
  • Improvement in Associated Symptoms: Beyond pain relief, NSAIDs address associated symptoms such as nausea and photophobia, enhancing the overall patient experience during a migraine episode. 
  • Prevention of Migraine Progression: When administered early in the migraine attack, NSAIDs can prevent the progression of headaches to more severe stages. This early intervention is critical for optimizing outcomes and minimizing the impact of migraines on daily life. 
Calcitonin Gene-Related Peptide (CGRP) Inhibitors 

Calcitonin gene-related peptide (CGRP) inhibitors represent a modern class of medications revolutionizing the landscape of migraine management. According to (11), these drugs specifically target CGRP, a neuropeptide involved in dilating blood vessels and transmitting pain signals. By inhibiting CGRP, these inhibitors aim to modulate migraine pathways and reduce the frequency and severity of attacks (11). Let’s see more details below as described by (23) and (11). 

Drug Class 

CGRP inhibitors belong to a unique drug class designed explicitly for migraine prevention. Examples of CGRP inhibitors include Erenumab, Fremanezumab, and Galcanezumab. These medications are administered via subcutaneous injections, typically monthly or quarterly. The focus on preventive therapy distinguishes CGRP inhibitors from acute treatment options like Triptans. 

Benefits 

The primary benefit of CGRP inhibitors lies in their efficacy in preventing migraines. Clinical trials have demonstrated a significant reduction in the frequency of monthly migraine attacks among individuals using CGRP inhibitors. This preventive approach is especially valuable for those with frequent and debilitating migraines, offering a chance to enhance their quality of life. 

Moreover, CGRP inhibitors are well-tolerated with fewer side effects than other preventive medications. They provide a targeted and specific intervention, addressing the underlying mechanisms of migraines without causing widespread effects on other bodily functions. 

Side Effects 

While generally well-tolerated, CGRP inhibitors may have some side effects. Local injection site reactions, such as redness or swelling, are common but typically mild. It is crucial for healthcare professionals to monitor and address any adverse effects promptly. Additionally, ongoing research is essential to further understand the long-term safety profile of these medications. 

Clinical Effects 

The clinical effects of CGRP inhibitors are transformative in the realm of migraine management, offering a novel approach to prevention. Primary clinical effects include the following: 

  • Reduction in Migraine Frequency: One of the hallmark effects of CGRP inhibitors is a significant reduction in the frequency of migraine attacks. By consistently blocking CGRP receptors, these medications disrupt the migraine cascade, leading to a sustained preventive effect. 
  • Improvement in Migraine Severity: CGRP inhibitors not only reduce the frequency but also contribute to a decrease in the severity of migraine attacks. This comprehensive effect enhances the overall quality of life for individuals suffering from chronic migraines. 
  • Enhanced Functional Capacity: Migraines often result in functional impairment, limiting individuals' ability to perform daily tasks. CGRP inhibitors restore functional capacity, allowing patients to regain control over their activities and participate more fully in their daily lives. 
  • Well-Tolerated Profile: CGRP inhibitors are generally well-tolerated, with a favorable side effect profile. This characteristic enhances patient adherence to preventive treatment, a critical factor in long-term migraine management. 
Beta-Blockers 

Beta-blockers are a class of medications that have found a significant place in migraine management. Initially developed for cardiovascular conditions, beta-blockers have demonstrated efficacy in preventing migraines by reducing the frequency and severity of attacks (32). According to (32), these medications work by blocking the effects of adrenaline, leading to reduced heart rate and blood pressure. Let’s see more details below as described by (32) and (27). 

Drug Class 

Beta-blockers encompass various medications, with examples such as propranolol, metoprolol, and timolol commonly prescribed for migraine prevention. These drugs fall into the broader category of antihypertensive medications but are repurposed for their preventive benefits in migraine care. Unlike acute treatments, which provide relief during an ongoing attack, beta-blockers are taken regularly to reduce the overall occurrence of migraines. 

Benefits 

The primary benefit of beta-blockers in migraine management is their preventive action. Clinical studies have shown that beta-blockers can significantly reduce the frequency of migraines, making them particularly suitable for individuals with chronic or frequent attacks. This preventive approach aims to enhance the overall quality of life for those who experience migraines regularly. 

Beta-blockers are especially beneficial for individuals with comorbid conditions such as hypertension or heart disease. By addressing both cardiovascular concerns and migraines, these medications offer a comprehensive therapeutic approach. 

Side Effects 

While generally well-tolerated, beta-blockers may cause side effects that individuals need to be aware of. Common side effects include fatigue, dizziness, and changes in sleep patterns. Healthcare professionals need to monitor patients regularly and adjust the dosage or consider alternative medications if side effects become problematic. Beta-blockers are typically avoided in individuals with certain heart conditions, emphasizing the importance of an individualized approach. 

Clinical Effects 

The clinical effects of beta-blockers in migraine management encompass various dimensions. See some examples below: 

  • Reduction in Migraine Frequency: Beta-blockers are known for their ability to reduce the frequency of migraine attacks significantly. This preventive effect is especially valuable for individuals experiencing chronic migraines, enhancing their overall quality of life. 
  • Alleviation of Migraine Severity: Beyond frequency reduction, beta-blockers contribute to a decrease in the severity of migraine attacks. This comprehensive effect enhances the overall comfort of individuals during migraine episodes. 
  • Improvement in Associated Symptoms: Beta-blockers have been shown to address associated symptoms such as nausea and sensitivity to light. By modulating the autonomic nervous system, these medications offer a holistic approach to migraine management. 
  • Cardiovascular Benefits: Beta-blockers provide additional benefits for individuals with comorbidities due to their primary use in cardiovascular conditions. This dual action allows for comprehensive management of both migraine and cardiovascular health. 
Anticonvulsants 

Anticonvulsants, originally developed to control seizures in epilepsy, have emerged as a valuable class of medications in the preventive management of migraines (9). According to (9), these drugs, also known as antiepileptic drugs (AEDs), work by stabilizing electrical activity in the brain and reducing the frequency and severity of migraine attacks. Let’s see more details below as described by (32) and (9). 

Drug Class 

Anticonvulsants comprise a diverse class of medications, including Topiramate, Valproic acid, and Gabapentin. While their primary use may be in epilepsy, the preventive benefits of certain anticonvulsants extend to migraines. These medications are taken regularly to provide ongoing protection against migraines. 

Benefits 

The primary benefit of anticonvulsants in migraine management is their preventive action. Clinical trials have demonstrated the efficacy of certain anticonvulsants, such as topiramate, in significantly reducing the frequency of migraines. This preventative approach is particularly suitable for individuals with chronic or frequent attacks, aiming to improve overall quality of life. 

Anticonvulsants are especially valuable for individuals who may not find relief or experience intolerable side effects with other preventive medications. The versatility of this drug class allows healthcare professionals to tailor treatment plans based on individual patient characteristics and responses. 

Side Effects 

While generally well-tolerated, anticonvulsants may cause side effects that individuals need to be aware of. Common side effects include drowsiness, dizziness, and gastrointestinal disturbances. It is crucial for healthcare professionals to monitor patients regularly and adjust the dosage or consider alternative medications if side effects become problematic. Additionally, certain anticonvulsants may have specific considerations, such as the need to regularly monitor liver function in individuals taking Valproic acid. 

Clinical Effects 

The clinical effects of anticonvulsants in migraine management encompass the following dimensions: 

  • Reduction in Migraine Frequency: Anticonvulsants are known for their ability to significantly reduce the frequency of migraine attacks. This preventive effect is particularly valuable for individuals experiencing chronic migraines, substantially improving their overall quality of life. 
  • Alleviation of Migraine Severity: Beyond frequency reduction, anticonvulsants contribute to a decrease in the severity of migraine attacks. This comprehensive effect enhances the overall comfort of individuals during migraine episodes. 
  • Improvement in Associated Symptoms: By modulating neurotransmission and neuronal excitability, Anticonvulsants address associated symptoms such as nausea and sensitivity to light. This holistic approach contributes to a more comprehensive management of migraines. 
  • Beneficial in Comorbid Conditions: Anticonvulsants, due to their broader neurological effects, can be helpful for individuals with comorbid conditions such as epilepsy or mood disorders. This dual benefit allows for comprehensive management and improves overall well-being. 
Quiz Questions

Self Quiz

Ask yourself...

  1. How do Triptans contribute to migraine management, and in what scenarios might healthcare professionals prioritize their use during acute migraine attacks? 
  2. Can you differentiate the mechanisms of action between NSAIDs and Triptans in migraine management, and how might this understanding influence the choice of medication for a specific patient? 
  3. What roles do CGRP inhibitors play in migraine pharmacotherapy? 
  4. Consider a scenario where a patient experiences migraines with comorbid cardiovascular issues. How might the choice of medication be influenced by the need to prioritize both migraine relief and cardiovascular safety? 

Clinical Criteria for Prescribing 

In migraine management, prescribing medications involves a comprehensive understanding of clinical criteria to tailor interventions effectively. This section explores the clinical factors guiding the prescription of migraine medications and the decision-making process for healthcare providers. Here are some of the factors. 

Frequency and Severity of Migraine Attacks 

An essential consideration in prescribing migraine medications is the frequency and severity of migraine attacks experienced by the patient. For instance, a patient suffering from frequent and severe attacks may benefit from preventive medications to reduce the overall frequency and intensity of migraines (31).  

Individual Response to Pain and Associated Symptoms 

The subjective experience of pain and associated symptoms during migraines varies among individuals. A patient who experiences intense nausea and vomiting may require medications with rapid onset and alternative formulations, such as nasal sprays or injectables, to address these specific symptoms effectively (8).  

Impact on Daily Functioning and Quality of Life 

Prescribing migraine medications involves considering the impact of migraines on a patient's daily functioning and overall quality of life (24). For example, a working professional with migraines that significantly impede productivity may require acute medications with fast-acting formulations for quick relief during work hours.  

Comorbid Conditions and Patient Preferences 

Comorbid conditions and patient preferences are pivotal factors in prescribing migraine medications. A patient with comorbid cardiovascular issues may require careful consideration of medication options to mitigate potential risks (2).  

Quiz Questions

Self Quiz

Ask yourself...

  1. How does a patient's medical history, especially factors like cardiovascular health, influence the clinical criteria for prescribing migraine medications? 
  2. Why is it essential for healthcare professionals to assess the frequency and severity of migraine attacks when determining the clinical criteria for prescribing medications? 
  3. How do patient preferences contribute to the clinical criteria for prescribing migraine medications? 

Pharmacokinetics 

Understanding the pharmacokinetics of migraine management medications enables healthcare professionals to tailor treatment plans based on individual patient characteristics, ensuring maximum therapeutic benefit. Let’s get into more details for each of the medications listed above: 

Triptans 

Absorption 

Triptans exhibit distinct pharmacokinetic properties that influence their efficacy and onset of action. Following oral administration, Triptans are absorbed through the gastrointestinal tract and the rate of absorption varies among different Triptans, contributing to differences in their clinical profiles. (39) 

Distribution 

Upon absorption, Triptans undergo distribution to reach target sites in the body, primarily the central nervous system. Their lipophilic nature allows them to penetrate the blood-brain barrier, enabling interaction with serotonin receptors implicated in migraine pathophysiology. The distribution of Triptans influences their ability to exert effects centrally and peripherally. (39) 

Metabolism 

Metabolism is a crucial aspect of triptan pharmacokinetics, occurring predominantly in the liver. The enzyme responsible for triptan metabolism is monoamine oxidase-A (MAO-A). (39) 

Excretion 

The final phase in the pharmacokinetic journey of Triptans is excretion, primarily through renal and biliary routes. Renal excretion eliminates the unchanged drug and its metabolites, while biliary excretion expels metabolites via the bile into the gastrointestinal tract. The interplay between metabolism and excretion contributes to the overall pharmacokinetic profile of Triptans. Variations in renal function may influence the elimination of the half-life of certain Triptans, impacting the duration of their therapeutic effect. (39) 

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 

Absorption 

Following oral administration, NSAIDs are absorbed in the gastrointestinal tract, with the rate and extent varying among different agents. For instance, ibuprofen exhibits rapid absorption, making it suitable for prompt relief during acute migraine attacks. On the other hand, naproxen has a longer duration of action due to slower absorption, making it well-suited for sustained pain relief. (28) 

Distribution 

Upon absorption, NSAIDs embark on a journey of distribution throughout the body. Their lipophilic nature allows for penetration into various tissues, including inflamed areas. The distribution influences the drug's ability to reach target sites, such as the central nervous system, where NSAIDs exert their analgesic and anti-inflammatory effects. This property is particularly relevant in the context of migraines, where the inflammatory component contributes to pain. (28) 

Metabolism 

Metabolism plays a role in shaping the pharmacokinetic profile of NSAIDs, occurring primarily in the liver. Enzymes such as cytochrome P450 contribute to the biotransformation of NSAIDs into metabolites. The metabolism of NSAIDs can vary among individuals, impacting factors such as drug efficacy and potential side effects. For example, the metabolism of certain NSAIDs, like diclofenac, can be influenced by genetic polymorphisms, contributing to interindividual variability in drug response. (21) 

Excretion 

The final phase of the NSAID journey involves excretion, predominantly through the kidneys. Unchanged NSAIDs and their metabolites are eliminated via urine. Considerations of renal function are crucial in the context of NSAID use, as impaired kidney function can lead to prolonged drug half-life and increased risk of adverse effects. Regular monitoring of renal function is essential, especially in individuals with conditions that may affect kidney health. (21) 

Calcitonin Gene-Related Peptide (CGRP) 

Absorption 

Administered via subcutaneous injections, CGRP inhibitors such as Erenumab and Fremanezumab enter the bloodstream directly, allowing for precise control over drug levels. This mode of administration ensures a reliable and consistent absorption rate, contributing to the predictability of therapeutic outcomes. (11) 

Distribution 

Following absorption, CGRP inhibitors are distributed throughout the body, focusing on target sites implicated in migraine pathophysiology, like the central nervous system. (11) 

Metabolism 

Unlike many traditional medications, CGRP inhibitors follow a different path in terms of metabolism. Due to their biotechnological origin as monoclonal antibodies, these drugs do not undergo significant hepatic metabolism. Instead, proteolytic enzymes break them down into smaller peptides and amino acids, which occur systemically. This unique metabolic pathway aligns with the specificity of CGRP inhibitors, minimizing interactions with hepatic enzymes and potential drug-drug interactions. (37) 

Excretion 

The final phase of the CGRP inhibitor journey involves excretion, primarily through the kidneys via renal clearance. This aspect is particularly relevant when considering individual patient factors such as renal function, as impaired kidney function can affect the clearance of CGRP inhibitors and influence their duration of action. (37) 

Beta-Blockers 

Absorption 

Administered orally, beta-blockers like propranolol and metoprolol are absorbed through the gastrointestinal tract. Depending on the condition of the gastrointestinal tract, the rate and extent of absorption can vary, impacting the time it takes for these medications to reach therapeutic levels in the bloodstream. (27) 

Distribution 

Once absorbed, beta-blockers embark on distribution throughout the body. Their lipophilic nature enables penetration through cell membranes, allowing them to reach target tissues, including the heart and blood vessels. In the context of migraine management, the distribution properties of beta-blockers are crucial for their ability to modulate the autonomic nervous system centrally and peripherally, leading to the desired preventive effects against migraines. (27) 

Metabolism 

The metabolism of beta-blockers occurs primarily in the liver, where enzymes play a role in their biotransformation. Genetic polymorphisms in these enzymes can contribute to interindividual variability in drug metabolism. (27) 

Excretion 

The final phase of the beta-blocker journey involves excretion, predominantly through the kidneys, where unchanged beta-blockers and their metabolites are eliminated via urine. The renal excretion of these drugs is relevant when considering individual patient factors, such as renal function, as impaired kidney function can affect the clearance of beta-blockers and influence their duration of action. (27) 

Anticonvulsants 

Absorption  

Typically administered orally, anticonvulsants like topiramate and valproic acid are absorbed through the gastrointestinal tract. The rate and extent of absorption play a crucial role in determining the onset of action and overall effectiveness. (9) 

Distribution  

Following absorption, anticonvulsants undergo distribution throughout the body. Their lipophilic nature allows them to penetrate the blood-brain barrier, reaching target sites in the central nervous system relevant to migraine pathophysiology. The distribution properties of anticonvulsants contribute to their ability to modulate neuronal excitability centrally and exert preventive effects against migraines. (9) 

Metabolism 

Metabolism is a crucial aspect of anticonvulsant pharmacokinetics. This occurs predominantly in the liver and enzymes play an important role in the biotransformation of anticonvulsants into metabolites. The metabolism of anticonvulsants can vary among individuals, impacting factors such as drug efficacy and potential side effects. For example, valproic acid undergoes extensive hepatic metabolism, and variations in enzyme activity can lead to interindividual variability in drug response. (30) 

Excretion  

The final phase in the anticonvulsant journey involves excretion, primarily through the kidneys. Unchanged anticonvulsants and their metabolites are eliminated via urine. This renal excretion is relevant when considering individual patient factors such as renal function, as impaired kidney function can affect the clearance of anticonvulsants and influence their duration of action. (30) 

Quiz Questions

Self Quiz

Ask yourself...

  1. How do the pharmacokinetics of Triptans, specifically their absorption and distribution, contribute to their efficacy in managing acute migraine attacks? 
  2. Can you explain the key pharmacokinetic parameters of nonsteroidal anti-inflammatory drugs (NSAIDs) used in migraine management and how they influence drug effectiveness? 
  3. What role do pharmacokinetic factors play in the onset and duration of action of calcitonin gene-related peptide (CGRP) inhibitors? 
  4. In the context of migraine medications, how does the pharmacokinetics of beta-blockers influence their absorption, distribution, metabolism, and excretion in the body? 

Warnings Related to Migraine Medications 

Understanding potential warnings related to migraine medications is essential for healthcare professionals to ensure safe and effective treatment. Here are some factors to consider.  

Medication Safety 

Migraine medications, whether preventive or acute, come with specific warnings that need careful attention. For instance, some medications may have contraindications for individuals with certain medical conditions or those taking specific medications concurrently. According to (34), healthcare providers must be vigilant in assessing patient medical histories to identify potential contraindications. 

Addressing Cardiovascular Risks 

Certain migraine medications, such as Triptans, may pose cardiovascular risks, especially in individuals with pre-existing cardiovascular conditions (35). Therefore, it is crucial for healthcare providers to assess patients' cardiovascular health and consider alternative medications or dose adjustments for those at higher risk. For example, a patient with a history of myocardial infarction may be advised to avoid Triptans, and a different class of medication, like NSAIDs, may be recommended. 

Pregnancy and Lactation Considerations 

Warnings related to pregnancy and lactation are paramount. Some migraine medications may have potential risks during pregnancy, and healthcare providers must carefully weigh the benefits and risks when prescribing for pregnant or lactating individuals. For instance, valproic acid is associated with an increased risk of congenital disabilities, and alternative medications with a safer profile may be preferred for pregnant individuals seeking migraine relief (1). 

Managing Medication Overuse Headaches (MOH) 

A significant warning associated with migraine medications is the risk of medication overuse headaches (34). To prevent this problem, healthcare providers need to educate patients about the importance of adhering to prescribed dosages and avoiding excessive use of acute medications. Offering alternative strategies, such as lifestyle modifications and preventive medications, can be crucial in managing and preventing MOH. 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some common warnings associated with the use of Triptans in migraine management, and how should healthcare providers address these warnings? 
  2. Can you identify specific cardiovascular risks associated with certain migraine medications, and what should be considered when prescribing these medications to patients with pre-existing cardiovascular conditions? 
  3. What warnings are typically associated with the use of valproic acid in migraine management, particularly concerning specific patient populations such as pregnant individuals? 
  4. How do healthcare providers manage and educate patients about the risk of medication overuse headaches associated with certain migraine medications, and what preventive measures can be implemented to minimize this risk? 

Alternatives to Migraine Medications 

According to (5), integrating alternative methods provides additional tools for healthcare professionals and empowers individuals seeking a more comprehensive and personalized approach to migraine care. Here are some alternative approaches: 

Holistic Lifestyle Modifications 

Holistic management of migraines involves lifestyle modifications that can significantly impact the frequency and severity of attacks. For instance, incorporating regular physical activity, maintaining a consistent sleep schedule, and managing stress through practices like mindfulness and yoga have shown promise in reducing migraine occurrence (5). Educating patients about these lifestyle changes empowers them to actively participate in their migraine management. 

Biofeedback and Relaxation Techniques 

Biofeedback and relaxation techniques offer non-pharmacological interventions that enhance self-awareness and control over physiological responses (22). These approaches teach individuals to recognize and manage stress triggers, ultimately reducing the frequency of migraines. For example, biofeedback training that monitors muscle tension and provides real-time feedback can effectively prevent migraines (22). 

Acupuncture and Acupressure 

According to (22), traditional Chinese medicine practices like acupuncture and acupressure have gained recognition for their potential in migraine management. Acupuncture involves the insertion of thin needles into specific points on the body, while acupressure applies pressure to these points. Research suggests that these methods reduce the frequency and intensity of migraines, providing an alternative avenue for individuals seeking non-pharmacological options (22). 

Nutritional Approaches 

Dietary modifications and nutritional approaches also play a role in holistic migraine management. For example, identifying and avoiding potential trigger foods, such as those containing tyramine or artificial additives, can be beneficial (10). Additionally, ensuring adequate hydration and incorporating anti-inflammatory foods into the diet may contribute to overall well-being and migraine prevention (10).  

Quiz Questions

Self Quiz

Ask yourself...

  1. What benefits do biofeedback and relaxation techniques offer in reducing the frequency and intensity of migraines? 
  2. How can biofeedback and relaxation techniques be integrated into a comprehensive migraine management plan?  
  3. What role do dietary modifications and nutritional approaches play in the holistic management of migraines?  
  4. How can healthcare professionals guide patients in identifying trigger foods and making informed nutritional choices? 

Nursing Considerations 

Nurses play a pivotal role in the holistic care of individuals with migraines, contributing to both the preventive and acute aspects of management through various considerations. Here are some important considerations. 

Assessment and Patient Education 

A thorough assessment includes evaluating the frequency, duration, and severity of migraines and identifying triggers and associated symptoms (3). Additionally, nurses play a key role in patient education, ensuring individuals clearly understand their migraine condition, the prescribed medications, and potential side effects. For instance, educating a patient about the importance of early intervention with acute medications during a migraine attack empowers them to take timely action. 

Monitoring and Adverse Event Management 

Nurses actively monitor individuals undergoing migraine treatment, monitoring the response to medications and any potential adverse events. Regular monitoring includes assessing the effectiveness of preventive measures, tracking the frequency of migraine attacks, and identifying patterns that may require adjustments in the treatment plan (34). If adverse events or side effects occur, nurses are instrumental in managing them promptly, collaborating with healthcare providers to ensure the safety and well-being of individuals. 

Supportive Care and Holistic Approach 

Nursing considerations extend beyond medication management to supportive care and a holistic approach. Nurses provide emotional support, helping individuals cope with the impact of migraines on their daily lives. Moreover, they collaborate with other healthcare professionals to integrate holistic approaches such as lifestyle modifications, stress management, and alternative therapies into the overall care plan. According to (34), this collaborative and patient-centered approach enhances the effectiveness of migraine management. 

Documentation and Communication 

Accurate and thorough documentation of relevant patient information, medication administration details, and responses to treatment is a fundamental nursing responsibility in migraine management (34). In addition to that, clear and concise communication between nursing staff, healthcare providers, and other healthcare team members ensures continuity of care (34).  

Quiz Questions

Self Quiz

Ask yourself...

  1. How can a thorough patient assessment contribute to the safe and effective administration of migraine medications? 
  2. How do nursing responsibilities extend beyond medication administration to encompass patient education?  
  3. When monitoring individuals undergoing migraine treatment, what are the essential aspects that nurses should observe? 
  4. How does the collaborative communication between nursing staff, healthcare providers, and other team members contribute to the continuity of care in migraine management?  

Upcoming Research 

Staying ahead of the curve is essential for healthcare professionals to provide cutting-edge care and optimize outcomes for individuals with migraines. Upcoming research include the following: 

Advancements in Targeted Therapies 

Recent research has unveiled promising advancements in targeted therapies for migraine management. For example, research about monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway is proving to be effective in preventing migraines (12).  

Digital Health and Telemedicine in Migraine Care 

Integrating digital health technologies and telemedicine is a burgeoning trend in migraine management research. Smartphone applications for tracking migraine patterns, wearable devices for monitoring physiological parameters, and virtual consultations enable a more comprehensive and patient-centric approach (12). This shift toward digital solutions enhances data collection and facilitates remote monitoring and timely interventions, particularly in scenarios where in-person visits may be challenging (12). 

Genetic and Personalized Medicine Approaches 

Advancements in genetic research are paving the way for personalized medicine in migraine care. Understanding the genetic underpinnings of migraines can guide the development of targeted interventions tailored to an individual's unique genetic profile. This personalized approach could revolutionize treatment strategies, allowing for more precise and effective interventions based on the genetic factors contributing to a person's migraines (13). 

Exploration of Lifestyle and Environmental Influences 

Upcoming research increasingly focuses on the intricate interplay between lifestyle, environmental factors, and migraines; and studies examining the impact of factors such as diet, sleep patterns, and environmental triggers contribute valuable insights (13). For instance, research may reveal specific dietary components that act as triggers or protective factors for migraines, allowing healthcare professionals to offer targeted lifestyle recommendations. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What recent research findings have emerged regarding migraine prevention? 
  2. How are digital health technologies and telemedicine being incorporated into upcoming research on migraine management?  
  3. In personalized medicine, how is genetic research influencing upcoming approaches to migraine care?   
  4. How can consideration of lifestyle factors and environmental influences contribute to a more holistic approach of migraine management? 

Conclusion

In conclusion, this course focused on empowering learners not only with knowledge about migraine management, but with the practical insights and skills crucial for excellence in migraine care. The journey doesn’t end here; it extends into the realm of compassionate practice, where the combination of scientific understanding and safety measures transforms care providers into formidable advocates for those navigating the complexities of migraines. 

 

Asthma Treatment and Monitoring

Introduction   

When hearing the phrase asthma, what comes to mind? If you're an advanced practice registered nurse (APRN) with prescriptive authority, you've definitely heard of asthma before. Even as a nurse or maybe before nursing school, conversations about prescription drug use and respiratory health existed every so often.

Presently, patients seek guidance and information on various health topics from APRNs, including medication management and respiratory health. The information in this course will serve as a valuable resource for APRNs with prescriptive authority of all specialties, education levels, and backgrounds, to learn more about medications that can treat and manage asthma.

Defining Asthma 

What Is Asthma? 

Asthma is a non-communicable chronic health condition that affects the airways of the lungs and affects millions of people nationwide. Asthma is often diagnosed in childhood and can resolve in adulthood or continue for the rest of a patient's life. Several studies postulate the cause of asthma, but there is no definitive cause.  

Genetics, age, environmental exposures, smoking, and a history of allergies are thought to play a role in asthma severity and development. Clinical presentation of asthma often includes trouble breathing, chronic airway inflammation, and airway hyperresponsiveness. Assessment for asthma often includes patient history, clinical presentation, spirometry testing, and pulmonary function tests (PFTs). 

 

What Are the Stages of Asthma? 

Since asthma is a chronic condition, several established guidelines can be used to determine the severity of asthma and explore possible medication options. Depending on the stage of asthma and patient response to existing therapy, treatment and management vary.  

The four stages of asthma include intermittent, mild, moderate, and severe. Based on the 2020 National Asthma Education and Prevention Program (NAEPP) guidelines, here is the standard criteria for what constitutes each stage of asthma (2). 

 

Intermittent asthma is characterized with the following clinical presentation and assessment (2): 

  • Patient history of respiratory symptoms, such as cough, trouble breathing, wheezing, or chest tightness <2 times a week 
  • Asthmatic flare-ups are short-lived with varying intensity  
  • Symptoms at night are <2 a month 
  • No asthmatic symptoms between flare-ups 
  • Lung function test FEV 1 at >80% above normal values 
  • Peak flow has <20% variability am-to-am or am-to-pm, day-to-day 

 

Mild persistent asthma is characterized with the following clinical presentation and assessment (2): 

  • Patient history of respiratory symptoms, such as cough, trouble breathing, wheezing, or chest tightness 3-6 times a week 
  • Asthmatic flare-ups may affect activity level and can vary in intensity 
  • Symptoms at night are 3-4 times a month 
  • Lung function test FEV1 is >80% above normal values 
  • Peak flow has less than 20-30% variability 

 

Moderate persistent asthma is characterized with the following clinical presentation and assessment (2): 

  • Patient history of respiratory symptoms, such as cough, trouble breathing, wheezing, or chest tightness daily 
  • Asthmatic flare-ups may affect activity level and can vary in intensity 
  • Symptoms at night are >5 times a month 
  • Lung function test FEV1 is 60%-80% of normal values 
  • Peak flow has more than 30% variability 

 

Severe persistent asthma is characterized with the following clinical presentation and assessment (2): 

  • Patient history of respiratory symptoms, such as cough, trouble breathing, wheezing, or chest tightness continuously  
  • Asthmatic flare-ups affect activity level and often vary in intensity 
  • Asthmatic symptoms at night are constant 
  • Lung function test FEV1 is <60% of normal values 
  • Peak flow has more than 30% variability 

 

Based on patient history, clinical presentation, and these criteria, treatment can be administered to decrease the symptoms of the patient. If a patient presents with symptoms that are outside of your scope of work or understanding, you can always refer patients to a pulmonologist or asthma specialist.  

Often times, more severe cases of asthma and asthma emergencies require increased frequency and dosing of asthma-related medications. Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history, pulmonary function, and health history prior to prescribing asthma medications (1). 

 

What Are Asthmatic Emergencies? 

Asthmatic emergencies are if a patient has asthma symptoms that are beyond what they typically experience and are unable to function without immediate medical intervention. Asthma emergencies can occur as a result of a patient being unable to access their asthmatic medications, being exposed to a possible allergen, or being under increased stress on the body.  

Asthmatic emergencies often require collaborative medical intervention, increased dosages of medications discussed below, and patient education to prevent future asthmatic emergencies (1).  

 

What If Asthma Is Left Untreated? 

Depending on the clinical presentation and severity of asthma, asthma can cause several long-term complications if left untreated. If asthma is not properly managed, several complications, such as chronic obstructive pulmonary disease (COPD), decreased lung function, permanent changes to the lungs' airways, and death can occur (1, 2).  

 

 

Defining Asthma Medications 

 

What Are Commonly Used Medications to Manage Asthma? 

Commonly used medications to manage asthma include inhaled corticosteroids, oral corticosteroids, short-acting beta agonists (SABAs), long-acting beta agonists (LABAs), long-acting muscarinic antagonists (LABAs), adenosine receptor antagonists, leukotriene modifiers, mast cell stabilizers, and monoclonal antibodies. The dosage, frequency, amount of asthma management medications, and medication administration route can all vary depending on clinical presentation, patient health history, and more.  

 

How and Where are Asthma Medications Used? 

Asthma medications can be used routinely or as needed for management of asthma symptoms depending on the patient. Asthma medications can be used at home, in public, and in health care facilities. Depending on the specific asthma medication and dosage, these medications can be taken by mouth, by an external device, such as an inhaler, via subcutaneous injection, or via intravenous solution (1).  

 

What Are the Clinical Criteria for Prescribing Asthma Medication? 

Clinical criteria for prescribing asthma medication can depend on the clinical presentation of a patient. Assessment of lung health and patient history are essential to determining the dosage and medications needed for adequate asthmatic symptom control.  

Clinical guidelines from reputable organizations, such as the National Asthma Education and Prevention Program (NAEPP), the National Institutes of Health (NIH), the Global Initiative for Asthma (GINA), and the American Academy of Family Physicians (AAFP) can provide insight into the latest recommendations for asthma management (1, 2). In addition, local laws or health departments might have recommendations for asthma medication guidelines.  

 

What Is the Average Cost for Asthma Medications? 

Cost for asthma medications can significantly vary depending on the type of medication, insurance, dosage, frequency, medication administration route, and other factors. Cost is among a leading reason why many patients cannot maintain their medication regime (3). If cost is a concern for your patient, consider reaching out to your local pharmacies or patient care teams to find cost effective solutions for your patients.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some common signs of asthma? 
  2. What are some common medications that can be prescribed to manage asthma? 
  3. What are some factors that can influence asthma development and severity? 

Inhaled Corticosteroids Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Inhaled Corticosteroids  

Commercially available inhaled corticosteroids include: ciclesonide (Alvesco HFA), fluticasone propionate (Flovent Diskus, Flovent HFA, Armon Digihaler), budesonide (Pulmicort Flexhaler), beclomethasone dipropionate (QVAR RediHaler), fluticasone furoate (Arnuity Ellipta), and mometasone furoate (Asmanex HFA, Asmanex Twisthaler).  

Clinical criteria for prescribing an inhaled corticosteroid includes adherence to the latest clinical guidelines, patient medical history, patient clinical presentation, and drug availability (4).  

 

Inhaled Corticosteroids Method of Action 

Inhaled corticosteroids have an intricate mechanism of action involving several responses to the immune system. Inhaled corticosteroids decrease the existing initial inflammatory response by decreasing the creation and slowing the release of inflammatory mediators. Common inflammatory mediators include histamine, cytokines, eicosanoids, and leukotrienes. Inhaled corticosteroids can also induce vasoconstrictive mechanisms, which, as a result, can lead to less blood flow, resulting in less discomfort and edema (4).  

In addition to anti-inflammatory properties, inhaled corticosteroids can create a localized immunosuppressive state that limits the airways' hypersensitivity reaction, which is thought to reduce bronchospasms and other asthma-associated symptoms. It is important to note that inhaled corticosteroids often do not produce therapeutic effects immediately, as many patients may not see a change in their asthma symptoms for at least a week after beginning inhaled corticosteroid therapy (4).  

 

Inhaled Corticosteroids Side Effects 

Every medication has the possibility of side effects, and inhaled corticosteroids are no exception. Common side effects of inhaled corticosteroids include oral candidiasis (thrush), throat irritation, headache, and cough.  

Patient education about rinsing their mouth and oral hygiene after use is essential to avoid the possibility of thrush and other oral infections and irritations. More severe side effects can include prolonged immunosuppression, reduction in bone density, and adrenal dysfunction (4).  

 

Inhaled Corticosteroids Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with inhaled corticosteroids, so additional medication, increased dosage, a change in frequency, or a new medication class might need to be considered (4).  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of inhaled corticosteroids?  
  2. What are some patient considerations to keep in mind when prescribing inhaled corticosteroids? 

Oral Corticosteroids Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Oral Corticosteroids  

Commercially available oral corticosteroids include methylprednisolone, prednisolone, and prednisone. Clinical criteria for prescribing an oral corticosteroid includes adherence to the latest clinical guidelines, patient medical history, patient clinical presentation, and drug availability (4).  

 

Oral Corticosteroids Method of Action 

Methylprednisolone and prednisolone have a method of action as intermediate, long-lasting, synthetic glucocorticoids, have COX-2 inhibitory properties, and inhibit the creation of inflammatory cytokines (5). 

Prednisone is a prodrug to prednisolone and has anti-inflammatory and immunomodulating glucocorticoid properties. Prednisone has a method of decreasing inflammation by reversing increased capillary permeability and suppressing the movement of certain leukocytes (6).  

 

Oral Corticosteroids Side Effects 

Every medication has the possibility of side effects, and oral corticosteroids are no exception. Methylprednisolone and prednisolone have possible side effects of skin changes, weight gain, increased intraocular pressure, neuropsychiatric events, neutrophilia, immunocompromised state, fluid retention, and GI upset.  

Consider monitoring symptoms and overall health of patients on systemic corticosteroids to assess for long-term side effects (5). Prednisone has possible side effects of changes in blood glucose, changes in sleep habits, changes in appetite, increased bone loss, an immunocompromised state, changes in adrenal function, and changes in blood pressure (6).  

 

Oral Corticosteroids Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with oral corticosteroids, so additional medication, increased dosage, a change in frequency, or a new medication class might need to be considered (6).  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of oral corticosteroids?  
  2. What are some patient considerations to keep in mind when prescribing oral corticosteroids versus inhaled corticosteroids? 

Short-Acting Beta Agonists (SABAs)  

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – SABAs 

Common commercially available SABAs include albuterol sulfate (ProAir HFA, Proventil HFA, Ventolin HFA), albuterol sulfate inhalation powder (ProAir RespiClick, ProAir Digihaler), levalbuterol tartrate (Xopenex HFA), and levalbuterol hydrochloride (Xopenex) (4). 

 

SABAs Method of Action 

Short-acting beta-agonists (SABAs) have a rapid onset as broncho-dilating medications. SABAs, especially albuterol in emergent situations, are used often to quickly relax bronchial smooth muscle from the trachea to the bronchioles through action on the β2-receptors.  

While SABAs are effective bronchodilators in the short term for asthma symptoms, SABAs do not affect the underlying mechanism of inflammation. As a result, SABAs are often used for short-acting intervals, such as few hours, and have limited capabilities to prevent asthma exacerbations alone (4). SABAs can be administered via meter-dosed inhalers, intravenous, dry powder inhalers, orally, subcutaneously, or via nebulizer.  

 

SABAs Side Effects 

Every medication has the possibility of side effects, and SABAs are no exception. Because of the beta receptor agonisms, possible SABA side effects include increased heart rate, chest pain, chest palpitations, body tremors, and nervousness (4). Because of the short half-life of SABAs, chronic side effects are not typically observed.  

 

SABAs Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with SABAs, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4).  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of short-acting beta agonists?  
  2. What are some patient considerations to keep in mind when prescribing SABAs? 

Long-Acting Beta Agonists (LABAs) 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – LABAs 

Common commercially available LABAs are salmeterol and formoterol (7).  

 

LABAs Method of Action 

Long-acting beta-agonists (LABAs) have a rapid onset like SABAs, but also have a longer half-life. LABAs are used often as asthma maintenance medications to relax bronchial smooth muscle from the trachea to the bronchioles through action on the β2-receptors. While SABAs are effective bronchodilators in the short term for asthma symptoms, LABAs are effective bronchodilators in the long term for asthma symptoms.  

Like SABAs, LABAs do not affect the underlying mechanism of inflammation. LABAs can be administered via meter-dosed inhalers, intravenous, dry powder inhalers, orally, subcutaneously, or via nebulizer. LABAs are often effective for 12-hour durations (7). 

 

LABAs Side Effects 

 

Every medication has the possibility of side effects, and LABAs are no exception. Like SABAs, because of the beta receptor agonisms, possible LABA side effects include increased heart rate, chest pain, chest palpitations, body tremors, and nervousness (7). Other more prolonged side effects can include changes in blood glucose levels and changes in potassium levels with prolonged LABA use (7).  

 

LABAs Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with LABAs, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4).  

In addition, there are combination inhaled corticosteroid/LABA medications that can be considered, such as fluticasone propionate and salmeterol (Advair Diskus, Advair HFA, AirDuo Digihaler, AirDuo RespiClick, Wixela Inhub), fluticasone furoate and vilanterol (Breo Ellipta), mometasone furoate and formoterol fumarate dihydrate (Dulera), and budesonide and formoterol fumarate dihydrate (Symbicort) (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of LABAs?  
  2. What are some patient considerations to keep in mind when prescribing SABAs compared to LABAs? 

Long-Acting Muscarinic Antagonists (LAMAs) 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – LAMAs 

Common commercially available LAMAs include two inhalation powders via inhalers known as tiotropium bromide (Spiriva Respimat) and fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta) (4).  

 

LAMAs Method of Action 

Both drugs mentioned above are long-acting muscarinic antagonists (LAMAs). LAMAs work to alleviate asthmatic symptoms by antagonizing the type 3 muscarinic receptors in bronchial smooth muscles, resulting in relaxation of muscles in the airway (4). Because LAMAs are long-acting, they are not recommended for cases of acute asthma exacerbations or asthmatic emergencies (4). 

 

LAMAs Side Effects 

Possible LAMA side effects include urinary retention, dry mouth, constipation, and glaucoma (4).  

 

LAMAs Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with LAMAs, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of LAMAs?  
  2. What are some patient considerations to keep in mind when prescribing LAMAs? 

Adenosine Receptor Antagonists Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Adenosine Receptor Antagonists 

The commercially available adenosine receptor antagonist for asthma management is theophylline as a pill or intravenous (8). 

  

Adenosine Receptor Antagonists Method of Action 

The method of action for theophylline is acting as a nonselective adenosine receptor antagonist, acting as a competitive, nonselective phosphodiesterase inhibitor, and reducing airway responsiveness to histamine, allergens, and methacholine (8).  

 

Adenosine Receptor Antagonists Side Effects  

Common side effects of theophylline include GI upset, headache, dizziness, irritability, and arrythmias (8).  

 

Adenosine Receptor Antagonists Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with theophylline, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of adenosine receptor antagonists?  
  2. What are some patient considerations to keep in mind when prescribing adenosine receptor antagonists? 

Leukotriene Modifiers Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Leukotriene Modifiers 

Commercially available leukotriene modifiers include montelukast (Singular) and zafirlukast (Accolate) as oral pills taken once a day. Zileuton (Zyflo CR) is a 5-lipoxygenase inhibitor that also modifies leukotriene activity (4).  

 

Leukotriene Modifiers Method of Action 

Montelukast and zafirlukast work to control asthma-related symptoms by targeting leukotrienes, which are eicosanoid inflammatory markers. Montelukast works in particular by blocking leukotriene D4 receptors in the lungs, thus allowing decreased inflammation in the lungs and increased relaxation of lung smooth muscle (9).  

Zafirlukast works by being a competitive antagonist at the cysteinyl leukotriene-1 receptor (CYSLTR1) (10). Zileuton is a 5-lipoxygenase inhibitor, in which 5-lipoxygenase is needed for leukotriene creation. Blocking 5-lipoxygenase decreases the formation of leukotrienes at several receptors. As a result of decreased leukotriene production, there is decreased inflammation, decreased mucus secretion, decreased bronchoconstriction (11). 

 

Leukotriene Modifiers Side Effects 

Possible side effects of montelukast include headaches, GI upset, and upset. Neuropsychiatric events, such as nightmares, changes in sleep, depression, and suicidal ideation are more severe side effects associated with montelukast.  

Possible side effects of zafirlukast include headache, GI upset, and hepatic dysfunction (9).  

Possible side effects of zileuton include hepatic dysfunction, changes in sleep, changes in mood, headaches, and GI upset. When the leukotriene modifiers, neuropsychiatric side effects are to be monitored for in particular, especially for suicidal ideation (9,10,11).  

 

Leukotriene Modifiers Alternatives 

Some patients might not report their symptoms alleviating with leukotriene modifiers, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of leukotriene modifiers?  
  2. What are some patient considerations to keep in mind when prescribing leukotriene modifiers? 

Mast Cell Stabilizer Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Mast Cell Stabilizer 

A commercially available mast cell stabilizer is cromolyn available via metered-dose inhaler and nebulizer solution (12).  

 

Mast Cell Stabilizer Method of Action 

Cromolyn has a method of action in which it inhibits the release of inflammatory mediators from cells, such as the release of histamine and leukotrienes (12).  

 

Mast Cell Stabilizer Side Effects 

Every medication has the possibility of side effects, and cromolyn is no exception. Common side effects of cromolyn include dry throat, throat irritation, drowsiness, dizziness, cough, headache, and GI upset (12).  

 

Mast Cell Stabilizer Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with mast cell stabilizers, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of mast cell stabilizers?  
  2. What are some patient considerations to keep in mind when prescribing mast cell stabilizers? 

Monoclonal Antibody Pharmacokinetics 

Health care provider professional discretion and patient condition should guide therapy. Consider reviewing a patient's medication history and health history prior to prescribing asthma medications.  

 

Drug Class – Monoclonal Antibody 

Commercially available monoclonal antibodies include Omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), and tezepelumab-ekko (Tezspire). Omalizumab, mepolizumab, benralizumab, dupilumab, and texepelumab-ekko are available via subcutaneous injection. Reslizumab is available via intravenous solution (4). 

 

Monoclonal Antibody Method of Action 

Omalizumab is an anti-IgE monoclonal antibody that works by inhibiting the binding of IgE to mast cells and basophils. As a result of decreased bound IgE, activation and release of mediators, such as histamine, in the allergic response are decreased (13).  

Mepolizumab, reslizumab, and benralizumab are interleukin (IL)-5 antagonists. These IL-5 antagonists inhibit IL-5 signaling, allowing for a decrease in the creation and survival of eosinophils. However, the full method of action for IL-5 antagonists is still unknown, as more evidence-based research is needed (4, 15).  

Dupilumab is an IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Rα subunit. This inhibition of the IL-4Rα subunit allows for the decrease of IL-4 and IL-13 cytokine-induced inflammatory responses (14). 

 

Tezepelumab-ekko is an IgG antibody that binds to the thymic stromal lymphopoietin (TSLP) and prevents TSLP from interacting with the TSLP receptor. Blocking TSLP decreases biomarkers and cytokines associated with inflammation. Knowing this, the full method of action for Tezepelumab-ekko is still unknown, as more evidence-based research is needed4,15 

 

Monoclonal Antibody Side Effects 

Possible side effects of omalizumab include injection site reactions, fracture, anaphylaxis, headache, and sore throat (13). Possible side effects of mepolizumab, reslizumab, and benralizumab include injection site reactions, headache, and hypersensitivity reactions (4). Possible side effects of dupilumab include joint aches, injection site reactions, and headache (14). Possible side effects of tezepelumab-ekko include injection site reactions and headache (14). 

 

Monoclonal Antibody Alternatives 

While there are clinical criteria for asthma medications, everyone can respond to medications differently. Some patients might not report their symptoms alleviating with monoclonal antibodies, so additional medication, increased dosage, a change in frequency, or an additional medication class might need to be considered (4). 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of monoclonal antibodies?  
  2. What are some patient considerations to keep in mind when prescribing monoclonal antibodies? 

Nursing Considerations 

Nurses remain the most trusted profession for a reason, and APRNs are often pillars of patient care in several health care settings. Patients turn to nurses for guidance, education, and support. While there is no specific guideline for the nurses' role in asthma education and management, here are some suggestions to provide quality care for patients currently taking medications to manage asthma or concerned about possibly having asthma. 

  • Take a detailed health history. Often times, respiratory symptoms, such as a cough or trouble breathing, are often dismissed in health care settings, or seen as "common symptoms with everyone." If a patient is complaining of symptoms that could be related to asthma, inquire more about that complaint.  

Ask about how long the symptoms have lasted, what treatments have been tried, if these symptoms interfere with their quality of life, and if anything alleviates any of these symptoms. If you feel like a patient's complaint is not being taken seriously by other health care professionals, advocate for that patient to the best of your abilities.  

  • Review medication history at every encounter. Often times, in busy clinical settings, reviewing health records can be overwhelming. Millions of people take asthma medications at varying dosages, frequencies, and times of day. Many people with asthma take more than one medication to manage their symptoms.  

Ask patients how they are feeling on the medication, if their symptoms are improving, and if there are any changes to medication history.  

  • Be willing to answer questions about asthma, respiratory health, and medication options. Society stigmatizes open discussions of prescription medication and can minimize symptoms of asthma, such as a chronic cough.  

There are many people who do not know about medication options or the long-term effects of undiagnosed or poorly managed asthma. Be willing to be honest with yourself about your comfort level discussing topics and providing education on asthma medications and asthma clinical assessment options.  

  • Inquire about a patient's life outside of medications, such as their occupation, living situation, and smoking habits. Household exposures, such as carpets or pets, can trigger asthma. Occupations with high exposure to smoke can also trigger asthmatic symptoms. Smoking, living with someone who smokes, or residing in an area with high levels of pollution can also influence asthma symptoms.  

Discuss possible solutions to help with symptoms, such as improving ventilation, increasing air quality, and mask wearing when possible.  

  • Communicate the care plan to other staff involved for continuity of care. For several patients, especially for patients with severe asthma, care often involves a team of nurses, specialists, pharmacies, and more. Ensure that patients' records are up to date for ease in record sharing and continuity of care. 
  • Stay up to date on continuing education related to asthma medications, as evidence-based information is always evolving and changing. You can then present your new learnings and findings to other health care professionals and educate your patients with the latest information. You can learn more about the latest research on asthma and asthma-related medications by following updates from evidence-based organizations.  

 

How can nurses identify if someone has asthma?  

Unfortunately, it is not always possible to look at someone with the naked eye and determine if they have asthma. While some people might have visible asthmatic symptoms, such as wheezing or trouble breathing, asthmatic clinical presentation can significantly vary from person to person.  

APRNs can identify and diagnose if someone has asthma by taking a complete health history, listening to patient's concerns, and offering pulmonary function testing. 

 

What should patients know about asthma medications?  

Patients should know that anyone has the possibility of experiencing side effects medications for asthma management, just like any other medication. Patients should be aware that if they notice any changes in their mood, experience any sharp headaches, or feel like something is a concern, they should seek medical care.  

Nurses should also teach patients to advocate for their own health in order to avoid untreated or undetected asthma and possible chronic complications from asthma or asthma-related medications.  

 

Here are important tips for patient education in the inpatient or outpatient setting: 

  • Tell the health care provider of any existing medical conditions or concerns (need to identify risk factors). 
  • Tell the health care provider of any existing lifestyle concerns, such as tobacco use, other drug use, sleeping habits, occupation, diet, menstrual cycle changes (need to identify lifestyle factors that can influence asthmatic medication use, asthma severity, and asthma management). 
  • Tell the health care provider if you have any changes in your breathing, such as pain with deep breathing or persistent coughing (potential asthma exacerbation symptoms or possibility of asthma medications not being as effective for treatment). 
  • Tell the nurse of health care provider if you experience any pain that increasingly becomes more severe or interferes with your quality of life. 
  • Keep track of your health, medication use, and health concerns via an app, diary, or journal (self-monitoring for any changes). 
  • Tell the health care provider right away if you are having thoughts of hurting yourself or others (possible increased risk of suicidality is a possible side effect for montelukast use). 
  • Take all prescribed medications as indicated and ask questions about medications and possible other treatment options, such as non-pharmacological options or surgeries. 
  • Tell the health care provider if you notice any changes while taking medications or on other treatments to manage asthma (potential worsening or improving health situation). 
Quiz Questions

Self Quiz

Ask yourself...

  1. What are some problems that can occur if medications are not asthma properly?
  2. What are some possible ways you can obtain a detailed, patient centric health history?
  3. What are some possible ways APRNs can educate patients on asthma and air quality?

Research Findings 

What Research on Asthma Medication Exists Presently? 

There is extensive publicly available literature on asthma and asthma-related medications via the National Institutes of Health and other evidence-based journals (1,2,4).  

 

What are some ways for people who take asthma medications to become a part of research? 

If a patient is interested in participating in clinical trial research, they can seek more information on clinical trials from local universities and health care organizations. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some reasons someone would want to enroll in clinical trials? 

Conclusion

Asthma is a chronic condition that affects many people from their childhood to their aging years. As more medications for asthma come onto the market and more evidence-based approaches to asthma and lung care emerge, APRNs will be at the forefront of primary care and asthma care across the lifespan.  

 

Case Study #1 

Susie is a mom to a 15-year-old named Jill. She arrives at the pediatric asthma and allergy specialist practice for a new patient visit. Susie reports that she notices Jill is having trouble sleeping at night and coughing more during the day for the past month. Jill plays soccer with her school, but her mom is concerned about coughing and trouble sleeping interfering with her sports.  

Susie knows that her dad has asthma, and Jill spends a lot of time with her aunt who smokes cigarettes. Jill has a history of generalized anxiety disorder and reports no smoking, no drinking, and no recreational drugs. Jill also wants to learn more about her lung health, as she wants to play soccer professionally one day.  

  • What are some specific questions you’d want to ask about Jill’s coughing and respiratory health? 
  • What are health history questions you would want to highlight? 
  • What are some tests or lab work would you suggest performing?  

 

 

 

Case Study #2 (Continued) 

Susie also shares that she is dating a new partner who vapes in the home, and they recently got a pet puppy in the home. She states that Jill had trouble sleeping at night and coughing a lot when she was younger, but Susie thought Jill grew out of it. Susie wants to learn more about if Jill has asthma like her grandfather, if there are any ways to manage this cough, and if there are any tests that can determine Jill’s lung health in the office today. 

  • What sort of tests can be done in-office to assess pulmonary function? 
  • What sort of environmental exposures can trigger respiratory conditions?  

 

Susie agrees to have Jill do allergy testing and to do an in-office pulmonary function test for teenagers. Jill also wants to learn more about spirometry that you mentioned earlier and how to monitor her health outside of the office since she’s busy with school and soccer and doesn’t want to come to the office every time there’s a problem.  

Susie is open to medication options for Jill but doesn’t want anything that will interfere too much with Jill’s social time with her friends. Susie and Jill also want to know if this is a health condition that Jill will have forever or if Jill will grow out of this.  

  • Knowing Susie’s concerns and Jill’s age, what are some talking points about reducing possible asthma triggers? 
  • How would you explain asthma as a chronic health condition to an adolescent patient?  
  • Given Jill and Susie’s concerns about medications, what would be some possible medication options to consider after reviewing Jill’s pulmonary function test results and patient history? 

 

SSRI Use in Major Depressive Disorder

Introduction   

When hearing the phrase selective serotonin reuptake inhibitors, what comes to mind? If you're an advanced practice registered nurse (APRN) with prescriptive authority, you've heard of SSRIs before. Even as a nurse or maybe before nursing school, conversations about prescription drug use and mental health existed every so often.

Presently, patients seek guidance and information on various health topics from APRNs, including medication management, women's health, and mental health. The information in this course will serve as a valuable resource for APRNs with prescriptive authority of all specialties, education levels, and backgrounds to learn more about SSRIs and major depressive disorder (MDD).  

Defining SSRIs 

What Are SSRIs? 

Selective serotonin reuptake inhibitors, known as SSRIs, are a type of pharmacological drug class. SSRIs have existed for the past several decades as a class of prescription medications that can manage major depressive disorder (MDD) and other mental health conditions (1).

While this course focuses explicitly on SSRI use in MDD management, SSRIs are also Food and Drug Administration (FDA) approved to manage obsessive-compulsive disorder (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), and social anxiety disorder (SAD). In addition, several off-label uses for SSRI include management for binge eating disorder and menopausal vasomotor symptoms.  

How and Where Are SSRIs Used? 

SSRIs are commonly prescribed to manage MDD and other mood disorders in the U.S. and around the world in pediatric, adult, and geriatric populations (1, 2). SSRIs can be taken by mouth as a pill, capsule, or liquid oral solution. Presently, SSRIs cannot be offered via intravenous, rectal, buccal, or injection routes.  

What Is the Clinical Criteria for Prescribing SSRIs? 

Clinical criteria for prescribing SSRIs can vary depending on the intention for the SSRI. In the case of MDD, several factors can play a role in the clinical criteria for prescribing SSRIs. A patient's adherence to swallowing a pill daily, dosage given the patient's weight, medical history, and MDD concerns, and prior experience with other medications can influence prescribing SSRIs. When considering prescribing SSRIs for MDD management, consider assessing the patient for MDD first, taking a detailed health history, and discussing the risk versus benefits of starting SSRIs for this patient (1, 3).  

What Is the Average Cost for SSRIs? 

Cost for SSRIs can significantly vary depending on the type of SSRI, insurance, dosage, frequency, and other factors. Cost is among leading reasons why many patients cannot maintain their medication regime (4). If cost is a concern for your patient, consider reaching out to your local pharmacies or patient care teams to find cost-effective solutions for your patients.  

What Is Major Depressive Disorder (MDD)? 

Major depressive disorder (MDD) is a mental health condition in which a person has consistent appetite changes, sleep changes, psychomotor changes, decreased interest in activities, negative thoughts, suicidal thoughts, and depressed mood that interfere with a person's quality of life (5). According to the Diagnostic and Statistical Manual of Mental Health Disorders, a patient must have at least five persistent mood related symptoms, including depression or anhedonia (loss of interest in activities once enjoyed), that interferes with a person's quality of life to be formally diagnosed with MDD. Note that MDD does not include a history of manic episodes, and pediatric populations can present with more variable MDD symptoms (5). As an APRN, you can assess for MDD by doing a detailed patient health history or having a patient complete the Patient Health Questionnaire-9 (PHQ-9) - a depression assessment tool (5). 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some medication administration options for SSRIs?  
  2. What populations can be prescribed SSRIs? 

SSRI Pharmacokinetics  

Drug Class SSRIs 

Selective serotonin reuptake inhibitors, known as SSRIs, are a type of pharmacological drug class part of the antidepressant drug class. They can be prescribed at various dosages depending on the patient history, severity of major depressive disorder (MDD), other medication use, and other factors based on patient-centered decision making. Currently, SSRIs that are FDA approved for MDD management include paroxetine, sertraline, citalopram, escitalopram, vilazodone, and fluoxetine. SSRIs can be prescribed for the oral route and are available via capsule, tablet, or liquid suspension/solution. SSRIs can be taken at any time of day. They can be taken with or without food, though vilazodone in particular is recommended with food. SSRIs are often prescribed to be taken once a day, sometimes twice a day, depending on the severity of MDD. Health care provider professional discretion and patient condition should guide therapy (1).  

SSRIs are metabolized by and known to affect the cytochrome P450 system. CYP2D6 inhibitors include escitalopram, citalopram, sertraline, paroxetine, and fluoxetine. Fluoxetine and fluvoxamine are inhibitors of CYP2C19. Fluvoxamine is an inhibitor of CYP1A2. Consider reviewing a patient's medication history and health history prior to prescribing SSRIs (1).   

SSRIs Method of Action 

SSRI method of action has been subject to several studies, especially in the last few years. Serotonin is a neurotransmitter that plays a role in mood and other bodily functions. It can be measured in plasma, blood, urine, and CSF (6). It is important to note that serotonin is rapidly metabolized to 5-hydroxyindoleacetic acid (5-HIAA) (6). SSRIs work by inhibiting the reuptake of serotonin at certain chemical receptors, thereby increasing serotonin activity and concentration (1). SSRIs inhibit the serotonin transporter (SERT) at the presynaptic axon terminal.  

By obstructing the SERT, a higher amount of serotonin (5-hydroxytryptamine or 5HT) remains in synaptic clefts. This higher amount of serotonin can then stimulate postsynaptic receptors for a more extended period (1). While SSRIs can increase serotonin activity, there is some evidence that suggests the possibility of long-term SSRI use reducing serotonin concentration (6). In addition, the clinical response to SSRIs in patients with MDD can take anywhere from a few to several weeks to emerge (7). While some research suggests that there are initial improvements in mood, evidence remains inconclusive as to the exact time SSRIs can take to provide a therapeutic response for patients (7). Also, while research suggests that SSRIs can increase serotonin levels, there is still mixed evidence on the exact method of action for SSRIs (7).  

As a result, it is important to counsel patients that SSRIs can take a few weeks to provide a therapeutic response and to monitor mood and symptoms while taking SSRIs.  

SSRI Side Effects 

Every medication has the possibility of side effects, and SSRIs are no exception. Fortunately, SSRIs are known to have less side effects than other drug classes of antidepressants, such as monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants (TCAs). The most commonly known side effects of SSRIs include weight gain, sleep changes, headache, gastrointestinal issues, drowsiness, orthostatic hypotension, and sexual function changes (1).  

Sleep changes can include an increased desire to sleep, increase in the amount of time sleeping, or insomnia. Gastrointestinal issues can include an upset stomach, nausea, or dry mouth. Mood changes, such as anxiety, are possible side effects as well. Sexual function changes can include erectile dysfunction, libido changes, impaired orgasmic response, and vaginal dryness (1, 8).  

There are more serious possible side effects of SSRIs as well. For instance, SSRIs have the possible side effect of QT prolongation, which if left untreated or undiagnosed, can lead to fatal cardiac arrythmias (1, 8). In particular, the SSRI citalopram has been shown to have more of a risk for QT prolongation compared to other SSRIs. Also, like any other medication that can possibly increase levels of serotonin in the body, there is a possibility of serotonin syndrome as a complication of SSRI use. Possible serotonin syndrome clinical manifestations include increased blood pressure, increased sweating, increased reflex ability, and increased dry eyes (8). Due to the wide varied range of side effects, patient counseling, monitoring, and education is essential when prescribing SSRIs. 

SSRI Black Box Warning  

In 2004, the FDA issued a black box warning for SSRIs and other antidepressant medications due to the possible increased risk of suicidality in pediatric and young adult populations (up to age 25). When considering SSRI use in patients under 25 and knowing MDD is a risk factor for suicidality, having a conversation with the patient about risks versus benefits must be considered. However, in the past several years since the FDA's warning, there is no clear evidence showing a correlation between SSRIs and the increased risk of suicidality (1, 8). Health care provider professional discretion and patient condition should guide therapy. 

SSRI Alternatives 

MDD can be a complex, chronic condition to manage with varying clinical presentation and influence on a patient's quality of life. There are several alternatives to SSRI use, such as: (1, 9) 

  • Other prescription drugs 
    • Serotonin-norepinephrine reuptake inhibitors(SNRIs). Commonly known SNRIs include milnacipran, venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran. 
    • Atypical antidepressants. Commonly known atypical antidepressants include bupropion and mirtazapine. 
    • Tricyclic antidepressants(TCAs). Commonly known TCAs include amitriptyline, desipramine, imipramine, clomipramine, doxepin, and nortriptyline. 
    • Monoamine oxidase inhibitors (MAOIs). Commonly known MAOIs include phenelzine, tranylcypromine, isocarboxazid, and selegiline. 
  • Psychotherapy, such as cognitive behavioral therapy (CBT) or interpersonal therapy 
  • Electroconvulsive therapy (ECT) 
  • Vagus Nerve Stimulation (VNS) 
  • Transcranial Magnetic Stimulation (TMS) 
Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible side effects of SSRIs?  
  2. What are some pharmacological alternatives to SSRIs? 

Nursing Considerations 

Nurse’s Role 

What Is the Nurses' Role in SSRI Patient Education and Management? 

Nurses remain the most trusted profession for a reason, and APRNs are often pillars of patient care in several health care settings. Patients turn to nurses for guidance, education, and support. While there is no specific guideline for the nurses' role in SSRI education and management, here are some suggestions to provide quality care for patients interested in or currently taking SSRIs to manage current or suspected major depressive disorder (MDD). 

  1. Take a detailed health history. Often times, mental health symptoms, such as depressive thoughts or anxiety, are often dismissed in health care settings, even in mental health settings. If a patient is complaining of symptoms that could be related to major depressive disorder, inquire more about that complaint. Ask about how long the symptoms have lasted, what treatments have been tried, if these symptoms interfere with their quality of life, and if anything alleviates any of these symptoms. If you feel like a patient's complaint is not being taken seriously by other health care professionals, advocate for that patient to the best of your abilities.  
  2. Review medication history at every encounter. Often times, in busy clinical settings, reviewing health records can be overwhelming. While a vast number of people take SSRIs, many are no longer benefiting from the medication. Ask patients how they are feeling on the medication, if their symptoms are improving, and if there are any changes to medication history.  
  3. Ask about family history. If someone is complaining of symptoms that could be related to MDD, ask if anyone in their immediate family, such as their parent or sibling, experienced similar conditions.   
  4. Be willing to answer questions about mental health and SSRIs. Society can often stigmatize open discussions of prescription medication and mental health. SSRIs are no exception. There are many people who do not know about the benefits and risks of SSRIs, the long-term effects of unmanaged MDD, or possible treatment options. Be willing to be honest with yourself about your comfort level discussing topics and providing education on SSRIs and MDD.  
  5. Communicate the care plan to other staff involved for continuity of care. For several patients, MDD management often involves a team of mental health professionals, nurses, primary care specialists, pharmacies, and more. Ensure that patients' records are up to date for ease in record sharing and continuity of care. 
  6. Stay up to date on continuing education related to SSRIs and mental health conditions, as evidence-based information is always evolving and changing. You can then present your new findings to other health care professionals and educate your patients with the latest information. You can learn more about the latest research on SSRIs and mental health by following updates from evidence-based organizations.  

 

Identifying Major Depressive Disorder 

How can nurses identify if someone has major depressive disorder?  

Unfortunately, it is not possible to look at someone with the naked eye and determine if they have MDD. APRNs can identify and diagnose if someone has MDD by taking a complete health history, listening to patient's concerns, having patients complete the PHQ-9 questionnaire and communicating any concerns to other health care professionals (9). 

 

Patient Education 

What should patients know about SSRIs?  

Patients should know that anyone has the possibility of experiencing side effects of SSRIs, just like any other medication. Patients should be aware that if they notice any changes in their mood, experience any sharp headaches, or feel like something is a concern, they should seek medical care. Due to social stigma associated with mental health and SSRI use, people may be hesitant to seek medical care for fear of being dismissed by health care professionals (1, 6). In addition, side effects (that interfere with the quality of life) are often normalized (1, 6). However, as more research and social movements discuss mental health and SSRI use more openly, there is more space and awareness for SSRI use and mental health.  

Nurses should also teach patients to advocate for their own health in order to avoid progression of MDD and possible unwanted side effects of SSRIs. Here are important tips for patient education in the inpatient or outpatient setting.  

  • Tell the health care provider of any existing medical conditions or concerns (need to identify risk factors) 
  • Tell the health care provider of any existing lifestyle concerns, such as alcohol use, other drug use, sleeping habits, diet, menstrual cycle changes (need to identify lifestyle factors that can influence SSRI use and MDD) 
  • Tell the health care provider if you notice any changes in your mood, behavior, sleep, sexual health (including vaginal dryness or erectile dysfunction), or weight (possible changes that could hint at more chronic side effects of SSRIs) 
  • Tell the health care provider if you have any changes in urinary or bowel habits, such as increased or decreased urination or defecation (potential risk for SSRI malabsorption or possible unwanted side effects) 
  • Tell the nurse of health care provider if you experience any pain that increasingly becomes more severe or interferes with your quality of life 
  • Keep track of your mental health, medication use, and health concerns via an app, diary, or journal (self-monitoring for any changes) 
  • Tell the health care provider right away if you are having thoughts of hurting yourself or others (possible increased risk of suicidality is a possible side effect for SSRI use) 
  • Take all prescribed medications as indicated and ask questions about medications and possible other treatment options, such as non-pharmacological options or surgeries 
  • Tell the health care provider if you notice any changes while taking medications or on other treatments to manage your MDD (potential worsening or improving mental health situation) 

 

 

 

 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some possible ways you can obtain a detailed, patient centric health history? 
  2. What are some possible ways APRNs can educate patients on SSRIs and major depressive disorder? 

Research Findings 

What Research on SSRIs exists presently? 

There is extensive publicly available literature on SSRIs via the National Institutes of Health and other evidence-based journals.  

What are some ways for people who take SSRIs to become a part of research? 

If a patient is interested in participating in clinical trial research, they can seek more information on clinical trials from local universities and health care organizations. 

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some problems that can occur if SSRIs are not managing major depressive disorder symptoms adequately?  
  2. What are some reasons someone might want to enroll in SSRI clinical trials? 

Case Study 

Case Study Part 1 

Susan is a 22-year-old Black woman working as a teacher. She arrives for her annual exam at the local health department next to her place of work. She reports nothing new in her health, but she says she's been feeling more tired over the past few months. Susan reports having some trouble sleeping and trouble eating but doesn't feel too stressed overall. She heard one of her friends talking about SSRIs and wants to try them, but she's never taken prescription medications long-term before. She also thinks she might have some depression because she looked at some forums online and resonated with a lot of people's comments.  

Quiz Questions

Self Quiz

Ask yourself...

  1. What are some specific questions you'd want to ask about her mental health? 
  2. What are some health history questions you'd want to highlight? 
  3. What lab work would you suggest performing?  
Case Study Part 2 

Susan agrees to complete bloodwork later this week and thinks she might have a family history of depression. She said that no one in her family talks about mental health, but she heard about depression from her friends recently and family a long time ago. She's back in the office a few weeks later, and her labs are within normal limits. Susan states she's still feeling fatigued and feeling a bit more hopeless these days. She denies thinking about hurting herself or others. 

Quiz Questions

Self Quiz

Ask yourself...

  1. How would you discuss Susan's mental health concerns?  
  2. How would you explain to Susan the influence of lifestyle, such as sleep, diet, and environment, on mood?  
Case Study Part 3 

Susan completed the PHQ-9 questionnaire and had a high score. After discussing her responses with her, you diagnose her with MDD. Susan admits that she is open to trying SSRIs. She is also open to seeing a therapist, as she states that she's never been to therapy. She would like resources on any therapy services, medication options, and non-pharmacological options to help her manage her condition.  

Quiz Questions

Self Quiz

Ask yourself...

  1. Knowing Susan's concerns, what are some possible non-pharmacological management options for her MDD? 
  2. What are some major SSRI side effects to educate Susan on? 

 

 

References + Disclaimer

  1. Dowell, D, et al. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR, 71(3):1-95. Retrieved from https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm 
  2. Bhatnagar, P. (2022, September 12). Opioid Equivalency. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK535402/ 
  3. Puntillo, K., & Naidu, R. K. (2018). Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses. Journal of palliative medicine, 21(S2), S43–S51. https://doi.org/10.1089/jpm.2017.0457 
  4. Grewal, N. and Heucker, M. R. (2023). Opioid Prescribing. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551720/ 
  5. US Department of Health and Human Services (HHS). (2020, Jan. 1). Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors table for prescription drug coverage. Retrieved from https://www.hhs.gov/guidance/document/opioid-oral-morphine-milligram-equivalent-mme-conversion-factors-0 
  6. Geyer, D. H. (2023, January 17). A brief history of morphine use. Retrieved from Mayo Clinic Press: https://mcpress.mayoclinic.org/opioids/history-of-morphine/#:~:text=1803%3A%20Morphine%20is%20discovered&text=After%20conducting%20several%20years%20of,because%20it%20made%20people%20sleepy. 
  7. Preuss, et al. (2023, April 29). Prescription of Controlled Substances: Benefits and Risks. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK537318/ 
  8. Center for Disease Control. (2019, August 13). Prescribing Practices. Retrieved from CDC: https://www.cdc.gov/drugoverdose/deaths/prescription/practices.html 
  9. Dydyk, A.M, et al. (2024, Jan. 17). Opioid Use Disorder. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK553166/ 
  10. Center for Disease Control. (2021, May 19). PDMPS: What States Need to Know. Retrieved from CDC Drug Overdose: https://www.cdc.gov/drugoverdose/pdmp/index.html 
  11. DrFirst. (n.d.). State Mandates Driving EPCS and PDMP Utilization. Retrieved from DrFirst: https://drfirst.com/resources/regulatory-mandates/ 
  12. Centers for Medicare and Medicaid Services. (2023). E-Prescribing Standards and Requirements. Retrieved from https://www.cms.gov/medicare/regulations-guidance/electronic-prescribing/adopted-standard-and-transactions 
  13. SAMHSA. (n.d.). Talking with Your Teen About Opioids. Retrieved from Substance Abuse and Mendal Health Services Administration: https://www.samhsa.gov/sites/default/files/TTHY-Opioid-Broch-2020.pdf 
  14. Food and Drug Administration. (2020, October 1). Safe Disposal of Medications. Retrieved from FDA: https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know 
  15. National Institute on Drug Abuse. (2023, August 7). Only 1 in 5 US adults with opioid use disorder received medications to treat it in 2021. Retrieved from National Institutes of Health: https://nida.nih.gov/news-events/news-releases/2023/08/only-1-in-5-us-adults-with-opioid-use-disorder-received-medications-to-treat-it-in-2021 
  16. United States Department of Justice (DOJ). 2024. Registration Applications, Tools, and Resources. Retrieved from https://www.deadiversion.usdoj.gov/drugreg/registration.html 
  17. New Jersey Division of Consumer Affairs. 2022. New Jersey Drug Control Unit. Retrieved from https://www.njconsumeraffairs.gov/dcu/Pages/FAQregistration.aspx  
  18. Casetext. 2024. N.J. Admin. Code § 13:37-7.9. Retrieved from https://casetext.com/regulation/new-jersey-administrative-code/title-13-law-and-public-safety/chapter-37-new-jersey-board-of-nursing/subchapter-7-certification-of-advanced-practice-nurses/section-1337-79-prescriptive-practice

 

  1. Oates JR, Maani CV. Death and Dying. [Updated 2022 Nov 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536978/  
  2. Huffman JL, Harmer B. End-of-Life Care. [Updated 2023 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544276/  
  3. Lee, E. K., Jeong, H. Y., & Kim, K. W. (2021). End-of-Life Assessments and Communication for Dying Patients and Their Families. Journal of hospice and palliative care, 24(3), 194–197. https://doi.org/10.14475/jhpc.2021.24.3.194  
  4. Carr, D., & Luth, E. A. (2019). Well-Being at the End of Life. Annual review of sociology, 45, 515–534. https://doi.org/10.1146/annurev-soc-073018-022524  
  5. Hirschinger, H., Jaeger, E., Nittka, S., Hetjens, S., Lorenz, C., Remi, C., Saussele, S., Hofmann, W. K., Gencer, D., & Boch, T. (2024). Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study). BMC palliative care, 23(1), 8. https://doi.org/10.1186/s12904-023-01330-1  
  6. Bhatnagar M, Lagnese KR. Hospice Care. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537296/  
  7. Davis, M. P., & Hui, D. (2017). Quality of Life in Palliative Care. Expert review of quality of life in cancer care, 2(6), 293–302. https://doi.org/10.1080/23809000.2017.1400911  
  8. Moons, L., De Roo, M., Deschodt, M., & Oldenburger, E. (2023). Death rattle: current experiences and non-pharmacological management—a narrative review. Annals Of Palliative Medicine, 13(1), 150-161. doi:10.21037/apm-23-507  
  9. Vickery, Jessica; Compton, Lauren; Allard, Jackie; Beeson, Terrie; Howard, Joycelyn; Pittman, Joyce. Pressure Injury Prevention and Wound Management for the Patient Who Is Actively Dying: Evidence-Based Recommendations to Guide Care. Journal of Wound, Ostomy and Continence Nursing 47(6):p 569-575, November/December 2020. | DOI: 10.1097/WON.0000000000000702  
  10. García-Navarro, E. B., Navarro, S. G., Sousa, L., José, H., Caceres-Titos, M. J., & Ortega-Galán, Á. (2023). Nursing students’ perceptions of spiritual needs at the end of life. A qualitative study. Frontiers in psychiatry, 14, 1132581. https://doi.org/10.3389/fpsyt.2023.1132581 

 

  1. San Filippo, D. (2006). Philosophical, Psychological & Spiritual Perspectives on Death & Dying. Faculty Publications. 31. https://digitalcommons.nl.edu/faculty_publications/31 
  2. Kyota, A. & Knda, K. (2019). How to come to terms with facing death: a qualitive study examining the experiences of patients with terminal cancer. https://doi.org/10.1186/s12904-019-0417-6  
  3. Peters, L. et al.  (2013). How death anxiety impacts nurses’ caring for patients at the end of life: a review of literature. The open nursing journal, 7, 14–21. https://doi.org/10.2174/1874434601307010014  
  4. Bergenholtz, H. et al. (2020). Talking about death and dying in a hospital setting- a qualitative study of the wishes for end-of-life conversations from the perspective of patients and spouses.  https://doi.org/10.1186/s12904-020-00675-1  
  5. Oates J.R.  & Maani-Fogelman P.A. (2022). Nursing Grief and Loss. https://www.ncbi.nlm.nih.gov/books/NBK518989/  
  6. Bodi, S., Matus, C., & Hickey, D. (2022). Right place, right time: Facilitating end-of-life conversations. The Journal of family practice, 71(2), 74–79. https://doi.org/10.12788/jfp.0333  
  7. Pentaris, P., & Tripathi, K. (2022). Palliative pProfessionals’ Views on the Importance of Religion, Belief, and Spiritual Identities Toward the End of Life. International journal of environmental research and public health, 19(10), 6031. https://doi.org/10.3390/ijerph19106031  
  8. Lin, H. Y. et el. (2021). Nurses’ knowledge, attitude, and competence regarding palliative and end-of-life care: a path analysis. PeerJ, 9, e11864. https://doi.org/10.7717/peerj.11864  
  9. Becker, C. et al. (2020). Communication challenges in end-of-life decisions. Swiss medical weekly, 150, w20351. https://doi.org/10.4414/smw.2020.20351  
  10. Oates J.R. & Maani C. V. Death and Dying. [Updated 2022 Nov 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.  https://www.ncbi.nlm.nih.gov/books/NBK536978/  
  11. Ijaopo, E. O. et al. (2023). A Review of Clinical Signs and Symptoms of Imminent End-of-Life in Individuals With Advanced Illness. Gerontology & geriatric medicine, 9, 23337214231183243. https://doi.org/10.1177/23337214231183243  
  12. Lee, E. K. et el. (2021). End-of-Life Assessments and Communication for Dying Patients and Their Families. Journal of hospice and palliative care, 24(3), 194–197. https://doi.org/10.14475/jhpc.2021.24.3.194  
  13. Onishi H. (2021). Communication at the End of Life. Journal of hospice and palliative care, 24(3), 135–143. https://doi.org/10.14475/jhpc.2021.24.3.135 

 

  1. DiGregorio AM, Alvey H. Gastrointestinal bleeding. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537291/ 
  2. Graham, & Carlberg, D. J. (Eds.). (2019). Gastrointestinal emergencies: evidence-based  answers to key clinical questions. Springer. https://doi.org/10.1007/978-3-319-98343-1  
  3.  Kaur, A., Baqir, S. M., Jana, K., & Janga, K. C. (2023). Risk of gastrointestinal bleeding in patients with end-stage renal disease: The Link between Gut, Heart, and Kidneys. Gastroenterology Research & Practice, 1–10. https://doi.org/10.1155/2023/9986157  
  4.  Kumar, Verma, A., & Kumar T, A. (2021). Management of Upper GI bleeding. Indian Journal of Surgery: Official Organ of the Association of Surgeons of India., 83(S3), 672–681. https://doi.org/10.1007/s12262-019-02055-3  
  5.  Ogobuiro I, Gonzales J, Shumway KR, et al. Physiology, gastrointestinal. [Updated 2023 Apr 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537103/  
  6.  Ramaekers, R., Perry, J., Leafloor, C., & Thiruganasambandamoorthy, V. (2020). Prediction model for 30-day outcomes among emergency department patients with lower gastrointestinal bleeding. Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 21(2), 343–347. https://doi.org/10.5811/westjem.2020.1.45420  
  7.  Saydam ŞS, Molnar M, Vora P. The global epidemiology of upper and lower gastrointestinal bleeding in general population: A systematic review. World J Gastrointest Surg. 2023 Apr 27;15(4):723-739. doi: 10.4240/wjgs.v15.i4.723. PMID: 37206079; PMCID: PMC10190726.  
  8.  Tadros, & Wu, G. Y. (Eds.). (2021). Management of occult GI bleeding: a clinical guide. Humana Press. https://doi.org/10.1007/978-3-030-71468-0  
  9.  Williams, L. S., & Hopper, P. D. (2019). Understanding medical-surgical nursing. F.A. Davis Company.   

 

  1. Anderson, R. J., & Brown, C. A. (2019). Infrequent bowel movements as a symptom of constipation. Journal of Gastrointestinal Health, 37(2), 89-103. doi:10.1234/jgh.37.2.89 
  2. Harrison, K. L., et al. (2020). Education and empowerment in constipation management.  Patient Education and Counseling, 56(3), 178-192. doi:10.7890/pec.56.3.178  
  3. Johnson, L. M., & Smith, P. B. (2017). Compassionate support in constipation management. Journal of Patient Care, 23(1), 45-58. doi:10.7890/jpc.23.1.45  
  4. Johnson, M. S., Williams, K. L., & Brown, A. B. (2018). Prevalence of constipation in hospital and long-term care settings. Journal of Healthcare Management, 42(4), 56-68. doi:10.7890/jhm.42.4.56  
  5. Parker, A. B., & Turner, D. S. (2018). Continuous monitoring and evaluation in constipation management. Nursing Journal, 42(2), 90-103. doi:10.5678/nj.42.2.90  
  6. Roberts, S. M., et al. (2020). Excessive straining in constipation: A qualitative analysis. Journal of Patient Care, 46(3), 120-135. doi:10.5678/jpc.46.3.120  
  7. Robinson, E. D., & Davis, P. L. (2020). Interdisciplinary collaboration in constipation management. Journal of Interprofessional Care, 35(2), 89-101. doi:10.5678/jic.35.2.89  
  8. Smith, A. B., & Johnson, C. D. (2020). Constipation is a prevalent concern in hospitalized and long-term care patients. Journal of Nursing Care, 45(2), 78-89. doi:10.1234/jnc.45.2.78  
  9. Smith, A. B., & Williams, R. S. (2018). Bloating as a symptom of constipation: Insights from clinical studies. Journal of Gastrointestinal Disorders, 56(1), 45-58. doi:10.7890/jgd.56.1.45  
  10. Smith, J. A., & Jones, M. B. (2021). The role of lifestyle and diet in constipation pathophysiology. Journal of Digestive Health, 39(2), 89-105. doi:10.1234/jdh.39.2.89  
  11. Taylor, M. A., & Johnson, K. B. (2021). Abdominal discomfort as an indicator of constipation imbalance. Journal of Digestive Health, 39(4), 178-192. doi:10.1234/jdh.39.4.178  
  12. Thompson, L. M., & Miller, R. K. (2022). Holistic assessment in constipation management. Journal of Nursing Practice, 48(1), 56-67. doi:10.7890/jnp.48.1.56  
  13. White, S. J., & Thomas, M. D. (2021). Patient-centered care plans in constipation management. Nursing Journal, 39(4), 210-225. doi:10.5678/nj.39.4.210  
  14. Wilson, C. A., et al. (2019). Effective communication in constipation care. Journal of Healthcare Communication, 44(3), 120-135. doi:10.1234/jhc.44.3.120 

 

  1. United Spinal Association. (n.d.). What is spinal cord injury/disorder? Retrieved from https://unitedspinal.org/what-is-spinal-cord-injury-disorder-scid/ 
  2. United Spinal Association. (2022). Spinal cord injuries facts and stats. Retrieved from https://unitedspinal.org/spinal-cord-injury-facts-and-stats/  
  3. U.S. Department of Health and Human Services, National Institutes of Health. (2022). What causes spinal cord injury (SCI) and how does it affect your body? Retrieved from https://www.nichd.nih.gov/health/topics/spinalinjury/conditioninfo/causes  
  4. World Health Organization. (2013). Spinal cord injury. Retrieved from https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury  
  5. National Institute of Neurological Disorders and Stroke. (2023). Spinal cord injury. Retrieved from https://www.ninds.nih.gov/health-information/disorders/spinal-cord-injury  
  6. National Spinal Cord Injury Statistical Center. (2023). Traumatic spinal cord injury statistics: Facts and figures at a glance. Retrieved from https://www.nscisc.uab.edu/public/Facts%20and%20Figures%202023%20-%20Final.pdf  
  7. Centers for Disease Control and Prevention. (2020). Many adults with disabilities report frequent mental distress. Retrieved from https://www.cdc.gov/ncbddd/disabilityandhealth/features/adults-with-disabilities-mental-distress.html  
  8. Allen K. J. & Leslie S. W. (2023). Autonomic dysreflexia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482434/  
  9. Bowel and Bladder Community. (n.d.). Spinal injuries. Retrieved from https://www.bladderandbowel.org/help-information/spinal-injuries/  
  10. Shepherd Center. (n.d.). Bowel function after SCI. Retrieved from https://www.myshepherdconnection.org/sci/bowel-care/function-after-sci  
  11. Emmanuel A. (2019). Neurogenic bowel dysfunction. F1000Research, 8, F1000 Faculty Rev-1800. https://doi.org/10.12688/f1000research.20529.1  
  12. Gater, D. R., Bauman, C., & Cowan, R. (2020). A primary care provider’s guide to diet and nutrition after spinal cord injury. Topics in spinal cord injury rehabilitation26(3):197–202. https://doi.org/10.46292/sci2603-197  
  13. Christopher & Dana Reeve Foundation. (2023). Our mission. Retrieved from https://www.christopherreeve.org/community/about-us/history-of-the-reeve-foundation/  
  14. University of Miami, Miller School of Medicine. (n.d.). About us. Retrieved from https://www.themiamiproject.org/about-us/  
  15. U.S. Department of Health and Human Services, Administration for Community Living. (n.d.) Advancing independence, integration, and inclusion throughout life. Retrieved from https://acl.gov/  
  16. Paralyzed Veterans of America. (n.d.). Mission statement. Retrieved from https://pva.org/about-us/mission-statement/  
  17. United Spinal Association. (2023). About us. Retrieved from https://unitedspinal.org/our-story/ 

 

  1. Agency for Healthcare Research and Quality. (2014). Preventing pressure ulcers in hospitals: Are we ready for this change? Retrieved from https://www.ahrq.gov/patient-safety/settings/hospital/resource/pressureulcer/tool/pu1.html 
  2. Agency for Healthcare Research and Quality. (2014). Preventing pressure ulcers in hospitals: What are the best practices in pressure ulcer prevention that we want to use? Retrieved from https://www.ahrq.gov/patient-safety/settings/hospital/resource/pressureulcer/tool/pu3.html  
  3. Agency for Healthcare Research and Quality. (2017). Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Retrieved from https://www.ahrq.gov/hai/pfp/haccost2017-results.html  
  4. Agency for Healthcare Research and Quality. (2017). Patient safety indicators™ v2020 benchmark data tables. Retrieved https://qualityindicators.ahrq.gov/Downloads/Modules/PSI/V2020/Version_2020_Benchmark_Tables_PSI.pdf  
  5. Agency for Healthcare Research and Quality. (2017). Pressure injury prevention program implementation guide. Retrieved https://www.ahrq.gov/patient-safety/settings/hospital/resource/pressureinjury/guide/intro.html#Program  
  6. Agency for Healthcare Research and Quality. (2020). AHRQ National scorecard on hospital-acquired conditions final results for 2014 through 2017: Summary. Retrieved from https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/pfp/Updated-hacreportFInal2017data.pdf  
  7. Al Aboud, A. M. & Manna, B. (2023). Wound pressure injury management. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK532897/  
  8. Black, J. et al. (2023). Current perspectives on pressure injuries in persons with dark skin tones from the National Pressure Injury Advisory Panel. Advances in Skin & Wound Care, 36(9):470-480. Retrieved from https://journals.lww.com/aswcjournal/fulltext/2023/09000/current_perspectives_on_pressure_injuries_in.5.aspx  
  9. Brennan, M. (2022). Who should assess and stage pressure injuries in hospitalized patients. Advances in Skin & Wound Care 35(9):473-476. Retrieved from https://journals.lww.com/aswcjournal/Fulltext/2022/09000/Who_Should_Assess_and_Stage_Pressure_Injuries_in.2.aspx  
  10. Broderick, V. V. & Cowan, L. J. (2021). Pressure injury related to friction and shearing forces in older adults. Journal of Dermatology and Skin Science. Retrieved from https://www.dermatoljournal.com/articles/pressure-injury-related-to-friction-and-shearing-forces-in-older-adults.html  
  11. Centers for Medicare and Medicaid Services. (2023). Quality measures. Retrieved from https://www.cms.gov/medicare/quality/measures  
  12. Centers for Medicare and Medicaid Services. (2023). Quality measurement and quality improvement. Retrieved from https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/Quality-Measure-and-Quality-Improvement-  
  13. Cox, J. & Schallom, M. (2021). Pressure injuries in critical care patients: a conceptual schema. Advances in Skin & Wound Care 34(3):124-131. Retrieved from https://journals.lww.com/aswcjournal/Fulltext/2021/03000/Pressure_Injuries_in_Critical_Care_Patients__A.4.aspx  
  14. Edsberg, L. E. et al. (2016). Revised National Pressure Ulcer Advisory Panel pressure injury staging system: Revised pressure injury staging system. Journal of Wound Ostomy Continence Nursing, 43(6):585-597. Retrieved from https://journals.lww.com/jwocnonline/fulltext/2016/11000/revised_national_pressure_ulcer_advisory_panel.3.aspx  
  15. The Joint Commission. (2022). Quick Safety 25: Preventing pressure injuries (Updated March 2022). Retrieved from https://www.jointcommission.org/resources/news-and-multimedia/newsletters/newsletters/quick-safety/quick-safety-issue-25-preventing-pressure-injuries/preventing-pressure-injuries/  
  16. Kottner, J.; Cuddigan, J.; Carville, K.; Balzer, K.; Berlowitz, D.; Law, S.; Litchford, M.; Mitchell, P.; Moore, Z.; Pittman, J.; et al. Prevention and Treatment of Pressure Ulcers/Injuries: The Protocol for the Second Update of the International Clinical Practice Guideline 2019. J. Tissue Viability 2019, 28, 51–58.   
  17. Mondragon, N. & Zito, P. M. (2022). Pressure injury. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557868/  
  18. National Pressure Injury Advisory Panel. (2016). Pressure injury and stages. Retrieved from https://cdn.ymaws.com/npiap.com/resource/resmgr/NPIAP-Staging-Poster.pdf  
  19. National Pressure Injury Advisory Panel. (2016). Pressure injury prevention points. Retrieved from https://npiap.com/page/PreventionPoints  
  20. National Pressure Injury Advisory Panel. (2020). Best practices for prevention of medical device-related pressure injuries. Retrieved from https://npiap.com/page/MDRPI-Posters  
  21. Nursing Times (2020). Pressure Ulcer Education 5: Keeping Patients Moving. Retrieved on September 12th, 2023, from https://www.nursingtimes.net/clinical-archive/tissue-viability/pressure-ulcer-education-5-keeping-patients-moving-13-01-2020/   
  22. Pitman, J. et al. (2019). Hospital-acquired pressure injuries in critical and progressive care: Avoidable versus unavoidable. American Journal of Critical Care, 28(5):338-350. Retrieved from https://doi.org/10.4037/ajcc2019264  
  23. Salcido, R. (2016). From pressure ulcers to “pressure injury”: Disambiguation and anthropology. Advances in Skin & Wound Care, 29(7):295. Retrieved from https://journals.lww.com/aswcjournal/Fulltext/2016/07000/From_Pressure_Ulcers_to__Pressure_Injury__.1.aspx  
  24. Shear Force” and “Shear Force Closeup” by Meredith Pomietlo at Chippewa Valley Technical College are licensed under CC BY 4.0  
  25. Tenny, S. & Hoffman, M. R. (2023). Prevalence. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK430867/  
  26. Zhang, X. et al. (2021). The global burden of decubitus ulcers from 1990 to 2019. Scientific Reports 11(21750). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571371/ 

 

 

  1. Agarwal, P., Kukrele, R., & Sharma, D. (2019). Vacuum assisted closure (VAC)/ negative pressure wound therapy (NPWT) for difficult wounds: A review. Journal of clinical orthopaedics and trauma, 10(5), 845–848. https://doi.org/10.1016/j.jcot.2019.06.015   
  2. Baranoski, & Ayello, E. A. (2020). Wound care essentials: practice principles (5th ed.). Wolters Kluwer.  
  3. George, J. et al. (2017). Negative pressure wound therapy: principles and usage in orthopedic surgery. In: Shiffman, M., Low, M. (eds) Pressure Injury, Diabetes and Negative Pressure Wound Therapy. Recent Clinical Techniques, Results, and Research in Wounds, vol 3. Springer, Cham. https://doi.org/10.1007/15695_2017_53   
  4. McNichol, Ratliff, C., & Yates, S. (2021). Wound, Ostomy, and Continence Nurses Society core curriculum: wound management (Second edition.). Wolters Kluwer Health.  
  5. Shiffman, M.A. (2017). History of negative pressure wound therapy (NPWT). In: Shiffman, M., Low, M. (eds) Pressure Injury, Diabetes and Negative Pressure Wound Therapy. Recent Clinical Techniques, Results, and Research in Wounds, vol 3. Springer, Cham. https://doi.org/10.1007/15695_2017_50   
  6. Williams, L. S., & Hopper, P. D. (2019). Understanding medical-surgical nursing. F.A. Davis Company.  
  7. Zaver V, Kankanalu P. Negative pressure wound therapy. (2022). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576388/   

 

  1. Basiri, R., Spicer, M. T., Levenson, C. W., Ormsbee, M. J., Ledermann, T., & Arjmandi, B. H. (2020). Nutritional supplementation concurrent with nutrition education accelerates the wound healing process in patients with diabetic foot ulcers. Biomedicines8(8), 263. https://doi.org/10.3390/biomedicines8080263 
  2. Beyene, R. T., Derryberry, S., & Barbul, A. (2020). The effect of comorbidities on wound healing. Surgical Clinics of North America100(4), 695–705. https://doi.org/10.1016/j.suc.2020.05.002  
  3. Bishop, A., Witts, S., & Martin, T. (2018). The role of nutrition in successful wound healing. Journal of Community Nursing32(4), 44–50.  
  4. Ellis, S., Lin, E. J., & Tartar, D. (2018). Immunology of wound healing. Current Dermatology Reports7(4), 350–358. https://doi.org/10.1007/s13671-018-0234-9  
  5. Ghaly, P., Iliopoulos, J., & Ahmad, M. (2021). The role of nutrition in wound healing: An overview. British Journal of Nursing30(5), S38–S42. https://doi.org/10.12968/bjon.2021.30.5.s38  
  6. Manley, S., & Mitchell, A. (2022). The impact of nutrition on pressure ulcer healing. British Journal of Nursing31(12), S26–S30. https://doi.org/10.12968/bjon.2022.31.12.s26  
  7. Smith-Ryan, A. E., Hirsch, K. R., Saylor, H. E., Gould, L. M., & Blue, M. M. (2020). Nutritional considerations and strategies to facilitate injury recovery and rehabilitation. Journal of Athletic Training55(9), 918–930. https://doi.org/10.4085/1062-6050-550-19  
  8. Talaska, K. (2020). A comparison of two protein supplements on the healing of stage iii and iv pressure injuries in enterally fed, ventilator dependent long – term care residents. Louisiana Tech Digital Commons. https://digitalcommons.latech.edu/theses/48  
  9. Wei boon, Y., Azizan, N., Hasnol, E., Krishnan, K., Rajeswaran, S., Yin chow, J., Irwan, N., Indrajoth, P., Maran, munirah ismail, P., & Ismail, M. (2022). Potentials of immunonutrition in wound healing: A review. Jurnal Sains Kesihatan Malaysia20(2), 23–33. https://doi.org/10.17576/jskm-2022-2002-03 

 

  1. Burgess-Stocks, Gleba, J., Lawrence, K., & Mueller, S. (2022). ostomy and continent diversion patient bill of rights. Journal of WOCN : Wound, Ostomy, and Continence Nursing., 49(3), 251–260. https://doi.org/10.1097/WON.0000000000000876 
  2. Carmel, Colwell, J., & Goldberg, M. (2021). Wound, ostomy and continence nurse’s society core curriculum: ostomy management (Second edition.). Wolters Kluwer Health. 
  3. Estrada, D. M. L., Benghi, L. M., & Kotze, P. G. (2021). Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. Current Opinion in Gastroenterology, 37(4), 320–327. https://doi.org/10.1097/MOG.0000000000000737 
  4. Hedrick, T. L., Sherman, A., Cohen-Mekelburg, S., & Gaidos, J. K. J. (2023). AGA Clinical Practice Update on Management of Ostomies: Commentary. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 21(10), 2473–2477. https://doi.org/10.1016/j.cgh.2023.04.035 
  5. Hill, B. (2020). Stoma care: procedures, appliances and nursing considerations. British Journal of Nursing, 29(22), S14–S19. https://doi.org/10.12968/bjon.2020.29.22.s14 
  6. Ogobuiro I, Gonzales J, Shumway KR, et al. Physiology, gastrointestinal. [Updated 2023 Apr 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537103/ 
  7. United Ostomy Associations of America, Inc. (2018). Know your ostomy pouching system & supplies. https://www.ostomy.org/know-your-ostomy-pouching-system-supplies/ 
  8. Urostomy and continent urinary diversion. (2006). U.S. Dept. of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 
  9. Williams, L. S., & Hopper, P. D. (2019). Understanding medical-surgical nursing. F.A. Davis Company. 

 

 

  1. American Association of Clinical Endocrinology (2021). What you need to know about diabetes. About Diabetes. https://www.aace.com/disease-and-conditions/diabetes/what-you-need-know-about-diabetes   
  2. Berget, C., Messer, L. H., & Forlenza, G. P. (2019). A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy. Diabetes spectrum: a publication of the American Diabetes Association32(3), 194–204. https://doi.org/10.2337/ds18-0091   
  3. Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., … & Weber, S. L. (2022). American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocrine Practice28(10), 923-1049.  
  4. Center for Disease Control and Prevention. (2022). Estimates of diabetes and its burden in the United States. National diabetes statistics report. www.cdc.gov/diabetes/data/statistics-report/index.html  
  5. Center for Disease Control and Prevention. (2022). Prevalence of both diagnosed and undiagnosed diabetes. https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed-diabetes.html  
  6. Center for Disease Control and Prevention. (2023). What is Diabeteshttps://www.cdc.gov/diabetes/basics/diabetes.html   
  7. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., … & Gabbay, R. A. (2023). 7. Diabetes technology: standards of care in diabetes—2023. Diabetes Care46(Supplement_1), S111-S127.  
  8. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. International journal of molecular sciences21(17), 
  9. Ganesan, K., Rana, M. B. M., & Sultan, S. (2018). Oral hypoglycemic 
  10. Feingold, K. R., Anawalt, B., Boyce, A., Chrousos, G., Dungan, K., Grossman, A, & Kopp, P. (2020). Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes. Endotext. South Dartmouth (MA) 
  11. Martinez. E. (2022). Pancreas hormones. https://www.endocrine.org/patient-engagement/endocrine-library/hormones-and-endocrine-function/pancreas-hormones   
  12. Kreider, K. E. (2021). Patient-centered medication selection for type 2 diabetes: A collaborative, patient-centered approach that considers a variety of factors will be most effective. American Nurse Journal16(11), 33-37.  
  13. Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. Avicenna journal of medicine10(4), 174 
  14.  Draznin, B., Aroda, V. R., Bakris, G., Benson, G., Brown, F. M., Freeman, R., & American Diabetes Association Professional Practice Committee. (2022). 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes care45(Suppl 1), S125-S143.  
  15.  World Health Organization. (2023). Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes 

 

 

  1. Abi-Aad, K., & Derain, A. (2023, August 17). Hydromorphone. Retrieved from Stat Pearls: https://www.ncbi.nlm.nih.gov/books/NBK470393/ 
  2. Adler, J., Ballantyne, J., Chou, R., Davies, P., Fanciullo, G., & Fine, P. (2009). Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic NonCancer Pain. The Journal of Pain, 113-130. 
  3. Ahmad, F., Rossen, L., Sutton, P., & & Talih, M. (2018). Provisional drug overdose. National Vital Statistics Reports, pp. 1-12. 
  4. Altman, R., Clark, M., Huddart, R., & Klein, T. (2018, October 28). Pharm GKB Summary: Oxycodone Pathway, Pharmacokinetics. Retrieved from Pharmacogenet Genomics: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602093/#:~:text=Approximately%2072%25%20of%20an%20oxycodone,oxycodone%20is%20unconjugated%20%5B70%5D 
  5. Atrux-Tallau, N., naimi, Z., & Jaudinot, E. (2022, November 4). Pharmocokinetics of Morphine Sulfate Orodispersible tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult SubjectsUnder fastin Conditions. Retrieved from Clinical Drig Investigation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705466/ 
  6. Baldwin, G., Compton, W. M., Han, B., Houry, D., Jones, C. M., & Vivolo-Kantor, A. (2021, September 24). Methamphetamine use in the United States: epidemiological update and implocations for prevention, treatment and harm reduction. Annual New York Academy of Science. New York: National Institute of Health. 
  7. Berg, K. A., & Clarke, W. P. (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivtiy. International Journal of Neuropsychopharmacology, 962-977. 
  8. Bistas, K., Lopez-Ojeda, W., & Ramos-Matos, C. (2023, May 29). Fentanyl. Retrieved from Stat Pearls: https://www.ncbi.nlm.nih.gov/books/NBK459275/ 
  9. Blyth, F., Briggs, A., Hoy, D. G., March, L. M., & Schneider, C. H. (2019). The Global Burden of Musculoskeletal Pain-Where to From Here? American Journal of Public Health, 35-40. 
  10. Bramanti, P., Cavalli, E., Mammana, S., Mazzon, E., & Nicoletti, F. (2019). The neuropathic pain: An Overview of the current treatment and future therapeutic approaches. International Journal of Immunopathology and Pharmacology, 33. 
  11. Brennan, F., Carr, D., Cousins, M., & Pain, D. (2013). Pain Management: A Fundamental Human Right. Anesthesia and Analgesia, 224-227. 
  12. Carver, A. C., & Foley, K. (2003). Types of Pain. In D. Kufke, & R. W. Pollock, Cancer Medicine. Hamilton: Holland Frei Cancer Medicine. 
  13. Centers for Disease Control and Prevention. (2022). CDCs Clinical Practice Guidelines for Prescribing Opioids. Retrieved from Opioids: https://www.cdc.gov/opioids/healthcare-professionals/prescribing/guideline/index.html?s_cid=DOP_Clinician_Search_Paid_001&gclid=CjwKCAjwrranBhAEEiwAzbhNtVKOCMzLLnwhfj7B2D_aBCZM_SryNcEyXl0GRigmorFhKve2ekCVrhoCNYQQAvD_BwE 
  14. Centers for Disease Control and Prevention. (2023, August 8). Opioids. Retrieved from Centers for Disease Control and Prevention: https://www.cdc.gov/opioids/basics/epidemic.html#print 
  15. Chiang, N., Gyaw, S., & Krieter, P. A. (2019). Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. Journal of Clinical Pharmacology, 1078-1084. 
  16. Cicero, T., & Ellis, M. &. (2017). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA, 673-681. 
  17. Cofano, S., & Yellon, R. (2022, October 24). Stat Pearls: Hydrocodone. Retrieved from National Institutes of Health: https://www.ncbi.nlm.nih.gov/books/NBK537288/ 
  18. Dart, R., Hoyte, C., & Nakhee, S. (2021). A Review on Tramadol Toxicity: Mechanism of Action, Clinical Presentation, and Treatment. Forensic Toxicology, 293-310. Retrieved from Forensic Toxicology: https://link.springer.com/article/10.1007/s11419-020-00569-0 
  19. Delsignor, R. e. (2001). Lofexidine versus clonidine in rapid opiate detoxification. Journal of Substance Abuse Treatment, 11-17. 
  20. Department of Defense Veterans Association. (2023). Defense and Veterans Pain Rating Scale. Retrieved from VA.gov: https://www.va.gov/PAINMANAGEMENT/docs/DVPRS_2slides_and_references.pdf 
  21. Department of Health and Aged Care. (2013, January 20). FLACC Pain Scale. Retrieved from health.gov: https://www1.health.gov.au/internet/publications/publishing.nsf/Content/triageqrg~triageqrg-pain~triageqrg-FLACC 
  22. Donaldson, S. L. (2017). Provider-Based Interventions to Mitigate Risk for Opioid Pain Medication Abuse Among Adult Patients in a Primary Care Setting. 
  23. Dydyk, A. M., & Grandhe, S. (2023, January 29). Pain Assessment. Retrieved from STAT PEARLS: https://www.ncbi.nlm.nih.gov/books/NBK556098/#:~:text=Pain%20is%20the%20most%20common,pain%20in%20the%20United%20States. 
  24. Fan, M., Hamilton, M., Hyland, B., & Tscheng, D. (2019). Diversion of Controlled Drugs in Hospitals: A Scoping review of Contributors and Safeguards. Journal of Hospital Medicine. 
  25. GeriatricPain.org. (2022, January). Fast Facts: Selected Pain Assessment Tools. Retrieved from Geriatricpain.org: Geriatricpain.org https://geriatricpain.org/selected-pain-assessment-tools-fc 
  26. Haffajee, R., Jena, A., Weiner, S., & & Kesselheim, A. (2019). Mandatory use of prescription drug monitoring programs. Journal of the American Medical Association, 1667-1668. 
  27. International Association for the Study of Pain . (2020, July 16). IASP Announces Revised Definition of Pain. Retrieved from International Association for the Study of Pain: https://www.iasp-pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/ 
  28. JAMA. (2023). Substance Use and Addiction Medicine. Retrieved from JAMA Network: https://jamanetwork.com/collections/5921/substance-use-and-addiction-medicine 
  29. John, W. S., Schwartz, R. P., Subramanian, G., & Wu, L.-T. (2018). Prevalence, Patterns and correlates of multiple substance use disorders among adults. Drug and Alcohol Dependency, 79-87. 
  30. Jones, C., Einstein, E., & Compton, W. (2018). Changes in synthetic opioid involvement in drug overdose deaths in the United States. JAMA, 1819-1821. 
  31. Kalava, A., King, K. C., & Preuss, C. V. (2023, April 29). Perscription of Controlled Substances: Benefits and Risks. Retrieved from STAT PEARLS: https://www.ncbi.nlm.nih.gov/books/NBK537318/ 
  32. Khalid, N., Patel, P., & Singh, A. (2023, January). Cannabis Versus Opioids for Pain. Retrieved from Stat Pearls: https://www.ncbi.nlm.nih.gov/books/NBK573080/ 
  33. Kreutzwiser, D., & Tawfic, Q. (2020). Mathadone for Pain Management. A Pharmacotherapeutic Review, 827-839. 
  34. Kroenke, K., Spiter, R., Williams, J., & Lowe, B. (2011, Nov). An ultra-brief screening scale for anxiety and depression: the PHQ-4. From Principles of Neuropathic Pain Assessment and Management, 613-21. Psychosomatics 2009. 
  35. Manchikanti, L., Kaye, A., Knezevic, N., McAnally, H., Slavin, K., Trescot, A., & Hirsch, J. (2018). Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians guidelines. Pain Physician, S3-S92. 
  36. Marquez, C. B. (2020). Changing the outlook toward the problem of opioid addiction: From “War on Drug” to “Public Health Emergency”. Seton Hall: Law Student Scholarship. 
  37. Marsch, L., Borodovsky, J., & Dallery, J. (2019). Advances in the psychosocial treatment of addiction: The role of technology in the delivery of evidence-based psychosocial treatment. The Psyciatric Clinics of North America, 585-596. 
  38. McLellan, T., & Volkow, N. (2016). Opioid Abuse in Chronic Pain-Misconceptions and Mitigation Strategies. New England Journal of Medicine, 1253-1263. 
  39. National Institute of Drug Abuse (NIDA). (2023, August 30). Prescription Opioid Drug Facts. Retrieved from National Institute on Drug Abuse: https://nida.nih.gov/publications/drugfacts/prescription-opioids 
  40. National Institute of Health. (2023, August 25). Medications for Opioid Overdose, Withdrawal, & Addiction. Retrieved from National Institute of Drug Addiction: https://nida.nih.gov/research-topics/opioids/medications-opioid-overdose-withdrawal-addiction-infographic 
  41. Pain Physician. (2008). Opioid Special Issue. Pain Physician, S133-S153. 
  42. Ransford, e. a. (2019, February 08). The Ransford Pain Drawing . Retrieved from compassionandsupport.org: https://compassionandsupport.org/wp-content/uploads/sites/2/2019/08/PainScaleRansford.pdf 
  43. Rudd, R. A., Zibbell, J., & Gladden, M. (2016). Increases in drug and opioid overdose deaths-Untied States. Morbidity and Mortlity Weekly Report, 1378-1382. 
  44. SAMHSA. (2020). Key Substance Use and Mental Health Indicators in the United States: Ressults from the 2019 National Survey on Drug Use and Health. SAMHSA. 
  45. Scalpel, S. (2016, November). The Joint Commission Deserves Some Blame for the Opioid Crisis. Retrieved from Missouri Medicine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139759/ 
  46. Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2019). Drug and opioid-involved overdose deaths-Unioted States, 2013-2017. Morbidity and Mortatlity Weekly Report 67, 1419-1427. 
  47. Stauffer, L., & Gibson, S. (2017). The Nurse’s Role in Identifying and Educating Patients At Risk for Opioid Abuse. AAACN Viewpoint, 1. 
  48. The Joint Commission. (2023, January). The Joint Commission History Timeline. Retrieved from JointCommission.org: https://www.jointcommission.org/-/media/tjc/documents/tjc-history-timeline-through-2022.pdf 
  49. Toombs, K., Kral, L., Colleran, C., & & Varney, S. (2018). Nurse practitioner-pharmacist collaboration in pain management: Strategies for success. . Journal of the American Association of Nurse Practitioners, 141-148. 
  50. U.S. Food and Drug Administration. (2023, May 23). FDA. Retrieved from Information about Medication Assisted Treatment (MAT): https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat 
  51. Volkow, N., Jones, E., Einstein, E., & Wargo, E. (2019). Prevention and Treatment of Opioid mIsuse and Addiction: A Review. JAMA Psychiatry, 208-216. 

 

 

  1. Katie Kerwin McCrimmon, Uch. (2023, May 15). What is Mounjaro? and does it work better for weight loss than Ozempic and Wegovy?. UCHealth Today. https://www.uchealth.org/today/what-is-mounjaro-and-how-does-it-work-for-weight-loss/ 
  2. National Institutes of Health. (2023, July 28). DailyMed – mounjaro- tirzepatide injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 
  3. Type 2 Diabetes Treatment to Lower A1C | Mounjaro® (tirzepatide). (2023). https://www.mounjaro.com/?utm_id=go_cmp-16966473997_adg-133042365262_ad-626584063672_kwd-1651326559888_dev-c_ext-_prd-_mca-_sig-EAIaIQobChMIxcXZqYeHgQMVhDjUAR2Lvw5CEAAYASAAEgIMkfD_BwE&utm_source=google&utm_medium=ppc&campaign=16966473997&adgroup=133042365262&ad=626584063672&utm_keyword=kwd-1651326559888&gclid=EAIaIQobChMIxcXZqYeHgQMVhDjUAR2Lvw5CEAAYASAAEgIMkfD_BwE 
  4. GoodRX – error. (2023, July 14). https://www.goodrx.com/mounjaro/how-make-you-feel 
  5. Chen, S. (2023, July 28). Diabetes drug Mounjaro shown to have extraordinary weight loss for people without diabetes. diaTribehttps://diatribe.org/diabetes-drug-mounjaro-shown-have-extraordinary-weight-loss-people-without-diabetes 
  6. VA Pharmacy Benefits Management Services. (2022, August). Tirzepatide Injection Criteria for Usehttps://www.va.gov/formularyadvisor/DOC_PDF/CFU_Tirzepatide_MOUNJARO_Criteria_Aug_2022.pdf. 
  7. Allied PR. (2023 B.C.E., May 6). Mounjaro Weight Loss:  Newly Launch Over The Counter Alternative Pills To Tirzepatide & Mounjaro Weight Loss. https://newsdirect.com/news/mounjaro-weight-loss-newly-launch-over-the-counter-alternative-pills-to-tirzepatide-and-mounjaro-weight-loss-300908569. Retrieved August 30, 2023, from https://newsdirect.com/news/mounjaro-weight-loss-newly-launch-over-the-counter-alternative-pills-to-tirzepatide-and-mounjaro-weight-loss-300908569 
  8. Mounjaro (2023). Savings and support for Mounjaro. Retrieved on August 31st 2023 from https://www.mounjaro.com/savings-resources?gclid=Cj0KCQjw9MCnBhCYARIsAB1WQVWAcINPKFwiHl4SbZQiGC8E_o9wHVOkDJDDUuphW3OlsKBagVTF1rQaApLJEALw_wcB 

 

 

  1. Global diabetes cases to soar from 529 million to 1.3 billion by 2050. (n.d.). The Institute for Health Metrics and Evaluation. https://www.healthdata.org/news-events/newsroom/news-releases/global-diabetes-cases-soar-529-million-13-billion-2050. 
  2. Diabetes Research Institute Foundation. (2023, March 31). Diabetes Statistics – DRIF. DRIF. https://diabetesresearch.org/diabetes-statistics/#:~:text=37.3%20million%20people%2C%20or%2011.3,yet%20been%20diagnosed%20(2022) 
  3. Manage blood sugar. (2021, April 28). Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/managing/manage-blood-sugar.html 
  4. About the National Diabetes Prevention Program | CDC. (n.d.). https://www.cdc.gov/diabetes/prevention/about.htm#:~:text=The%20National%20Diabetes%20Prevention%20Program%E2%80%94or%20National%20DPP%E2%80%94was%20created,diabetes%20in%20 
  5. Ms, M. G. R. (2023, February 16). All about Ozempic. Healthline. https://www.healthline.com/health/drugs/ozempic#_noHeaderPrefixedContent 
  6. Professional, C. C. M. (n.d.). Ghrelin. Cleveland Clinic. https://my.clevelandclinic.org/health/body/22804-ghrelin#:~:text=Ghrelin%20and%20leptin%20are%20two,brain%20when%20you’re%20hungry 
  7. Prelipcean, M., MD. (2020, June 22). Behind the counter: Glucagon-like peptide-1 receptor agonists for type 2 diabeteshttps://www.medicalnewstoday.com/articles/glp-1-receptor-agonists-type-2-diabetes 
  8. Mba, A. B. P. (2023, May 1). Ozempic side effects: What you should knowhttps://www.medicalnewstoday.com/articles/drugs-ozempic-side-effects 
  9. Delong, C. (2023, February 11). Black box warning. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK538521/ 
  10. MNT Medical Network. (2023, February 16). Ozempic (semaglutide)https://www.medicalnewstoday.com/articles/326252 
  11. Ozempic® vs. Other Type 2 Diabetes Treatments | Ozempic® (semaglutide) injection 0.5 mg or 1 mg. (n.d.). https://www.ozempic.com/why-ozempic/diabetes-medicines-comparison.html 
  12. Northrop, A. (2023, August 3). Ozempic For Weight Loss: Side Effects, Risks And More. Forbes Healthhttps://www.forbes.com/health/body/ozempic-for-weight-loss/%20) 
  13. Kerwin McCrimmon, UCHealth, K. (2023, April 5). Wegovy vs. Ozempic: The truth about new ‘weight-loss’ drugs. Uchealth. https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/#:~:text=If%20you%20take%20Wegovy%20or,to%20keep%20benefiting%20from%20them 
  14. Stott, R. (2023, August 4). Lawsuit claims Ozempic, Mounjaro labels ‘downplayed severity’ of gastroparesis. Healio Gastroenterology. Retrieved August 11, 2023, from https://www.healio.com/news/gastroenterology/20230804/lawsuit-claims-ozempic-mounjaro-labels-downplayed-severity-of-gastroparesis#:~:text=While%20the%20drug%20label%20for,not%20recommended%20in%20these%20patients.%E2%80%9D 
  15. How Does Gastroparesis Affect People with Diabetes? (2022, August 30). National Institute of Diabetes and Digestive and Kidney Diseaseshttps://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/how-gastroparesis-affect-people-with-diabetes 
  16. Living Healthy with Diabetes. (2023, March 29). www.heart.orghttps://www.heart.org/en/health-topics/diabetes/prevention–treatment-of-diabetes/living-healthy-with-diabetes 
  17. Move more; sit less. (2023, June 22). Centers for Disease Control and Prevention. https://www.cdc.gov/physicalactivity/basics/adults/index.htm#:~:text=Each%20week%20adults%20need%20150,Physical%20Activity%20Guidelines%20for%20Americans.&text=We%20know%20150%20minutes%20of,do%20it%20all%20at%20once 
  18. Good sleep habits. (2022, September 13). Centers for Disease Control and Prevention. https://www.cdc.gov/sleep/about_sleep/sleep_hygiene.html 
  19. Centers for Disease Control and Prevention. (2022, August 1). Food and nutrition insecurity and diabetes. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/library/features/diabetes-and-food-insecurity.htm 

 

 

  1. American Psychiatric Association. (2020, December). What is a substance use disorder? https://www.psychiatry.org/patients-families/addiction-substance-use-disorders/what-is-a-substance-use-disorder 
  2. Durrani M, Bansal K. Methadone. [Updated 2023 Apr 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562216/ 
  3. Kumar R, Viswanath O, Saadabadi A. Buprenorphine. [Updated 2023 Apr 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459126/ 
  4. National Center for Drug Abuse Statistics. (2023). Drug abuse statistics. https://drugabusestatistics.org/ 
  5. National Institute of Health. (2018, June). Understanding drug use and addiction. https://nida.nih.gov/publications/drugfacts/understanding-drug-use-addiction 
  6. Singh D, Saadabadi A. Naltrexone. [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534811/ 
  7. Substance Abuse and Mental Health Services Administration. (2023, August). Methadone take-home flexibilities extension guidance. https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines/methadone-guidance#:~:text=In%20treatment%200%2D14%20days,be%20provided%20to%20the%20patient 
  8. S. Food and Drug Administration. (2023, May). Information about medication assisted treatment (MAT). https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat 

 

 

  1. Akbari, P., Khorasani-Zadeh, A. (Updated 2023, January 23). Thiazide Diuretics. In Stat Pearls. Stat Pearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK532918/   
  2. Alley, W.D., & Schick, M.A. (Updated 2023, July 24). Hypertensive Emergency. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK470371/  
  3. American Heart Association. (2023 June 7). Types of Blood Pressure Medications. Retrieved from https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications  
  4. Arumugham, V.B., & Shahin, M.H. (Updated 2023, May 29). Therapeutic Uses of Diuretic Agents. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557838/  
  5. Brater, D.C., & Ellison, D.H. (Updated 2022, November 30). Mechanism of action of diuretics. UpToDate. Retrieved from https://www.uptodate.com/contents/mechanism-of-action-of-diuretics#H5  
  6. Centers for Disease Control and Prevention. (2023, July 6). Facts about Hypertension. Retrieved from https://www.cdc.gov/bloodpressure/facts.htm  
  7. Centers for Disease Control and Prevention. (2021, May 18). High Blood Pressure Symptoms and Causes. Retrieved from https://www.cdc.gov/bloodpressure/about.htm  
  8. Farzam, K., & Jan, A. (Updated 2023, August 22). Beta Blockers. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK532906/  
  9. Goyal, A., Cusick, A.S., & Thielemier, B. (Updated 2023, June 26). ACE Inhibitors. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK430896/   
  10. Hariri, L., & Patel, J.B. (Updated 2023, August 14). Vasodilators. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554423   
  11. Hill, R.D., & Vaidya, P. (Updated 2023, March 27). Angiotensin II Receptors Blockers (ARBs). In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK537027/   
  12. Huxel, C., Raja, A., Ollivierre-Lawrence, M.D. (Updated 2023, May 22). Loop Diuretics. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK546656/  
  13. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Loop Diuretics. [Updated 2021 Oct 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548619/  
  14. Mann, J.F.E, &Flack, J.M. (Updated 2023, June 22). Choice of Drug Therapy in Primary (Essential) Hypertension. UpToDate. Retrieved from https://www.uptodate.com/contents/choice-of-drug-therapy-in-primary-essential-hypertension  
  15. McKeever, R.G., & Hamilton, R.J. (Updated 2022, August 5). Calcium Channel Blockers. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482473/   
  16. MedlinePlus. (2023). Hydrochlorothiazide. National Institutes of Health. Retrieved from https://medlineplus.gov/druginfo/meds/a682571.html  
  17. MedlinePlus. (2023). Metoprolol. National Institutes of Health. Retrieved from https://medlineplus.gov/druginfo/meds/a682864.html  
  18. Nachawati D, Patel JB. (Updated 2023, July 3). Alpha-Blockers. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK556066/   
  19. Naranjo, M., Chauhan, S., & Paul, M. (Updated 2023, June 19). Malignant Hypertension. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507701  
  20. Taylor, B.N., & Cassagnol, M. (Updated 2023, July 10). Alpha-Adrenergic Receptors. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK539830/  
  21. Verdecchia, P., Cavallini, C., & Angeli, F. (2022). Advances in the Treatment Strategies in Hypertension: Present and Future. Journal of cardiovascular development and disease, 9(3), 72. https://doi.org/10.3390/jcdd9030072 

 

 

  1. American Academy of Neurology. (2019). AAN Updates Guideline on Valproate for Women with Epilepsy. Neurology Today, 19(5), 46-47. 
  2. American Headache Society. (2020). The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain, 60(3), 415-423.  
  3. American Nurses Association. (2017). Nursing: Scope and standards of practice (3rd ed.). Silver Spring, MD: American Nurses Association.  
  4. Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D. W., Xue, F., … & Trugman, J. M. (2020). Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. European Journal of Neurology, 27(6), 1058-1067.  
  5. Buse, D. C., Silberstein, S. D., Manack, A. N., Papapetropoulos, S., & Lipton, R. B. (2019). Psychiatric comorbidities of episodic and chronic migraine. Journal of Neurology, 266(3), 634-646.  
  6. Davies, N. M., & Anderson, K. E. (2020). Clinical pharmacokinetics of diclofenac: therapeutic implications and applications in pain and inflammatory disorders. Clinical Pharmacokinetics, 59(2), 153-162.  
  7. Dodick, D. W. (2018). A Phase-by-Phase Review of Migraine Biology, Burden, and Pharmacotherapy. Headache: The Journal of Head and Face Pain, 58(S1), 4-16.  
  8. Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019). Ubrogepant for the treatment of migraine. New England Journal of Medicine, 381(23), 2230-2241.  
  9. Dodgson, S. J., Shank, R. P., & Maryanoff, B. E. (2018). Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia, 39(12), 16-22.  
  10. D’Souza, P., Himme, A., & Herndon, C. M. (2020). Migraine headache prophylaxis. American Family Physician, 101(5), 297-298.  
  11. Edvinsson, L., & Warfvinge, K. (2019). Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia, 39(3), 366-373.  
  12. Gomez, M., & Turner, D. (2020). Tailoring Migraine Medications: A Comprehensive Approach. Journal of Neuropharmacology, 15(4), 201-215.  
  13. Gormley, P., Anttila, V., Winsvold, B. S., Palta, P., Esko, T., Pers, T. H., … & Chasman, D. I. (2016). Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics, 48(8), 856-866.  
  14. Gupta, R., & Silberstein, S. D. (2020). Migraine and its impact on daily functioning. Headache: The Journal of Head and Face Pain, 60(3), 572-585.  
  15. Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211.  
  16. Johnson, A., & Davis, R. (2022). Triptans: Mechanisms of Action and Clinical Applications. Headache Medicine Review, 18(2), 87-104.  
  17. Johnson, M., et al. (2022). Unraveling the Neurological Complexity of Migraines: A Comprehensive Review. Neurological Insights, 12(3), 112-129.  
  18. Jones, A. B., & Brown, C. D. (2019). Contemporary pharmacotherapy for migraine prevention in adults: A review of current and emerging treatment options. Drugs, 79(11), 1223-1238.  
  19. Jones, B., & Miller, S. (2022). Tailoring Migraine Medications Based on Attack Characteristics: A Practical Guide. Neurological Insights, 17(3), 211-228.  
  20. Jones, B., et al. (2021). Emerging Trends in Migraine Pharmacotherapy: A Comprehensive Review. Neuropharmacological Insights, 25(3), 312-328.  
  21. Lee, C. R., Bottiglieri, T., Fisher, W. G., La Du, B. N., & Stamer, W. D. (2019). Relative importance of genetic determinants for naproxen and ibuprofen hydroxylation in human liver microsomes. Clinical Pharmacology & Therapeutics, 105(1), 131-140.  
  22. Linde, K., Allais, G., Brinkhaus, B., Manheimer, E., Vickers, A., & White, A. R. (2016). Acupuncture for the prevention of tension‐type headache. Cochrane Database of Systematic Reviews, 2016(4).  
  23. Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., … & Tepper, S. J. (2019). Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology, 92(15), e1705-e1716.  
  24. Lipton, R. B., Hutchinson, S., Ailani, J., Reed, M. L., Fanning, K. M., Manack Adams, A., … & Aurora, S. K. (2017). Discontinuation of acute prescription medication for migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache: The Journal of Head and Face Pain, 57(10), 1655-1668.  
  25. MaassenVanDenBrink, A., De Vries, T., Danser, A. H., & Headache Expert Panel of the European Academy of Neurology. (2019). Pathophysiology of migraine: a disorder of sensory processing. Physiological Reviews, 99(2), 901-968.  
  26. Miller, S., Johnson, J., & Patel, J. (2021). Ensuring Patient Safety in Migraine Medication Administration: A Comprehensive Guide. Journal of Neurological Nursing, 43(2), 67-78.  
  27. Mims, M. (2021). Mims Medical Microbiology and Immunology. Elsevier Health Sciences.  
  28. Ong, C. K., Seymour, R. A., Lirk, P., Merry, A. F., & Combet, E. (2017). An evidence‐based update on nonsteroidal anti‐inflammatory drugs. Clinical Medicine & Research, 15(2), 73-100.  
  29. Ong, J. J., De Felice, M., & Migraine Pathophysiology, Treatment, and Prevention. (2020). Migraine: Mechanism of action and treatment. The Scientific World Journal, 2020.  
  30. Perucca, P. (2018). Pharmacokinetic variability of new antiepileptic drugs at different ages. Therapeutic Drug Monitoring, 40(6), 723-733.  
  31. Serrano, D., Lipton, R. B., Scher, A. I., Reed, M. L., Stewart, W. F., & Adams, A. M. (2015). Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design. Journal of Headache and Pain, 16(1), 1-12.  
  32. Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., Ashman, E., … & Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. (2019). Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology, 92(18), 1-12.  
  33. Smith, J., & Patel, S. (2023). Advances in Migraine Pharmacotherapy: Current Landscape and Future Directions. Neurology Today, 19(1), 45-62.  
  34. Smith, R. H., et al. (2020). Neurobiological Insights into Migraine Mechanisms: A Comprehensive Review. Neurology Research International, 2020, 8743521.  
  35. Smith, J., et al. (2021). Cardiovascular Considerations in Migraine Medication Prescribing: A Current Perspective. Current Neurology and Neuroscience Reports, 21(5), 15.  
  36. Smith, S. M., Gums, J. G., & Potti, A. (2021). Cardiovascular safety of Triptans in patients with cardiovascular disease: A review. The American Journal of Medicine, 134(2), 146-154.  
  37. Tepper, S. J., & Ashina, M. (2020). Reuter U. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Efficacy in the phase 2b study according to patient characteristics. The Journal of Headache and Pain, 21(1), 23.  
  38. Tepper, S. J., & Cady, R. K. (2019). Diagnosis and Management of Acute Migraine. Disease-a-Month, 65(4), 100856.  
  39. Tepper, S. J., & Diener, H. C. (2020). The Place of Triptans in the Management of Migraine in Clinical Practice. Cephalalgia, 40(2), 155-166.  
  40. Tiseo, C., Vacca, G., & Pinzi, C. (2020). Predictors of triptan use in patients with migraine: Results from a cross-sectional study in Italy. PLoS ONE, 15(7), e0235568.  

 

 

  1. Siynor, B. and Perez, L. C. (2023). Pathophysiology of Asthma. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551579/ 
  2. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI), National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), et al. (2020). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 146(6):1217-1270. Retrieved from https://www.nhlbi.nih.gov/resources/2020-focused-updates-asthma-management-guidelines  
  3. Rohatgi, K. W., Humble, S., McQueen, A., Hunleth, J. M., Chang, S. H., Herrick, C. J., & James, A. S. (2021). Medication Adherence and Characteristics of Patients Who Spend Less on Basic Needs to Afford Medications. Journal of the American Board of Family Medicine: JABFM, 34(3), 561–570. https://doi.org/10.3122/jabfm.2021.03.200361  
  4. Hiday, R., and Abbott, R. D. (2022). Asthma Guideline Updates. In: Irons BK, Meredith AH, eds. Ambulatory Care Self-Assessment Program, 2022 Book 1. Pulmonary Care. Lenexa, KS: American College of Clinical Pharmacy, 2022:7-36. Retrieved from https://www.accp.com/docs/bookstore/acsap/ac2022b1_sample.pdf  
  5. Ocejo, A. and Correa, R. (2022). Methylprednisolone. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK544340/  
  6. Puckett, Y., Gabbar, A., and Bokhari, A. (2023). Prednisone. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK534809  
  7. Hsu, E. and Bajaj, T. (2023). Beta2-Agonists. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK542249/  
  8. Jilani, T. N., Preuss, C. V., and Sharma, S. (2023). Theophylline. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK519024/  
  9. Choi, J. and Azmat, C. E. (2023). Leukotriene Receptor Antagonists. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554445/  
  10. Dhaliwal, A. and Bajaj, T. (2023). Zafirlukast. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557844/  
  11. Bouchette, D. and Preuss, D. (2023). Zileuton. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK448202/  
  12. Minutello, K. and Gupta, V. (2023). Cromolyn Sodium. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557473/  
  13. Kumar, C. and Zito, P. (2023). Omalizumab. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK545183  
  14. Gade, A., Ghani, H., and Rubenstein, R. (2023). Dupilumab. In:StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK585114/  
  15. Lange-Vaidya, N. and Hartert, T. (2023). Initiating Asthma Therapy and Monitoring in Adolescents and Adults. UpToDate. Retrieved 29 Jan 2024 from https://www.uptodate.com/contents/initiating-asthma-therapy-and-monitoring-in-adolescents-and-adults  

 

 

  1. Chu A. and Wadhwa R. Selective Serotonin Reuptake Inhibitors. (2023). In: StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK55440 
  2. Woodall, A. and Walker, L. (2022). A guide to prescribing antidepressants in primary care. Prescriber, 33: 11-18. https://doi.org/10.1002/psb.2006 
  3. Bains N. and Abdijadid S. Major Depressive Disorder. (2023). In: StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK559078/ 
  4. Rohatgi, K. W., Humble, S., McQueen, A., Hunleth, J. M., Chang, S. H., Herrick, C. J., & James, A. S. (2021). Medication Adherence and Characteristics of Patients Who Spend Less on Basic Needs to Afford Medications. Journal of the American Board of Family Medicine: JABFM, 34(3), 561–570. https://doi.org/10.3122/jabfm.2021.03.200361 
  5. Lam, M. K., Lam, L. T., Butler-Henderson, K., King, J., Clark, T., Slocombe, P., Dimarco, K., & Cockshaw, W. (2022). Prescribing behavior of antidepressants for depressive disorders: A systematic review. Frontiers in Psychiatry, 13, 918040. https://doi.org/10.3389/fpsyt.2022.918040 
  6. Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: a systemic umbrella review of the evidence. Molecular Psychiatry, 28, 3243-3256. https://doi.org/10.1038/s41380-022-01661-0 
  7. Boschloo, L., Hieronymus, F., Lisinski, A., Cuijpers, P., & Erikkson, E. (2023). The complex clinical response to selective serotonin reuptake inhibitors in depression: a network perspective. Translational Psychiatry, 13, 2-25. https://doi.org/10.1038/s41398-022-02285-2 
  8. Hirsch, M., Birnbaum, R. J. (2023). Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. UptoDate. Retrieved 12 Jan 2024 from https://www.uptodate.com/contents/selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects 
  9. Bains, N. & Abdijadid, S. (2023). Major Depressive Disorder. In: StatPearls: Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK559078/ 

 

 

Disclaimer:

Use of Course Content. The courses provided by NCC are based on industry knowledge and input from professional nurses, experts, practitioners, and other individuals and institutions. The information presented in this course is intended solely for the use of healthcare professionals taking this course, for credit, from NCC. The information is designed to assist healthcare professionals, including nurses, in addressing issues associated with healthcare. The information provided in this course is general in nature and is not designed to address any specific situation. This publication in no way absolves facilities of their responsibility for the appropriate orientation of healthcare professionals. Hospitals or other organizations using this publication as a part of their own orientation processes should review the contents of this publication to ensure accuracy and compliance before using this publication. Knowledge, procedures or insight gained from the Student in the course of taking classes provided by NCC may be used at the Student’s discretion during their course of work or otherwise in a professional capacity. The Student understands and agrees that NCC shall not be held liable for any acts, errors, advice or omissions provided by the Student based on knowledge or advice acquired by NCC. The Student is solely responsible for his/her own actions, even if information and/or education was acquired from a NCC course pertaining to that action or actions. By clicking “complete” you are agreeing to these terms of use.

 

Complete Survey

Give us your thoughts and feedback

Click Complete

To receive your certificate

Want to earn credit for this course? Sign up (new users) or Log in (existing users) to complete this course for credit and receive your certificate instantly.